**DERMATOONKOLOJİ**

**KONULARA GÖRE KAYNAKLAR**

***Deri gelişimi ve histolojik yapısı***

**1.** Ku John, El-Hashash Ahmed HK. Distribution and extracellular matrix environment of premelanoblasts during skin development in Xiphophorus hybrids. Anatomy & Physiology: Current Research, 2017; 7: 1-6.

**2.** Lachner J, Mlitz V, Tschacler E, et al. Epidermal cornification is preceded by the expression of a keratinocyte-specific set of pyroptosis-related genes. Scientific Reports, 2017; 7: 1-11.

**3.** Beverdam A. http://php.med.unsw.edu.au/embryology/ Larsen’s Human Embryology – Chapter 7. The Developing Human: Clinically Oriented Embryology, 2017.

**4.** Ünver Saraydın S, Başımoğlu Koca Y, Günay Y, Koptagel E, Sıçanda prenatal ve neonatal dönemde deri gelişimi, Fırat Üniversitesi Sağlık Bilimleri (Tıp) Dergisi, 1999; 13(1):25-30.

**5.** Driskell RR, Watt FM. Understanding fibroblast heterogeneity in the skin. Trends Cell Biol, 2015; 25: 92-99.

**6.** Dequeant ML, Pourquie O. Segmental patterning of the vertebrate embriyonic axis. Nat. Rev. Genet, 2008; 9:370-382.

**7.** Forni MF, Trombetta-Lima M, Sogayar MC. Stem cells in embryonic skin development. Biological research, 2012; 45:215-22.

**8.** Kulukian A, Fuchs E. Spindle orientation and epidermal morphogenesis. Philosophical Transactions of the Royal Society of London B: Biological Sciences, 2013; 368: 1629.

**9.** Xu Y, Hong Y, Xu M, Ma K. Et al. Role of keratinocyte growth factor in the differentiation of sweat gland-like cells from human umbilical cord-derived mesenchymal stem cells. Stem Cells T.M, 2016; 5: 106-116.

**10.** Andl T, Reddy ST, Gaddapara T, et al: WNT signals are required for the initiation of hair follicle development. Dev Cell, 2002; 2: 643-53.

**11.** Huelsken J, Vogel R, Erdmann B, et al: beta-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell, 2001; 105:533-45.

**12.** Lulevich V, Yang H, Isseroff R, et al. Single cell mechanichs of keratinocyte cells. Ultramicroscopy, 2010; 110: 1435-1442.

**13.** Fuchs E. Annual review of cell and developmental biology. 1995; 11: 123-153.

**14.** D. DePianto, P.A. Coulombe., Experimental Cell Research, 2004; 301: 68–76.

**15.** Lindberg, M and Forslind, B. The Skin as a Barrier. In: Loden, M and Maibach, HI, editors. Dry Skin and Moisturizers: Chemistry and Function. Boca Raton: CRC Press, 2000; p.27-37.

**16.** Slominski A, Tobin DJ, Shibahara S, et al., Melanin pigmentation in mammalian skin and its hormonal regulation, American Physiological Society, 2004; 84: 1155-1228.

**17.** Papadopoulos P, Langerhans cell histiocytosis: Its oral and maxillofacial dimension.Balk J Stom, 2012; 16:69-73.

**18.** Polakovicova s, Polak S, Merkel cells and Merkel cell carcinoma of genitourinary system tumor with aggressive behavior and poor prognosis. Anat Physiol 2017; 7: 1-6.

**19.** James WD, Berger TG, Elston DM, Andrews diseases of the skin: Clinical dermatology (10th ed.) Philadelphia: Elsevier Saunders, 2006.

**20.** Mauro, T., & Goldsmith, L. (2008). Biology of eccrine, apocrine, and apoeccrine sweat glands. In K. Wolff, L.A. Goldsmith, S.I. Katz, B.A. Gilchrest, A.S. Paller, & D.J. Leffell (Eds.), Fitzpatrick’s dermatology in general medicine (7th ed., pp. 713–720). New York: McGraw-Hill., 2008.

**21.** Ünver Saraydın S, Pilosebase ünitenin histolojisi. Güncel Dermatoloji Dergisi, 2017; 2(1):1-6.

**22.** Danby, FW, Why we have sebaceous glands. Journal of the American Academy of Dermatology, . 2005; 52 (6), 1071–1072.

***Genetik Karsinogenezis***

1. McKusick VA, ed. Online Mendelian Inheritance In Man (OMIM). The Johns Hopkins University. Lymphoproliferative Syndrome, X-Linked, Entry Number; 308240: Last Edit Date; 7/20/2005.
2. [zur Hausen H](https://www.ncbi.nlm.nih.gov/pubmed/?term=zur%20Hausen%20H%5BAuthor%5D&cauthor=true&cauthor_uid=10793105). Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. [J Natl Cancer Inst.](https://www.ncbi.nlm.nih.gov/pubmed/10793105) 2000 May 3;92: 690-698.
3. Ramoz N, Rueda LA, Bouadjar B et al. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 2002; 32: 579-581.
4. Orth G, Jablonska S, Favre M, et al. Characterization of two types of human papillomaviruses in lesions of epidermodysplasia verruciformis Proc Natl Acad Sci 1978; 75: 1537-1541.
5. National Cancer Institute. Cancer Genetics Overview (PDQ)-Health Professional Version. <https://www.cancer.gov/about-cancer/causes-prevention/genetics/overview-pdq>.
6. American Cancer Society: Cancer Facts and Figures 2018. Atlanta, Ga: American Cancer Society, 2018. “online” ulaşım. Son gözden geçirme 5 Ocak 2018.
7. Zhang J, Walsh MF, Wu G, et al. Germline mutations in predisposition genes in pediatric cancer. N Eng J Med 2015; 373: 2336-2346.
8. Cancer Facts and Figures 2016. <http://www.cancer.org/aca/groups/content/> @reserach/documantes/document/acspc-04079.pdf.
9. Fogel AL, Sarin KY, Teng JMC. Genetic disease associated with an increased risk of skin cancer development in childhood. Curr opin Pediatr 2017; 29: 426433.
10. Sarıalioğlu F. Kanseri Anlamak. Türk Kanser Araştırma ve Savaş Vakfı, 4. Baskı, 2005 – İzmir
11. Knudson, A. G. Mutation and cancer: Statistical study of retinoblastoma. *Proceedings of the National Academy of Sciences 1971;* ***68****, 820–823.*
12. Fab Z, Li J, Du J, et al. A missence mutation in PTCH2 underlies dominantly inherited NBCCS in a Chinese family. J Med Genet 2008; 45: 303-308.
13. Smith MJ, Beetz C, Williams SG, et al. Germline mutations in SUFU vause Gorlins syndrome- associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol 2014; 32: 4155-4161.
14. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008; 8: 743-754.
15. [Rimkus](https://www.ncbi.nlm.nih.gov/pubmed/?term=Rimkus%20TK%5BAuthor%5D&cauthor=true&cauthor_uid=26891329) TK, [Carpenter](https://www.ncbi.nlm.nih.gov/pubmed/?term=Carpenter%20RL%5BAuthor%5D&cauthor=true&cauthor_uid=26891329) RL, [Qasem](https://www.ncbi.nlm.nih.gov/pubmed/?term=Qasem%20S%5BAuthor%5D&cauthor=true&cauthor_uid=26891329) S,  [Chan](https://www.ncbi.nlm.nih.gov/pubmed/?term=Chan%20M%5BAuthor%5D&cauthor=true&cauthor_uid=26891329) M,  [Lo](https://www.ncbi.nlm.nih.gov/pubmed/?term=Lo%20HW%5BAuthor%5D&cauthor=true&cauthor_uid=26891329) HW. Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors. Cancers (Basel). 2016; 8: 22-29.
16. [Tas S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tabs%20S%5BAuthor%5D&cauthor=true&cauthor_uid=15196999), [Avci O](https://www.ncbi.nlm.nih.gov/pubmed/?term=Avci%20O%5BAuthor%5D&cauthor=true&cauthor_uid=15196999). Induction of the differentiation and apoptosis of tumor cells in vivo with efficiency and selectivity. [Eur J Dermatol.](https://www.ncbi.nlm.nih.gov/pubmed/15196999) 2004; 14:96-102.
17. [Cunniff](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cunniff%20C%5BAuthor%5D&cauthor=true&cauthor_uid=28232778) C, [Bassetti](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bassetti%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=28232778) JA, [Ellis](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ellis%20NA%5BAuthor%5D&cauthor=true&cauthor_uid=28232778) NA. Bloom's Syndrome: clinical spectrum, molecular pathogenesis, and cancer predisposition. [Mol Syndromol](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260600/). 2017; 8: 4–23.
18. NIH. GARD - Genetic and Rare Disease Information Center. Broke-Spiegler syndromu [homepage on internet]. Updated August 02, 2015. Available from: <https://rarediseases.info.nih.gov/diseases/10179/brooke-spiegler-syndrome>
19. Genetic Home Reference. Cowden syndrome. [homepage on internet]. Updated February 20, 2018. Available from: <https://ghr.nlm.nih.gov/condition/cowden-syndrome>.
20. Jaju PD, Ransohoff KJ, Tang JY, Sarin KY. Familial skin cancer syndromes: Increased risk of nonmelanotic skin cancers and extracutaneous tumors. [J Am Acad Dermatol.](https://www.ncbi.nlm.nih.gov/pubmed/26892653) 2016 Mar;74(3):437-451.
21. Caspari AA. Epidermodysplasia verruciformis. [homepage on internet]. Updated January 08, 2016. Availabe from: <https://emedicine.medscape.com/article/1131981-overview>
22. Ramoz N, Rueda LA, Bouadjar B, Montoya LS, Orth G, Favre M. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis**.** Nature Genet. 2002; 32: 579-581, 2002.
23. Fine JD, Bruckner-Tuderman L, Eady RA, et al. Inherited epidermolysis bullosa: updated recommmendations on diagnosis and classification. J Am Acad Dermatol 2014; 70: 1103-1126.
24. [Nyström](https://www.ncbi.nlm.nih.gov/pubmed/?term=Nystr%26%23x000f6%3Bm%20A%5BAuthor%5D&cauthor=true&cauthor_uid=27966558) A,  [Bruckner-Tuderman](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bruckner-Tuderman%20L%5BAuthor%5D&cauthor=true&cauthor_uid=27966558) L. Gene Therapy for Epidermolysis Bullosa: Sticky Business. [Mol Ther](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167791/). 2016; ; 24: 2035–2036.
25. Mellerio JE, Robertson SJ, Bernardis C, et al. Management of cutaneous squamouos cell carcinoma in patients with epidermolysiss bullosa: best clinical practice quidelines. Br J Dermatol 2016; 174: 56-67.
26. NIH. GARD - Genetic and Rare Disease Information Center. Familial cylindromatosis

 [homepage on internet]. Updated January 02, 2018. Available from: <https://rarediseases.info.nih.gov/diseases/9707/familial-cylindromatosis>

1. NIH. GARD - Genetic and Rare Disease Information Center. Xeroderma pigmentosum.

[homepage on internet]. Updated May 2010. Available from: <https://ghr.nlm.nih.gov/condition/xeroderma-pigmentosum>

1. Debniak T. Familial malignant melanoma – vverview. [Hered Cancer Clin Pract](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392520/). 2004; 2: 123–129.
2. Aoude LG, Wadt KA, Pritchard AL, Hayward NK. [Genetics of familial melanoma: 20 years after CDKN2A.](https://www.ncbi.nlm.nih.gov/pubmed/25431349) Pigment Cell Melanoma Res. 2015 Mar;28(2):148-160.
3. NIH. GARD - Genetic and Rare Disease Information Center. Muir-Torre syndrome. [homepage on internet]. Updated June 15. 2015. Available from: https://rarediseases.info.nih.gov/diseases/6821/muir-torre-syndrome
4. Genetic Home Reference. Cowden syndrome. [homepage on internet]. Updated February 27, 2018. Available from: https://ghr.nlm.nih.gov/condition/multiple-familial-trichoepithelioma#genes
5. [Grønskov](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gr%26%23x000f8%3Bnskov%20K%5BAuthor%5D&cauthor=true&cauthor_uid=17980020) K, Ek J,, [Brondum-Nielsen K,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Brondum-Nielsen%20K%5BAuthor%5D&cauthor=true&cauthor_uid=17980020) Oculocutaneous albinism [Orphanet J Rare Dis](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211462/). 2007; 2: 43.
6. NIH. GARD - Genetic and Rare Disease Information Center. Rothmund-thomson-syndrome. [homepage on internet]. Updated: February 27, 2018. Available from:https://ghr.nlm.nih.gov/condition/rothmund-thomson-syndrome#inheritance
7. NORD-National Organization for Rare Disorders. [homepage on internet]. Available from <https://rarediseases.org/rare-diseases/werner-syndrome/>

***Viral karsinogenezis***

1. Boyle P, Levin B. International Agency for Research on Cancer. Word Health Organization. Word cancer report 2008. Lyon Geneva: International Agency for Research on Cancer: Distributed by WHO Press; 2008.
2. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attiributable to infections in 2008: a review and synthetic analysis. The Lancet Oncology. 2012; 13:607-615.
3. zur Hausen H. The search for infectious causes of human canccers: where and why (Nobel lecture). Angew Chem Int Ed Engl. 2009; 48:5798-5808.
4. Mesri EA, Feitelson M, Munger K. Human viral oncogenesis: a cancer hallmarks. Cell Host Microbe 2014; 15:266-282.
5. McFadden K, Luftig MA. Interplay between DNA tumor viruses and the host DNA damage response. Current Topics in Microbiol and Immunol. 2013; 371:229-257.
6. Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV- associated hepatocellular carcinoma. Nature Rev Cancer. 2013; 13:123-135.
7. Zhang J et al. Germline mutation in cancer predisposition genes in pediatric cancer. N Eng J Med 2015; 373:2336-2346.
8. Brozou T, et al. Genetic predisposition in children with cancer- affected families acceptance of Trios-WES. Eur J Pediatr 2018; 177: 53-60.
9. Ellerman V, Bang O. Experimentalle leukemie bei huhnern. Zentralbi Bakteriol Parasitenkd Infektionskr Hyg. 1908; 46: 595-597 (orijinali elde edilememiştir).
10. Rous P. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J Exp Med 1911; 13: 397-399. [PubMed: 19867421]
11. Shobe RE, Hurst EW. Infectious papillomatosis of rabbits: with a note on the histopathology. J Exp Med 1933; 58:607-625. [PubMed: 9870219]
12. Bittner JJ. Some possible effects of nursing on the mammary tumor incidence in mice. Science 1936; 84:162-169. [PubMed: 17793252]
13. Rao TV. Oncogenic virus basics [homepage on the internet]. Available from: <https://www.slideshare.net/doctorrao/oncogenic-virus>
14. Stehelin D, Vermus HE, Bishop JM, Vogt PK. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 1976; 260: 170-173.
15. CDC- Centers of Disease and Prevention . Human papilloma virus and cancer – 2015 <https://www.cdc.gov/cancer/hpv/statistics/cases.htm>
16. [Zheng](https://www.ncbi.nlm.nih.gov/pubmed/?term=Zheng%20ZM%5BAuthor%5D&cauthor=true&cauthor_uid=16720315) ZM, Carl C. Baker CC. Papillomavirus genome structure experssion, and pos-trancriptional regulation. Front Biosci 2006; 11: 2286-2302.
17. [zur Hausen H](https://www.ncbi.nlm.nih.gov/pubmed/?term=zur%20Hausen%20H%5BAuthor%5D&cauthor=true&cauthor_uid=10793105). Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. [J Natl Cancer Inst.](https://www.ncbi.nlm.nih.gov/pubmed/10793105) 2000 May 3;92: 690-698.
18. Lewandrowsky F, Lutz W. Ein fall einer bisher noch nicht beschriebenen Hauterkrankung (Epidermodysplasia verruciformis). Arch Dermatol Syph 1922; 141: 193-203 (okunmamıştır, tarihi önemi nedeni ile verilmiştir).
19. Shope RE, Hurst W. Infectious papillomatosis of rabbits. J Exp Med 1933; 58:607-624.
20. Rous P, Beard JW. The progression to carcinoma of virus-induced rabbit papillomas (Shope) J Exp Med. 1935;62:523–548.
21. Orth G, Jablonska S, Favre M, et al. Characterization of two types of human papillomaviruses in lesions of epidermodysplasia verruciformis Proc Natl Acad Sci 1978; 75: 1537-1541.
22. Gewirtzman A, Barlett B, Tyring S. Epidermodysplasia verruciformis and human papilloma virus. Curr Opin Infect Dis 2008; 21: 141-146.
23. Ramoz N, Rueda LA, Bouadjar B et al. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 2002; 32: 579-581.
24. Meyers JM, Munger K. The viral etiology of skin cancer. J Invest Dermatol 2014; 134:E29-E32.
25. Feng H, Shuda M, Chang Y et al. Clonal integration of a polymavirus in human Merkel cell carcinoma Science 2008; 319: 1096-1100.
26. [Liu W](https://www.ncbi.nlm.nih.gov/pubmed/?term=Liu%20W%5BAuthor%5D&cauthor=true&cauthor_uid=27521569), [MacDonald M](https://www.ncbi.nlm.nih.gov/pubmed/?term=MacDonald%20M%5BAuthor%5D&cauthor=true&cauthor_uid=27521569), You J2. Merkel cell polyomavirus infection and Merkel cell carcinoma. [Curr Opin Virol.](https://www.ncbi.nlm.nih.gov/pubmed/27521569) 2016; 20:20-27.
27. [Zeng Q](https://www.ncbi.nlm.nih.gov/pubmed/?term=Zeng%20Q%5BAuthor%5D&cauthor=true&cauthor_uid=22210138), [Gomez BP](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gomez%20BP%5BAuthor%5D&cauthor=true&cauthor_uid=22210138), [Viscidi RP](https://www.ncbi.nlm.nih.gov/pubmed/?term=Viscidi%20RP%5BAuthor%5D&cauthor=true&cauthor_uid=22210138), et al. Development of a DNA vaccine targeting Merkel cell polyomavirus. [Vaccine.](https://www.ncbi.nlm.nih.gov/pubmed/22210138) 2012; 30: 1322-1229.
28. Ganem D, KSHV infection and the pathogenesis of Kaposi’s sarcoma. Ann Rev Pathol. 2006; I: 273-296.
29. [Dow](https://www.ncbi.nlm.nih.gov/pubmed/?term=Dow%20DE%5BAuthor%5D&cauthor=true&cauthor_uid=24567845) DE, [Cunningham](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cunningham%20CK%5BAuthor%5D&cauthor=true&cauthor_uid=24567845) CK,[Buchanan](https://www.ncbi.nlm.nih.gov/pubmed/?term=Buchanan%20AM%5BAuthor%5D&cauthor=true&cauthor_uid=24567845) AM. A review of human herpesvirus 8, the Kaposi's sarcoma-associated herpesvirus, in the pediatric population. [J Pediatric Infect Dis Soc](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933043/). 2014; 3: 66–76.
30. Javier RT, Butel JS. The history of tumor virology. Cancer Res 2008; 68:7693-7706.
31. Lisitsyn N, Lisitsyn N, Wigler M. Cloning the difference between two complex genomes. Science. 1993; 259: 946-951.
32. Chang Y, Cesarman E, Pessin MS, et al. Indentification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 194; 266: 1865-1869.
33. [Jit M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Jit%20M%5BAuthor%5D&cauthor=true&cauthor_uid=29446090), [Brisson M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Brisson%20M%5BAuthor%5D&cauthor=true&cauthor_uid=29446090). Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14 year old girls against human papillomavirus. [Int J Cancer.](https://www.ncbi.nlm.nih.gov/pubmed/29446090) 2018 Feb 15. doi: 10.1002/ijc.31321. [Epub ahead of print]
34. Hariri S, Schuler MS, Naleway AL, Daley MF, et al. [Human papillomavirus vaccine effectiveness against incident genital warts among female health-plan enrollees, United States.](https://www.ncbi.nlm.nih.gov/pubmed/28641366) Am J Epidemiol. 2018; 187:298-305.
35. [Zeng Q](https://www.ncbi.nlm.nih.gov/pubmed/?term=Zeng%20Q%5BAuthor%5D&cauthor=true&cauthor_uid=22210138), [Gomez BP](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gomez%20BP%5BAuthor%5D&cauthor=true&cauthor_uid=22210138), [Viscidi RP](https://www.ncbi.nlm.nih.gov/pubmed/?term=Viscidi%20RP%5BAuthor%5D&cauthor=true&cauthor_uid=22210138), [Peng S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Peng%20S%5BAuthor%5D&cauthor=true&cauthor_uid=22210138), [He L](https://www.ncbi.nlm.nih.gov/pubmed/?term=He%20L%5BAuthor%5D&cauthor=true&cauthor_uid=22210138), [Ma B](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ma%20B%5BAuthor%5D&cauthor=true&cauthor_uid=22210138), [Wu TC](https://www.ncbi.nlm.nih.gov/pubmed/?term=Wu%20TC%5BAuthor%5D&cauthor=true&cauthor_uid=22210138), [Hung CF](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hung%20CF%5BAuthor%5D&cauthor=true&cauthor_uid=22210138). Development of a DNA vaccine targeting Merkel cell polyomavirus. [Vaccine.](https://www.ncbi.nlm.nih.gov/pubmed/22210138) 2012; 30:1322-1329.
36. Alemany R. Cancer selective adenoviruses. Mol Aspects Med 2007; 28: 42-58.
37. Khuri FR, Nemunaitis J, Ganly I et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885.
38. Lamont JP, Nemunaitis J, Kuhn JA, Landers SA, McCarty TM. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in reccurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol 2000; 7: 588-92.
39. Cross D, Burmester JK. Gene therapy for cancer treatment: past, present and future. Clin Med Res 2006: 4: 218-227.
40. Cockle J, Scott K. What is oncolytic virotherapy. Arch Dis Child Educ Pract Ed 2018; 103: 43-45.

***Kimyasal karsinogenezis***

1. Pott P, Cancer Scroti, In: Chirurgical observations relative to the cataract, the polypus of the nose, the cancer of the scrotum, the different kinds of ruptures, and the modification of the toes and feet. London: Hawes, Clarke, Collins; 1775. p. 63–8.
2. Yamagiwa K, Ichikawa K. Experimental study of the pathogenesis of carcinoma. J Cancer Res 1918;3:1–21.
3. Kennaway EL. Further experiments on cancer-producing substances. Biochem J 1930;24:497–504.
4. Berenblum I. The mechanism of carcinogenesis. A study of the significance of cocarcinogenic action and relatedphenomena. Cancer Res 1941;1:807.
5. *http://www.who.int/topics/chemical\_safety/en/*
6. <https://ntp.niehs.nih.gov/update/2016/11/rocrelease/index.html>
7. [*http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014*](http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014)
8. De Gruijl FR, Tensen CP. Pathogenesis of Skin Carcinomas and a Stem Cell as Focal Origin. *Frontiers in Medicine*. 2018; 5:165.
9. Monica Neagu1,2, Constantin Caru ntu3,4, Carolina Constantin 1, Daniel Boda4,Sabina Zur ac5, Demetrios A. Spandidos 6 and Aristidis M. Tsatsa kis7, Chemically induced skin carcinogenesis: Updates in experimental models.*ONCOLOGY REPORTS* 3 2016; 2516 (5): 2516-2528.
10. Hunt KM, Srivastava RK, Elmets CA, Athar M. The mechanistic basis of arsenicosis: Pathogenesis of skin cancer. *Cancer letters*. 2014; 354(2):211-219.
11. Paramita Mandal1, Molecular insight of arsenic-induced carcinogenesis and its prevention, *Naunyn-Schmiedeberg's Arch Pharmacol* 2017; 390: 443–55**.**
12. Siddens LK, Larkin A, Krueger SK, et al. Polycyclic aromatic hydrocarbons as skin carcinogens: Comparison of benzo[*a*]pyrene, dibenzo[*def,p*]chrysene and three environmental mixtures in the FVB/N mouse. *Toxicology and applied pharmacology*. 2012; 264: 377-86.
13. MM Pratt, K John, AB MacLean, S Afework, DH Philips, MC Poirier; Polycyclic aromatik hydrocarbon (PAH) exposure and DNA adduct semi-quantitation in archived human tissues, *Int J Environ Res Public Health*, 2011; 8: 2675-91.

***Ultraviyoleye bağlı karsinogenezis***

1. McKenzie RL, Aucamp PJ, Bais AF, et al. Ozone depletion and climate change: impacts on UV radiation. Photochem Photobiol Sci 2011;10:182–98.
2. Diffey BL. What is light? Photodermatol Photoimmunol Photomed 2002;18:68–74.
3. Sayre RM, Dowdy JC, Lott DL, et al. Commentary on ‘UVBSPF’: the SPF labels of sunscreen products convey more than just UVB protection. Photodermatol Photoimmunol Photomed 2008;24:218–20.
4. Armstrong BK, Kricker A. How much melanoma is caused by sun exposure? Melanoma Res 1993;3:395–401.
5. Mancebo SE, Wang SQ. Skin cancer: role of ultraviolet radiation in carcinogenesis. Rev Environ Health. 2014;29(3):265-73.
6. Kullavanijaya P, Lim HW. Photoprotection. J Am Acad Dermatol 2005;52:937–58.
7. Matsumura Y, Ananthaswamy HN. Toxic effects of ultraviolet radiation on the skin. Toxicology and applied Pharmacology 2004;195:298–308.
8. Jansen R, Wang SQ, Burnett M, et al. Photoprotection: part I. Photoprotection by naturally occurring, physical, and systemic agents. J Am Acad Dermatol 2013;69:853.
9. Hönigsmann H. Erythema and pigmentation. Photodermatol Photoimmunol Photomed 2002;18:75–81.
10. Young AR, Potten CS, Nikaido O, et al.Human melanocytes and keratinocytes exposed to UVB or UVA in vivo show comparable levels of thymine dimers. J Invest Dermatol 1998;111:936–40.
11. Clydesdale GJ, Dandie GW, Muller HK. Ultraviolet light induced injury: immunological and inflammatory effects. Immunol Cell Biol 2001;79:547–68.
12. Lim HW, Honigsmann H, Hawk J. Photodermatology. New York,NY, USA: CRC Press; 2013.
13. Matsumura Y, Ananthaswamy HN. Toxic effects of ultraviolet radiation on the skin. Toxicology and applied pharmacology 2004;195:298–308.
14. Haratake A, Uchida Y, Mimura K, et al. Intrinsically aged epidermis displays diminished UVB-induced alterations in barrier function associated with decreased proliferation. J Invest Dermatol 1997;108:319–23.
15. Roos WP, Kaina B. DNA damage induced cell death: From specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett 2013;332:237-48.
16. Cadet J, Douki T, Ravanat JL. Oxidatively generated damage to cellular DNA by UVB and UVA radiation. Photochem Photobiol 2015;91:140-55.
17. Cannistraro VJ, Pondugula S, Song Q, Taylor JS. Rapid deamination of cyclobutane pyrimidine dimer photoproducts at TCG sites in a translationally and rotationally positioned nucleosome in vivo. J Biol Chem 2015;290:26597-609.
18. Horikoshi N, Tachiwana H, Kagawa W, et al. Crystal structure of the nucleosome containing ultraviolet light induced cyclobutane pyrimidine dimer. Biochem Biophys Res Commun 2016;471:117-22.
19. Limoli CL, Giedzinski E, Bonner WM, et al. UV induced replication arrest in the xeroderma pigmentosum variant leads to DNA double strand breaks, gamma -H2AX formation, and Mre11 relocalization. Proc Natl Acad Sci U S A 2002;99:233-8.
20. Batista LF, Kaina B, Meneghini R, et al. How DNA lesions are turned into powerful killing structures: Insights from UV‑induced apoptosis. Mutat Res 2009;681:197-208.
21. Nováková E, Vyšín L, Burian T, et al. Breaking DNA strands by extreme-ultraviolet laser pulses in vacuum. Phys Rev E Stat Nonlin Soft Matter Phys 2015;91:042718.
22. Dunkern TR, Kaina B. Cell proliferation and DNA breaks are involved in ultraviolet light‑induced apoptosis in nucleotide excision repair‑deficient Chinese hamster cells. Mol Biol Cell 2002;13:348-61.
23. Melnikova VO, Ananthaswamy HN. Cellular and molecular events leading to the development of skin cancer. Mutat Res-Fund Mol M 2005;571:91–106.
24. Shen Y, White E. p53-dependent apoptosis pathways. Adv Cancer Res 2001;82:55–84.
25. Takeuchi T, Uitto J, Bernstein EF. A novel in vivo model for evaluating agents that protect against ultraviolet A‑induced photoaging. J Invest Dermatol 1998;110:343-7.
26. Draper DO, Sunderland S. Examination of the law of grotthus-draper: Does ultrasound penetrate subcutaneous fat in humans? J Athl Train 1993;28:246-50.
27. Zhang X, Rosenstein BS, Wang Y, et al. Identification of possible reactive oxygen species involved in ultraviolet radiation induced oxidative DNA damage. Free Radic Biol Med 1997;23:980-5.
28. Dong TK, Ona K, Scandurra AE, et al. Deficient nucleotide excision repair in squamous cell carcinoma cells. Photochem Photobiol 2016;92:760-6.
29. Park JM, Kang TH. Transcriptional and posttranslational regulation of nucleotide excision repair: The guardian of the genome against ultraviolet radiation. Int J Mol Sci 2016;17:e1840.
30. Gillet LC, Schärer OD. Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem Rev 2006;106:253-76.
31. Mareddy S, Reddy J, Babu S, Balan P. Xeroderma pigmentosum: Man deprived of his right to light. Scientific World Journal 2013;2013:534752.
32. Feehan RP, Shantz LM. Molecular signaling cascades involved in nonmelanoma skin carcinogenesis. Biochem J 2016;473:2973-94.
33. Muthusamy V, Piva TJ. The UV response of the skin: A review of the MAPK, NFkappaB and TNFalpha signal transduction pathways. Arch Dermatol Res 2010;302:5-17.
34. Klotz LO, Pellieux C, Briviba K, et al. Mitogen-activated protein kinase (p38, JNK, ERK) activation pattern induced by extracellular and intracellular singlet oxygen and UVA. Eur J Biochem 1999;260:917-22.
35. Peus D, Vasa RA, Beyerle A, et al. UVB activates ERK1/2 and p38 signaling pathways via reactive oxygen species in cultured keratinocytes. J Invest Dermatol 1999;112:751-6.
36. Ren X, Shi Y, Zhao D, et al. Naringin protects ultraviolet B induced skin damage by regulating p38 MAPK signal pathway. J Dermatol Sci 2016;82:106-14.
37. Cooper SJ, MacGowan J, Ranger-Moore J, et al. Expression of dominant negative c-jun inhibits ultraviolet B‑induced squamous cell carcinoma number and size in an SKH-1 hairless mouse model. Mol Cancer Res 2003;1:848-54.
38. Ahsan H, Aziz MH, Ahmad N. Ultraviolet B exposure activates Stat3 signaling via phosphorylation at tyrosine705 in skin of SKH1 hairless mouse: A target for the management of skin cancer? Biochem Biophys Res Commun 2005;333:241-6.
39. Bachelor MA, Bowden GT. UVA-mediated activation of signaling pathways involved in skin tumor promotion and progression. Semin Cancer Biol 2004;14:131-8.
40. Green AC, Williams GM, Logan V, et al. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011;29:257–63.
41. Guo L, Huang ZX, Chen XW, et al. Differential expression profiles of microRNAs in NIH3T3 cells in response to UVB irradiation. Photochem Photobiol 2009;85:765-73.
42. Agilan B, Rajendra Prasad N, Kanimozhi G, et al. Caffeic acid inhibits chronic UVB‑induced cellular proliferation through JAK-STAT3 signaling in mouse skin. Photochem Photobiol 2016;92:467-74.
43. Pothof J, Verkaik NS, van IJcken W, et al. MicroRNA‑mediated gene silencing modulates the UV‑induced DNA‑damage response. EMBO J 2009;28:2090-9.
44. Kraemer A, Chen IP, Henning S, et al. UVA and UVB irradiation differentially regulate microRNA expression in human primary keratinocytes. PLoS One 2013;8:e83392.
45. Dziunycz P, Iotzova-Weiss G, Eloranta JJ, et al. Squamous cell carcinoma of the skin shows a distinct microRNA profile modulated by UV radiation. J Invest Dermatol 2010;130:2686-9.
46. Zhou BR, Xu Y, Permatasari F, et al. Characterization of the miRNA profile in UVB‑irradiated normal human keratinocytes. Exp Dermatol 2012;21:317-9.
47. Singh A, Willems E, Singh A, et al. Ultraviolet radiation induced tumor necrosis factor alpha, which is linked to the development of cutaneous SCC, modulates differential epidermal microRNAs expression. Oncotarget 2016;7:17945-56.
48. Bode AM, Dong Z. Signal transduction pathways: Targets for chemoprevention of skin cancer. Lancet Oncol 2000;1:181-8.
49. Yang A, Currier D, Poitras JL, et al. Increased skin tumor incidence and keratinocyte hyper-proliferation in a mouse model of Down syndrome. PLoS One 2016;11:e0146570.
50. Rebel HG, Bodmann CA, van de Glind GC, et al. UV induced ablation of the epidermal basal layer including p53 mutant clones resets UV carcinogenesis showing squamous cell carcinomas to originate from interfollicular epidermis.Carcinogenesis 2012;33:714-20.
51. Ambothi K, Prasad NR, Balupillai A. Ferulic acid inhibits UVB‑radiation induced photocarcinogenesis through modulating inflammatory and apoptotic signaling in Swiss albino mice. Food Chem Toxicol 2015;82:72-8.
52. Radhiga T, Agilan B, Muzaffer U, et al. Phytochemicals as modulators of ultraviolet-B radiation induced cellular and molecular events: A review. J Radiat Cancer Res 2016;7:e2.
53. Daya-Grosjean L, Sarasin A. The role of UV induced lesions in skin carcinogenesis: An overview of oncogene and tumor suppressor gene modifications in xeroderma pigmentosum skin tumors. Mutat Res 2005;571:43-56.
54. Gunaseelan S, Balupillai A, Govindasamy K, et al. The preventive effect of linalool on acute and chronic UVB-mediated skin carcinogenesis in Swiss albino mice. Photochem Photobiol Sci 2016;15:851-60.
55. Mulliken JS, Russak JE, Rigel DS. The effect of sunscreen on melanoma risk. Dermatol Clin 2012;30:369–76.
56. Calzavara-Pinton P, Sala R, Arisi MC, et al. Photobiology, photodermatology and sunscreens: a comprehensive overview. Part 1: damage from acute and chronic solar exposure. G Ital Dermatol Venereol 2013;148:89–106.
57. Ramasam K, Shanmugam M, Balupilla A, et al. Ultraviolet radiation-induced carcinogenesis: Mechanisms and experimental models. Journal of Radiation and Cancer Research 2017; 8: 4-19.

***Nonmelanoma deri kanserlerinde epidemiyoloji***

1.Apalla Z, Nashan D, Weller RB, Castellsagué X. Skin Cancer: Epidemiology, Disease Burden, Pathophysiology, Diagnosis, and Therapeutic Approaches. Dermatol Ther (Heidelb). 2017; 7(Suppl 1): 5-19.

2.Rubió-Casadevall J, Hernandez-Pujol AM, Ferreira-Santos MC,ve ark.Trends in incidence and survival analysis in non-melanoma skin cancer from 1994 to 2012 in Girona, Spain: A population-based study. Cancer Epidemiol. 2016; 45: 6-10.

3.Katalinic A, Kunze U, Schäfer T. Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer) Br J Dermatol. 2003; 149: 1200–1206.

4.Wu S, Cho E, Li WQ, Qureshi AA. History of Keratinocyte Carcinoma and Risk of Melanoma: A Prospective Cohort Study. J Natl Cancer Inst. 2017 Apr 1;109(4).

5**.**Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012; 166: 1069-80.

6.Pandeya N, Olsen CM, Whiteman DC. The incidence and multiplicity rates of keratinocyte cancers in Australia. Med J Aust. 2017; 207: 339-343.

7.Pondicherry A, Martin R, Meredith I, Rolfe J, Emanuel P, Elwood M. The burden of non-melanoma skin cancers in Auckland, New Zealand. Australas J Dermatol. 2018 Jan 19. doi: 10.1111/ajd.12751.

8.Devine C, Srinivasan B, Sayan A, Ilankovan V. Epidemiology of basal cell carcinoma: a 10-year comparative study. Br J Oral Maxillofac Surg. 2017 Dec 15. pii: S0266-4356(17)30746-5. doi: 10.1016/j.bjoms.2017.11.018.

9.Verkouteren JAC, Ramdas KHR, Wakkee M, Nijsten T. Epidemiology of basal cell carcinoma: scholarly review.Br J Dermatol. 2017; 177: 359-372.

10.Michal Freedman D, Kitahara CM, Linet MS, ve ark. Ambient temperature and risk of first primary basal cell carcinoma: A nationwide United States cohort study. J Photochem Photobiol B. 2015; 148: 284-289.

11.Khalesi M, Whiteman DC, Rosendahl C,ve ark. NHMRC Centre of Research Excellence in Sun and Health. Basal cell carcinomas on sun-protected vs. sun-exposed body sites: a comparison of phenotypic and environmental risk factors. Photodermatol Photoimmunol Photomed. 2015; 31: 202-11.

12.Kricker A, Weber M, Sitas F,ve ark.Early Life UV and Risk of Basal and Squamous Cell Carcinoma in New South Wales, Australia. Photochem Photobiol. 2017; 93: 1483-1491.

13.Ray GT, Kulldorff M, Asgari MM. Geographic Clusters of Basal Cell Carcinoma in a Northern California Health Plan Population. JAMA Dermatol. 2016; 152: 1218-1224.

14.Goldenberg G, Karagiannis T, Palmer JB, ve ark. Incidence and prevalence of basal cell carcinoma (BCC) and locally advanced BCC (LABCC) in a large commercially insured population in the United States: A retrospective cohort study. J Am Acad Dermatol. 2016; 75: 957-966.

15.Lubeek SF, van Vugt LJ, Aben KK, van de Kerkhof PC, Gerritsen MP. The Epidemiology and Clinicopathological Features of Basal Cell Carcinoma in Patients 80 Years and Older: A Systematic Review. JAMA Dermatol. 2017; 153: 71-78.

16.Muzic JG, Schmitt AR, Wright AC,ve ark.Incidence and Trends of Basal Cell Carcinoma and Cutaneous Squamous Cell Carcinoma: A Population-Based Study in Olmsted County, Minnesota, 2000 to 2010. Mayo Clin Proc. 2017; 92: 890-898.

17.Abbas OL, Borman H. Basal cell carcinoma: a single-center experience. ISRN Dermatol. 2012; 2012: 246542.

18.Tiftikcioğlu YO, Karaaslan O, Aksoy HM, Aksoy B, Koçer U. Basal cell carcinoma in Turkey. J Dermatol. 2006; 33: 91-5.

19.Hakverdi S, Balci DD, Dogramaci CA, Toprak S, Yaldiz M. Retrospective analysis of basal cell carcinoma. Indian J Dermatol Venereol Leprol. 2011; 77: 251.

20.Ceylan C, Oztürk G, Alper S. Non-melanoma skin cancers between the years of 1990 and 1999 in Izmir, Turkey: demographic and clinicopathological characteristics. J Dermatol. 2003; 30: 123-31.

21.Bozkurt K, Bektaş Sert S, Doğru N. Şırnak İlinin Kanser İstatistikleri. Turk J Pathol 2011; 27: 230-234.

22.Kasap Ş, Pektaş ML, Dere Y, Altıparmak M. Muğla’daki Cilt Kanseri Olgularının Retrospektif Değerlendirilmesi. Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi 2015; 2: 34-37.

23.Aktürk A, Yıldız KD, Bilen N, Bayramgürler D, Kıran R, Onyedi M. Kocaeli Üniversitesi Tıp Fakültesine 1996-2003 Yılları Arasında Başvuran Deri Kanseri Olguları. Turkiye Klinikleri J Dermatol 2006; 16: 44-9.

24.Emiroğlu N, Cengiz FP. Kütahya Tavşanlı Yöresi Melanom Dışı Deri Kanserlerinin Retrospektif Analizi. Turkiye Klinikleri J Dermatol 2015; 25: 39-44

25.Yalçın B, Kalkan G, Pancar GŞ, Seçkin HY, Müslehiddinoğlu A. Tokat Devlet Hastanesine 2007-2011 Yılları Arasında Başvuran Deri Kanseri Olguları. Turkish Journal of Dermatology . 2014; 8: 84-87.

26.Asgari MM, Ray GT, Geier JL, Quesenberry CP. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population. J Am Acad Dermatol. 2017; 76: 632-638.

27.Armstrong LTD, Magnusson MR, Guppy MPB. Risk factors for recurrence of facial basal cell carcinoma after surgical excision: A follow-up analysis. J Plast Reconstr Aesthet Surg. 2017; 70: 1738-1745.

28.Miszczyk J, Charytonowicz M, Dębski T, Noszczyk B. Incomplete excision of basal cell carcinoma (BCC) in the head and neck region: to wait, or not to wait? Postepy Dermatol Alergol. 2017; 34: 607-611.

29.Burton KA, Ashack KA, Khachemoune A. Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease. Am J Clin Dermatol. 2016; 17: 491-508.

30.Curry JL, Torres-Cabala CA, Kim KB,ve ark. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol. 2014; 53: 376-84.

31.Danhof R, Lewis K, Brown M. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin. Am J Clin Dermatol. 2017 Sep 8. doi: 10.1007/s40257-017-0319-4.

32.Mohan SV, Chang J, Li S, Henry AS, Wood DJ, Chang AL. Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal CellCarcinoma. JAMA Dermatol. 2016; 152: 527-32.

33.Gjersvik P. Study on the Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma: Not a Case-Control Study. JAMA Dermatol. 2016; 152: 1172.

34.Puig S, Sampogna F, Tejera-Vaquerizo A. Study on the Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma: Not a Case-Control Study. JAMA Dermatol. 2016; 152: 1172-1173.

35.Bhutani T, Abrouk M, Sima CS, ve ark. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. J Am Acad Dermatol. 2017; 77: 713-718.

36.Madeleine MM, Patel NS, Plasmeijer EI,ve ark.The Keratinocyte Carcinoma Consortium (KeraCon) Immunosuppression Working Group. Epidemiology of keratinocyte carcinomas after organ transplantation. Br J Dermatol. 2017; 177: 1208-1216.

37.Gandini S, Stanganelli I, Palli D, De Giorgi V, Masala G, Caini S. Atopic dermatitis, naevi count and skin cancer risk: A meta-analysis. J Dermatol Sci. 2016; 84: 137-143.

38.Lindelöf B, Lapins J, Dal H. Shift in Occupational Risk for Basal Cell Carcinoma from Outdoor to Indoor Workers: A Large Population-based Case-control Register Study from Sweden. Acta Derm Venereol. 2017; 97: 830-833.

39.Rodrigues M. Skin Cancer Risk (Nonmelanoma Skin Cancers/Melanoma) in Vitiligo Patients. Dermatol Clin. 2017; 35: 129-134.

40.Husein-Elahmed H, Gutierrez-Salmeron MT, Aneiros-Cachaza J, Naranjo-Sintes R. Basal cell carcinoma arising in outdoor workers versus indoor workers: a retrospective study. Cutis. 2017; 99: 55-60.

41.Trakatelli M, Barkitzi K, Apap C, Majewski S, De Vries E; EPIDERM group. Skin cancer risk in outdoor workers: a European multicenter case-control study. J Eur Acad Dermatol Venereol. 2016; 30(Suppl 3): 5-11.

***Melanomda epidemiyoloji***

1. Ali Z., Yousaf N., Larkin J. Melanoma epidemiology, biology and prognosis. EJC Supplements. 2013: 81-91.
2. Melanom Çalışma Grubu. Türkiye Melanom Yol Haritası. 2012; 15-18.
3. Garbe C., Leiter U. Melanoma epidemiology and trends. Clinics in Dermatology. 2009; 27(1): 3-9.
4. Rastrelli M., Tropea S., Rossi C.R. Melanoma: Epidemiology, Risk Factors, Pathogenesis, Diagnosis and Classification. In Vivo 2014; 28: 1005-1012.
5. Özçelik S., Akyol M. Melanoma Epidemiyolojisi. Turkderm. 2007; 41 Özel Sayı 2: 1-5.

**Bazal hücreli karsinom**

**Skuamöz hücreli karsinom**

1. Sánchez G, Nova J, Rodriguez-Hernandez AE, Medina RD, Solorzano-Restrepo C, Gonzalez J, Olmos M, Godfrey K, Arevalo-Rodriguez I. Sun protection for preventing basal cell and squamous cell skin cancers. Cochrane Database Syst Rev. 2016 Jul 25;7:CD011161.
2. Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol. 2018 Feb;78(2):237-247.
3. Paolino G, Donati M, Didona D, Mercuri SR, Cantisani C. Histology of Non-Melanoma Skin Cancers: An Update. Biomedicines. 2017 Dec 20;5(4).
4. Apalla Z, Nashan D, Weller RB, Castellsagué X. Skin Cancer: Epidemiology, Disease Burden, Pathophysiology, Diagnosis, and Therapeutic Approaches. Dermatol Ther (Heidelb). 2017;7(Suppl 1):5-19.
5. Marks R. The epidemiology of non-melanoma skin cancer: who, why and what can we do about it. J Dermatol. 1995 Nov;22(11):853-7.
6. Pondicherry A, Martin R, Meredith I, Rolfe J, Emanuel P, Elwood M. The burden of non-melanoma skin cancers in Auckland, New Zealand. Australas J Dermatol. 2018 Jan 19.
7. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012 May;166(5):1069-80.
8. TC sağlık bakanlığı Türkiye Halk sağlığı Kurumu Türkiye kanser istatistikleri, 2017
9. Burton AK, Ashack KA, Khachemoune A. Cutaneous squamous cell carcinoma: A Review of High-Risk and metastatic disease. Am J Clin Dermatol. 2016 Oct;17(5):491-508.
10. Ceylan C, Öztürk G, Alper S. Non-melanoma skin cancers between the years of 1990 and 1999 in Izmir, Turkey: demographic and clinicopathological characteristics. J Dermatol. 2003 Feb;30(2):123-31.
11. Rosso S, Zanetti R, Martinez C, Tormo MJ, Schraub S, Sancho-Garnier H, Franceschi S, Gafà L, Perea E, Navarro C, Laurent R, Schrameck C, Talamini R, Tumino R, Wechsler J. The multicentre south European study 'Helios'. II: Different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer. 1996 Jun;73(11):1447-54.
12. Xiang F, Lucas R, Hales S, Neale R. Incidence of nonmelanoma skin cancer in relation to ambient UV radiation in white populations, 1978-2012: empirical relationships. JAMA Dermatol. 2014 Oct;150(10):1063-71.
13. Colegio OR, O’Toole ED, Ponten F, Lundeberg J, Asplund A. Princeples of Tumor Biology and Pathogenesis of BCCs and SCCs. Bolognia JL, Schaffer JV, Cerroni L editors. In: Dermatology, fourth edition. Elsevier, 2018, p1858-1870.
14. Fartasch M, Diepgen TL, Schmitt J, Drexler H. The relationship between occupational sun exposure and non-melanoma skin cancer: clinical basics, epidemiology, occupational disease evaluation, and prevention. Dtsch Arztebl Int. 2012 Oct;109(43):715-20.
15. Motaparthi K, Kapil JP, Velazquez EF. Cutaneous Squamous Cell Carcinoma: Review of the Eighth Edition of the American Joint Committee on Cancer Staging Guidelines, Prognostic Factors, and Histopathologic Variants. Adv Anat Pathol. 2017 Jul;24(4):171-194.
16. Didona D, Paolino G, Bottoni U, Cantisani C. Non Melanoma Skin Cancer Pathogenesis Overview. Biomedicines. 2018 Jan 2;6(1).
17. Green A.C., Olsen C.M. Cutaneous Squamous cell carcinoma: an epidemiological review), HIV/AIDS (Zhao H, Shu G, Wang S. The risk of non-melanoma skin cancer in HIV-infected patients: new data and meta-analysis. Int J STD AIDS. 2016 Jun;27(7):568-75.
18. Zhao H, Shu G, Wang S. The risk of non-melanoma skin cancer in HIV-infected patients: new data and meta-analysis. Int J STD AIDS. 2016 Jun;27(7):568-75.
19. Soyer PH, Rigel DS, McMeniman E. Actinic keratosis, Basal cell carcinoma and squamous cell carcinoma. Bolognia JL, Schaffer JV, Cerroni L editors. In: Dermatology fourth edition. Elsevier, 2018 p 1872-1893.
20. Mellerio JE, Robertson SJ, Bernardis C, Diem A, Fine JD, George R, Goldberg D, Halmos GB, Harries M, Jonkman MF, Lucky A, Martinez AE, Maubec E, Morris S, Murrell DF, Palisson F, Pillay EI, Robson A, Salas-Alanis JC, McGrath JA. Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines. Br J Dermatol. 2016 Jan;174(1):56-67.
21. Junqueira AL, Wanat KA, Farah RS. Squamous neoplasms arising within tattoos: clinical presentation, histopathology and management. Clin Exp Dermatol. 2017 Aug;42(6):601-606.
22. Harwood CA, Arron ST, Proby CM, Asgari MM, Bouwes Bavinck JN, Green AC, Toland AE; KeraCon Consortium. Organ transplantation and cutaneous squamous cell carcinoma: progress, pitfalls and priorities in immunosuppression-associated keratinocyte carcinoma. Br J Dermatol. 2017 Nov;177(5):1150-1151.
23. Madeleine MM, Patel NS, Plasmeijer EI, Engels EA, Bouwes Bavinck JN, Toland AE, Green AC; the Keratinocyte Carcinoma Consortium (KeraCon) Immunosuppression Working Group. Epidemiology of keratinocyte carcinomas after organ transplantation. Br J Dermatol. 2017 Nov;177(5):1208-1216.
24. Kallini JR, Hamed N, Khachemoune A. Squamous cell carcinoma of the skin: epidemiology, classification, management, and novel trends. Int J Dermatol. 2015 Feb;54(2):130-40.
25. Stern RS; PUVA Follow-Up Study. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol. 2012 Apr;66(4):553-62.
26. Bhutani T, Abrouk M, Sima CS, Sadetsky N, Hou J, Caro I, Chren MM, Arron ST. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. J Am Acad Dermatol. 2017 Oct;77(4):713-718.
27. Wu JH, Cohen DN, Rady PL, Tyring SK. BRAF inhibitor-associated cutaneous squamous cell carcinoma: new mechanistic insight, emerging evidence for viral involvement and perspectives on clinical management. Br J Dermatol. 2017 Oct;177(4):914-923.
28. Gandini S, Palli D, Spadola G, Bendinelli B, Cocorocchio E, Stanganelli I, Miligi L, Masala G, Caini S. Anti-hypertensive drugs and skin cancer risk: a review of the literature and meta-analysis. Crit Rev Oncol Hematol. 2018 Feb;122:1-9.
29. Ibiebele TI, van der Pols JC, Hughes MC, Marks GC, Williams GM, Green AC. Dietary pattern in association with squamous cell carcinoma of the skin: a prospective study. Am J Clin Nutr. 2007 May;85(5):1401-8.
30. Parekh V, Seykora JT. Cutaneous Squamous Cell Carcinoma. Clin Lab Med. 2017 Sep;37(3):503-525.
31. Al-Rohil RN, Tarasen AJ, Carlson JA, Wang K, Johnson A, Yelensky R, Lipson D, Elvin JA, Vergilio JA, Ali SM, Suh J, Miller VA, Stephens PJ, Ganesan P, Janku F, Karp DD, Subbiah V, Mihm MC, Ross JS. Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies. Cancer. 2016 Jan 15;122(2):249-57.
32. Li YY, Hanna GJ, Laga AC, Haddad RI, Lorch JH, Hammerman PS. Genomic analysis of metastatic cutaneous squamous cell carcinoma. Clin Cancer Res. 2015 Mar 15;21(6):1447-56.)
33. Yesantharao P, Wang W, Ioannidis NM, Demehri S, Whittemore AS, Asgari MM. Cutaneous squamous cell cancer (cSCC) risk and the human leukocyte antigen (HLA) system. Hum Immunol. 2017 Apr;78(4):327-335.
34. Yu X, Li Z. The role of miRNAs in cutaneous squamous cell carcinoma. J Cell Mol Med. 2016 Jan;20(1):3-9.
35. Fernandez Figueras MT. From actinic keratosis to squamous cell carcinoma: pathophysiology revisited. J Eur Acad Dermatol Venereol. 2017 Mar;31 Suppl 2:5-7.
36. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):23-4.
37. Kallini JR, Hamed N, Khachemoune A. Squamous cell carcinoma of the skin: epidemiology, classification, management, and novel trends. Int J Dermatol. 2015 Feb;54(2):130-40.
38. Gürer MA. Deri tümörleri ve nevuslar. Tüzün Y, Gürer MA, Serdaroğlu S. Oğuz O, Aksungur VL. Dermatoloji cilt 2. S:1759- 1962.
39. Stratigos A, Garbe C, Lebbe C, Malvehy J, del Marmol V, Pehamberger H, Peris K, Becker JC, Zalaudek I, Saiag P, Middleton MR, Bastholt L, Testori A, Grob JJ; European Dermatology Forum (EDF); European Association of Dermato-Oncology (EADO); European Organization for Research and Treatment of Cancer (EORTC). Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer. 2015 Sep;51(14):1989-2007.
40. Kwiek B, Schwartz RA. Keratoacanthoma (KA): An update and review. J Am Acad Dermatol. 2016 Jun;74(6):1220-33.
41. Savage JA, Maize JC Sr. Keratoacanthoma clinical behavior: a systematic review. Am J Dermatopathol. 2014 May;36(5):422-9.
42. Warszawik-Hendzel O, Olszewska M, Maj M, Rakowska A, Czuwara J, Rudnicka L.Non-invasive diagnostic techniques in the diagnosis of squamous cell carcinoma. J Dermatol Case Rep. 2015 Dec 31;9(4):89-97.
43. Fahradyan A, Howell AC, Wolfswinkel EM, Tsuha M, Sheth P, Wong AK. Updates on the Management of Non-Melanoma Skin Cancer (NMSC). Healthcare (Basel). 2017 Nov 1;5(4).
44. Work Group; Invited Reviewers, Kim JYS, Kozlow JH, Mittal B, Moyer J, Olenecki T, Rodgers P. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018 Mar;78(3):560-578.
45. Arca E. Keratinositik Tümörler. Dermoskopi Atlası. Editör Özdemir F. S:169-205.
46. Lallas A, Argenziano G, Zendri E, Moscarella E, Longo C, Grenzi L, Pellacani G, Zalaudek I. Update on non-melanoma skin cancer and the value of dermoscopy in its diagnosis and treatment monitoring. Expert Rev Anticancer Ther. 2013 May;13(5):541-58.
47. Zalaudek I, Argenziano G. Dermoscopy of actinic keratosis, intraepidermal carcinoma and squamous cell carcinoma. Curr Probl Dermatol. 2015;46:70-6.
48. National Comprehensive Cancer Center. NCCN clinical practice guidelines in oncology; squamous cell carcinoma (V1.2017). Available at: www.nccn.org. Accessed October 3, 2016.
49. Gandhi MR, Panizza B, Kennedy D. Detecting and defining the anatomic extent of large nerve perineural spread of malignancy: comparing "targeted" MRI with the histologic findings following surgery. Head Neck. 2011 Apr;33(4):469-75.
50. Schmitt AR, Brewer JD, Bordeaux JS, Baum CL. Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American Joint Committee on Cancer criteria and a proposed alternative system. JAMA Dermatol. 2014 Jan;150(1):19-24.
51. Tejera-Vaquerizo A, García-Doval I, Llombart B, Cañueto J, Martorell-Calatayud A, Descalzo-Gallego MA, Sanmartín O. Systematic review of the prevalence of nodal metastases and the prognostic utility of sentinel lymph node biopsy in cutaneous squamous cell carcinoma. J Dermatol. 2018 Apr 27.
52. Amin MB, Edge S, Greene Fet al,eds. AJCC Cancer Staging Manual (8th ed). New York: Springer International Publishing; 2017.
53. Dotto GP, Rustgi AK. Squamous cell cancers: A unified Perspective on biology and genetics.
54. Brinkman JN, Hajder E, van der Holt B, Den Bakker MA, Hovius SE, Mureau MA. The Effect of Differentiation Grade of Cutaneous Squamous Cell Carcinoma on Excision Margins, Local Recurrence, Metastasis, and Patient Survival: A Retrospective Follow-Up Study. Ann Plast Surg. 2015 Sep;75(3):323-6.
55. Carter JB, Johnson MM, Chua TL, Karia PS, Schmults CD. Outcomes of primary cutaneous squamous cell carcinoma with perineural invasion: an 11-year cohort study. JAMA Dermatol. 2013 Jan;149(1):35-41.
56. Eigentler TK, Leiter U, Häfner HM, Garbe C, Röcken M, Breuninger H. Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study. J Invest Dermatol. 2017 Nov;137(11):2309-2315.
57. Belkin D, Carucci JA. Mohs surgery for squamous cell carcinoma. Dermatol Clin. 2011 Apr;29(2):161-74, vii.
58. Ribero S, Stucci LS, Daniels GA, Borradori L. Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence? Curr Opin Oncol. 2017 Mar;29(2):129-135.
59. Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, Certain A, Duval X, Crickx B, Buffard V, Basset-Seguin N, Saez P, Duval-Modeste AB, Adamski H, Mansard S, Grange F, Dompmartin A, Faivre S, Mentré F, Avril MF. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011 Sep 1;29(25):3419-26.
60. Winkler JK, Schneiderbauer R, Bender C, Sedlaczek O, Fröhling S, Penzel R, Enk A, Hassel JC. Anti-programmed cell death-1 therapy in nonmelanoma skin cancer. Br J Dermatol. 2017 Feb;176(2):498-502.
61. Borradori L, Sutton B, Shayesteh P, Daniels GA. Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases. Br J Dermatol. 2016 Dec;175(6):1382-1386.
62. Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors. J Am Acad Dermatol. 2018 Feb;78(2):249-261.
63. Stratigos A, Garbe C, Lebbe C, Malvehy J, del Marmol V, Pehamberger H, Peris K, Becker JC, Zalaudek I, Saiag P, Middleton MR, Bastholt L, Testori A, Grob JJ; European Dermatology Forum (EDF); European Association of Dermato-Oncology (EADO); European Organization for Research and Treatment of Cancer (EORTC). Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer. 2015 Sep;51(14):1989-2007.

***Bowen hastalığı***

1.Morton CA, Birnie AJ, Eedy DJ. British Association of Dermatologists’ guidelines for the management of squamous cell carcinoma *in situ* (Bowen’s disease) 2014. Br J Dermatol 2014;170(2):245–260.

2.Ali H, Shipman AR, Orpin SD. John Templeton Bowen, MD, 1857-1940: the centenary of his most famous publication. Clin Exp Dermatol 2012;37(7):825–828.

3.Eedy DJ, Gavin AT. Thirteen-year retrospective study of Bowen’s disease in Northern Ireland. Br J Dermatol 1987;117(6):715–20.

4.Thestrup-Pedersen K, Ravnborg L, Reymann F. Morbus Bowen. A description of the disease in 617 patients. Acta Derm Venereol 1988;68(3):236–9.

5.Kossard S, Rosen R. Cutaneous Bowen’s disease. An analysis of 1001 cases according to age, sex, and site. J Am Acad Dermatol 1992;27(3):406–10.

6.Kovacs A, Yonemoto K, Katsuoka K, Nishiyama S, Harhai I. Bowen’s disease: statistical study of a 10-year period. J Dermatol 1996;23(4):267–74.

7.Arlette JP, Trotter MJ. Squamous cell carcinoma in situ of the skin: history, presentation, biology and treatment. Australas J Dermatol 2004;45(1):1–10.

8.Bath-Hextall FJ, Matin RN, Wilkinson D, Leonardi-Bee J. Interventions for cutaneous Bowen’s disease. [Cochrane Review] The Cohrane Library, Issue 6, 2013. Art. No.:CD007281. DOI: 10.1002/14651858.CD007281.pub2.

9.Yerebakan O, Ermis O, Yilmaz E, Basaran E. Treatment of arsenical keratosis and Bowen’s disease with acitretin. Int J Dermatol. 2002;41(2):84-7.

10.Haneke E. Important malignant and new nail tumors. J Dtsch Dematol Ges 2017;15(4):367-386.

11.Iftner A, Klug SJ, Garbe C, et al. The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. Cancer Research 2003;63(21):7515–9.

12.Shimizu A, Tamura A, Abe M, et al. Human papillomavirus type 56-associated Bowen disease. Br J Dermatol 201;167(5):1161–1164.

13.Cox NH. Body site distribution of Bowen’s disease. Br J Dermatol 1994;130(6):714–716.

14.Saito T, Uchi H, Moroi Y, Kiryu H, Furue M. Subungual Bowen disease revealed by longitudinal melanonychia. J Am Acad Dermatol 2012;67(5): e240–e241.

15.Zalaudek I, Leinweber B, Citarella L, et al. Dermoscopy of Bowen’s disease. Br J Dermatol 2004;150 (6):1112-6.

16.Bugatti L, Filosa G. Nonpigmented skin lesions. Bowen disease. In: Micali G, Lacarrubba F, editors. Dermoscopy in clinical practice. Beyond pigmented lesions. Boca Raton: CRC Press, 2016; p. 145-149.

17.Zalaudek I, Kreusch J, Giacomel J, Ferrara G, Catricalà C, Argenziano G. How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part II. Nonmelanocytic skin tumors. J Am Acad Dermatol. 2010;63(3):377-86.

18.Pan Y, Chamberlain AJ, Bailey M, Chong AH, Haskett M, Kelly JW. Dermatoscopy aids in the diagnosis of the solitary red scaly patch or plaque-features distinguishing superficial basal cell carcinoma, intraepidermal carcinoma, and psoriasis. J Am Acad Dermatol 2008;59(2):268-74.

19.Inoue T, Kobayashi K, Sawada M et al. Dermoscopic features of pigmented Bowen’s disease in a Japanese female mimicking malignant melanoma. Dermatol Res Pract 2010; doi: 10.1155/2010/543091.

20.Payapvipapong K, Tanaka M. Dermoscopic classification of Bowen’s disease. Australas J Dermatol. 2015;56(1):32-5.

21.Yang Y, Lin J, Fang S, Han S, Song Z. What’s new in dermoscopy of Bowen’s disease: two new dermoscopic signs and its differential diagnosis. Int J Dermatol 2017;56(10):1022-1025.

22. Paolino G, Donati M, Didona D, Mercuri SR, Cantisani C. Histology of Non-Melanoma Skin Cancers: An Update.Biomedicines. 2017; doi: 10.3390/biomedicines5040071.

23. Shaw KS, Nguyen GH, Lacouture M, Deng L. Combination of imiquimod with cryotherapy in the treatment of penile intraepithelial neoplasia. J Am Acad Dermatol Case Rep. 2017;3(6):546-549.

24.Morton C, Horn M, Leman J, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial. Arch Dermatol 2006;142(6):729–35.

25.Patel GK, Goodwin R, Chawla M, et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen’s disease): A randomised, double-blind placebo-controlled trial. J Am Acad Dermatol 2006;54(6):1025–32.

26.Soong LC,Keeling CP. Cryosurgery + 5% 5-fluorouracil for treatment of superficial basal cell carcinoma and Bowen’s disease. J Cutan Med Surg 2018; doi: 10.1177/1203475418758973.

**Aktinik keratoz**

1. Siegel JA, Korgavkar K, Weinstock MA. Current perspective on actinic keratosis: a review. Br J Dermatol 2017;177:350-358.

2. Duncan KO, Geisse JK, Leffel DJ. Epidermal and Appendageal Tumors. In: Wolf K, Goldsmith LA, Katz SI, et al., eds. Dermatology in General Medicine. New York McGraw Hill Medical; 2012:1261-1283.

3. Werner RN, Stockfleth E, Connolly SM, et al. Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum - Short version. J Eur Acad Dermatol Venereol 2015;29:2069-2079.

4. Costa C, Scalvenzi M, Ayala F, Fabbrocini G, Monfrecola G. How to treat actinic keratosis? An update. Journal of Dermatological Case Reports 2015;9:29-35.

5. Foley P, Stockfleth E, Peris K, et al. Adherence to topical therapies in actinic keratosis: A literature review. J Dermatolog Treat 2016;27:538-545.

6. Tüzün Y, Erdogan BÇ. Aktinik keratoz. In: Tüzün Y, Serdaroglu S, Erdem C, Özpoyraz M, Önder M, Öztürkcan S, eds. Dermatolojide Tedavi. İstanbul: Nobel Tıp kitabevleri; 2010:35-38.

7. Rossi R, Mori M, Lotti T. Actinic keratosis. Int J Dermatol 2007;46:895-904.

8. Timares L, Katiyar SK, Elmets CA. DNA damage, apoptosis and langerhans cells--Activators of UV-induced immune tolerance. Photochem Photobiol 2008;84:422-436.

9. Frazer IH. The actinic keratosis virome: can we prevent squamous cell carcinoma with a vaccine? Curr Probl Dermatol 2015;46:28-35.

10. Schmitt JV, Miot HA. Actinic keratosis: a clinical and epidemiological revision. An Bras Dermatol 2012;87:425-434.

11. Gürer MA. Deri tümörleri ve nevüsler. In: Tüzün Y, Gürer MA, Serdaroğlu S, Oğuz O, Aksungur VL, eds. Dermatolojide Tedavi. İstanbul: Nobel Tıp Kitabevleri; 2008:1759-1962.

12. Arenberger P, Arenbergerova M. New and current preventive treatment options in actinic keratosis. J Eur Acad Dermatol Venereol 2017;31 Suppl 5:13-17.

13. de Berker D, McGregor JM, Mohd Mustapa MF, Exton LS, Hughes BR. British Association of Dermatologists' guidelines for the care of patients with actinic keratosis 2017. Br J Dermatol 2017;176:20-43.

14. Huerta-Brogeras M, Olmos O, Borbujo J, et al. Validation of dermoscopy as a real-time noninvasive diagnostic imaging technique for actinic keratosis. Arch Dermatol 2012;148:1159-1164.

15. Fernandez Figueras MT. From actinic keratosis to squamous cell carcinoma: pathophysiology revisited. J Eur Acad Dermatol Venereol 2017;31 Suppl 2:5-7.

16. Incel P, Gurel MS, Erdemir AV. Vascular patterns of nonpigmented tumoral skin lesions: confocal perspectives. Skin Res Technol 2015;21:333-339.

17. Janda M. Teledermatology: its use in the detection and management of actinic keratosis. Curr Probl Dermatol 2015;46:101-107.

18. Ceilley RI, Jorizzo JL. Current issues in the management of actinic keratosis. J Am Acad Dermatol 2013;68:S28-38.

19. de Berker D, McGregor JM, Hughes BR. Guidelines for the management of actinic keratoses. Br J Dermatol 2007;156:222-230.

20. Chetty P, Choi F, Mitchell T. Primary care review of actinic keratosis and its therapeutic options: a global perspective. Dermatol Ther (Heidelb) 2015;5:19-35.

21. Weiss J, Ulrich M, Bukhalo M, Osterdal ML, Bang B, Hanke CW. A seamless phase I/II dose-finding trial assessing ingenol disoxate (LEO 43204) for field treatment of actinic keratosis on the scalp. Br J Dermatol 2017;176:1456-1464.

22. Wolf JE, Jr., Rigel DS. Understanding efficacy end-points in studies of field-directed therapy for actinic keratosis. Int J Dermatol 2013;52:1063-1070.

23. Bourcier M, Stein Gold L, Guenther L, Andreassen CM, Selmer J, Goldenberg G. A dose-finding trial with a novel ingenol derivative (ingenol disoxate: LEO 43204) for field treatment of actinic keratosis on full face or 250 cm2 on the chest. J Dermatolog Treat 2017:1-7.

24. Rubel DM, Spelman L, Murrell DF, et al. Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial. Br J Dermatol 2014;171:1164-1171.

25. Lacour JP, Ulrich C, Gilaberte Y, et al. Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator-blinded, controlled, phase III study throughout Europe. J Eur Acad Dermatol Venereol 2015;29:2342-2348.

26. Khanna R, Bakshi A, Amir Y, Goldenberg G. Patient satisfaction and reported outcomes on the management of actinic keratosis. Clin Cosmet Investig Dermatol 2017;10:179-184.

27. Chen AC, Martin AJ, Choy B, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med 2015;373:1618-1626.

28. Uhlenhake EE. Optimal treatment of actinic keratoses. Clin Interv Aging 2013;8:29-35.

29. Piamphongsant T. Chronic environmental arsenic poisoning. Int J Dermatol 1999;38:401-410.

30. Pratt M, Wadden P, Gulliver W. Arsenic keratosis in a patient from Newfoundland and Labrador, Canada: Case report and review. J Cutan Med Surg 2016;20:67-71.

31. Wong SS, Tan KC, Goh CL. Cutaneous manifestations of chronic arsenicism: review of seventeen cases. J Am Acad Dermatol 1998;38:179-185.

32. Sengupta SR, Das NK, Datta PK. Pathogenesis, clinical features and pathology of chronic arsenicosis. Indian J Dermatol Venereol Leprol 2008;74:559-570.

33. DiGiovanna JJ. Retinoid chemoprevention in the high-risk patient. J Am Acad Dermatol 1998;39:S82-85.

34. Yerebakan O, Ermis O, Yilmaz E, Basaran E. Treatment of arsenical keratosis and Bowen's disease with acitretin. Int J Dermatol 2002;41:84-87.

35. Khandpur S, Sharma VK. Successful treatment of multiple premalignant and malignant lesions in arsenical keratosis with a combination of acitretin and intralesional 5-fluorouracil. J Dermatol 2003;30:730-734.

36. Turner RJ, Sviland L, Charlton F, Farr PM. PUVA-related punctate keratoses of the hands and feet. J Am Acad Dermatol 2000;42:476-479.

37. van Praag MC, Bavinck JN, Bergman W, et al. PUVA keratosis. A clinical and histopathologic entity associated with an increased risk of nonmelanoma skin cancer. J Am Acad Dermatol 1993;28:412-417.

38. Sezer E, Durmaz EÖ. Bazal hücreli karsinom ve skuamöz hücreli karsinom dışındaki keratinositik tümörler. Türkiye Klinikleri J Dermatol 2013;6:19-23.

**Akantomalar**

1. Kazlouskaya V, Lambe J, Elston D. Solitary epidermolytic acanthoma. J Cutan Pathol 2013;40:701-707.

2. Banky JP, Turner RJ, Hollowood K. Multiple scrotal epidermolytic acanthomas; secondary to trauma? Clin Exp Dermatol 2004;29:489-491.

3. Hirone T, Fukushiro R. Disseminated epidermolytic acanthoma. Nonsystematized multiple verrucoid lesions showing granular degeneration. Acta Derm Venereol 1973;53:393-402.

4. Ackerman AB, Goldman G. Combined epidermolytic hyperkeratosis and focal acantholytic dyskeratosis. Arch Dermatol 1974;109:385-386.

5. Knipper JE, Hud JA, Cockerell CJ. Disseminated epidermolytic acanthoma. Am J Dermatopathol 1993;15:70-72.

6. Kerr PE, Murphy MJ. Warty (follicular) dyskeratoma on the mons pubis. Int J Womens Dermatol 2017;3:154-156.

7. Tanay A, Mehregan AH. Warty dyskeratoma. Dermatologica 1969;138:155-164.

8. Kaugars GE, Lieb RJ, Abbey LM. Focal oral warty dyskeratoma. Int J Dermatol 1984;23:123-130.

9. Kaddu S, Dong H, Mayer G, Kerl H, Cerroni L. Warty dyskeratoma--"follicular dyskeratoma": analysis of clinicopathologic features of a distinctive follicular adnexal neoplasm. J Am Acad Dermatol 2002;47:423-428.

10. Allon I, Buchner A. Warty dyskeratoma/focal acantholytic dyskeratosis--an update on a rare oral lesion. J Oral Pathol Med 2012;41:261-267.

11. Requena l, Requena C, Cockerell CJ. Dermatology. In: Bolognia JL, Jorizzo JL, Shaffer JV, eds. Dermatology. New York: Elsevier; 2012:1795-1815.

12. Megahed M, Scharffetter-Kochanek K. Acantholytic acanthoma. Am J Dermatopathol 1993;15:283-285.

13. Grichnik JM, Rhodes AR, Sober AJ, Bahadoran P, Fitzptrick TB. Benign neoplasias and hyperplasias of melanocytes. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, eds. Fitzpatrick's dermatology in general medicine. New York: McGraw Hill; 2012:1377-1444.

14. Praetorius C, Sturm RA, Steingrimsson E. Sun-induced freckling: ephelides and solar lentigines. Pigment Cell Melanoma Res 2014;27:339-350.

15. Byrom L, Barksdale S, Weedon D, Muir J. Unstable solar lentigo: A defined separate entity. Australas J Dermatol 2016;57:229-234.

16. Thomas VD, Snavely NR, Lee KK, Swanson NA. Benign epithelial tumors,hamartomas and hyperplasias. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, eds. Fitzpatrick's dermatology in general medicine. Nee York: Mc Graw Hill; 2012:1319-1336.

17. Kim KW, Chang J, Lee S, et al. Clinical analysis of seborrheic keratoses in the ear: a retrospective study and literature review. Eur Arch Otorhinolaryngol 2015;272:1113-1117.

18. Odom RB, James WD, Berger TG. Epidermal nevi, neoplasms and cysts. Andrew's disease of the skin. Philadelphia: Elsevier; 2006:634-683.

19. Sezer E, Durmaz EÖ. Bazal Hücreli Karsinom ve Skuamöz Hücreli Karsinom Dışındaki Keratinositik Tümörler. Turkiye Klinikleri Journal of Dermatology Special Topics 2013;6:19-23.

20. Minagawa A. Dermoscopy-pathology relationship in seborrheic keratosis. J Dermatol 2017;44:518-524.

21. Hafner C, Vogt T. Seborrheic keratosis. J Dtsch Dermatol Ges 2008;6:664-677.

22. Asagami C, Muto M, Hirota T, Shimizu T, Hamamoto Y. Anti-tumor effects of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in seborrheic keratosis. J Investig Dermatol Symp Proc 1996;1:94-96.

23. Chung E, Marghoob AA, Carrera C, Marchetti MA. Clinical and Dermoscopic Features of Cutaneous Melanoacanthoma. JAMA Dermatol 2015;151:1129-1130.

24. Shankar V, Nandi J, Ghosh K, Ghosh S. Giant melanoacanthoma mimicking malignant melanoma. Indian J Dermatol 2011;56:79-81.

25. Cantudo-Sanagustin E, Gutierrez-Corrales A, Vigo-Martinez M, Serrera-Figallo MA, Torres-Lagares D, Gutierrez-Perez JL. Pathogenesis and clinicohistopathological caractheristics of melanoacanthoma: A systematic review. J Clin Exp Dent 2016;8:e327-336.

26. Andrews BT, Trask DK. Oral melanoacanthoma: a case report, a review of the literature, and a new treatment option. Ann Otol Rhinol Laryngol 2005;114:677-680.

27. Betti R, Bruscagin C, Inselvini E, Palvarini M, Crosti C. Successful cryotherapic treatment and overview of multiple clear cell acanthomas. Dermatol Surg 1995;21:342-344.

28. Özdamar S, Gököz A, Yalçın B, Şahin S, Bükülmez G. Clear cell acanthoma. Ankara Patoloji Bülteni 2000;17:179-191.

29. Innocenzi D, Barduagni F, Cerio R, Wolter M. Disseminated eruptive clear cell acanthoma--a case report with review of the literature. Clin Exp Dermatol 1994;19:249-253.

30. Tempark T, Shwayder T. Clear cell acanthoma. Clin Exp Dermatol 2012;37:831-837.

31. Mehregan DR, Hamzavi F, Brown K. Large cell acanthoma. Int J Dermatol 2003;42:36-39.

32. Shahriari N, Grant-Kels JM, Rabinovitz HS, Oliviero M, Scope A. In vivo reflectance confocal microscopy features of a large cell acanthoma: report of a case. Dermatol Pract Concept 2016;6:67-70.

33. Sanchez Yus E, del Rio E, Requena L. Large-cell acanthoma is a distinctive condition. Am J Dermatopathol 1992;14:140-147; discussion 148.

34. Schwartz RA. Keratoacanthoma. J Am Acad Dermatol 1994;30:1-19; quiz 20-12.

35. Savage JA, Maize JC, Sr. Keratoacanthoma clinical behavior: a systematic review. Am J Dermatopathol 2014;36:422-429.

36. Kulkarni RP, Plaisier S, Ra SH, et al. Genetic profiling of BRAF inhibitor-induced keratoacanthomas reveals no induction of MAP kinase pathway expression. J Invest Dermatol 2013;133:830-833.

37. Kwiek B, Schwartz RA. Keratoacanthoma (KA): An update and review. J Am Acad Dermatol 2016;74:1220-1233.

38. Goette DK. Benign lichenoid keratosis. Arch Dermatol 1980;116:780-782.

39. Pitney L, Weedon D, Pitney M. Multiple lichen planus-like keratoses: Lichenoid drug eruption simulant and under-recognised cause of pruritic eruptions in the elderly. Australas J Dermatol 2016;57:54-56.

40. Watanabe S, Sawada M, Dekio I, Ishizaki S, Fujibayashi M, Tanaka M. Chronology of lichen planus-like keratosis features by dermoscopy: a summary of 17 cases. Dermatol Pract Concept 2016;6:29-35.

***Malign melanomada epidemiyoloji, patogenez, klinik ve tanı***

1. Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer. Adv Exp Med Biol 2014;810:120-140.

2. Rastrelli M, Tropea S, Rossi CR, Alabiac M. Melanoma:epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo 2014;28:1005-1012).

3. Markovic SN, Erickson LA, Rao RD, el al and Melanoma Study Group of the Mayo Clinic Cancer Center. Malignant melanoma in the 21st century, part 1:epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc 2007;3:364-380.

4. Siegel RL, Miller KD, Jemal A. 2016 Cancer statistics. Cancer J Clin 2016;66:7-30.

5. MacKie RM, Hauschild A, Eggermont AM. Epidemiology of invasive cutaneous melanoma. Ann Oncol 2009;20:1-7.

6. Lasithiotakis K, Leiter U, Krüger-McKie RM, Hauschild A, et al. Epidemiology of invasive cutaneous melanoma. Ann Oncol 2010;20(Suppl 6):vi1-7.

7. Lasithiotakis K,Riegel DS. Epidemiology of melanoma. Semin Cutan Med Surg 2010;4:204-209.

8. Krasagakis S, Tosca A, Garbe C. Comparative analysis of incidence and clinical features of cutaneous melanoma in Crete (Greece) and southern Germany (central Baden-Württemberg). Br J Dermatol 2006;6:1123-1127.

9. Riegel DS. Epidemiology of melanoma. Semin Cutan Med Surg 2010;4:204-209.

10. Sera F, Gandini S, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma. II. Sun exposure. Eur J Cancer 2015;41:45-60.

11. İnternational Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer: The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic review. Int J Cancer 2007;120:1116-1122.

12. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001;44:755-761.

13. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997;73:198-203.

14. Elwood JM, Gallagher RP, Worth AJ, et al. Etiological differences between subtypes of cutaneous malignant melanoma:Western Canada Melanoma Study. J Natl Cancer Inst 1987;78:37-44.

15. Bevona C, Goggins W, Quinn T, et al. Cutaneous melanomas associated with nevi. Arch Dermatol 2003;139:1620-1624.

16. Holly EA, Kelly JW, Shpall SN, et al. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol 1987;17:459-468.

17. Grob JJ, Guvernet J, Aymar D, et al. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. Cancer 1990;66:387-395.

18. Halpern AC, Guerry D 4th, Elder DE, et al.Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case-control study. Arch Dermatol 1991;127:995-999.).

19. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risc factors for cutaneous melanoma:I Common and atypical nevi. Eur J Cancer 2005;41:28-44.).

20. Carrera C, Marghoob AA. Discriminating nevi from melanomas: Clues and pitfalls. Dermatol Clin 2016;34:395-409.

21. Watt AJ, Kotsis SV, Chung KC. Risk of melanoma arising in large congenital melanocytic nevi: a systematic review. Plast Recontr Surg 2004;113:1968-1974.

22. Tannous ZS, Mihm MC Jr., Sober AJ, et al. Congenital melanocytic nevi: clinical and histopathologica features, risk of melanoma, and clinical management. J Am Acad Dermatol 2005;52:197-203.

23. Watt AJ, Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi: a central risk factor for cutaneous melanoma. JAMA 1997;277:1439-1444.

24. Purdue MP, From L, Armstrong BK. Genes, environment, and Melanoma Study Group. Etiologic and other factors predicting nevus associated cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 2005;14:2015-2022

25. Daltro LR, Yaegashi LB, Freitas RA, et al. Atypical cellular blue nevus or malignant blue nevus ?. An Bras Dermatol 2017;92(1):110-112.

26. Lallas A, Apalla Z, Ioannides D, et al. Update on dermoscopy of Spitz/Reed naevi and management guidelines by the International Dermoscopy Society. Br J Dermatol 2017;1-11 doi:10.1111/bjd.15339. [Epub ahead of print])

27. Tsao H, Niendorf K. Genetic testing in hereditary melanoma. J Am Acad Dermatol 2004;51:803-808.

28. Stam-Posthuma JJ, van Duinen C, Scheffer E, et al. Multiple primary melanomas. J Am Acad Dermatol 2001;44:22-27.8

29. Veierod MB, Weiderpass E, Thörn M, et al. A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women. J Natl Cancer Inst 2003;95:1530-1538.

30. Markovic SN, Titus-Ernstoff L, Perry AE, Spencer SK, et al. Pigmentary characteristics and moles in relation to melanoma risk. Int J Cancer 2005;116:144-149.

31. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.

32. Swaika A, Crozier JA, Joseph RW. Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Des Dev Ther 2014;8:775-787.

33. Russo AE, Torrisi E, Bevelacqua Y, et al. Melanoma: molecular pathogenesis and emerging target therapies (Review). Int J Oncol 2009;34:1481-1489.

34. Liu Y, Sheikh MS. Melanoma: molecular pathogenesis and therapeutic management. Mol Cell Pharmacol 2014;6(3):228-251.

35. Clark WH, From L, Bernardino EA, et al. The histogenesis and biologic behaviour of primary human malignant melanomas of the skin. Cancer Res 1969;29:705-726.

36. Reed RJ, Ichinose H, Clark WH Jr. Common and uncommon melanocytic nevi and borderline melanomas. Semin Oncol1975;2:119-147.

37. Kühnl-Petzoldt C. Superficial spreading melanoma:histological findings and problems of differentiation. Arch Derm Forsch 1974;250:309-321.

38. Steiner A, Konrad K, Pehamberger H. Verrucous malignant melanoma. Arch Dermatol 1988;124:1534-1537.

39. Duncan LM,: The classification of cutaneous melanoma. Hematol Oncol Clin N Am 2009;23:501-513.

40. Mishima Y, Matsunaka M. Pagetoid premalignant melanosis and melanoma: differentiation from Hutchinson's melanotic freckle. J Invest Dermatol 1975;95:434-440.

41. Seiji M, TakahashiM. Acral melanoma in Japan. Hum Pathol 1982;13:607-609.

42. O'Leary J, Berend KR, JohnsonJL, et al. Subungual melanoma. Clin Ortoph 2000;378:206- 212.

43. HarringtonP, O'Kelly A, Trail IA, et al. Amelanotic subungual melanoma mimicking pyogenic granuloma in the hand. J R Coll Surg Edinb 2002;47;638-640.

44. Emanuel PO, Idrees MT, Leytin A, et al. Aggressive osteogenic desmoplastic melanoma: a case report. J Cutan Pathol 2007;34:423-426.

45. Maher J, CameronA, Wallace S, et al. Balloon cell melanoma: a case report with polarized and non-polarized dermatoscopy and dermatopathology. Dermatol Pract Concept 2014;4:69-73.

46. Uzuncakmak TK, Zindanci I, Zemheri EI, et al. Primary myxoid melanoma with dermoscopic findings. Derm Pract Concept 2017;7:59-61.

47. Chung BY, Ahn IS, Cho SI, et al. Primary malignant rhabdoid melanoma. Ann Dermatol 2011;23 (suppl 2):S155-S159.

48. Bali A, Roy M, Chikkannaiah P, Dhorigol V. Cutaneous clear cell sarcoma: A rare aggressive tumor with potential diagnostic challenge. J Lab Physicians 2012;4:53-55.

49. Feller L, Khammissa RAG, Lmmer J. A review of the aetiopathogenesis and clinival and histopathological features of oral mucosal melanoma. Sci World 2017;9189812 doi:101155 [Epub] 2017May 30.

50. Tseng D, Kim J, Warrick A, et al. Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract. J Am Acad Dermatol 2014;7:229-236.)

51. Anbari KK, Schushter LM, Bucky LP, et al. Melanoma of unknown primary site. Cancer 1997;79:1816-1821.

52. Blackwood MA, Holmes R, Synnestvedt M, et al. Multipl primary melanoma revisited. Cancer 2002:94:2248-2255.

53. Monzon J, Liu L, Brill H, et al. CDKN2A mutations in multipl primary melanomas. New Eng J Med 1998;338:879-887.

54. Lalor L, Busam K, Shah K. Prepubertal melanoma arising within a medium-sized congenital melanocytic nevus. Ped Dermatol 2016;33(6):372-374.

55. Daltro LR, Yaegashi LB, Freitas RA, et al. Atypical cellular blue nevus or malignant blue nevus ?. An Bras Dermatol 2017;92:110-112.

56. Bevona C, Sober AJ. Melanoma incidence trends. Dermatol Clin2002;20:589-595.

57. Thomas L, Tranchand P, Berard F, et al. Semiological value of ABCDE criteria in the diagnosis of cutaneous pigmented tumors. Dermatology 1998;197:11-17.

58. Branstrom R, Hedblad MA, Krakau I, et al. Layperson's perceptual discrimination of pigmented skin lesions. J Am Acad Dermatol 2002;46:667-673.

59. Scope A, Dusza SW, Halpern AC, et al. The "ugly duckling"sign: agreement between observers. Arch Dermatol 2008;144:58-64.

60. Neila J, Soyer HP. Key points in dermoscopy for diagnosis of melanomas, including difficult to diagnose melanomas, on the trunk and extremities. J Dermatol 2011;38:3-9.

61. Wolner ZJ, Yélamos O, Liopyris K, et al. Enhancing skin cancer diagnosis with dermoscopy. Dermatol Clin 2017;35:417-437.

62. Hofmann-Wellenhoff R, Wurm EM, Ahlgrimm-Siess V, et al. Reflectance confocal microscopy-state-of-art and research overview. Semin Cutan Med Surg 2009;28:172-179.

63. Elder DE. Pathology of melanoma. Surg Oncol Clin N Am 2015;24:229-237.

64. LeBoit PE, Burg G, Weedon D, et al. Melanocytic tumors. In: Leboit PE, Burg G, Weedon D, et al, editors. Pathology and genetics of skin tumors. Lyon (France):IARC Press; 2006. p 49-120.

65. Viros A, Fridlyand J, Bauer J, et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 2008;5:e120.

66. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970;172:902-908.

67. Gimotty PA, Elder DE, Fraker DL, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 2007;25:1129-1134.

68. Chen LL, Jaimes N, Barker CA, et al. Desmoplastic melanoma: a review. J Am Acad Dermatol 2013;68(5):825-833.

69. Elder, Mandala M, Massi D. Tissue prognostic biomarkers in primary cutaneous melanoma. Virchows Arch 2014;464:265-281) .

70. Huang SK, Hoon DSB. Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients. Mol Oncol 2016;10:450-463.

71. Lade-Keller J, Riber-hansen R, Guldberg P, et al. Immunuhistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker. J Clin Pathol 2014;67:520-528.

72. North JP, Vemula SS, Bastian BC. Chromosomal copy number analysis in melanoma diagnostics. Methods Mol Biol 2014;1102:199-226.

73. Serrati S, De Summa S, Pialto B, et al. Next-generation sequencing: advances and applications in cancer diagnosis. OncoTargets Ther 2016;9:7355-7365.

74. Moroi Y. Significance of sentinel lymph node biopsy in malignant melanoma: overview of international data. Int J Clin Oncol 2009;14:485-489.

75. Balch CM, Gershenwald JE, Soong S, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-6206.

**Melanomada tedavi ve izlem**

1. Russo AE, Torrisi E, Bevelacqua Y, et al. Melanoma: molecular pathogenesis and emerging targeted therapies (review). Int J Oncol 2009;34:1481-1489.

2. Leilabadi SN, Chen A, Tsai S, et al. Update and review on the surgical management of primary cutaneous melanoma. Healthcare 2014;2:234-249.

3. Coit DG, Andtbacka RA, Anker CJ, et al. Melanoma: Clinical Practice Guidelines in Oncology. J Natl Comp Canc Netw 2012;10:366-400.

4. Balch CM, Gershenwald JE, Soong S, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-6206.

5. Deutsch GB, Kirchoff DD. Metastasectomy for stage IV melanoma. Surg Oncol Clin N Am 2015;24:279-298.

6. Speicher PJ, Meriwether CH, Tyler DS. Regional therapies for in-transit disease. Surg Oncol Clin N Am 2015;24:309-322.

7. Shi W. Role for radiation therapy in melanoma. Surg Oncol Clin N Am 2015;24:323-335.

8. Banzi M, De Blasio S, Lallas A, et al. Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma. Oncotarg Ther 2016;9:2725-2733.

9. Moschos SJ, Pinnamaneni R. Targeted therapies in melanoma. Surg Oncol Clin N Am 2015; 24:347-358.

10. Swaika A, Crozier JA, Joseph RW. Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Des Dev Ther 2014;8:775-787.

11. Grilley-Olson JE, Bedard PL, Fasolo A, et al. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors. Invest N Drugs 2016;34:740-749.

12. Grimaldi AM, Simeone E, Festino L, et al. MEK inhibitors in the treatment of melanoma and solid tumors. Am J Clin Dermatol 2017; published online.DOI 10.1007/s40257-017-0292-y.

13. Liu Y, Sheikh MS. Melanoma: molecular pathogenesis and therapeutic management. Mol Cell Pharmacol 2015;6:228-245.

14. Saranga-Perry V, Ambe C, Zager JS, et al. Recent developments in the medical and surgical treatment of melanoma. CA Cancer J Clin 2014;64:171-185.

15. Izar B, Sharfman W, Hodi FS, et al. A first-in-human phase I, multicenter, open-label, dose escalation study of the oral RAF/VEGF-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. Cancer Med 2017;6:1904-1914.

16. Fountzilas C, Patel S, Mahalingam D. Review: Oncolytic virotherapy, updates and future directions. Oncotarget, Advance Publications 2017; www.impactjournals.com/oncotarget)

17. Rodriguez-Cerdeira C, Gregorio MC, Lopez-Barcenas A, et al. Advances in immunotherapy for melanoma: a comprehensive review. Mediators Inflamm. 2017;2017:3264217. doi: 10.1155/2017/3264217. Epub 2017 Aug 1. Review

18. Feeny KJ, Mastrangelo MJ. Intralesional therapy for in-transit and satellite metastases in melanoma. Surg Oncol Clin N Am 2015; 24:299-308.

19. Dummer R, Hauschild A, Lindenblatt N, et al. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26(suppl5):v126-v132.

20. Mar VJ, Chamberlain AJ, Kelly JW, et al. Clinical practice guidelines for the diagnosis and management of melanoma: melanomas that lack of classical clinical features. Med J Aust 2017;207:348-350.

21. Dummer R, Siano M, Hunger RE,et al. The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. Swiss Med Wkly 2016 Feb 22;146:w14279.).

***Benign melanositik tümörler***

1. Grichnik JM, Rhodes AR, Sober AJ. Benign neoplasias and Hyperplasias of melanocytes. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick’s Dermatology in general medicine. 8th ed. United States of America: McGraw-Hill Companies, 2012; p. 1377-1410.

2. Melanocytic Nevi and Neoplasms. In: James WD, Berger T, Elston D, Andrews GC, editors. Andrews' Diseases of the Skin, Clinical Dermatology. 12th ed. China: Elsevier, 2016; p. 680-698.

3. Balin SJ, Barnhill RL. Benign Melanocytic Neoplasms. In: Bolognia JL, Schaffer JV, Cerroni L, editors. Dermatology. 4th ed. China: Elsevier, 2018; p. 1954-1988.

4. Krengel S, Scope A, Dusza SW, et al. New recommendations for the categorization of cutaneous features of congenital melanocytic nevi. J Am Acad Dermatol. 2013;68:441-451.

5. Kadonaga JN, Frieden IJ. Neurocutaneous melanosis: definition and review of the literature. J Am Acad Dermatol. 1991;24:747-755.

6. Bauer J, Curtin JA, Pinkel D, Bastian BC. Congenital melanocytic nevi frequently harbor. J Invest Dermatol. 2007;127:179-182.

7. DeDavid M, Seth JO, Provost N, et al. Neurocutaneous melanosis: clinical features of large congenital melanocytic nevi in patients with manifest central nervous system melanosis. J Am Acad Dermatol. 1996;35:529-538.

8. Agero ALC, Benvenuto-Andrade C, Dusza SW, et al. Asymptomatic neurocutaneous melanocytosis in patients with large congenital melanocytic nevi: a study of cases from an Internet-based registry. J Am Acad Dermatol. 2005;53:959-965.

9. Lovett A, Maari C, Decarie JC, et al. Large congenital melanocytic nevi and neurocutaneous melanocytosis: one pediatric center's experience. J Am Acad Dermatol. 2009;61:766-774.

10. Rhodes AR, Sober AJ, Day CL, et al. The malignant potential of small congenital nevocellular nevi. An estimate of association based on a histologic study of 234 primary cutaneous melanomas. J Am Acad Dermatol. 1982;6(2):230-41.

11. Swerdlow AJ, English JSC, Qiao Z. The risk of melanoma in patients with congenital nevi: a cohort study. J Am Acad Dermatol. 1995;32:595-599.

12. Marghoob AA, Schoenbach SP, Kopf AW, et al. Large congenital melanocytic nevi and the risk for the development of malignant melanoma. A prospective study. Arch Dermatol. 1996;132:170-175.

13. DeDavid M, Orlow SJ, Provost N, et al. A study of large congenital melanocytic nevi and associated malignant melanomas: review of cases in the New York University Registry and the world literature. J Am Acad Dermatol. 1997;36:409-415.

14. Bett BJ. Large or multiple congenital melanocytic nevi: occurrence of cutaneous melanoma in 1008 persons. J Am Acad Dermatol. 2005;52:793-797.

15. Krengel S, Hauschild A, and Schäfer T. Melanoma risk in congenital melanocytic naevi: a systematic review. Br J Dermatol. 2006;155:1-8.

16. Egan CL, Oliveria S, Elenitsas R, et al. Cutaneous melanoma risk and phenotypic changes in large congenital nevi: A follow-up study of 46 patients. J Am Acad Dermatol. 1998;39:923-932.

17. Kishi K, Okabe K, Ninomiya R, et al. Early serial Q-switched ruby laser therapy for medium-sized to giant congenital melanocytic naevi. Br J Dermatol. 2009;161:345-352.

18. Kopf AW, Levine LJ, Rigel DS, Friedman RJ, Levenstein M. Prevalence of congenital-nevus-like nevi, nevi spili, and café au lait spots. Arch Dermatol. 1985;121(6):766-9.

19. Kopf AW, Levine LJ, Rigel DS, Friedman RJ, Levenstein M. Congenital-nevus-like nevi, nevi spili, and café-au-lait spots in patients with malignant melanoma. J Dermatol Surg Oncol. 1985;11(3):275-80.

20. Schaffer JV, Orlow SJ, Lazova R, Bolognia JL. Speckled lentiginous nevus: within the spectrum of congenital melanocytic nevi. Arch Dermatol. 2001;137:172-178.

21. Sarin KY, McNIff JM, Kwok S, et al. Activating. J Invest Dermatol. 2014;134:1766-1768.

22. Abecassis S, Spatz A, Cazeneuve C, et al. Melanoma within naevus spilus: 5 cases. Ann Dermatol Venerol. 2006;133: 323-328.

23. Chiu HH, Chen GS, Wu CS, Ke CL, Cheng ST. Phakomatosis cesioflammea with late-onset glaucoma and acquired nevus spilus-like lesion - 15 years of follow-up. Int J Dermatol. 2009;48(4):416-8.

24. Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res. 2011;24:879-897.

25. Kelly JW, Rivers JK, MacLennan R, Harrison S, Lewis AE, Tate BJ. Sunlight: a major factor associated with the development of melanocytic nevi in Australian schoolchildren. J Am Acad Dermatol. 1994;30(1):40-8.

26. Zhu G, Duffy DL, Eldridge A, et al. A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: a maximum-likelihood combined linkage and association analysis in twins and their sibs. Am J Hum Genet. 1999;65:483-492.

27. Robinson WA, Lemon M, Elefanty A, Harrison-Smith M, Markham N, Norris D. Human acquired naevi are clonal. Melanoma Res. 1998;8(6):499-503.

28. Gill M, Celebi JT. B-RAF and melanocytic neoplasia. J Am Acad Dermatol. 2005;53(1):108-14.

29. Lin J, Takata M, Murata H, et al. Polyclonality of BRAF mutations in acquired melanocytic nevi. J Natl Cancer Inst. 2009;101(20):1423-7.

30. Elder DE. Dysplastic naevi: an update. Histopathology. 2010;56:112-120.

31. Grichnik JM, Ali WN, Burch JA, et al. KIT expression reveals a population of precursor melanocytes in human skin. J Invest Dermatol. 1996;106(5):967-71.

32. Schaffer JV, Bolognia JL. The biology of melanocytic nevi. In: Nordlund JJ, Boissy RE, Hearing VJ, editors. The Pigmentary System: Physiology and Pathophysiology. 2nd ed. Oxford: Blackwell Publishing, 2006: p. 1092–125.

33. Banky JP, Kelly JW, English DR, Yeatman JM, Dowling JP. Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma. Arch Dermatol. 2005;141(8):998-1006.

34. Rongioletti F, Ball RA, Marcus R, Barnhill RL. Histopathological features of flexural melanocytic nevi: a study of 40 cases. J Cutan Pathol. 2000;27:215-217.

35. Grin CM, Saida T. Pigmented nevi of the palms and soles. In: Marghoob AA, Braun B, Kopf AW, editors. Atlas of Dermoscopy. London: Taylor & Francis, 2005: p. 271-279.

36. Lanschuetzer CM, Laimer M, Nischler E, Hintner H. Epidermolysis bullosa nevi. Dermatol Clin. 2010;28:179-183.

37. Carlson JA, Mu XC, Slominski A, et al. Melanocytic proliferations associated with lichen sclerosus. Arch Dermatol. 2002;138:77-87.

38. Clark WH, Hood AF, Tucker MA, Jampel RM. Atypical melanocytic nevi of the genital type with a discussion of reciprocal parenchymal-stromal interactions in the biology of neoplasia. Hum Pathol. 1998;29:S1-24.

39. Gleason BC, Hirsch MS, Nucci MR, et al. Atypical genital nevi. A clinicopathologic analysis of 56 cases. Am J Surg Pathol. 2008;32:51-57.

40. Pharis DB, Zitelli JA. Sunburn, trauma, and the timing of biopsies of melanocytic nevi. Dermatol Surg. 2001;27(9):835-6.

41. Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H. Cutaneous melanomas associated with nevi. Arch Dermatol. 2003;139(12):1620-4.

42. Lucas CR, Sanders LL, Murray JC, Myers SA, Hall RP, Grichnik JM. Early melanoma detection: nonuniform dermoscopic features and growth. J Am Acad Dermatol. 2003;48(5):663-71.

43. Wayte DM, Helwig EB: Halo nevi. Cancer. 1968;22:69-90.

44. Kolm I, Di Stefani A, Hofmann-Wellenhof R, et al. Dermoscopy patterns of halo nevi. Arch Dermatol. 2006;142:1627-1632.

45. Grichnik JM, Tucker MA. Atypical (dysplastic) melanocytic nevi. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick’s Dermatology in general medicine. 8th ed. United States of America: McGraw-Hill Companies, 2012; p. 1410-1416.

46. Clark WH Jr, Reimer RR, Greene M, Ainsworth AM, Mastrangelo MJ. Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch Dermatol. 1978;114(5):732-8.

47. Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA. 1997;277:1439-1444.

48. Hoffman-Wellenhof R, Blum A, Wolf IH, et al. Dermoscopic classification of atypical melanocytic nevi. Arch Dermatol. 1992;137:1575-1580.

49. Shors AR, Kim S, White E, et al. Dysplastic naevi with moderate to severe histological dysplasia: a risk factor for melanoma. Br J Dermatol. 2006;155:988-993.

50. Zembowicz A, Scolyer RA. Nevus/Melanocytoma/Melanoma: an emerging paradigm for classification of melanocytic neoplasms? Arch Pathol Lab Med. 2011;135(3):300-6.

51. Halpern AC, Guerry D, Elder DE, et al. Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case-control study. Arch Dermatol. 1991;127:995-999.

52. Garbe C, Buttner P, Weiss J, et al. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the central malignant melanoma registry of the German Dermatological Society. J Invest Dermatol. 1994;102:695-699.

53. Garbe C, Buttner P, Weiss J, et al. Associated factors in the prevalence of more than 50 common melanocytic nevi, atypical melanocytic nevi, and actinic lentigines: multicenter case-control study of the central malignant melanoma registry of the German Dermatological Society. J Invest Dermatol. 1994;102:700-705.

54. Roush GC, Nordlund JJ, Forget B, et al. Independence of dysplastic nevi from total nevi in determining risk for nonfamilial melanoma. Prev Med. 1988;17:273-279.

55. Nordlund JJ, Kirkwood J, Forget BM, et al. Demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects. Cancer Res. 1985;45:1855-1861.

56. MacKie RM, Freudenberger T, Aitchison TC. Personal risk-factor chart for cutaneous melanoma. Lancet. 1989;2:487-490.

57. Holly EA, Kelly JW, Shpall SN, Chiu SH. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol. 1987;17:459-468.

58. Duffy KL, Mann DJ, Petronic-Rosic V, Shea CR. Clinical decision making based on histopathologic grading and margin status of dysplastic nevi. Arch Dermatol. 2012;148:259-260.

59. Reddy KK, Farber MJ, Bhawan J, et al. Atypical (dysplastic) nevi outcomes of surgical excision and association with melanoma. JAMA Dermatol. 2013;149:928-934.

60. Strazzula L, Vedak P, Hoang MP, et al. The utility of re-excising mildly and moderately dysplastic nevi: A retrospective analysis. J Am Acad Dermatol. 2014;71:1071-1076.

61. Patterson JW. Nevus cell aggregates in lymph nodes. Am J Clin Pathol. 2004;121(1):13-5.

62. Dorsey CS, Montgomery H. Blue nevus and its distinction from Mongolian spot and the nevus of Ota. J Invest Dermatol. 1954;22:225-236.

63. Rodriguez HA, Ackerman LV. Cellular blue nevus. Clinicopathologic study of forty-five cases. Cancer. 1968;21:393-405.

64. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457(7229):599-602.

65. Carney JA, Ferreiro JA. The epithelioid blue nevus: a multicentric familial tumor with important associations, including cardiac myxoma and psammomatous melanotic schwannoma. Am J Surg Pathol. 1996;20:259-272.

66. Zembowicz A, Carney JA, Mihm MC. Pigmented epithelioid melanocytoma: a low-grade melanocytic tumor with metastatic potential indistinguishable from animal-type melanoma and epithelioid blue nevus. Am J Surg Pathol. 2004;28:31-40.

67. Zembowicz A, Knoepp SM, Bei T, et al. Loss of expression of protein kinase A regulatory subunit 1 alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions. Am J Surg Pathol. 2007;31:1764-1775.

68. Goldenhersh MA, Savin RC, Barnhill RL, Stenn KS. Malignant blue nevus. J Am Acad Dermatol. 1988;19:712-722.

69. Barnhill RL, Argenyi Z, Berwick M, et al. Atypical cellular blue nevi (cellular blue nevi with atypical features): lack of consensus for diagnosis and distinction from cellular blue nevi and malignant melanoma “malignant blue nevus”. Am J Surg Pathol. 2008;32:36-44.

70. Weedon D, Little J. Spindle and epithelioid cell nevi in children and adults. A review of 211 cases of the Spitz nevus. Cancer. 1977;40:217-225.

71. Bastian BC, LeBoit PE, Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol. 2000;157(3):967-72.

72. Barr R, Morales R, Graham J. Desmoplastic nevus. A distinct histologic variant of mixed spindle and epithelioid cell nevus. Cancer. 1980;46:557-564.

73. Dawe RS, Wainwright NJ, Evans AT, Lowe JG. Multiple widespread eruptive Spitz naevi. Br J Dermatol. 1998;138:872-874.

74. Spatz A, Calonje E, Handfield-Jones S, Barnhill RL. Spitz tumors in children: a grading system for risk stratification. Arch Dermatol. 1999;135:282-289.

75. Wiesner T, Obernauf AC, Murali R, et al. Germline muations in BAP1 predispose to melanocytic tumors. Nature Genet. 2011;43:1018-1021.

76. Wiesner T, Murali R, Fried I, et al. A distinct subset of Atypical Spitz Tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol. 2012;36:818-830.

77. Bastian BC, Wesselmann U, Pinkel D, Leboit PE. Molecular cytogenetic analysis of Spitz tumors shows clear differences to melanoma. J Invest Dermatol. 1999;113:1065-1069.

78. Raskin L, Ludgate M, Iyer RK, et al. Copy number variations and clinical outcome in atypical spitz tumors. Am J Surg Pathol. 2011;35:243-252.

79. Reed D, Kudchadkar R, Zager JS, Sondak VK, Messina JL. Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults. J Natl Compr Canc Netw. 2013;11(6):679-86.

80. Ludgate MW, Fullen DR, Lee J, et al. The atypical Spitz tumor of uncertain biologic potential. a series of 67 patients from a single institution. Cancer. 2009;115:631-641.

81. Hung T, Yang A, Mihm MC, Barnhill RL. The plexiform spindle cell nevus nevi and atypical variants: report of 128 cases. Hum Pathol. 2014;45:2369-2378.

82. Pulitzer DR, Martin PC, Cohen AP, Reed RJ. Histologic classification of the combined nevus. Analysis of the variable expression of melanocytic nevi. Am J Surg Pathol. 1991;15:1111-1122.

83. Scolyer RA, Zhuang L, Palmer AA, et al. Combined naevus: a benign lesion frequently misdiagnosed both clinically and pathologically as melanoma. Pathology. 2004;36:419-427.

84. Barnhill RL, Cerroni L, Cook M, et al. State of the art, nomenclature, and points of consensus and controversy concerning benign melanocytic lesions: outcome of an international workshop. Adv Anat Pathol. 2010;17:73-90.

85. Park HK, Leonard DD, Arrington JH, Lund HZ. Recurrent melanocytic nevi: clinical and histologic review of 175 cases. J Am Acad Dermatol. 1987;17:285-292.

86. Blum A, Hofmann-Wellenhof R, Marghoob AA, et al. Recurrent melanocytic nevi and melanomas in dermoscopy: results of a multicenter study of the International Dermoscopy Society. JAMA Dermatol. 2014;150:138-145.

***Benign deri eki tümörleri***

***Folikül kökenli benign deri eki tümörleri***

Alsaad KO, Obaidat NA, Ghazarian D. Skin adnexal neoplasms-part 1: An approach to tumours of the pilosebaceous unit. J Clin Pathol 2007; 60: 129-144.

2. Tellechea O, Reis JP, Gameiro AR, Cardosa JC, Ramos L, Coutinho I. Benign follicular tumors. An Bras Dermatol 2015; 90: 780-98.

3. Cribier B, Scrivener Y, Grosshans E. Tumors arising in nevus sebaseous: a study of 596 cases. J Am Acad Dermatol 2000; 42: 263-8.

4. Ghigliotti G, De Col E, Parodi A, Bombonato C, Argenziano G. Trichoblastoma: is a clinical or dermoskopic diagnosis posibble? JEADV 2016;

5. Stoica LE, Dascalu RC, Patraşcu V, Ciurea RN, Branişteanu DE, Georgescu DM. Solitary trichoepithelioma: clinical, dermatoscopic and histopathological findings. Rom J Morphol Embryol 2015; 56: 827-32.

6. Riyaz N, Sudhamani B, Riyaz A. Epithelioma Adenoides Cysticum: A Report of Two Cases in a Family. Int J Trichology 2016; 8(4): 165–167.

7. Khelifa E, Masouyé I, Kaya G, Le Gal FA. Dermoscopy of Desmoplastic Trichoepithelioma Reveals Other Criteria to Distinguish It from Basal Cell Carcinoma. Dermatology 2013;226:101–104.

8. Headington JT, French AJ. Primary neoplasms of the hair follicle. Histogenesis and classification. Arch Dermatol 1962; 86: 430-441.

9. Hunt SJ, Kilzer B, Santa Cruz DJ. Desmoplastic trichilemmoma: histologic variant resembling invasive carcinoma. J Cutan Pathol. 1990; 17(1):45-52.

10. Spiegel JH, Khodai N. Tricholemmoma of the nose. Am J Otolaryngol 2006; 27: 430-2.

11. Pihlblad M, Chelnis J, Schaefer D. Eyelid Desmoplastic Trichilemmoma: 2 Case Reports and Review. Ophthal Plast Reconstr Surg; 2014: 30: 136-137.

12. Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet 2004 May; 41: 323–326.

13. Hernandez-Nuneza A, Najera Botellob L, Romero Matea C, Martinez-Sancheza M, Utrera Busquetsa M et al. Retrospective Study of Pilomatricoma: 261 Tumors in 239 Patients. Actas Dermosifiliogr 2014;105:699-705.

14. Pirouzmanesh A, Reinisch JF, Gonzalez-Gomez I, Smith EM, Meara JG. Pilomatrixoma: a review of 346 cases. Plast Reconstr Surg 2003; 112(7): 1784-9.

15. Ozkaya DB, Su O, Taskin B, Tas B, Sar M, Onsun N. Bullous pilomatricoma. Eur J Dermatol. 2013 Jan-Feb;23(1):104-5.

16. Solivetti FM, Elia F, Drusco A. Panetta C, Amantea A, di Carlo A. Epithelioma of Malherbe: New ultrasound patterns. J Exp Clin Canc Res, 29 (2010), pp. 42-48

17. Satyaprakash AK, Sheehan DJ, Sangüeza OP. Proliferating trichilemmal tumors: A review of the literature. Dermatol Surg 2007; 33: 1102-1108.

18. Shimanovich I1, Krahl D, Rose C. Trichoadenoma of Nikolowski is a distinct neoplasm within the spectrum of follicular tumors. J Am Acad Dermatol. 2010; 62(2): 277-83

19. Mehregan AH, Brownstein MH. Pilar Sheath Acanthoma. Arch Dermatol 1978; 114: 1495-97.

20. Jo-Velasco M, Corrales-Rodriquez A, Frances-Rodriques L, Alegria-Landa V, Erana-Tomas I, Rütten A, Requena L. Plaque-like Pilar Sheath acanthoma: Histopathologic and immunohistochemical study of 3 unusual cases.

21. Haddad N, Haddad N, Oliveira Filho J, Reis MJL, Michalany AO, Nasser KR, Corbett AMF. Tumor of follicular infundibulum with unique features. An Bras Dermatol 2014;89: 964-6.

22. Gerding H, Zett A, Timmermann M. Bothersome Cutaneous Lesion for more than 30 years: Dilated pore of Winer. Klin Monatsbl Augenheilkd 2017; 234: 595-596.

23. Resnik KS, Kantor GR, Howe NR, Ditre CM. Dilated pore nevus. A histologic variant of nevus comedonicus. Am J Dermatopathol 2001; 23: 246-53.

24. Romero-Perez D, Garcia-Bustinduy M, Cribier B. Clinicopathologic study of 90 cases of trichofolliculoma. JEADV 2017; 31: 141-142.

25. Schulz T, Hartschuh W. The trichofooliculoma undergoes changes corresponding to the regressing normal hair follicle in its cycle. J Cutan Pathol 1998; 25: 341-353.

26. Lopez-Garcia DR, Teague D, Landis ET, Sangueza OP. Morphological Diversity of Trichodiscomas and Fibrofolliculomas. Am J Dermatopathol 2014; 36: 734–740.

27. Choe E, Lee JD, Cho SH. A solitary fibrofolliculoma on the concha of the ear. Int J Dermatol 2012; 51: 616-7.

28. Jensen DK, Villumsen A, Skytte AB, Madsen MG, Sommerlund M, Bendstrup E. Birt-Hogg-Dube syndrome: a case report and a review of the literature. Eur Clin Respir J 2017; 4: 1292378.

29. Nam JH, Min JH, Lee GY, Kim WS. A case of perifollicular fibroma. Ann Dermatol 2011; 23(2): 236-8.

30. Sau P, Lupton GP, Graham JH. Trichogerminoma. Report of 14 cases. J Cutan Pathol. 1992; 19(5):357-65.

31. Kim M, Choi M, Hong JS, Lee JH, Cho S. A case of trichogerminoma. Ann Dermatol 2010;22(4):431-4.

32. Shan SJ, Guo Y. Panfolliculoma and Histopathologic Variants: A Study of 19 Cases. Am J Dermatopathol 2014;36: 965–971.

33. Estrada-Castanon R, Vega-Memije ME,1 Cuevas-Gonzalez JC, Chavez-Lopez MG. Panfolliculoma: A Clinical Case Report. Int J Trichology 2017; 9(4): 187–189.

***Sebase bez kökenli benign deri eki tümörleri***

1. Lacobelli J, Harvey NT, Wood BA. Sebaceous lesions of the skin. Pathology 2017; 49(7): 688-697.

2. Pang SM, Chau YP. Cyclosporin-induced sebaceous hyperplasia in renal transplant patients. Ann Acad Med Singapore 2005; 34: 391-3.

3. Ranasinghe GC, Friedman AJ. Eruptive sebaceous hyperplasia: A rare consequence of systemic corticosteroids. J Drugs Dermatol 2018; 17: 118-120.

4. Alsaad KO, Obaidat NA, Ghazarian D. Skin adnexal neoplasms-part 1: An approach to tumours of the pilosebaceous unit. J Clin Pathol 2007; 60: 129-144.

5. Gupta V, Mridha AD, Sharma VK. Sebaceous hyperplasia and sebaceous adenomas presenting as leonine facies and improving with oral isotretinoin. Clin Exp Dermatol 2016; 41: 923-924.

6. Bourlond F, Velter C, Cribier B. Clinicopathological study of 47 cases of sebaceoma. Ann Dermatol Venereol 2016; 143 (12): 814-824.

7. Misago N, Suse T, Uemura T et al. Basal cell crcinoma with sebaceous differentiation. Am J Dermatopathol 2004; 26: 298-303.

***Ekrin/apokrin bez kökenli benign deri eki tümörleri***

1. Ciarloni L, Frouin E, Bodin F, Cribier B. Syringoma: A clinicopathological study of 244 cases. Ann Dermatol Venereol 2016; 143(8-9): 521-8.

2. Obaidat NA, Alsaad KO, Ghazarian D. Skin adnexal neoplasms-part 2: An approach to tumours of cutaneous sweet glands. J Clin Pathol 2007; 60: 145-159.

3. Park SH1, Kang SG, Choi HJ. Chondroid Syringoma of a Cheek. J Craniofac Surg 2017; 28(5):e480-e481.

4. Sawaya JL, Khachemoune A. Poroma: a review of eccrine, apocrine, and malignant forms. Int J Dermatol 2014; 53(9):1053-61.

5. Harvell, J.D., ve ark., Eccrine or apocrine poroma? Six poromas with divergent adnexal differentiation. Am J Dermatopathol 1996. 18(1): p. 1-9.

6. Marchetti MA, Marino ML, Virmani P, Dusza SW, Marghoob AA, Nazzaro G, Lallas A, Landi C, Cabo H, Quiñones R, Gomez E, Puig S, Carrera C. Dermoscopic features and patterns of poromas: a multicentre observational case-control study conducted by the International Dermoscopy Society. J Eur Acad Dermatol Venereol 2017. [Epub ahead of print]

7. Lee JY, Kang BS, Shim HS, Song IH, Kim M, Lee SH, Chung HW, Lee MH, Shin MJ. Clear Cell Hidradenoma: Characteristic Imaging Features on Ultrasonography, Computed Tomography, and Magnetic Resonance Imaging. J Ultrasound Med. 2018. [Epub ahead of print]

8. Nandeesh BN1, Rajalakshmi T. A study of histopathologic spectrum of nodular hidradenoma. Am J Dermatopathol 2012; 34(5):461-70.

9. Sellheyer K. Spiradenoma and cylindroma originate from the hair follicle bulge and not from the eccrine sweat gland: an immunohistochemical study with CD200 and other stem cell markers. J Cutan Pathol. 2015; 42(2):90-101.

10. Myers DJ; Fillman EP. Spiradenoma. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.2017 Oct 9.

11. David J. Myers; Eric P. Fillman. Cylindroma. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-2018 Feb 8.

12. Sangma MM, Dasiah SD, Bhat V R. Syringocystadenoma Papilliferum of the Scalp in an Adult Male – A Case Report. J Clin Diagn Res. 2013 Apr; 7(4): 742–743.

13. Chauhan P, Chauhan RK, Upadhyaya A, Kishore S. Dermoscopy of a rare case of linear syringocystadenoma papilliferum with review of the literature. Dermatol Pract Concept. 2018 Jan 31;8(1):33-38.

14. Madan NK1, Agarwal S, Nain M. Tubulopapillary hidradenoma: A rare case with cytohistopathological correlation. J Cytol. 2013 Apr;30(2):142-4.

Malign deri eki tümörleri

***Pilomatriks karsinomu***

Hardisson D, Linares MD, Cuevas-Santos J, Contreras F. Pilomatrix carcinoma: A clinicopathologic study of six cases and review of the literature. Am J Dermatopathol. 2001;23:394–401. doi: 10.1097/00000372-200110000-00002. [PubMed] [Cross Ref]

2. Mikhaeel NG, Spittle MF. Malignant pilomatrixoma with multiple local recurrences and distant metastases: A case report and review of the literature. Clin Oncol (R Coll Radiol) 2001;13:386–389. doi: 10.1053/clon.2001.9296. [PubMed] [Cross Ref]

3. Lan MY, Lan MC, Ho CY, Li WY, Lin CZ. Pilomatricoma of the head and neck: A retrospective review of 179 cases. Arch Otolaryngol Head Neck Surg. 2003;129:1327–1330. doi: 10.1001/archotol.129.12.1327. [PubMed] [Cross Ref]

4. Scheinfeld N. Pilomatrical carcinoma: A case in a patient with HIV and hepatitis C. Dermatol Online J. 2008;14:4. [PubMed]

5. Jani P, Chetty R, Ghazarian DM. An unusual composite pilomatrix carcinoma with intralesional melanocytes: Differential diagnosis, immunohistochemical evaluation, and review of the literature. Am J Dermatopathol. 2008;30:174–177. doi:10.1097/DAD.0b013e318165b8fe. [PubMed] [Cross Ref]

6. Sassmanshausen J, Chaffins M (2001) Pilomatrix carcinoma: a report of a case arising from a previously excised pilomatrixoma and review of the literature. J Am Acad Dermatol 44: 358-361.

7. Weedon D, Bell J, Mayze J (1980) Matrical carcinoma of the skin. J Cutan Pathol 7: 39-42.

8. Bremnes RM, Kvamme JM, Stalsberg H, Jacobsen EA (1999) Pilomatrix carcinoma with multiple metastasis: report of a case and review of the literature. Eur J Cancer 35: 433-437.

***Malign proliferatif trikolemmal tümör***

1. Satyaprakash AK, Sheehan DJ, Sangüeza OP. Proliferating trichilemmal tumors: a review of the literature. Dermatol Surg 2007;33:1102–8. doi: 10.1111/j.1524-4725.2007.33225.x

2. Jones EW. Proliferating epidermoid cysts. Arch Dermatol 1966;94:11–9.

3. Falleti J, Cuccuru A, Mignogna C. Proliferating trichilemmal cyst of the vulva. Clin Exp Dermatol 2009;34:459–60. doi: 10.1111/j.1365-2230.2009.03516.x

4. Moraloğlu Ö, Güngör T, Ozyer S, et al. Recurrent proliferating trichilemmal tumor of the vulva: a case report. J Low Genit Tract Dis 2013;17:71–4. doi: 10.1097/LGT.0b013e31824c199a

 5. Sau P, Graham JH, Helvig EB. Proliferating epithelial cysts. Clinicopathological analysis of 96 cases. J Cutan Pathol 1995;22:394–406.

 6. Batman PA, Evans HJ. Metastasising pilar tumour of scalp. J Clin Pathol 1986;39:757–60.

7. Tierney E, Ochoa MT, Rudkin G, Soriano TT. Mohs’ micrographic surgery of a proliferating trichilemmal tumor in a young black man. Dermatol Surg. 2005; 31(3):359-63

8. Weiss J, Heine M, Grimmel M, Jung EG. Malignant proliferating trichilemmal cyst. J Am Acad Dermatol 1995; 32:870-3

9. Takenaka H, Kishiomoto S, Shibagaki R, et al. Recurrent malignant proliferating trichilemmal tumour: local management with ethanol injection. Br J Dermatol 1998; 139(4):726-9

10. Saida T, Oohara K, Hori Y, et al. Development of a malignant proliferatingtrichilemmal cyst in a patient with multiple trichilemmal cysts. Dermatologica 1983; 166:203-8.

***Trikolemmal karsinom***

1. Allee JE, Cotsarelis G, Solky B, Cook JL. Multiplyrecurrent trichilemmal carcinoma with perineural invasion and cytokeratin 17 positivity. Dermatol Surg 2003;29:886-9.

2. Song MG, Min HG, Jung SY, Yang JM, Lee ES. Trichilemmal carcinoma with a cutaneous horn. Br J Dermatol 2000;143:646-7.

3. Misago N, Tanaka T, Kohda H. Trichilemmal carcinoma occurring in a lesion of solar keratosis. J Dermatol 1993;20:358-64.

4. Headington JT. Tumors of the hair follicle. A review. Am J Pathol 1976;85:479-514.

5. Ko T, Tada H, Hatoko M, Muramatsu T, Shirai T. Trichilemmal carcinoma developing in a burn scar: a report of two cases. J Dermatol 1996;23:463-8.

6. Jo JH, Ko HC, Jang HS, Kim MB, Oh CK, Kwon KS. Infiltrative trichilemmal carcinoma treated with 5% imiquimod cream. Dermatol Surg 2005;31:973-6.

***Trikoblastik karsinom***

1. Anderson PJ, Hodgkinson PD. Malignant pilar tumor of the scalp. Otolaryngol Head Neck Surg. 1999;121:669. [PubMed]

2. Iyengar B, Ramesh V. Hair cycle and the histogenesis of pilar tumours. Indian J Cancer. 1989;26:1–9. [PubMed]

3. Batman PA, Evans HJ. Metastasising pilar tumour of scalp. J Clin Pathol. 1986;39:757–760. [PMC free article] [PubMed]

4. Eduardo Calonje TB, Alexander Lazar, Phillip H Mckee. Malignant trichoblastoma. McKee's Pathology of the Skin - 4th ed. 2012: 1480-2.

5. Janitz J, Wiedersberg H. Trichilemmal pilar tumors. Cancer. 1980;45:1594–1597. [PubMed]

6. Rubinstein N, Lijovetzky G, Knobler HY, Wexler MR, Peled IJ. Pilar tumor of the nose. Cutis. 1985;36:251–252. [PubMed]

7. Morgan RF, Dellon A, Hoopes JE. Pilar tumors. Plast Reconstr Surg. 1979;63:520–524. [PubMed]

8. Batman PA, Evans HJ. Metastasising pilar tumour of scalp. J Clin Pathol. 1986;39:757–760. [PMC free article] [PubMed]

***Sebase karsinom***

1. Russel WG, Page DL, Hough AJ, Rogers LW. Sebaceous carcinoma of the meibomian gland origin. Am J Clin Pathol. 1980;73:504–11. [PubMed]

2. Rao NA et al. Hum Pathol. 1982;13(2):113-122.

3. Font RL. Sebaceous gland tumors. In: Spencer WH (ed). Ophthalmic Pathology. An Atlas and Textbook. 4th ed. Vol 4. Philadelphia: WB Saunders, 1996: 2278-2297.

4. Shields JA, Shields CL. Sebaceous gland tumors. In: Shields JA, Shields CL (eds). Atlas of Eyelid and Conjunctival Tumors. Philadelphia: Lippincott Williams & Wilkins, 1999: 38-49.

5. Shields JA, Demirci H, Marr BP, Eagle RC Jr, Shields CL. Sebaceous carcinoma of the ocular region: a review. Surv Ophthalmol 2005; 50: 103-122.

6. Pereira PR, Odashiro AN, Rodrigues-Reyes AA, Correa ZM, de Souza Filho JP, Burnier MN Jr. Histopathological review of sebaceous carcinoma of the eyelid. J Cutan Pathol 2005; 32: 496-501.

7. Ansai S, Hashimoto H, Aoki T, Hozumi Y, Aso K. A histochemical and immunohistochemical study of extra-ocular sebaceous carcinoma. Histopathology. 1993 Feb. 22(2):127-33. [Medline].

8. Bayer-Garner IB, Givens V, Smoller B. Immunohistochemical staining for androgen receptors: a sensitive marker of sebaceous differentiation. Am J Dermatopathol. 1999 Oct. 21(5):426-31. [Medline].

9. Schirren CG, Stefani FH, Sander CA, Kind P. Ocular sebaceous carcinoma and basal cell carcinoma show different profiles of cytokeratin intermediate filaments [abstract]. J Cutan Pathol. 1997. 24:123.

10. Martinka M, Trotter M, White V. Cytokeratin 7: aid to differential diagnosis of ocular sebaceous carcinomas, squamous cell and basal cell carcinomas [abstract]. J Cutan Pathol. 2000. 27:564.

11. Khan JA, Doane JF, Grove AS Jr. Sebaceous and meibomian carcinomas of the eyelid. Recognition, diagnosis, and management. Ophthal Plast Reconstr Surg 1991; 7: 61-66.

12. Toker E, Acar N, Öğüt M. Sebase bez karsinomu kapakta kitle: Şalazyon mu? Karsinom mu? Türk Oftalmoloji Gazetesi 2001; 31:548-552.

13. Swanson JD, Jr, Pazdur R, Sykes E. Metastatic sweat gland carcinoma: Response to 5-fluorouracil infusion. J Surg Oncol. 1989;41:69–72. [PubMed]

***Porokarsinom***

1.Pinkus H, Mehregan AH. Epidermotropic eccrine carcinoma. Arch Dermatol. 1963;88:597–606. [PubMed]

2.Kazakov, D.V., ve ark., Vulvar syringomas with deep extension: a potential histopathologic mimic of microcystic adnexal carcinoma. Int J Gynecol Pathol, 2011. 30(1): p. 92-4.

3.Robson A, Greene J, Ansari N, Kim B, Seed PT, McKee PH, et al. Eccrine Porocarcinoma (Malignant Eccrine Poroma) A Clinicopathologic Study of 69 Cases. Am J Surg Pathol. 2001;25:710–20. [PubMed]

4.Shiohara J, Koga H, Uhara H, Takata M, Saida T. Eccrine porocarcinoma: clinical and pathological studies of 12 cases. J Dermatol. 2007;181:516–22. [PubMed]

5.Orella JAL, Penalba AV, San Juan CC, Nadal RV, Morrondo JC, Alvarez TT. Eccrine Porocarcinoma: Report of nine cases. Dermat Surg. 1997;23:925–28. [PubMed].

**Malign ekrin spiradenom**

1. Dabska M. Malignant transformation of eccrine spiradenoma. Pol Med J 1972;11:388–96.

2. Ribeiro-Silva A, Shaletich C, Careta RS, et al. Spiradenocarcinoma of the breast arising in a long-standing spiradenoma. Ann Diagn Pathol 2004;8:162–6.

3. Tanaka Y, Bhunchet E, Shibata T. A case of malignant eccrine spiradenoma metastatic to intramammary lymph node. Breast Cancer 2008;15:175–80.

4. Tanese K, Sato T, Ishiko A. Malignant eccrine spiradenoma: case report and review of the literature, including 15 Japanese cases. Clin Exp Dermatol 2009;35:51–5.

5. Beekley AC, Brown TA, Porter C. Malignant eccrine spiradenoma: a previously unreported presentation and review of the literature. Am Surg 1999;65:236–40.

6. Seyhan T, Borman H, Bal N. Malignant eccrine spiradenoma of the scalp. J Craniofac Surg 2008;19:1608–12.

7. Chase DM, Basu T, Saffari B, et al. Malignant eccrine spiradenoma of the vulva: a case report and review of the literature. Int J Gynecol Cancer 2006;16:1465–9.

8. Agarwal S, Khanna R, Arya NC, et al. Malignant eccrine spiradenoma: an unusual presentation. Indian J Dermatol Venereol Leprol 2002;68: 290–1.

9. Tay JS, Tapen EM, Solari PG. Malignant eccrine spiradenoma. Case report and review of the literature. Am J Clin Oncol 1997;20:552–7.

10. Ishikawa M, Nakanishi Y, Yamazaki N, et al. Malignant ecrine spiradenoma: a case report and review of the literature. Dermatol Surg 2001;27:67–70.

**Malign nodüler hidradenom**

1. Soyer, H.P., ve ark., Spiradenocylindroma--more than a coincidence? Am J Dermatopathol, 1998. 20(3): p. 315-7.

2. Ohta M, Hiramoto M, Fujii M, Togo T. Nodular hidradenocarcinoma on the scalp of a young woman. case report and review of literature. Dermatol Surg 2004; 30: 1265–1268.

3. Wong T-Y, Suster S, Nogita T, Duncan LM, Dickershin RG, Mihm MC Jr. Clear cell eccrine carcinomas of the skin: a clinicopathologic study of nine patients. Cancer 1994; 73: 1631–1643.

4. Messing MJ, Richardson MS, Smith MT, King L, Gallup DG. Metastatic clear cell hidradenocarcinoma of the vulva. Gynecol Oncol 1993; 48: 264–268.

5. Tolland JP, Brenn T, Guldbakke KK, Schanbacher CF. Mohs micrographic surgery sentinel lymph node mapping, and estrogen receptor analysis for the treatment of malignant nodular hidradenoma. Dermatol Surg 2006; 32: 1294–1301.

***Malign kondroid siringoma***

1.D. Elder, R. Elenitsas, and B. D. Ragsdale, “Tumors of the epidermal appendages,” in Lever's Histopathology of the Skin, D. Elder, Ed., pp. 747–804, Lippincott-Raven, New York, NY, USA, 1997. View at Google Scholar

2. Mathiasen RA, Rasgon BM, Rumore G. Malignant chondroid syringoma of the face: A first reported case. Otolaryngol Head Neck Surg. 2005;133:305–7. [PubMed]

3. Argenyi ZB, Balogh K, Goeken JA. Immunohistochemical characterisation of chondroid syringomas. Am J Clin Pathol. 1988;90:662–9. [PubMed]

4.Requena C., Brotons S., Sanmartin O., Llombart B., Traves V., Guillen C., Requena L. Malignant syringoma of the face with bone invasion. Am. J. Dermatopathol. 2013;35(5):395–398. [PubMed]

5. Mathiasen RA, Rasgon BM, Rumore G. Malignant chondroid syringoma of the face: A first reported case. Otolaryngol Head Neck Surg. 2005;133:305–7. [PubMed]

***Ekrin adenokarsinom***

1. Dzubow LM, Grossman DJ, Johnson B. Eccrine adenocarcinoma – report of a case, treatment with Mohs surgery. J Dermatol Surg Oncol 1986; 12: 1049–1053.

2. Cohen KL, Peiffer RL, Lipper S. Mucinous sweat gland adenocarcinoma of the eyelid. American Journal of Ophthalmology. 1981;92:183–88. [PubMed]

3. Carson HJ, Gattuso P, Raslan WF, Reddy V. Muinous carcinoma of the eyelid. An immunohistochemical study. Am J Dermatopathol. 1995;17:494–498. [PubMed]

4. Hanby AM, McKee P, Jeffery M, Grayson W, Dublin E, Poulsom R, et al. Primary mucinous carcinoma of the skin express TFF1, TFF3, estrogen receptor, and progesterone receptors. Am J Surg Pathol. 1998;22:1125–1131. [PubMed]

5. Liszauer AD, Brownstein S, Codère F. Mucinous eccrine sweat gland adenocarcinoma of the eyelid. Can J Ophthalmol. 1988;23:17–21. [PubMed]

6.Chang AS, Busam K, Kraus DH. Applicability of lympho¬scintigraphy with sentinel node biopsy to eccrine carcinoma of the head and neck. Head Neck 2003; 25: 879–882.

7.Lin SS, Tai CJ, Lee WR, Chu JS, Wang KH. Giant eccrine adenocarcinoma with skin and lymph node metastases: favourable response to chemotherapy. J Eur Acad Dermatol Venereol 2009; 23: 332–333.

8. Adefusika JA, Pimentel JD, Chavan RN, Brewer JD. Primary mucinous carcinoma of the skin: the Mayo Clinic experience over the past 2 decades. Dermatol Surg 2015; 41: 201–208.

9. Ortiz KJ, Gaughan MD, Bang RH, Padilla RS, Crooks LA. A case of primary mucinous carcinoma of the scalp treated with mohs surgery. Dermatol Surg 2002; 28: 751–754.

***Mikrokistik adneksiyal karsinom***

1. Friedman, P.M., ve ark., Microcystic adnexal carcinoma: collaborative series review and update. J Am Acad Dermatol, 1999. 41(2 Pt 1): p. 22531.

2. Snow, S., ve ark., Microcystic adnexal carcinoma: report of 13 cases and review of the literature. Dermatol Surg, 2001. 27(4): p. 401-8.

3. Ban, M., ve ark., Microcystic adnexal carcinoma with lymph node metastasis. Dermatology, 2003. 207(4): p. 395-7 (abstract).

4. Gabillot-Carre, M., ve ark., Microcystic adnexal carcinoma: report of seven cases including one with lung metastasis. Dermatology, 2006. 212(3): p. 221-8 (abstract).

5. Kazakov, D.V., ve ark., Brooke-Spiegler syndrome: report of a case with combined lesions containing cylindromatous, spiradenomatous, trichoblastomatous, and sebaceous differentiation. Am J Dermatopathol, 2005. 27(1): p. 27-33.

6.Leibovitc, I, Huilgol, SC, Selva, D, Lun, K, Richards, R, Paver, P. "Microcystic adnexal carcinoma: treatment with Mohs micrographic surgery". Am Acad Dermatol. vol. 52. 2005. pp. 295-300.

***Agresif digital papiller adenokarsinom***

1. Duke, W.H., ve ark., Aggressive digital papillary adenocarcinoma (aggressive digital papillary adenoma and adenocarcinoma revisited). Am J Surg Pathol, 2000. 24(6): p. 775-84.

2. Bueno RA, Neumeister MW, Wilhelmi BJ. Aggressive digital papillary adenocarcinoma presenting as finger infection. Ann Plast Surg. 2002;49(3):326–7. [PubMed]

3. Scolyer RA, Karim RZ, Thompson JF, Stretch JR, McCarthy SW, Murali R. Digital papillary adenocarcinoma: a tumour that should be considered in the differential diagnosis of neoplasms involving the digits. Pathology. 2013;45(1):55–61. [PubMed]

4. Bueno RA, Neumeister MW, Wilhelmi BJ. Aggressive digital papillary adenocarcinoma presenting as finger infection. Ann Plast Surg. 2002;49(3):326–7. [PubMed]

5. Scolyer RA, Karim RZ, Thompson JF, Stretch JR, McCarthy SW, Murali R. Digital papillary adenocarcinoma: a tumour that should be considered in the differential diagnosis of neoplasms involving the digits. Pathology. 2013;45(1):55–61. [PubMed].

***Adenoid kistik karsinom***

1. Kato, N., ve ark., Primary cutaneous adenoid cystic carcinoma with lymph node metastasis. Am J Dermatopathol, 1998. 20(6): p. 571-7.

2. Seab, J.A. ve J.H. Graham, Primary cutaneous adenoid cystic carcinoma. J Am Acad Dermatol, 1987. 17(1): p. 113-8 (Abstract).

3. Chang, S.E., ve ark., Primary adenoid cystic carcinoma of skin with lung metastasis. J Am Acad Dermatol, 1999. 40(4): p. 640-2. 26.

4. Jones AS, Hamilton JW, Rowley H, Husband D, Helliwell TR. Adenoid cystic carcinoma of the head and neck. Clin Otolaryngol. 1997;22:434–43. [PubMed].

***Müsinöz ekrin karsinom***

1. Ajithkumar, T.V., ve ark., Bone marrow relapse in primary mucinous carcinoma of skin. Am J Clin Oncol, 1999. 22(3): p. 303-4.

2. Pilgrim, J.P., ve ark., Primary mucinous carcinoma of the skin with metastases to the lymph nodes. Am J Dermatopathol, 1985. 7(5): p. 461-9 (abstract).

3. Furue, M., ve ark., Clear-cell syringoma. Association with diabetes mellitus. Am J Dermatopathol, 1984. 6(2): p. 131-8.

4. Snow SN, Reizner GT. Mucinous eccrine carcinoma of the eyelid. Cancer 1992;70:2099–104.

5. Bindra M, Keegan DJ, Guenther T, Lee V. Primary cutaneous mucinous carcinoma of the eyelid in a young male. Orbit 2005;24:211–4.

6. Ortiz KJ, Gaughan MD, Bang RH, et al. A case of primary mucinous carcinoma of the scalp treated with mohs surgery. Dermatol Surg 2002;28:751–4.

7. Cecchi R, Rapicano V. Primary cutaneous mucinous carcinoma: report of two cases treated with Mohs’ micrographic surgery. Australas J Dermatol 2006;47:192–4.

8. Bertagnoli R, Cook DL, Goldman GD. Bilateral primary mucinous carcinoma of the eyelid treated with Mohs surgery. Dermatol Surg 1999;25:566–8.

***Siringoid ekrin karsinom***

1. Sidiropoulos M, Sade S, Al-Habeeb A, et al. Syringoid eccrine carcinoma: a clinicopathological and immunohistochemical study of four cases. J Clin Pathol. 2011;64:788-792.

2. Freeman RG, Winklemann RK. Basal cell tumor with eccrine differentiations (eccrine epithelioma). Arch Dermatol. 1969;100:234-242.

3. Nishizawa A, Nakanishi Y, Sasajima Y, et al. Syringoid carcinoma with apparently aggressive transformation: case report and review of the literature. Int J Dermatol. 2006;45:1218-1221.

4. Urso C, Bondi R, Paglierani M, et al. Carcinomas of sweat glands: report of 60 cases. Arch Pathol Lab Med. 2001;125:498-505.

5. Ohnishi T, Kaneko S, Egi M, et al. Syringoid eccrine carcinoma: report of a case with immunohistochemical analysis of cytokeratin expression. Am J Dermatopathol 2002;24:409e13.

6. Moy RL, Rivkin JE, Lee H, et al. Syringoid eccrine carcinoma. J Am Acad Dermatol 1991;24:857e60

***Malign silindiroma***

1. Durani BK, Kurzen H, Jaeckel A, Kuner N, Naeher H, Hartschuh W. Malignant transformation of multiple dermal cylindromas. Br J Dermatol. 2001;145:653–6. [PubMed]

2. Gerretsen AL, van der Putte SC, Deenstra W, van Vloten WA. Cutaneous cylindroma with malignant transformation. Cancer. 1993;72:1618–23. [PubMed]

3. Kim C, Kovich OI, Dosik J. Brooke - Spiegler syndrome. Dermatol Online J. 2007;13:10. [PubMed]

4. Lotem M, Trattner A, Kahanovich S, Rotem A, Sandbank M. Multiple dermal cylindroma undergoing a malignant transformation. Int J Dermatol. 1992;31:642–4. [PubMed]

5. De Francesco V, Frattasio A, Pillon B, Stinco G, Scott CA, Trotter D, et al. Carcinosarcoma arising in a patient with multiple cylindromas. Am J Dermatopathol. 2005;27:21–6. [PubMed]

6. Wyld L, Bullen S, Browning FS. Transcranial erosion of a benign dermal cylindroma. Ann Plast Surg. 1996;36:194–6. [PubMed]

7. Tellechea O, Reis JP, Ilheu O, Baptista AP. Dermal cylindroma.An immunohistochemical study of thirteen cases. Am J Dermatopathol. 1995;17:260–5. [PubMed]

8. Meybehm M, Fischer HP. Spiradenoma and dermal cylindroma: Comparative immunohistochemical analysis and histogenetic considerations. Am J Dermatopathol. 1997;19:154–61. [PubMed]

9. Weedon D. Tumors of cutaneous appendages. In: Weedon D, editor. Weedon's Skin Pathology. 3rd ed. China: Churchill Livingstone Elsevier; 2010. pp. 785–6.

10. Lo JS, Peschen M, Snow SN, Oriba HA, Mohs FE. Malignant cylindroma of the scalp. J Dermatol Surg Oncol. 1991;17:897–901. [PubMed]

11. Retamar RA, Stengel F, Saadi ME, Kien MC, Della Giovana P, Cabrera H, et al. Brooke-Spiegler syndrome-report of four families: Treatment with CO2 laser. Int J Dermatol. 2007;46:583–6. [PubMed]

***Kutanöz T hücreli lenfomalar***

1. Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. Lancet 1988; 1: 292-3.

2. Edelson RL. Cutaneous T cell lymphoma: mycosis fungoides, Sezary syndrome, and other variants. J Am Acad Dermatol 1980; 2: 89-106.

3. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127: 2375-90.

4. Picker LJ, Michie SA, Rott LS, et al. A unique phenotype of skin-associated lymphocytes in humans. Preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. Am J Pathol 1990; 136: 1053-68.

5. Pals ST, de Gorter DJ, Spaargaren M. Lymphoma dissemination: the other face of lymphocyte homing. Blood 2007; 110: 3102-11.

6. Campbell JJ, Clark RA, Watanabe R, et al. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 2010; 116: 767-71.

7. Whittaker S. T-cell receptor gene analysis in cutaneous T-cell lymphomas. Clin Exp Dermatol 1996; 21: 81-7.

8. Whittaker S. Biological insights into the pathogenesis of cutaneous T-cell lymphomas (CTCL). Semin Oncol 2006; 33: S3-6.

9. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19: 376-88.

10. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19: 2456-71.

11. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 581-93.

12. Lowenberg B. On the road to new drugs in acute myeloid leukemia. J Clin Oncol 2007; 25: 1-2.

13. Nickoloff BJ. Light-microscopic assessment of 100 patients with patch/plaque-stage mycosis fungoides. Am J Dermatopathol 1988; 10: 469-77.

14. Li G, Vowels BR, Benoit BM, et al. Failure to detect human T-lymphotropic virus type-I proviral DNA in cell lines and tissues from patients with cutaneous T-cell lymphoma. J Invest Dermatol 1996; 107: 308-13.

15. Boni R, Davis-Daneshfar A, Burg G, et al. No detection of HTLV-I proviral DNA in lesional skin biopsies from Swiss and German patients with cutaneous T-cell lymphoma. Br J Dermatol 1996; 134: 282-4.

16. Lisby G, Reitz MS, Jr., Vejlsgaard GL. No detection of HTLV-I DNA in punch skin biopsies from patients with cutaneous T-cell lymphoma by the polymerase chain reaction. J Invest Dermatol 1992; 98: 417-20.

17. Whittaker SJ, Luzzatto L. HTLV-1 provirus and mycosis fungoides. Science 1993; 259: 1470; author reply 1.

18. Tan RS, Butterworth CM, McLaughlin H, et al. Mycosis fungoides--a disease of antigen persistence. Br J Dermatol 1974; 91: 607-16.

19. Cohen SR, Stenn KS, Braverman IM, et al. Clinicopathologic relationships, survival, and therapy in 59 patients with observations on occupation as a new prognostic factor. Cancer 1980; 46: 2654-66.

20. Morales-Suarez-Varela MM, Olsen J, Johansen P, et al. Occupational risk factors for mycosis fungoides: a European multicenter case-control study. J Occup Environ Med 2004; 46: 205-11.

21. Morales-Suarez-Varela MM, Olsen J, Johansen P, et al. Occupational sun exposure and mycosis fungoides: a European multicenter case-control study. J Occup Environ Med 2006; 48: 390-3.

22. van Leeuwen MT, Turner JJ, Falster MO, et al. Latitude gradients for lymphoid neoplasm subtypes in Australia support an association with ultraviolet radiation exposure. Int J Cancer 2013; 133: 944-51.

23. Tuyp E, Burgoyne A, Aitchison T, et al. A case-control study of possible causative factors in mycosis fungoides. Arch Dermatol 1987; 123: 196-200.

24. Fletcher CL, Orchard GE, Hubbard V, et al. CD30(+) cutaneous lymphoma in association with atopic eczema. Arch Dermatol 2004; 140: 449-54.

25. Morales MM, Olsen J, Johansen P, et al. Viral infection, atopy and mycosis fungoides: a European multicentre case-control study. Eur J Cancer 2003; 39: 511-6.

26. Whittemore AS, Holly EA, Lee IM, et al. Mycosis fungoides in relation to environmental exposures and immune response: a case-control study. J Natl Cancer Inst 1989; 81: 1560-7.

27. Huang KP, Weinstock MA, Clarke CA, et al. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts. Arch Dermatol 2007; 143: 45-50.

28. Scarisbrick JJ, Child FJ, Evans AV, et al. Secondary malignant neoplasms in 71 patients with Sezary syndrome. Arch Dermatol 1999; 135: 1381-5.

29. Evans AV, Scarisbrick JJ, Child FJ, et al. Cutaneous malignant melanoma in association with mycosis fungoides. J Am Acad Dermatol 2004; 50: 701-5.

30. Deepak P, Sifuentes H, Sherid M, et al. T-Cell Non-Hodgkin&#39;s Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors: Results of the REFURBISH Study. The American Journal Of Gastroenterology 2012; 108: 99.

31. Shapiro PE, Pinto FJ. The histologic spectrum of mycosis fungoides/Sezary syndrome (cutaneous T-cell lymphoma). A review of 222 biopsies, including newly described patterns and the earliest pathologic changes. Am J Surg Pathol 1994; 18: 645-67.

32. Smoller BR, Bishop K, Glusac E, et al. Reassessment of Histologic Parameters in the Diagnosis of Mycosis Fungoides. The American Journal of Surgical Pathology 1995; 19: 1423-30.

33. Scarabello A, Leinweber B, Ardigo M, et al. Cutaneous lymphomas with prominent granulomatous reaction: a potential pitfall in the histopathologic diagnosis of cutaneous T- and B-cell lymphomas. Am J Surg Pathol 2002; 26: 1259-68.

34. Kempf W, Ostheeren-Michaelis S, Paulli M, et al. Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC). Arch Dermatol 2008; 144: 1609-17.

35. Li JY, Pulitzer MP, Myskowski PL, et al. A case-control study of clinicopathologic features, prognosis, and therapeutic responses in patients with granulomatous mycosis fungoides. Journal of the American Academy of Dermatology; 69: 366-74.e4.

36. Vergier B, de Muret A, Beylot-Barry M, et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. Blood 2000; 95: 2212-8.

37. Arulogun SO, Prince HM, Ng J, et al. Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood 2008; 112: 3082-7.

38. Ralfkiaer E. Immunohistological markers for the diagnosis of cutaneous lymphomas. Semin Diagn Pathol 1991; 8: 62-72.

39. Kallinich T, Muche JM, Qin S, et al. Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. J Invest Dermatol 2003; 121: 1045-52.

40. Capriotti E, Vonderheid EC, Thoburn CJ, et al. Chemokine receptor expression by leukemic T cells of cutaneous T-cell lymphoma: clinical and histopathological correlations. J Invest Dermatol 2007; 127: 2882-92.

41. Dummer R, Kamarashev J, Kempf W, et al. Junctional CD8+ cutaneous lymphomas with nonaggressive clinical behavior: a CD8+ variant of mycosis fungoides? Arch Dermatol 2002; 138: 199-203.

42. Wain EM, Orchard GE, Whittaker SJ, et al. Outcome in 34 patients with juvenile-onset mycosis fungoides: a clinical, immunophenotypic, and molecular study. Cancer 2003; 98: 2282-90.

43. Hoppe RT, Medeiros LJ, Warnke RA, et al. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 1995; 32: 448-53.

44. Vermeer MH, van Doorn R, Dukers D, et al. CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas Ligand, and killing inhibitory receptors and their relationship with clinical behavior. J Clin Oncol 2001; 19: 4322-9.

45. Vermeer MH, Geelen FA, Kummer JA, et al. Expression of cytotoxic proteins by neoplastic T cells in mycosis fungoides increases with progression from plaque stage to tumor stage disease. Am J Pathol 1999; 154: 1203-10.

46. Edinger JT, Clark BZ, Pucevich BE, et al. CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol 2009; 33: 1860-8.

47. Meyerson HJ, Awadallah A, Pavlidakey P, et al. Follicular center helper T-cell (TFH) marker positive mycosis fungoides/Sezary syndrome. Mod Pathol 2013; 26: 32-43.

48. Klemke CD, Fritzsching B, Franz B, et al. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sezary syndrome from other cutaneous T-cell lymphomas. Leukemia 2006; 20: 1123-9.

49. Gjerdrum LM, Woetmann A, Odum N, et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 2007; 21: 2512-8.

50. Wong HK, Wilson AJ, Gibson HM, et al. Increased expression of CTLA-4 in malignant T-cells from patients with mycosis fungoides -- cutaneous T cell lymphoma. J Invest Dermatol 2006; 126: 212-9.

51. Berger CL, Tigelaar R, Cohen J, et al. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood 2005; 105: 1640-7.

52. Tiemessen MM, Mitchell TJ, Hendry L, et al. Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma. J Invest Dermatol 2006; 126: 2217-23.

53. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-85.

54. Willemze R, Beljaards RC, Meijer CJ. Classification of primary cutaneous T-cell lymphomas. Histopathology 1994; 24: 405-15.

55. Sausville EA, Worsham GF, Matthews MJ, et al. Histologic assessment of lymph nodes in mycosis fungoides/Sezary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system. Hum Pathol 1985; 16: 1098-109.

56. Price NM, Fuks ZY, Hoffman TE. Hyperkeratotic and verrucous features of mycosis fungoides. Arch Dermatol 1977; 113: 57-60.

57. Roenigk HH, Jr., Castrovinci AJ. Mycosis fungoides bullosa. Arch Dermatol 1971; 104: 402-6.

58. Eisman S, O'Toole EA, Jones A, et al. Granulomatous mycosis fungoides presenting as an acquired ichthyosis. Clin Exp Dermatol 2003; 28: 174-6.

59. van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol 2002; 138: 191-8.

60. Magro CM, Schaefer JT, Crowson AN, et al. Pigmented purpuric dermatosis: classification by phenotypic and molecular profiles. Am J Clin Pathol 2007; 128: 218-29.

61. Smith NP, Samman PD. Mycosis fungoides presenting with areas of cutaneous hypopigmentation. Clin Exp Dermatol 1978; 3: 213-6.

62. Lambroza E, Cohen SR, Phelps R, et al. Hypopigmented variant of mycosis fungoides: demography, histopathology, and treatment of seven cases. J Am Acad Dermatol 1995; 32: 987-93.

63. Furlan FC, de Paula Pereira BA, da Silva LF, et al. Loss of melanocytes in hypopigmented mycosis fungoides: a study of 18 patients. J Cutan Pathol 2014; 41: 101-7.

64. Ally MS, Pawade J, Tanaka M, et al. Solitary mycosis fungoides: a distinct clinicopathologic entity with a good prognosis: a series of 15 cases and literature review. J Am Acad Dermatol 2012; 67: 736-44.

65. Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005; 53: 1053-63.

66. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-22.

67. Lamberg SI, Green SB, Byar DP, et al. Clinical staging for cutaneous T-cell lymphoma. Ann Intern Med 1984; 100: 187-92.

68. Green SB, Byar DP, Lamberg SI. Prognostic variables in mycosis fungoides. Cancer 1981; 47: 2671-7.

69. Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010; 28: 4730-9.

70. Fuks ZY, Bagshaw MA, Farber EM. Prognostic signs and the management of the mycosis fungoides. Cancer 1973; 32: 1385-95.

71. Hamminga L, Hermans J, Noordijk EM, et al. Cutaneous T-cell lymphoma: clinicopathological relationships, therapy and survival in ninety-two patients. Br J Dermatol 1982; 107: 145-55.

72. Sausville EA, Eddy JL, Makuch RW, et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sezary syndrome. Definition of three distinctive prognostic groups. Ann Intern Med 1988; 109: 372-82.

73. Weinstock MA, Horm JW. Population-based estimate of survival and determinants of prognosis in patients with mycosis fungoides. Cancer 1988; 62: 1658-61.

74. Marti RM, Estrach T, Reverter JC, et al. Prognostic clinicopathologic factors in cutaneous T-cell lymphoma. Arch Dermatol 1991; 127: 1511-6.

75. Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003; 139: 857-66.

76. van Doorn R, Van Haselen CW, van Voorst Vader PC, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000; 136: 504-10.

77. Zackheim HS, Amin S, Kashani-Sabet M, et al. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 1999; 40: 418-25.

78. Fraser-Andrews EA, Woolford AJ, Russell-Jones R, et al. Detection of a peripheral blood T cell clone is an independent prognostic marker in mycosis fungoides. J Invest Dermatol 2000; 114: 117-21.

79. Toro JR, Stoll HL, Jr., Stomper PC, et al. Prognostic factors and evaluation of mycosis fungoides and Sezary syndrome. J Am Acad Dermatol 1997; 37: 58-67.

80. Scarisbrick JJ, Whittaker S, Evans AV, et al. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood 2001; 97: 624-30.

81. Benton EC, Crichton S, Talpur R, et al. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer 2013; 49: 2859-68.

82. Greene MH, Pinto HA, Kant JA, et al. Lymphomas and leukemias in the relatives of patients with mycosis fungoides. Cancer 1982; 49: 737-41.

83. Epstein EH, Jr., Levin DL, Croft JD, Jr., et al. Mycosis fungoides. Survival, prognostic features, response to therapy, and autopsy findings. Medicine (Baltimore) 1972; 51: 61-72.

84. Harland CC, Whittaker SJ, Ng YL, et al. Coexistent cutaneous T-cell lymphoma and B-cell chronic lymphocytic leukaemia. Br J Dermatol 1992; 127: 519-23.

85. Brousset P, Lamant L, Viraben R, et al. Hodgkin's disease following mycosis fungoides: phenotypic and molecular evidence for different tumour cell clones. J Clin Pathol 1996; 49: 504-7.

86. Scarisbrick JJ, Child F, Spittle M, et al. Systemic Hodgkin's lymphoma in a patient with Sezary syndrome. Br J Dermatol 2000; 142: 771-5.

87. Hallermann C, Kaune Kjell M, Tiemann M, et al. High frequency of primary cutaneous lymphomas associated with lymphoproliferative disorders of different lineage. Annals of Hematology 2007; 86: 509-15.

88. Delfau-Larue MH, Dalac S, Lepage E, et al. Prognostic significance of a polymerase chain reaction-detectable dominant T-lymphocyte clone in cutaneous lesions of patients with mycosis fungoides. Blood 1998; 92: 3376-80.

89. Bunn PA, Jr., Huberman MS, Whang-Peng J, et al. Prospective staging evaluation of patients with cutaneous T-cell lymphomas. Demonstration of a high frequency of extracutaneous dissemination. Ann Intern Med 1980; 93: 223-30.

90. Tsai EY, Taur A, Espinosa L, et al. Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol 2006; 142: 577-84.

91. Sibaud V, Beylot-Barry M, Thiébaut R, et al. Bone Marrow Histopathologic and Molecular Staging in Epidermotropic T-Cell Lymphomas. American Journal of Clinical Pathology 2003; 119: 414-23.

92. Binnick AN, Wax FD, Clendenning WE. Alopecia mucinosa of the face associated with mycosis fungoides. Arch Dermatol 1978; 114: 791-2.

93. Coskey RJ, Mehregan AH. Alopecia mucinosa. A follow-up study. Arch Dermatol 1970; 102: 193-4.

94. Emmerson RW. Follicular mucinosis. A study of 47 patients. Br J Dermatol 1969; 81: 395-413.

95. Pinkus H, Macaulay WL, Lund HZ, et al. Alopecia mucinosa: Inflammatory plaques with alopecia characterized by root-sheath mucinosis. AMA Archives of Dermatology 1957; 76: 419-26.

96. Hempstead RW, Ackerman AB. Follicular mucinosis. A reaction pattern in follicular epithelium. Am J Dermatopathol 1985; 7: 245-57.

97. Cerroni L, Fink-Puches R, Back B, et al. Follicular mucinosis: a critical reappraisal of clinicopathologic features and association with mycosis fungoides and Sezary syndrome. Arch Dermatol 2002; 138: 182-9.

98. Gerami P, Rosen S, Kuzel T, et al. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma. Arch Dermatol 2008; 144: 738-46.

99. Agar N, Whittaker SJ. Folliculotropic mycosis fungoides (stage IIA) progressing to Sezary syndrome: a case report. Br J Dermatol 2008; 159: 1197-9.

100. Burns MK, Chan LS, Cooper KD. Woringer-Kolopp disease (localized pagetoid reticulosis) or unilesional mycosis fungoides? An analysis of eight cases with benign disease. Arch Dermatol 1995; 131: 325-9.

101. Berti E, Tomasini D, Vermeer MH, et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol 1999; 155: 483-92.

102. Haneke E, Tulusan AH, Weidner F. Histological features of "pagetoid reticulosis" (Woringer-Kolopp) in pre-mycosis fungoides. Arch Dermatol Res 1977; 258: 265-73.

103. Deneau DG, Wood GS, Beckstead J, et al. Woringer-Kolopp disease (pagetoid reticulosis). Four cases with histopathologic, ultrastructural, and immunohistologic observations. Arch Dermatol 1984; 120: 1045-51.

104. Mackie RM, Turbitt ML. A case of pagetoid reticulosis bearing the T cytotoxic suppressor surface marker on the lymphoid infiltrate: further evidence that pagetoid reticulosis is not a variant of mycosis fungoides. Br J Dermatol 1984; 110: 89-94.

105. Wood GS, Weiss LM, Hu CH, et al. T-cell antigen deficiencies and clonal rearrangements of T-cell receptor genes in pagetoid reticulosis (Woringer-Kolopp disease). N Engl J Med 1988; 318: 164-7.

106. Durupt F, Thomas L, Etienne J. Panton-Valentine leukocidin, exfoliative toxins, and skin infections. Arch Dermatol 2008; 144: 1069-70; author reply 70.

107. Li JY, Pulitzer MP, Myskowski PL, et al. A case-control study of clinicopathologic features, prognosis, and therapeutic responses in patients with granulomatous mycosis fungoides. J Am Acad Dermatol 2013; 69: 366-74.

108. Ikonomou IM, Aamot HV, Heim S, et al. Granulomatous slack skin with a translocation t(3;9)(q12;p24). Am J Surg Pathol 2007; 31: 803-6.

109. Balus L, Bassetti F, Gentili G. Granulomatous slack skin. Arch Dermatol 1985; 121: 250-2.

110. Burns RE, Whitehouse FW. Evidence for impaired glucose tolerance in uncomplicated psoriasis. Preliminary report. Arch Dermatol 1973; 107: 371-2.

111. Helm KF, Cerio R, Winkelmann RK. Granulomatous slack skin: a clinicopathological and immunohistochemical study of three cases. Br J Dermatol 1992; 126: 142-7.

112. LeBoit PE, Beckstead JH, Bond B, et al. Granulomatous slack skin: clonal rearrangement of the T-cell receptor beta gene is evidence for the lymphoproliferative nature of a cutaneous elastolytic disorder. J Invest Dermatol 1987; 89: 183-6.

113. DeGregorio R, Fenske NA, Glass LF. Granulomatous slack skin: a possible precursor of Hodgkin's disease. J Am Acad Dermatol 1995; 33: 1044-7.

114. Noto G, Pravata G, Miceli S, et al. Granulomatous slack skin: report of a case associated with Hodgkin's disease and a review of the literature. Br J Dermatol 1994; 131: 275-9.

115. Wollina U, Graefe T, Fuller J. Granulomatous slack skin or granulomatous mycosis fungoides -- a case report. Complete response to percutaneous radiation and interferon alpha. J Cancer Res Clin Oncol 2002; 128: 50-4.

116. Balus L, Manente L, Remotti D, et al. Granulomatous slack skin. Report of a case and review of the literature. Am J Dermatopathol 1996; 18: 199-206.

117. Benton EC, Morris SL, Robson A, et al. An unusual case of granulomatous slack skin disease with necrobiosis. Am J Dermatopathol 2008; 30: 462-5.

118. Trotter MJ, Whittaker SJ, Orchard GE, et al. Cutaneous histopathology of Sezary syndrome: a study of 41 cases with a proven circulating T-cell clone. J Cutan Pathol 1997; 24: 286-91.

119. Chu AC, Robinson D, Hawk JL, et al. Immunologic differentiation of the Sezary syndrome due to cutaneous T-cell lymphoma and chronic actinic dermatitis. J Invest Dermatol 1986; 86: 134-7.

120. D'Incan M, Souteyrand P, Bignon YJ, et al. Hydantoin-induced cutaneous pseudolymphoma with clinical, pathologic, and immunologic aspects of Sezary syndrome. Arch Dermatol 1992; 128: 1371-4.

121. Matutes E, Robinson D, O'Brien M, et al. Candidate counterparts of Sezary cells and adult T-cell lymphoma-leukaemia cells in normal peripheral blood: an ultrastructural study with the immunogold method and monoclonal antibodies. Leuk Res 1983; 7: 787-801.

122. Lutzner M, Edelson R, Schein P, et al. Cutaneous T-cell lymphomas: the Sezary syndrome, mycosis fungoides, and related disorders. Ann Intern Med 1975; 83: 534-52.

123. Miller RA, Coleman CN, Fawcett HD, et al. Sezary syndrome: a model for migration of T lymphocytes to skin. N Engl J Med 1980; 303: 89-92.

124. Willemze R, van Vloten WA, Hermans J, et al. Diagnostic criteria in Sezary's syndrome: a multiparameter study of peripheral blood lymphocytes in 32 patients with erythroderma. J Invest Dermatol 1983; 81: 392-7.

125. Bernengo MG, Quaglino P, Novelli M, et al. Prognostic factors in Sezary syndrome: a multivariate analysis of clinical, haematological and immunological features. Ann Oncol 1998; 9: 857-63.

126. Bernengo MG, Novelli M, Quaglino P, et al. The relevance of the CD4+ CD26– subset in the identification of circulating Sézary cells. British Journal of Dermatology 2001; 144: 125-35.

127. Kelemen K, Guitart J, Kuzel TM, et al. The usefulness of CD26 in flow cytometric analysis of peripheral blood in Sezary syndrome. Am J Clin Pathol 2008; 129: 146-56.

128. Vonderheid EC, Bernengo MG, Burg G, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002; 46: 95-106.

129. Fraser-Andrews EA, Russell-Jones R, Woolford AJ, et al. Diagnostic and prognostic importance of T-cell receptor gene analysis in patients with Sezary syndrome. Cancer 2001; 92: 1745-52.

130. Matutes E, Brito-Babapulle V, Swansbury J, et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 1991; 78: 3269-74.

131. Lamberg SI, Bunn PA, Jr. Cutaneous T-cell lymphomas. Summary of the Mycosis Fungoides Cooperative Group-National Cancer Institute Workshop. Arch Dermatol 1979; 115: 1103-5.

132. Schechter GP, Sausville EA, Fischmann AB, et al. Evaluation of circulating malignant cells provides prognostic information in cutaneous T cell lymphoma. Blood 1987; 69: 841-9.

133. Vonderheid EC, Sobel EL, Nowell PC, et al. Diagnostic and prognostic significance of Sezary cells in peripheral blood smears from patients with cutaneous T cell lymphoma. Blood 1985; 66: 358-66.

134. Russell-Jones R, Whittaker S. T-cell receptor gene analysis in the diagnosis of Sezary syndrome. J Am Acad Dermatol 1999; 41: 254-9.

135. Prince HM, Duvic M, Martin A, et al. Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/Sezary syndrome receiving placebo. J Am Acad Dermatol 2012; 67: 867-75.

136. Kaye FJ, Bunn PA, Jr., Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321: 1784-90.

137. Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eur J Cancer 2006; 42: 1014-30.

138. Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010; 28: 4485-91.

139. Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol 1998; 134: 949-54.

140. Van Scott EJ, Kalmanson JD. Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN2). Control of delayed hypersensitivity to HN2 by desensitization and by induction of specific immunologic tolerance. Cancer 1973; 32: 18-30.

141. Hoppe RT, Abel EA, Deneau DG, et al. Mycosis fungoides: management with topical nitrogen mustard. J Clin Oncol 1987; 5: 1796-803.

142. Ramsay DL, Halperin PS, Zeleniuch-Jacquotte A. Topical mechlorethamine therapy for early stage mycosis fungoides. J Am Acad Dermatol 1988; 19: 684-91.

143. Vonderheid EC, Tan ET, Kantor AF, et al. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol 1989; 20: 416-28.

144. Kim YH, Martinez G, Varghese A, et al. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol 2003; 139: 165-73.

145. Zackheim HS, Epstein EH, Jr., Crain WR. Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. J Am Acad Dermatol 1990; 22: 802-10.

146. Breneman D, Duvic M, Kuzel T, et al. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 2002; 138: 325-32.

147. Duvic M, Olsen EA, Omura GA, et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2001; 44: 940-7.

148. Coors EA, Schuler G, Von Den Driesch P. Topical imiquimod as treatment for different kinds of cutaneous lymphoma. Eur J Dermatol 2006; 16: 391-3.

149. Deeths MJ, Chapman JT, Dellavalle RP, et al. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol 2005; 52: 275-80.

150. Kannangara AP, Levitan D, Fleischer AB, Jr. Six patients with early-stage cutaneous T-cell lymphoma successfully treated with topical 5-fluorouracil. J Drugs Dermatol 2010; 9: 1017-8.

151. Briffa D, Warin A, Harrington Stanley C, et al. PHOTOCHEMOTHERAPY IN MYCOSIS FUNGOIDES. The Lancet; 316: 49-53.

152. Gilchrest BA, Parrish JA, Tanenbaum L, et al. Oral methoxsalen photochemotherapy of mycosis fungoides. Cancer 1976; 38: 683-9.

153. Abel EA, Sendagorta E, Hoppe RT, et al. PUVA treatment of erythrodermic and plaque-type mycosis fungoides. Ten-year follow-up study. Arch Dermatol 1987; 123: 897-901.

154. Herrmann JJ, Roenigk HH, Jr., Hurria A, et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 1995; 33: 234-42.

155. Querfeld C, Rosen ST, Kuzel TM, et al. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol 2005; 141: 305-11.

156. Ramsay DL, Lish KM, Yalowitz CB, et al. Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol 1992; 128: 931-3.

157. Clark C, Dawe RS, Evans AT, et al. Narrowband TL-01 phototherapy for patch-stage mycosis fungoides. Arch Dermatol 2000; 136: 748-52.

158. Zane C, Leali C, Airo P, et al. "High-dose" UVA1 therapy of widespread plaque-type, nodular, and erythrodermic mycosis fungoides. J Am Acad Dermatol 2001; 44: 629-33.

159. Quereux G, Brocard A, Saint-Jean M, et al. Photodynamic therapy with methyl-aminolevulinic acid for paucilesional mycosis fungoides: a prospective open study and review of the literature. J Am Acad Dermatol 2013; 69: 890-7.

160. Kim ST, Kang DY, Kang JS, et al. Photodynamic therapy with methyl-aminolaevulinic acid for mycosis fungoides. Acta Derm Venereol 2012; 92: 264-8.

161. Mori M, Campolmi P, Mavilia L, et al. Monochromatic excimer light (308 nm) in patch-stage IA mycosis fungoides. J Am Acad Dermatol 2004; 50: 943-5.

162. Cotter GW, Baglan RJ, Wasserman TH, et al. Palliative radiation treatment of cutaneous mycosis fungoides--a dose response. Int J Radiat Oncol Biol Phys 1983; 9: 1477-80.

163. Hoppe RT, Cox RS, Fuks Z, et al. Electron-beam therapy for mycosis fungoides: the Stanford University experience. Cancer Treat Rep 1979; 63: 691-700.

164. Spittle MF. Mycosis fungoides: electron beam therapy in England. Cancer Treat Rep 1979; 63: 639-41.

165. Jones GW, Hoppe RT, Glatstein E. Electron beam treatment for cutaneous T-cell lymphoma. Hematology/oncology clinics of North America 1995; 9: 1057-76.

166. Morris SL, McGovern M, Bayne S, et al. Results of a 5-Week Schedule of Modern Total Skin Electron Beam Radiation Therapy. International Journal of Radiation Oncology • Biology • Physics; 86: 936-41.

167. Jones GW, Rosenthal D, Wilson LD. Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sezary syndrome). Cancer 1999; 85: 1985-95.

168. Hamminga B, Noordijk EM, van Vloten WA. Treatment of mycosis fungoides: total-skin electron-beam irradiation vs topical mechlorethamine therapy. Arch Dermatol 1982; 118: 150-3.

169. Chinn DM, Chow S, Kim YH, et al. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. International Journal of Radiation Oncology • Biology • Physics; 43: 951-8.

170. Becker M, Hoppe RT, Knox SJ. Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides. International Journal of Radiation Oncology • Biology • Physics; 32: 1445-9.

171. Wilson LD, Quiros PA, Kolenik SA, et al. Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. J Am Acad Dermatol 1996; 35: 69-73.

172. Jones GW, Kacinski BM, Wilson LD, et al. Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol 2002; 47: 364-70.

173. Kamstrup MR, Lindahl LM, Gniadecki R, et al. Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: an open-label prospective phase II study. Br J Dermatol 2012; 166: 399-404.

174. Harrison C, Young J, Navi D, et al. Revisiting Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides. International Journal of Radiation Oncology • Biology • Physics; 81: e651-e7.

175. Bunn PA, Jr., Ihde DC, Foon KA. The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas. Cancer 1986; 57: 1689-95.

176. Olsen EA, Rosen ST, Vollmer RT, et al. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol 1989; 20: 395-407.

177. Papa G, Tura S, Mandelli F, et al. Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice? Br J Haematol 1991; 79 Suppl 1: 48-51.

178. Husken AC, Tsianakas A, Hensen P, et al. Comparison of pegylated interferon alpha-2b plus psoralen PUVA versus standard interferon alpha-2a plus PUVA in patients with cutaneous T-cell lymphoma. J Eur Acad Dermatol Venereol 2012; 26: 71-8.

179. Rook AH, Wood GS, Yoo EK, et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999; 94: 902-8.

180. Kaplan EH, Rosen ST, Norris DB, et al. Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990; 82: 208-12.

181. Cooper DL, Braverman IM, Sarris AH, et al. Cyclosporine treatment of refractory T-cell lymphomas. Cancer 1993; 71: 2335-41.

182. Molin L, Thomsen K, Volden G, et al. Oral retinoids in mycosis fungoides and Sezary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1987; 67: 232-6.

183. Gniadecki R, Assaf C, Bagot M, et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol 2007; 157: 433-40.

184. Assaf C, Bagot M, Dummer R, et al. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol 2006; 155: 261-6.

185. Dreno B, Claudy A, Meynadier J, et al. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate. Br J Dermatol 1991; 125: 456-9.

186. Stadler R, Otte HG, Luger T, et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 92: 3578-81.

187. Kuzel TM, Roenigk HH, Jr., Samuelson E, et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome. J Clin Oncol 1995; 13: 257-63.

188. Thomsen K, Hammar H, Molin L, et al. Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1989; 69: 536-8.

189. Singh F, Lebwohl MG. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series. J Am Acad Dermatol 2004; 51: 570-3.

190. Talpur R, Ward S, Apisarnthanarax N, et al. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002; 47: 672-84.

191. Whittaker S, Ortiz P, Dummer R, et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056). Br J Dermatol 2012; 167: 678-87.

192. Bunn PA, Jr., Hoffman SJ, Norris D, et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 1994; 121: 592-602.

193. Dearden C, Matutes E, Catovsky D. Pentostatin treatment of cutaneous T-cell lymphoma. Oncology (Williston Park, NY) 2000; 14: 37-40.

194. Kurzrock R, Pilat S, Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol 1999; 17: 3117-21.

195. Zackheim HS, Kashani-Sabet M, Hwang ST. Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. J Am Acad Dermatol 1996; 34: 626-31.

196. Wollina U, Graefe T, Kaatz M. Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up. J Cancer Res Clin Oncol 2001; 127: 128-34.

197. Wollina U, Dummer R, Brockmeyer NH, et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 2003; 98: 993-1001.

198. Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000; 18: 2603-6.

199. Marchi E, Alinari L, Tani M, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005; 104: 2437-41.

200. Quereux G, Marques S, Nguyen JM, et al. Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sezary syndrome. Arch Dermatol 2008; 144: 727-33.

201. Dummer R, Quaglino P, Becker JC, et al. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol 2012; 30: 4091-7.

202. Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2012; 119: 4115-22.

203. Querfeld C, Rosen ST, Guitart J, et al. Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O(6)-methylguanine-DNA methyltransferase and mismatch repair proteins. Clin Cancer Res 2011; 17: 5748-54.

204. Bigler RD, Crilley P, Micaily B, et al. Autologous bone marrow transplantation for advanced stage mycosis fungoides. Bone Marrow Transplant 1991; 7: 133-7.

205. Olavarria E, Child F, Woolford A, et al. T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol 2001; 114: 624-31.

206. Burt RK, Guitart J, Traynor A, et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect. Bone Marrow Transplant 2000; 25: 111-3.

207. Molina A, Nademanee A, Arber DA, et al. Remission of refractory Sezary syndrome after bone marrow transplantation from a matched unrelated donor. Biol Blood Marrow Transplant 1999; 5: 400-4.

208. Guitart J, Wickless SC, Oyama Y, et al. Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma. Arch Dermatol 2002; 138: 1359-65.

209. Molina A, Zain J, Arber DA, et al. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol 2005; 23: 6163-71.

210. Duarte RF, Schmitz N, Servitje O, et al. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant 2008; 41: 597-604.

211. Duvic M, Donato M, Dabaja B, et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol 2010; 28: 2365-72.

212. Delioukina M, Zain J, Palmer JM, et al. Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transplant 2012; 47: 65-72.

213. Paralkar VR, Nasta SD, Morrissey K, et al. Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas. Bone Marrow Transplant 2012; 47: 940-5.

214. Perez M, Edelson R, Laroche L, et al. Inhibition of antiskin allograft immunity by infusions with syngeneic photoinactivated effector lymphocytes. J Invest Dermatol 1989; 92: 669-76.

215. Berger CL, Perez M, Laroche L, et al. Inhibition of autoimmune disease in a murine model of systemic lupus erythematosus induced by exposure to syngeneic photoinactivated lymphocytes. J Invest Dermatol 1990; 94: 52-7.

216. Berger CL, Xu AL, Hanlon D, et al. Induction of human tumor-loaded dendritic cells. Int J Cancer 2001; 91: 438-47.

217. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 1987; 316: 297-303.

218. Fraser-Andrews E, Seed P, Whittaker S, et al. Extracorporeal photopheresis in Sezary syndrome. No significant effect in the survival of 44 patients with a peripheral blood T-cell clone. Arch Dermatol 1998; 134: 1001-5.

219. Zic JA, Stricklin GP, Greer JP, et al. Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol 1996; 35: 935-45.

220. Russell-Jones R. Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for randomized studies. Br J Dermatol 2000; 142: 16-21.

221. Wollina U, Looks A, Meyer J, et al. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial. J Am Acad Dermatol 2001; 44: 253-60.

222. Dippel E, Schrag H, Goerdt S, et al. Extracorporeal photopheresis and interferon-alpha in advanced cutaneous T-cell lymphoma. Lancet 1997; 350: 32-3.

223. Haley HR, Davis DA, Sams WM. Durable loss of a malignant T-cell clone in a stage IV cutaneous T-cell lymphoma patient treated with high-dose interferon and photopheresis. J Am Acad Dermatol 1999; 41: 880-3.

224. Yoo EK, Cassin M, Lessin SR, et al. Complete molecular remission during biologic response modifier therapy for Sezary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity. J Am Acad Dermatol 2001; 45: 208-16.

225. Suchin KR, Cucchiara AJ, Gottleib SL, et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. Arch Dermatol 2002; 138: 1054-60.

226. Heald P, Rook A, Perez M, et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol 1992; 27: 427-33.

227. Evans AV, Wood BP, Scarisbrick JJ, et al. Extracorporeal photopheresis in Sezary syndrome: hematologic parameters as predictors of response. Blood 2001; 98: 1298-301.

228. Foss FM, Bacha P, Osann KE, et al. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma 2001; 1: 298-302.

229. Knox S, Hoppe RT, Maloney D, et al. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 1996; 87: 893-9.

230. Bernengo MG, Quaglino P, Comessatti A, et al. Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients. Haematologica 2007; 92: 784-94.

231. Alinari L, Geskin L, Grady T, et al. Subcutaneous alemtuzumab for Sezary Syndrome in the very elderly. Leuk Res 2008; 32: 1299-303.

232. Querfeld C, Mehta N, Rosen ST, et al. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leukemia & Lymphoma 2009; 50: 1969-76.

233. Kim YH, Duvic M, Obitz E, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007; 109: 4655-62.

234. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109: 31-9.

235. Fantin VR, Loboda A, Paweletz CP, et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res 2008; 68: 3785-94.

236. Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 4293-7.

237. Whittaker SJ, Foss FM. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. Cancer Treat Rev 2007; 33: 146-60.

238. Querfeld C, Kuzel TM, Kim YH, et al. Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Leuk Lymphoma 2011; 52: 1474-80.

239. Querfeld C, Rosen ST, Guitart J, et al. Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome. Blood 2014; 123: 1159-66.

240. LeBoit PE. Lymphomatoid papulosis and cutaneous CD30+ lymphoma. Am J Dermatopathol 1996; 18: 221-35.

241. Kadin ME. Primary Ki-1-positive anaplastic large-cell lymphoma: a distinct clinicopathologic entity. Ann Oncol 1994; 5 Suppl 1: 25-30.

242. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95: 3653-61.

243. DeCoteau JF, Butmarc JR, Kinney MC, et al. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood 1996; 87: 3437-41.

244. Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol 1993; 28: 973-80.

245. Kadin ME, Vonderheid EC, Weiss LM. Absence of Epstein-Barr viral RNA in lymphomatoid papulosis. J Pathol 1993; 170: 145-8.

246. Humme D, Lukowsky A, Steinhoff M, et al. Dominance of nonmalignant T-cell clones and distortion of the TCR repertoire in the peripheral blood of patients with cutaneous CD30+ lymphoproliferative disorders. J Invest Dermatol 2009; 129: 89-98.

247. Kamstrup MR, Ralfkiaer E, Skovgaard GL, et al. Potential involvement of Notch1 signalling in the pathogenesis of primary cutaneous CD30-positive lymphoproliferative disorders. Br J Dermatol 2008; 158: 747-53.

248. Thomsen K, Wantzin GL. Lymphomatoid papulosis. A follow-up study of 30 patients. J Am Acad Dermatol 1987; 17: 632-6.

249. Weinman VF, Ackerman AB. Lymphomatoid papulosis. A critical review and new findings. Am J Dermatopathol 1981; 3: 129-63.

250. Weiss LM, Wood GS, Trela M, et al. Clonal T-cell populations in lymphomatoid papulosis. Evidence of a lymphoproliferative origin for a clinically benign disease. N Engl J Med 1986; 315: 475-9.

251. Macaulay WL. Lymphomatoid papulosis: A continuing self-healing eruption, clinically benign—histologically malignant. Archives of Dermatology 1968; 97: 23-30.

252. Macaulay WL. Lymphomatoid papulosis update. A historical perspective. Arch Dermatol 1989; 125: 1387-9.

253. Kempf W, Kutzner H, Cozzio A, et al. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Br J Dermatol 2008; 158: 1280-7.

254. Assaf C, Hirsch B, Wagner F, et al. Differential expression of TRAF1 aids in the distinction of cutaneous CD30-positive lymphoproliferations. J Invest Dermatol 2007; 127: 1898-904.

255. Whittaker S, Smith N, Jones RR, et al. Analysis of beta, gamma, and delta T-cell receptor genes in lymphomatoid papulosis: cellular basis of two distinct histologic subsets. J Invest Dermatol 1991; 96: 786-91.

256. Steinhoff M, Hummel M, Anagnostopoulos I, et al. Single-cell analysis of CD30+ cells in lymphomatoid papulosis demonstrates a common clonal T-cell origin. Blood 2002; 100: 578-84.

257. Gellrich S, Wernicke M, Wilks A, et al. The Cell Infiltrate in Lymphomatoid Papulosis Comprises a Mixture of Polyclonal Large Atypical Cells (CD30-Positive) and Smaller Monoclonal T cells (CD30-Negative). Journal of Investigative Dermatology; 122: 859-61.

258. Kadin ME. Characteristic immunologic profile of large atypical cells in lymphomatoid papulosis. Possible implications for histogenesis and relationship to other diseases. Arch Dermatol 1986; 122: 1388-90.

259. Willemze R, Meyer CJ, Van Vloten WA, et al. The clinical and histological spectrum of lymphomatoid papulosis. Br J Dermatol 1982; 107: 131-44.

260. El Shabrawi-Caelen L, Kerl H, Cerroni L. Lymphomatoid papulosis: reappraisal of clinicopathologic presentation and classification into subtypes A, B, and C. Arch Dermatol 2004; 140: 441-7.

261. Magro CM, Crowson AN, Morrison C, et al. CD8+ lymphomatoid papulosis and its differential diagnosis. Am J Clin Pathol 2006; 125: 490-501.

262. Saggini A, Gulia A, Argenyi Z, et al. A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases. Am J Surg Pathol 2010; 34: 1168-75.

263. Cardoso J, Duhra P, Thway Y, et al. Lymphomatoid papulosis type D: a newly described variant easily confused with cutaneous aggressive CD8-positive cytotoxic T-cell lymphoma. Am J Dermatopathol 2012; 34: 762-5.

264. Black MM, Jones EW. "Lymphomatoid" pityriasis lichenoides: a variant with histological features simulating a lymphoma. A clinical and histopathological study of 15 cases with details of long term follow up. Br J Dermatol 1972; 86: 329-47.

265. Verallo VM, Haserick JR. Mucha-Habermann's disease simulating lymphoma cutis. Report of two cases. Arch Dermatol 1966; 94: 295-9.

266. Kempf W, Kazakov DV, Scharer L, et al. Angioinvasive lymphomatoid papulosis: a new variant simulating aggressive lymphomas. Am J Surg Pathol 2013; 37: 1-13.

267. Scarisbrick JJ, Evans AV, Woolford AJ, et al. Regional lymphomatoid papulosis: a report of four cases. Br J Dermatol 1999; 141: 1125-8.

268. Ashworth J, Paterson WD, MacKie RM. Lymphomatoid Papulosis/Pityriasis Lichenoides in Two Children. Pediatric Dermatology 1987; 4: 238-41.

269. Zirbel GM, Gellis SE, Kadin ME, et al. Lymphomatoid papulosis in children. J Am Acad Dermatol 1995; 33: 741-8.

270. Lederman JS, Sober AJ, Harrist TJ, et al. Lymphomatoid papulosis following Hodgkin's disease. J Am Acad Dermatol 1987; 16: 331-5.

271. Zackheim HS, LeBoit PE, Gordon BI, et al. Lymphomatoid papulosis followed by Hodgkin's lymphoma. Differential response to therapy. Arch Dermatol 1993; 129: 86-91.

272. Demierre MF, Goldberg LJ, Kadin ME, et al. Is it lymphoma or lymphomatoid papulosis? J Am Acad Dermatol 1997; 36: 765-72.

273. Basarab T, Fraser-Andrews EA, Orchard G, et al. Lymphomatoid papulosis in association with mycosis fungoides: a study of 15 cases. Br J Dermatol 1998; 139: 630-8.

274. Kadin ME. Lymphomatoid papulosis and associated lymphomas. How are they related? Arch Dermatol 1993; 129: 351-3.

275. Pierard GE, Ackerman AB, Lapiere CM. Follicular lymphomatoid papulosis. Am J Dermatopathol 1980; 2: 173-80.

276. de Souza A, el-Azhary RA, Camilleri MJ, et al. In search of prognostic indicators for lymphomatoid papulosis: a retrospective study of 123 patients. J Am Acad Dermatol 2012; 66: 928-37.

277. Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011; 118: 4024-35.

278. Lange Wantzin G, Thomsen K. Methotrexate in lymphomatoid papulosis. Br J Dermatol 1984; 111: 93-5.

279. Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol 1996; 34: 470-81.

280. Kleinhans M, Tun-Kyi A, Gilliet M, et al. Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma. Blood 2003; 101: 1487-93.

281. Boni R, Xin H, Kamarashev J, et al. Allelic deletion at 9p21-22 in primary cutaneous CD30(+) large cell lymphoma. J Invest Dermatol 2000; 115: 1104-7.

282. Mao X, Orchard G, Lillington DM, et al. Genetic alterations in primary cutaneous CD30+ anaplastic large cell lymphoma. Genes Chromosomes Cancer 2003; 37: 176-85.

283. Mao X, Orchard G, Russell-Jones R, et al. Abnormal activator protein 1 transcription factor expression in CD30-positive cutaneous large-cell lymphomas. Br J Dermatol 2007; 157: 914-21.

284. Wada DA, Law ME, Hsi ED, et al. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol 2011; 24: 596-605.

285. Beljaards RC, Kaudewitz P, Berti E, et al. Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis. A European Multicenter Study of 47 patients. Cancer 1993; 71: 2097-104.

286. Krishnan J, Tomaszewski MM, Kao GF. Primary cutaneous CD30-positive anaplastic large cell lymphoma. Report of 27 cases. J Cutan Pathol 1993; 20: 193-202.

287. Greisser J, Palmedo G, Sander C, et al. Detection of clonal rearrangement of T-cell receptor genes in the diagnosis of primary cutaneous CD30 lymphoproliferative disorders. J Cutan Pathol 2006; 33: 711-5.

288. Beljaards RC, Meijer CJ, Scheffer E, et al. Prognostic significance of CD30 (Ki-1/Ber-H2) expression in primary cutaneous large-cell lymphomas of T-cell origin. A clinicopathologic and immunohistochemical study in 20 patients. Am J Pathol 1989; 135: 1169-78.

289. Plaza JA, Feldman AL, Magro C. Cutaneous CD30-positive lymphoproliferative disorders with CD8 expression: a clinicopathologic study of 21 cases. J Cutan Pathol 2013; 40: 236-47.

290. Tomaszewski MM, Lupton GP, Krishnan J, et al. A comparison of clinical, morphological and immunohistochemical features of lymphomatoid papulosis and primary cutaneous CD30(Ki-1)-positive anaplastic large cell lymphoma. J Cutan Pathol 1995; 22: 310-8.

291. Liu HL, Hoppe RT, Kohler S, et al. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol 2003; 49: 1049-58.

292. Shehan JM, Kalaaji AN, Markovic SN, et al. Management of multifocal primary cutaneous CD30 anaplastic large cell lymphoma. J Am Acad Dermatol 2004; 51: 103-10.

293. Yu JB, Blitzblau RC, Decker RH, et al. Analysis of primary CD30+ cutaneous lymphoproliferative disease and survival from the Surveillance, Epidemiology, and End Results database. J Clin Oncol 2008; 26: 1483-8.

294. Yu JB, McNiff JM, Lund MW, et al. Treatment of primary cutaneous CD30+ anaplastic large-cell lymphoma with radiation therapy. Int J Radiat Oncol Biol Phys 2008; 70: 1542-5.

295. Duvic M, Reddy SA, Pinter-Brown L, et al. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res 2009; 15: 6217-24.

296. Willemze R, Jansen PM, Cerroni L, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 2008; 111: 838-45.

297. El Shabrawi-Caelen L, Cerroni L, Kerl H. The clinicopathologic spectrum of cytotoxic lymphomas of the skin. Semin Cutan Med Surg 2000; 19: 118-23.

298. Salhany KE, Macon WR, Choi JK, et al. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol 1998; 22: 881-93.

299. Hahtola S, Burghart E, Jeskanen L, et al. Clinicopathological characterization and genomic aberrations in subcutaneous panniculitis-like T-cell lymphoma. J Invest Dermatol 2008; 128: 2304-9.

300. Mehregan DA, Su WP, Kurtin PJ. Subcutaneous T-cell lymphoma: a clinical, histopathologic, and immunohistochemical study of six cases. J Cutan Pathol 1994; 21: 110-7.

301. Gonzalez CL, Medeiros LJ, Braziel RM, et al. T-cell lymphoma involving subcutaneous tissue. A clinicopathologic entity commonly associated with hemophagocytic syndrome. Am J Surg Pathol 1991; 15: 17-27.

302. Lozzi GP, Massone C, Citarella L, et al. Rimming of adipocytes by neoplastic lymphocytes: a histopathologic feature not restricted to subcutaneous T-cell lymphoma. Am J Dermatopathol 2006; 28: 9-12.

303. Perniciaro C, Winkelmann RK, Ehrhardt DR. Fatal systemic cytophagic histiocytic panniculitis: a histopathologic and immunohistochemical study of multiple organ sites. J Am Acad Dermatol 1994; 31: 901-5.

304. Massone C, Kodama K, Salmhofer W, et al. Lupus erythematosus panniculitis (lupus profundus): clinical, histopathological, and molecular analysis of nine cases. J Cutan Pathol 2005; 32: 396-404.

305. Kumar S, Krenacs L, Medeiros J, et al. Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T lymphocytes. Hum Pathol 1998; 29: 397-403.

306. Aronson IK, West DP, Variakojis D, et al. Panniculitis associated with cutaneous T-cell lymphoma and cytophagocytic histiocytosis. Br J Dermatol 1985; 112: 87-96.

307. Monterroso V, Bujan W, Jaramillo O, et al. Subcutaneous tissue involvement by T-cell lymphoma. A report of 2 cases. Arch Dermatol 1996; 132: 1345-50.

308. Perniciaro C, Zalla MJ, White JW, Jr., et al. Subcutaneous T-cell lymphoma. Report of two additional cases and further observations. Arch Dermatol 1993; 129: 1171-6.

309. Romero LS, Goltz RW, Nagi C, et al. Subcutaneous T-cell lymphoma with associated hemophagocytic syndrome and terminal leukemic transformation. J Am Acad Dermatol 1996; 34: 904-10.

310. Gonzalez EG, Selvi E, Lorenzini S, et al. Subcutaneous panniculitis-like T-cell lymphoma misdiagnosed as lupus erythematosus panniculitis. Clin Rheumatol 2007; 26: 244-6.

311. Guenova E, Schanz S, Hoetzenecker W, et al. Systemic corticosteroids for subcutaneous panniculitis-like T-cell lymphoma. Br J Dermatol 2014; 171: 891-4.

312. Rojnuckarin P, Nakorn TN, Assanasen T, et al. Cyclosporin in subcutaneous panniculitis-like T-cell lymphoma. Leuk Lymphoma 2007; 48: 560-3.

313. Hathaway T, Subtil A, Kuo P, et al. Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-cell lymphoma. Clin Lymphoma Myeloma 2007; 7: 541-5.

314. Mehta N, Wayne AS, Kim YH, et al. Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations. Clin Lymphoma Myeloma Leuk 2012; 12: 20-5.

315. Bashey S, Krathen M, Abdulla F, et al. Romidepsin is effective in subcutaneous panniculitis-like T-cell lymphoma. J Clin Oncol 2012; 30: e221-5.

316. Alaibac M, Berti E, Pigozzi B, et al. High-dose chemotherapy with autologous blood stem cell transplantation for aggressive subcutaneous panniculitis-like T-cell lymphoma. J Am Acad Dermatol 2005; 52: S121-3.

317. Ichii M, Hatanaka K, Imakita M, et al. Successful treatment of refractory subcutaneous panniculitis-like T-cell lymphoma with allogeneic peripheral blood stem cell transplantation from HLA-mismatched sibling donor. Leuk Lymphoma 2006; 47: 2250-2.

318. Sakurai E, Satoh T, Akiko Y-A, et al. Subcutaneous Panniculitis-Like T-Cell Lymphoma (SPTCL) with Hemophagocytosis (HPS) : Successful Treatment Using High-Dose Chemotherapy (BFM-NHL &amp; ALL-90) and Autologous Peripheral Blood Stem Cell Transplantation. Journal of Clinical and Experimental Hematopathology 2013; 53: 135-40.

319. Agnarsson BA, Vonderheid EC, Kadin ME. Cutaneous T cell lymphoma with suppressor/cytotoxic (CD8) phenotype: identification of rapidly progressive and chronic subtypes. J Am Acad Dermatol 1990; 22: 569-77.

320. Santucci M, Pimpinelli N, Massi D, et al. Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer 2003; 97: 610-27.

321. Robson A, Assaf C, Bagot M, et al. Aggressive epidermotropic cutaneous CD8+ lymphoma: a cutaneous lymphoma with distinct clinical and pathological features. Report of an EORTC Cutaneous Lymphoma Task Force Workshop. Histopathology 2015; 67: 425-41.

322. Petrella T, Maubec E, Cornillet-Lefebvre P, et al. Indolent CD8-positive lymphoid proliferation of the ear: a distinct primary cutaneous T-cell lymphoma? Am J Surg Pathol 2007; 31: 1887-92.

323. Greenblatt D, Ally M, Child F, et al. Indolent CD8(+) lymphoid proliferation of acral sites: a clinicopathologic study of six patients with some atypical features. J Cutan Pathol 2013; 40: 248-58.

324. Geraud C, Goerdt S, Klemke CD. Primary cutaneous CD8+ small/medium-sized pleomorphic T-cell lymphoma, ear-type: a unique cutaneous T-cell lymphoma with a favourable prognosis. Br J Dermatol 2011; 164: 456-8.

325. Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 2003; 101: 3407-12.

326. Berti E, Cerri A, Cavicchini S, et al. Primary cutaneous gamma/delta T-cell lymphoma presenting as disseminated pagetoid reticulosis. J Invest Dermatol 1991; 96: 718-23.

327. Munn SE, McGregor JM, Jones A, et al. Clinical and pathological heterogeneity in cutaneous gamma-delta T-cell lymphoma: a report of three cases and a review of the literature. Br J Dermatol 1996; 135: 976-81.

328. Guitart J, Weisenburger DD, Subtil A, et al. Cutaneous gammadelta T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. Am J Surg Pathol 2012; 36: 1656-65.

329. Battistella M, Beylot-Barry M, Bachelez H, et al. Primary cutaneous follicular helper T-cell lymphoma: a new subtype of cutaneous T-cell lymphoma reported in a series of 5 cases. Arch Dermatol 2012; 148: 832-9.

330. Ally MS, Prasad Hunasehally RY, Rodriguez-Justo M, et al. Evaluation of follicular T-helper cells in primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoma and dermatitis. J Cutan Pathol 2013; 40: 1006-13.

331. Cetinozman F, Jansen PM, Willemze R. Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma. Am J Surg Pathol 2012; 36: 109-16.

332. Beltraminelli H, Mullegger R, Cerroni L. Indolent CD8+ lymphoid proliferation of the ear: a phenotypic variant of the small-medium pleomorphic cutaneous T-cell lymphoma? J Cutan Pathol 2010; 37: 81-4.

333. Wobser M, Petrella T, Kneitz H, et al. Extrafacial indolent CD8-positive cutaneous lymphoid proliferation with unusual symmetrical presentation involving both feet. J Cutan Pathol 2013; 40: 955-61.

334. Garcia-Herrera A, Colomo L, Camos M, et al. Primary cutaneous small/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome. J Clin Oncol 2008; 26: 3364-71.

335. Friedmann D, Wechsler J, Delfau MH, et al. Primary cutaneous pleomorphic small T-cell lymphoma. A review of 11 cases. The French Study Group on Cutaneous Lymphomas. Arch Dermatol 1995; 131: 1009-15.

336. Sterry W, Siebel A, Mielke V. HTLV-1-negative pleomorphic T-cell lymphoma of the skin: the clinicopathological correlations and natural history of 15 patients. Br J Dermatol 1992; 126: 456-62.

337. Yamaguchi K. Human T-lymphotropic virus type I in Japan. Lancet 1994; 343: 213-6.

338. Pombo-de-Oliveira MS, Dobbin JA, Loureiro P, et al. Genetic mutation and early onset of T-cell leukemia in pediatric patients infected at birth with HTLV-I. Leuk Res 2002; 26: 155-61.

339. Glowacka I, Korn K, Potthoff SA, et al. Delayed seroconversion and rapid onset of lymphoproliferative disease after transmission of human T-cell lymphotropic virus type 1 from a multiorgan donor. Clin Infect Dis 2013; 57: 1417-24.

340. Taylor G. Molecular aspects of HTLV-I infection and adult T-cell leukaemia/lymphoma. J Clin Pathol 2007; 60: 1392-6.

341. Agar N, Morris S, Russell-Jones R, et al. Case report of four patients with erythrodermic cutaneous T-cell lymphoma and severe photosensitivity mimicking chronic actinic dermatitis. Br J Dermatol 2009; 160: 698-703.

342. Amano M, Kurokawa M, Ogata K, et al. New entity, definition and diagnostic criteria of cutaneous adult T-cell leukemia/lymphoma: human T-lymphotropic virus type 1 proviral DNA load can distinguish between cutaneous and smoldering types. J Dermatol 2008; 35: 270-5.

343. Yamaguchi T, Ohshima K, Karube K, et al. Clinicopathological features of cutaneous lesions of adult T-cell leukaemia/ lymphoma. Br J Dermatol 2005; 152: 76-81.

344. Lessin SR, Vowels BR, Rook AH. Retroviruses and cutaneous T-cell lymphoma. Dermatol Clin 1994; 12: 243-53.

345. DiCaudo DJ, Perniciaro C, Worrell JT, et al. Clinical and histologic spectrum of human T-cell lymphotropic virus type I-associated lymphoma involving the skin. J Am Acad Dermatol 1996; 34: 69-76.

346. Whittaker SJ, Ng YL, Rustin M, et al. HTLV-1-associated cutaneous disease: a clinicopathological and molecular study of patients from the U.K. Br J Dermatol 1993; 128: 483-92.

347. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 1991; 79: 428-37.

348. Bunn PA, Jr., Schechter GP, Jaffe E, et al. Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med 1983; 309: 257-64.

349. Ohshima K, Suzumiya J, Kato A, et al. Clonal HTLV-I-infected CD4+ T-lymphocytes and non-clonal non-HTLV-I-infected giant cells in incipient ATLL with Hodgkin-like histologic features. Int J Cancer 1997; 72: 592-8.

350. Adachi Y, Horio T. Chronic actinic dermatitis in a patient with adult T-cell leukemia. Photodermatol Photoimmunol Photomed 2008; 24: 147-9.

351. Smadja D, Bellance R, Cabre P, et al. Clinical characteristics of HTLV-1 associated dermato-polymyositis. Seven cases from Martinique. Acta Neurol Scand 1995; 92: 206-12.

352. Brites C, Weyll M, Pedroso C, et al. Severe and Norwegian scabies are strongly associated with retroviral (HIV-1/HTLV-1) infection in Bahia, Brazil. Aids 2002; 16: 1292-3.

353. Blas M, Bravo F, Castillo W, et al. Norwegian scabies in Peru: the impact of human T cell lymphotropic virus type I infection. Am J Trop Med Hyg 2005; 72: 855-7.

354. Goncalves DU, Guedes AC, Proietti AB, et al. Dermatologic lesions in asymptomatic blood donors seropositive for human T cell lymphotropic virus type-1. Am J Trop Med Hyg 2003; 68: 562-5.

355. Mayer EF, Ita F, Gonzalez E, et al. Association between onychodystrophy and human T-lymphotropic virus type 1 infection. Int J Infect Dis 2013; 17: e312-6.

356. Amano M, Setoyama M, Grant A, et al. Human T-lymphotropic virus 1 (HTLV-1) infection--dermatological implications. Int J Dermatol 2011; 50: 915-20.

357. Blas MM, Alva IE, Garcia PJ, et al. Association between human papillomavirus and human T-lymphotropic virus in indigenous women from the Peruvian Amazon. PLoS One 2012; 7: e44240.

358. Hirata T, Uchima N, Kishimoto K, et al. Impairment of host immune response against strongyloides stercoralis by human T cell lymphotropic virus type 1 infection. Am J Trop Med Hyg 2006; 74: 246-9.

359. Vandamme AM, Van Laethem K, Liu HF, et al. Use of a generic polymerase chain reaction assay detecting human T-lymphotropic virus (HTLV) types I, II and divergent simian strains in the evaluation of individuals with indeterminate HTLV serology. J Med Virol 1997; 52: 1-7.

360. Ishitsuka K, Tamura K. Treatment of adult T-cell leukemia/lymphoma: past, present, and future. Eur J Haematol 2008; 80: 185-96.

361. Bazarbachi A, Ghez D, Lepelletier Y, et al. New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol 2004; 5: 664-72.

362. Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012; 30: 837-42.

363. Shiratori S, Yasumoto A, Tanaka J, et al. A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia/lymphoma (ATL): clinical impact of graft-versus-leukemia/lymphoma effect. Biol Blood Marrow Transplant 2008; 14: 817-23.

364. Kern WF, Spier CM, Hanneman EH, et al. Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement. Blood 1992; 79: 2432-7.

365. Wong KF, Chan JK, Ng CS, et al. CD56 (NKH1)-positive hematolymphoid malignancies: an aggressive neoplasm featuring frequent cutaneous/mucosal involvement, cytoplasmic azurophilic granules, and angiocentricity. Hum Pathol 1992; 23: 798-804.

366. Kanavaros P, Lescs MC, Briere J, et al. Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 1993; 81: 2688-95.

367. Chan JK, Sin VC, Wong KF, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997; 89: 4501-13.

368. Rodriguez-Pinilla SM, Barrionuevo C, Garcia J, et al. EBV-associated cutaneous NK/T-cell lymphoma: review of a series of 14 cases from peru in children and young adults. Am J Surg Pathol 2010; 34: 1773-82.

369. Siu LL, Wong KF, Chan JK, et al. Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations. Am J Pathol 1999; 155: 1419-25.

370. Nakashima Y, Tagawa H, Suzuki R, et al. Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk/T-cell lymphoma, nasal type. Genes Chromosomes Cancer 2005; 44: 247-55.

371. Iwatsuki K, Satoh M, Yamamoto T, et al. Pathogenic link between hydroa vacciniforme and Epstein-Barr virus-associated hematologic disorders. Arch Dermatol 2006; 142: 587-95.

372. Chen HH, Hsiao CH, Chiu HC. Hydroa vacciniforme-like primary cutaneous CD8-positive T-cell lymphoma. Br J Dermatol 2002; 147: 587-91.

373. Iwatsuki K, Ohtsuka M, Akiba H, et al. Atypical hydroa vacciniforme in childhood: from a smoldering stage to Epstein-Barr virus-associated lymphoid malignancy. J Am Acad Dermatol 1999; 40: 283-4.

374. Barrionuevo C, Anderson VM, Zevallos-Giampietri E, et al. Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol 2002; 10: 7-14.

375. Tomita N, Kanamori H, Fujimaki K, et al. Epstein-Barr virus-associated extranodal NK/T-cell lymphoma following mosquito bites in an elderly patient without prior hypersensitivity. Leuk Lymphoma 2004; 45: 2153-5.

376. Mraz-Gernhard S, Natkunam Y, Hoppe RT, et al. Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course. J Clin Oncol 2001; 19: 2179-88.

377. Nakamura S, Suchi T, Koshikawa T, et al. Clinicopathologic study of CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract. Am J Surg Pathol 1995; 19: 284-96.

378. Massone C, Chott A, Metze D, et al. Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin: a morphologic, immunophenotypic, and molecular study of 50 patients. Am J Surg Pathol 2004; 28: 719-35.

379. Child FJ, Mitchell TJ, Whittaker SJ, et al. Blastic natural killer cell and extranodal natural killer cell-like T-cell lymphoma presenting in the skin: report of six cases from the UK. Br J Dermatol 2003; 148: 507-15.

380. Wong KF, Chan JK, Ng CS. CD56 (NCAM)-positive malignant lymphoma. Leuk Lymphoma 1994; 14: 29-36.

381. Jia H, Sun T. Extranodal NK/T-cell lymphoma mimicking cellulitis. Leuk Lymphoma 2004; 45: 1467-70.

382. Dunleavy K, Wilson WH, Jaffe ES. Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications. Current Opinion in Hematology 2007; 14: 348-53.

383. Lachenal F, Berger F, Ghesquieres H, et al. Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients. Medicine (Baltimore) 2007; 86: 282-92.

384. Martel P, Laroche L, Courville P, et al. Cutaneous involvement in patients with angioimmunoblastic lymphadenopathy with dysproteinemia: a clinical, immunohistological, and molecular analysis. Arch Dermatol 2000; 136: 881-6.

385. Jayaraman AG, Cassarino D, Advani R, et al. Cutaneous involvement by angioimmunoblastic T-cell lymphoma: a unique histologic presentation, mimicking an infectious etiology. J Cutan Pathol 2006; 33 Suppl 2: 6-11.

386. Huang C-T, Chuang S-S. Angioimmunoblastic T-Cell Lymphoma With Cutaneous Involvement: A Case Report With Subtle Histologic Changes and Clonal T-Cell Proliferation. Archives of Pathology & Laboratory Medicine 2004; 128: e122-e4.

387. Yoon GS, Chang SE, Kim HH, et al. Cutaneous relapse of angioimmunoblastic lymphadenopathy-type peripheral T-cell lymphoma mimicking an exanthematous drug eruption. Int J Dermatol 2003; 42: 816-8.

388. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000; 36: 69-86.

389. Hallermann C, Middel P, Griesinger F, et al. CD4+ CD56+ blastic tumor of the skin: cytogenetic observations and further evidence of an origin from plasmocytoid dendritic cells. Eur J Dermatol 2004; 14: 317-22.

390. Mao X, Onadim Z, Price EA, et al. Genomic alterations in blastic natural killer/extranodal natural killer-like T cell lymphoma with cutaneous involvement. J Invest Dermatol 2003; 121: 618-27.

391. Dijkman R, van Doorn R, Szuhai K, et al. Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood 2007; 109: 1720-7.

392. Petrella T, Bagot M, Willemze R, et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol 2005; 123: 662-75.

393. Petrella T, Comeau MR, Maynadie M, et al. 'Agranular CD4+ CD56+ hematodermic neoplasm' (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 2002; 26: 852-62.

394. Petrella T, Meijer CJ, Dalac S, et al. TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. Am J Clin Pathol 2004; 122: 307-13.

395. Hashikawa K, Niino D, Yasumoto S, et al. Clinicopathological features and prognostic significance of CXCL12 in blastic plasmacytoid dendritic cell neoplasm. J Am Acad Dermatol 2012; 66: 278-91.

396. Petrella T, Dalac S, Maynadie M, et al. CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Francais d'Etude des Lymphomes Cutanes (GFELC). Am J Surg Pathol 1999; 23: 137-46.

397. Bekkenk MW, Jansen PM, Meijer CJ, et al. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol 2004; 15: 1097-108.

398. Gilis L, Lebras L, Bouafia-Sauvy F, et al. Sequential combination of high dose methotrexate and L-asparaginase followed by allogeneic transplant: a first-line strategy for CD4+/CD56+ hematodermic neoplasm. Leuk Lymphoma 2012; 53: 1633-7.

**Kutanöz B hücreli lenfomalar**

1. Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood . 1997 Jul 1 [cited 2017 Oct 30];90(1):354–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9207472

2. Fink-Puches R, Zenahlik P, Bäck B, Smolle J, Kerl H, Cerroni L. Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients. Blood . 2002 Feb 1 [cited 2017 Oct 30];99(3):800–5.

3. Willemze R. Thirty years of progress in cutaneous lymphoma research. G Ital Dermatol Venereol . 2012;147(6):515–21.

4. Willemze R. Primary cutaneous B-cell lymphoma: classification and treatment. Curr Opin Oncol . 2006;18(5):425–31.

5. Suárez AL, Pulitzer M, Horwitz S, Moskowitz A, Querfeld C, Myskowski PL. Primary cutaneous B-cell lymphomas. J Am Acad Dermatol . 2013;69(3):329.e1-329.e13.

6. Grange F, Hedelin G, Joly P, et al. Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome. The French Study Group on Cutaneous Lymphomas. Blood . 1999;93(11):3637–42.

7. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood . 2005;105(10):3768–85.

8. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood . 2016;127(20):2375–90.

9. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood . 2009 ;113(21):5064–73.

10. Ferreri AJM, Campo E, Seymour JF, et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the “cutaneous variant.” Br J Haematol . 2004;127(2):173–83.

11. Swerdlow SH, Jaffe ES, Brousset P, et al. Cytotoxic T-cell and NK-cell Lymphomas. Am J Surg Pathol . 2014;38(10):e60–71.

12. Zinzani PL, Quaglino P, Pimpinelli N, et al. Prognostic Factors in Primary Cutaneous B-Cell Lymphoma: The Italian Study Group for Cutaneous Lymphomas. J Clin Oncol . 2006;24(9):1376–82.

13. Bouaziz J-D, Bastuji-Garin S, Poszepczynska-Guigne E, Wechsler J, Bagot M. Relative frequency and survival of patients with primary cutaneous lymphomas: data from a single-centre study of 203 patients. Br J Dermatol . 2006;154(6):1206–7.

14. Kim BK, Surti U, Pandya A, Cohen J, Rabkin MS, Swerdlow SH. Clinicopathologic, immunophenotypic, and molecular cytogenetic fluorescence in situ hybridization analysis of primary and secondary cutaneous follicular lymphomas. Am J Surg Pathol . 2005;29(1):69–82.

15. Bekkenk MW, Vermeer MH, Geerts ML, et al. Treatment of multifocal primary cutaneous B-cell lymphoma: a clinical follow-up study of 29 patients. J Clin Oncol . 1999;17(8):2471–8.

16. Grange F, Bekkenk MW, Wechsler J, et al. Prognostic Factors in Primary Cutaneous Large B-Cell Lymphomas: A European Multicenter Study. J Clin Oncol . 2001 Aug;19(16):3602–10.

17. Golling P, Cozzio A, Dummer R, French L, Kempf W. Primary cutaneous B-cell lymphomas – Clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome. Leuk Lymphoma . 2008;49(6):1094–103.

18. Massone C, Fink-Puches R, Laimer M, Rütten A, Vale E, Cerroni L. Miliary and agminated-type primary cutaneous follicle center lymphoma: Report of 18 cases. J Am Acad Dermatol . 2011;65(4):749–55.

19. Soon CWM, Pincus LB, Ai WZ, McCalmont TH. Acneiform presentation of primary cutaneous follicle center lymphoma. J Am Acad Dermatol . 2011;65(4):887–9.

20. Barzilai A, Feuerman H, Quaglino P, et al. Cutaneous B-Cell Neoplasms Mimicking Granulomatous Rosacea or Rhinophyma. Arch Dermatol . 2012;148(7):824–31.

21. Kluk J, Charles-Holmes R, Carr RA. Primary cutaneous follicle centre cell lymphoma of the scalp presenting with scarring alopecia. Br J Dermatol . 2011;165(1):205–7.

22. Goodlad JR, Krajewski AS, Batstone PJ, et al. Primary cutaneous diffuse large B-cell lymphoma: prognostic significance of clinicopathological subtypes. Am J Surg Pathol . 2003;27(12):1538–45.

23. Kodama K, Massone C, Chott A, Metze D, Kerl H, Cerroni L. Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood . 2005;106(7):2491–7.

24. Gulia A, Saggini A, Wiesner T, et al. Clinicopathologic features of early lesions of primary cutaneous follicle center lymphoma, diffuse type: Implications for early diagnosis and treatment. J Am Acad Dermatol . 2011;65(5):991–1000.e7.

25. Pimpinelli N, Santucci M, Carli P, et al. Primary cutaneous follicular center cell lymphoma: clinical and histological aspects. Curr Probl Dermatol . 1990;19:203–20.

26. Santucci M, Pimpinelli N. Primary cutaneous B-cell lymphomas. Current concepts. I. Haematologica . 2004;89(11):1360–71.

27. Leinweber B, Colli C, Chott A, Kerl H, Cerroni L. Differential diagnosis of cutaneous infiltrates of B lymphocytes with follicular growth pattern. Am J Dermatopathol . 2004;26(1):4–13.

28. Hoefnagel JJ, Vermeer MH, Jansen PM, Fleuren GJ, Meijer CJLM, Willemze R. Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance. Br J Dermatol . 2003;149(6):1183–91.

29. Cerroni L, Volkenandt M, Rieger E, Soyer HP, Kerl H. bcl-2 protein expression and correlation with the interchromosomal 14;18 translocation in cutaneous lymphomas and pseudolymphomas. J Invest Dermatol . 1994;102(2):231–5.

30. Child FJ, Russell-Jones R, Woolford AJ, et al. Absence of the t(14;18) chromosomal translocation in primary cutaneous B-cell lymphoma. Br J Dermatol . 2001;144(4):735–44.

31. de Leval L, Ferry JA, Falini B, Shipp M, Harris NL. Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma: evidence for derivation from germinal center B cells? Am J Surg Pathol . 2001;25(10):1277–82.

32. Senff NJ, Hoefnagel JJ, Jansen PM, et al. Reclassification of 300 Primary Cutaneous B-Cell Lymphomas According to the New WHO–EORTC Classification for Cutaneous Lymphomas: Comparison With Previous Classifications and Identification of Prognostic Markers. J Clin Oncol . 2007;25(12):1581–7.

33. Cerroni L, El-Shabrawi-Caelen L, Fink-Puches R, LeBoit PE, Kerl H. Cutaneous spindle-cell B-cell lymphoma: a morphologic variant of cutaneous large B-cell lymphoma. Am J Dermatopathol . 2000;22(4):299–304.

34. Goteri G, Ranaldi R, Simonetti O, et al. Clinicopathological features of primary cutaneous B-cell lymphomas from an academic regional hospital in central Italy: No evidence of Borrelia burgdorferi association. Leuk Lymphoma . 2007;48(11):2184–8.

35. Ponzoni M, Ferreri AJM, Mappa S, Pasini E, Govi S, Facchetti F, et al. Prevalence of Borrelia Burgdorferi Infection in a Series of 98 Primary Cutaneous Lymphomas. Oncologist . 2011;16(11):1582–8.

36. Wood GS, Kamath N V, Guitart J, et al. Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States. J Cutan Pathol . 2001;28(10):502–7.

37. Gerami P, Wickless SC, Querfeld C, Rosen ST, Kuzel TM, Guitart J. Cutaneous involvement with marginal zone lymphoma. J Am Acad Dermatol . 2010;63(1):142–5.

38. Ghatalia P, Porter J, Wroblewski D, Carlson JA. Primary cutaneous marginal zone lymphoma associated with juxta-articular fibrotic nodules in a teenager. J Cutan Pathol . 2013;40(5):477–84.

39. Cerroni L, Signoretti S, Höfler G, et al. Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. Am J Surg Pathol . 1997;21(11):1307–15.

40. Hamilton SN, Wai ES, Tan K, Alexander C, Gascoyne RD, Connors JM. Treatment and Outcomes in Patients With Primary Cutaneous B-Cell Lymphoma: The BC Cancer Agency Experience. Int J Radiat Oncol . 2013;87(4):719–25.

41. Magro CM, Yang A, Fraga G. Blastic Marginal Zone Lymphoma. Am J Dermatopathol . 2013;35(3):319–26.

42. Baldassano MF, Bailey EM, Ferry JA, Harris NL, Duncan LM. Cutaneous lymphoid hyperplasia and cutaneous marginal zone lymphoma: comparison of morphologic and immunophenotypic features. Am J Surg Pathol . 1999;23(1):88–96.

43. Cho-Vega JH, Vega F, Rassidakis G, Medeiros LJ. Primary cutaneous marginal zone B-cell lymphoma. Am J Clin Pathol . 2006;125 Suppl:S38-49.

44. Lee BA, Jacobson M, Seidel G. Epidermotropic marginal zone lymphoma simulating mycosis fungoides †. J Cutan Pathol . 2013;40(6):569–72.

45. Magro CM, Momtahen S, Lee BA, Swanson DL, Pavlovic MD. Epidermotropic B-Cell Lymphoma. Am J Dermatopathol . 2016;38(2):105–12.

46. Hope CB, Pincus LB. Primary Cutaneous B-cell Lymphomas. Clin Lab Med . 2017;37(3):547–74.

47. Hoefnagel JJ, Vermeer MH, Jansen PM, et al. Primary Cutaneous Marginal Zone B-Cell Lymphoma. Arch Dermatol . 2005;141(9):1139.

48. Edinger JT, Kant JA, Swerdlow SH. Cutaneous Marginal Zone Lymphomas Have Distinctive Features and Include 2 Subsets. Am J Surg Pathol . 2010;34(12):1830–41.

49. van Maldegem F, van Dijk R, Wormhoudt TAM, et al. The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develops in a T-helper type 2 inflammatory environment. Blood . 2008;112(8):3355–61.

50. Hallermann C, Kaune KM, Siebert R, et al. Chromosomal Aberration Patterns Differ in Subtypes of Primary Cutaneous B Cell Lymphomas. J Invest Dermatol . 2004;122(6):1495–502.

51. Streubel B, Chott A, Huber D, et al. Lymphoma-Specific Genetic Aberrations in Microvascular Endothelial Cells in B-Cell Lymphomas. N Engl J Med . 2004;351(3):250–9.

52. Monsálvez V, Montes-Moreno S, Artiga MJ, et al. MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma. Mod Pathol . 2013;26(2):171–81.

53. Gerami P, Wickless SC, Rosen S, et al. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma. J Am Acad Dermatol . 2008;59(2):245–54.

54. Bathelier E, Thomas L, Balme B, et al. Asymptomatic bone marrow involvement in patients presenting with cutaneous marginal zone B-cell lymphoma. Br J Dermatol . 2008;159(2):498–500.

55. Servitje O, Gallardo F, Estrach T, et al. Primary cutaneous marginal zone B-cell lymphoma: a clinical, histopathological, immunophenotypic and molecular genetic study of 22 cases. Br J Dermatol . 2002;147(6):1147–58.

56. Belousova IE, Vanecek T, Skreg S V, Rodionov AN, Samtsov A V, Kazakov D V. Unusual clinicopathological presentation of primary cutaneous diffuse large B-cell lymphoma, leg type, with multiple nodules and widespread garland-like lesions. Am J Dermatopathol . 2009;31(4):370–4.

57. Gokdemir G, Ari S, Altunay I, Polat N, Kutlubay Z. Primary cutaneous diffuse large B-cell lymphoma of the leg, with an atypical clinical picture of verrucous plaques associated with stasis dermatitis. Clin Exp Dermatol . 2010;35(3):e87–9.

58. Vermeer MH, Geelen FA, van Haselen CW, et al. Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group. Arch Dermatol . 1996;132(11):1304–8.

59. Hristov AC. Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: Diagnostic Considerations. Arch Pathol Lab Med . 2012;136(8):876–81.

60. Plaza JA, Kacerovska D, Stockman DL, et al. The Histomorphologic Spectrum of Primary Cutaneous Diffuse Large B-Cell Lymphoma: A Study of 79 Cases. Am J Dermatopathol . 2011;33(7):649–58.

61. Charli-Joseph Y, Cerroni L, LeBoit PE. Cutaneous Spindle-Cell B-Cell Lymphomas. Am J Surg Pathol . 2015;39(6):737–43.

62. Grange F, Petrella T, Beylot-Barry M, et al. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. Blood . 2004;103(10):3662–8.

63. Pimpinelli N, Santucci M, Giannotti B. Cutaneous B-cell lymphomas: facts and open issues. J Eur Acad Dermatol Venereol . 2004;18(2):126–8.

64. Hallermann C, Niermann C, Fischer R, Schulze H. Survival Data for 299 Patients with Primary Cutaneous Lymphomas: A Monocentre Study. Acta Derm Venereol . 2011;91(5):521–5.

65. Grange F, Beylot-Barry M, Courville P, et al. Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. Arch Dermatol . 2007;143(9):1144–50.

66. Murase T, Nakamura S, Kawauchi K, et al. An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome. Br J Haematol . 2000;111(3):826–34.

67. Ponzoni M, Ferreri AJM, Campo E, et al. Definition, Diagnosis, and Management of Intravascular Large B-Cell Lymphoma: Proposals and Perspectives From an International Consensus Meeting. J Clin Oncol . 2007;25(21):3168–73.

68. Sander CA, Flaig MJ, Jaffe ES. Cutaneous manifestations of lymphoma: a clinical guide based on the WHO classification. World Health Organization. Clin Lymphoma . 2001;2(2):86-100-2.

69. Klemke C-D. Cutaneous lymphomas. JDDG J der Dtsch Dermatologischen Gesellschaft . 2013;n/a-n/a. (Ahead of print)

70. Rubin MA, Cossman J, Freter CE, Azumi N. Intravascular large cell lymphoma coexisting within hemangiomas of the skin. Am J Surg Pathol . 1997;21(7):860–4.

71. Murase T, Yamaguchi M, Suzuki R, et al. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood . 2007;109(2):478–85.

72. Saurel CA, Personett DA, Edenfield BH, et al. Molecular analysis of intravascular large B-cell lymphoma with neoangiogenesis. Br J Haematol . 2011;152(2):234–6.

73. Ponzoni M, Arrigoni G, Gould VE, et al. Lack of CD 29 (beta1 integrin) and CD 54 (ICAM-1) adhesion molecules in intravascular lymphomatosis. Hum Pathol . 2000;31(2):220–6.

74. Kinoshita M, Izumoto S, Hashimoto N, et al. Immunohistochemical analysis of adhesion molecules and matrix metalloproteinases in malignant CNS lymphomas: a study comparing primary CNS malignant and CNS intravascular lymphomas. Brain Tumor Pathol . 2008;25(2):73–8.

75. Flaitz CM, Nichols CM, Walling DM, Hicks MJ. Plasmablastic lymphoma: an HIV-associated entity with primary oral manifestations. Oral Oncol . 2002;38(1):96–102.

76. Castillo JJ. Plasmablastic lymphoma: Are more intensive regimens needed? Leuk Res . 2011;35(12):1547–8.

77. Montes-Moreno S, Montalbán C, Piris MA. Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge. Leuk Lymphoma . 2012;53(2):185–94.

78. Colomo L, Loong F, Rives S, et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol . 2004;28(6):736–47.

79. Vezzoli P, Fiorani R, Girgenti V, et al. Cutaneous T-Cell/Histiocyte-Rich B-Cell Lymphoma: A Case Report and Review of the Literature. Dermatology . 2011;222(3):225–30.

80. Magro CM, Nash JW, Werling RW, Porcu P, Crowson N. Primary Cutaneous CD30+ Large Cell B-Cell Lymphoma. Appl Immunohistochem Mol Morphol . 2006;14(1):7–11.

81. Lima M. Cutaneous primary B-cell lymphomas: from diagnosis to treatment. An Bras Dermatol . 2015;90(5):687–706.

***Kutanöz B hücreli lenfomalar tedavi ve takibi***

1. Neelis KJ, Schimmel EC, Vermeer MH, Senff NJ, Willemze R, Noordijk EM. Low-Dose Palliative Radiotherapy for Cutaneous B- and T-Cell Lymphomas. Int J Radiat Oncol . 2009; 74(1): 154–8.

2. Senff NJ, Noordijk EM, Kim YH, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood . 2008; 112(5): 1600–9.

3. Suárez AL, Querfeld C, Horwitz S, Pulitzer M, Moskowitz A, Myskowski PL. Primary cutaneous B-cell lymphomas. J Am Acad Dermatol . 2013; 69(3): 343.e1-343.e11.

4. Zinzani PL, Tani M, Fanti S, et al. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol . 2007; 19(4): 769–73.

5. Piccinno R, Caccialanza M, Berti E. Dermatologic radiotherapy of primary cutaneous follicle center cell lymphoma. Eur J Dermatol . 2003; 13(1): 49–52.

6. Senff NJ, Willemze R. The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: results on a large cohort of primary cutaneous B-cell lymphomas and comparison with the system used by the Dutch Cutaneous Lymphoma Group. Br J Dermatol . 2007; 157(6): 1205–11.

7. Gulia A, Saggini A, Wiesner T, et al. Clinicopathologic features of early lesions of primary cutaneous follicle center lymphoma, diffuse type: Implications for early diagnosis and treatment. J Am Acad Dermatol . 2011; 65(5): 991–1000.e7.

8. Pashtan I, Mauch PM, Chen Y-H, Dorfman DM, Silver B, Ng AK. Radiotherapy in the management of localized primary cutaneous B-cell lymphoma. Leuk Lymphoma . 2013; 54(4): 726–30.

9. Parbhakar S, Cin AD. Primary cutaneous B-cell lymphoma: Role of surgery. Can J Plast Surg . 2011; 19(2): e12-4.

10. Zelenetz AD, Abramson JS, Advani RH, et al. Non-Hodgkin’s lymphomas. J Natl Compr Canc Netw . 2011; 9(5): 484–560.

11. Farkas A, Kemeny L, French LE, Dummer R. New and Experimental Skin-Directed Therapies for Cutaneous Lymphomas. Skin Pharmacol Physiol . 2009; 22(6): 322–34.

12. Perry A, Vincent BJ, Parker SRS. Intralesional corticosteroid therapy for primary cutaneous B-cell lymphoma. Br J Dermatol . 2010; 163(1): 223-5.

13. Kütting B, Bonsmann G, Metze D, Luger TA, Cerroni L. Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. J Am Acad Dermatol . 1997; 36(2 Pt 2): 311–4.

14. Zenone T, Catimel G, Barbet N, Clavel M. Complete remission of a primary cutaneous B cell lymphoma treated with intralesional recombinant interferon alpha-2a. Eur J Cancer . 1994; 30A(2): 246–7.

15. Coors EA, Schuler G, Von Den Driesch P. Topical imiquimod as treatment for different kinds of cutaneous lymphoma. Eur J Dermatol . 2006; 16(4): 391–3.

16. Richmond HM, Lozano A, Jones D, Duvic M. Primary Cutaneous Follicle Center Lymphoma Associated with Alopecia Areata. Clin Lymphoma Myeloma . 2008; 8(2): 121–4.

17. Bello C, Sotomayor EM. Monoclonal Antibodies for B-Cell Lymphomas: Rituximab and Beyond. Hematology . 2007; 2007(1): 233–42.

18. Marcus R. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin’s lymphoma. Semin Oncol . 2005; 32(1 Suppl 1): 36–43.

19. Morales A V., Advani R, Horwitz SM, et al. Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab. J Am Acad Dermatol . 2008; 59(6): 953–7.

20. Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol . 2005; 52(5): 847–53.

21. Peñate Y, Hernández-Machín B, Pérez-Méndez LI, et al. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma. Br J Dermatol . 2012; 167(1): 174–9.

22. Sokol L, Naghashpour M, Glass LF. Primary Cutaneous B-Cell Lymphomas: Recent Advances in Diagnosis and Management. Cancer Control . 2012; 19(3): 236–44.

23. Maza S, Gellrich S, Assaf C, et al. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in primary cutaneous B-cell lymphomas: first results of a prospective, monocentre study. Leuk Lymphoma . 2008; 49(9): 1702–9.

24. Dummer R, Hauschild A, Jost L, ESMO Guidelines Working Group. Cutaneous malignant melanoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol . 2008; 19(Supplement 2): ii86-ii88.

25. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood . 2005; 105(10): 3768–85.

26. Sharon V, Mecca PS, Steinherz PG, Trippett TM, Myskowski PL. Two pediatric cases of primary cutaneous B-cell lymphoma and review of the literature. Pediatr Dermatol . 2009; 26(1): 34–9.

27. Hoefnagel JJ, Vermeer MH, Jansen PM, et al. Primary Cutaneous Marginal Zone B-Cell Lymphoma. Arch Dermatol . 2005; 141(9): 1139.

28. Kennedy-Crispin M, Myskowski PL. Cryotherapy for primary cutaneous B-cell lymphoma. J Am Acad Dermatol . 2012; 67(6): e292–4.

29. Cozzio A, Kempf W, Schmid-Meyer R, et al. Intra-lesional low-dose interferon α2a therapy for primary cutaneous marginal zone B-cell lymphoma. Leuk Lymphoma . 2006; 47(5): 865–9.

30. Kyrtsonis M-C, Siakantaris MP, Kalpadakis C, et al. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. Eur J Haematol . 2006; 77(4): 300–3.

31. Cerroni L, Zöchling N, Pütz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol . 1997; 24(8): 457–61.

32. Kim MJ, Hong ME, Maeng CH, et al. Clinical features and treatment outcomes of primary cutaneous B-cell lymphoma: a single-center analysis in South Korea. Int J Hematol . 2015; 101(3): 273–8.

33. Grange F, Bekkenk MW, Wechsler J, et al. Prognostic Factors in Primary Cutaneous Large B-Cell Lymphomas: A European Multicenter Study. J Clin Oncol . 2001; 19(16): 3602–10.

34. Grange F, Beylot-Barry M, Courville P, et al. Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. Arch Dermatol . 2007; 143(9): 1144–50.

35. Fenot M, Quereux G, Brocard A, Renaut J-J, Dreno B. Rituximab for primary cutaneous diffuse large B-cell lymphoma-leg type. Eur J Dermatol . 2010; 20(6): 753–7.

36. Dummer R, Eichmüller S, Gellrich S, et al. Phase II Clinical Trial of Intratumoral Application of TG1042 (Adenovirus-interferon-γ) in Patients With Advanced Cutaneous T-cell Lymphomas and Multilesional Cutaneous B-cell Lymphomas. Mol Ther . 2010; 18(6): 1244–7.

37. Roschewski M, Dunleavy K, Wilson WH. Diffuse large B cell lymphoma: molecular targeted therapy. Int J Hematol . 2012; 96(5): 552–61.

38. Quintás-Cardama A, Kantarjian H, Cortes J. Third-Generation Tyrosine Kinase Inhibitors and Beyond. Semin Hematol . 2010; 47(4): 371–80.

39. Klemke C-D. Cutaneous lymphomas. JDDG J der Dtsch Dermatologischen Gesellschaft . 2014; 12(1): 7–30.

**Histiyositozis**

1. Jaffe R. The diagnostic histopathology of Langerhans cell histiocytosis. In: Histiocytic Disorders of Children and Adults. Basic Science, Clinical Features, and Therapy, Weitzman S, Egeler RM (Eds), Cambridge University Press, Cambridge 2005. p.14.

2. Jaffe R, Weiss LM, Facchetti F. Tumours derived from Langerhans cells. In: World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al (Eds), IARC Press, Lyon 2008. p.358.

3. Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016; 127:2672.

4. Stein SL, Paller AS, Haut PR, Mancini AJ. Langerhans cell histiocytosis presenting in the neonatal period: a retrospective case series. Arch Pediatr Adolesc Med. 2001 Jul;155(7):778-83.

5. Willman CL, Busque L, Griffith BB, Favara BE, McClain KL, Duncan MH, et al. Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. N Engl J Med. 1994;331:154–160.

6. Kenneth L McClain. Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis [internet] [cited 28 december 2017] Available from: https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-langerhans-cell-histiocytosis

7. Carstensen H, Ornvold K. The epidemiology of LCH in children in Denmark, 1975-89. Med Pediatr Oncol 1993; 21:387.

8. Baumgartner I, von Hochstetter A, Baumert B, et al. Langerhans'-cell histiocytosis in adults. Med Pediatr Oncol 1997; 28:9.

9. Berres ML, Lim KP, Peters T, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med 2014; 211:669.

10. Milne P, Bigley V, Bacon CM, et al. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood 2017; 130:167.

11. Durham BH, Roos-Weil D, Baillou C, et al. Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. Blood 2017; 130:176.

12. Héritier S, Emile JF, Barkaoui MA, et al. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. J Clin Oncol 2016; 34:3023.

13. Aricò M, Nichols K, Whitlock JA, et al. Familial clustering of Langerhans cell histiocytosis. Br J Haematol 1999; 107:883.

14. Pineles SL, Liu GT, Acebes X, et al. Presence of Erdheim-Chester disease and Langerhans cell histiocytosis in the same patient: a report of 2 cases. J Neuroophthalmol 2011; 31:217.

15. Wang KH, Cheng CJ, Hu CH, Lee WR. Coexistence of localized Langerhans cell histiocytosis and cutaneous Rosai-Dorfman disease. Br J Dermatol 2002; 147:770.

16. Grois N, Pötschger U, Prosch H, et al. Risk factors for diabetes insipidus in Langerhans cell histiocytosis. Pediatr Blood Cancer 2006; 46:228.

17. Malpas JS, Norton AJ. Langerhans cell histiocytosis in the adult. Med Pediatr Oncol 1996; 27:540.

18. Howarth DM, Gilchrist GS, Mullan BP, et al. Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome. Cancer 1999; 85:2278.

19. Braier J, Latella A, Balancini B, et al. Outcome in children with pulmonary Langerhans cell Histiocytosis. Pediatr Blood Cancer 2004; 43:765.

20. Odame I, Li P, Lau L, et al. Pulmonary Langerhans cell histiocytosis: a variable disease in childhood. Pediatr Blood Cancer 2006; 47:889.

21. Slater JM, Swarm OJ. Eosinophilic granuloma of bone. Med Pediatr Oncol 1980; 8:151.

22. Garg S, Mehta S, Dormans JP. Langerhans cell histiocytosis of the spine in children. Long-term follow-up. J Bone Joint Surg Am 2004; 86-A:1740.

23. D'Ambrosio N, Soohoo S, Warshall C, et al. Craniofacial and intracranial manifestations of Langerhans cell histiocytosis: report of findings in 100 patients. AJR Am J Roentgenol 2008; 191:589.

24. Annibali S, Cristalli MP, Solidani M, et al. Langerhans cell histiocytosis: oral/periodontal involvement in adult patients. Oral Dis 2009; 15:596.

25. Minkov M, Pötschger U, Grois N, et al. Bone marrow assessment in Langerhans cell histiocytosis. Pediatr Blood Cancer 2007; 49:694.

26. Braier JL, Rosso D, Latella A, et al. Importance of multi-lineage hematologic involvement and hypoalbuminemia at diagnosis in patients with "risk-organ" multi-system Langerhans cell histiocytosis. J Pediatr Hematol Oncol 2010; 32:e122.

27. Kaplan KJ, Goodman ZD, Ishak KG. Liver involvement in Langerhans' cell histiocytosis: a study of nine cases. Mod Pathol 1999; 12:370.

28. Nondahl SR, Finlay JL, Farrell PM, et al. A case report and literature review of "primary" pulmonary histiocytosis X of childhood. Med Pediatr Oncol 1986; 14:57.

29. Talmadge E King, Jr, MD. Pulmonary Langerhans cell histiocytosis [İnternet] [cited 28 december 2017] Available from: https://www.uptodate.com/contents/pulmonary-langerhans-cell-histiocytosis

30. Geissmann F, Thomas C, Emile JF, et al. Digestive tract involvement in Langerhans cell histiocytosis. The French Langerhans Cell Histiocytosis Study Group. J Pediatr 1996; 129:836.

31. Hait E, Liang M, Degar B, et al. Gastrointestinal tract involvement in Langerhans cell histiocytosis: case report and literature review. Pediatrics 2006; 118:e1593.

32. Grois NG, Favara BE, Mostbeck GH, Prayer D. Central nervous system disease in Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998; 12:287.

33. Grois N, Fahrner B, Arceci RJ, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr 2010; 156:873.

34. Fahrner B, Prosch H, Minkov M, et al. Long-term outcome of hypothalamic pituitary tumors in Langerhans cell histiocytosis. Pediatr Blood Cancer 2012; 58:606.

35. García Gallo MS, Martínez MP, Abalovich MS, et al. Endocrine manifestations of Langerhans cell histiocytosis diagnosed in adults. Pituitary 2010; 13:298.

36. Donadieu J, Rolon MA, Thomas C, et al. Endocrine involvement in pediatric-onset Langerhans' cell histiocytosis: a population-based study. J Pediatr 2004; 144:344.

37. Newman B, Hu W, Nigro K, Gilliam AC. Aggressive histiocytic disorders that can involve the skin. J Am Acad Dermatol 2007; 56:302.

38. Simko SJ, Garmezy B, Abhyankar H, et al. Differentiating skin-limited and multisystem Langerhans cell histiocytosis. J Pediatr 2014; 165:990.

39. Hicks J, Flaitz CM. Langerhans cell histiocytosis: current insights in a molecular age with emphasis on clinical oral and maxillofacial pathology practice. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 100:S42.

40. Allen CE, Ladisch S, McClain KL. How I treat Langerhans cell histiocytosis. Blood 2015; 126:26.

41. Sakai H, Ibe M, Takahashi H, Matsuo S, Okamoto K, Makino I, et al. Satisfactory remission achieved by PUVA therapy in Langerhans cell hisiocytosis in an elderly patient. J Dermatol. 1996;23:42–46.

42. Kwon OS, Cho KH, Song KY. Primary cutaneous Langerhans cell histiocytosis treated with photochemotherapy. J Dermatol. 1997;24:54–56.

43. Hoeger PH, Nanduri VR, Harper JI, Atherton DA, Pritchard J. Long term follow up of topical mustine treatment for cutaneous Langerhans cell histiocytosis. Arch Dis Child. 2000;82:483–487.

44. Lindahl LM, Fenger-Gron M, Iversen L. Topical nitrogen mustard therapy in patients with Langerhans cell histiocytosis. Br J Dermatol. 2012;166:642–645.

45. Failla V, Wauters O, Caucanas M, Nikkels-Tassoudji N, Nikkels AF. Photodynamic therapy for multi-resistant cutaneous Langerhans cell histiocytosis. Rare Tumors. 2010;2:e34.

46. Steen AE, Steen KH, Bauer R, Bieber T. Successful treatment of cutaneous Langerhans cell histiocytosis with low-dose methotrexate. Br J Dermatol. 2001;145:137–140.

47. McClain KL. Drug therapy for the treatment of Langerhans cell histiocytosis. Expert Opin Pharmacother. 2005;6:2435–2441.

48. Do JE, Lee JY, Kim YC. Successful treatment of cutaneous Langerhans' cell histiocytosis with targeted narrowband ultraviolet B phototherapy in an infant. Clin Exp Dermatol. 2009;34:e280–e281.

49. Chang SE, Koh GJ, Choi JH, Lee KH, Sung KJ, Moon KC, et al. Widespread skin-limited adult Langerhans cell histiocytosis: long-term follow-up with good response to interferon alpha. Clin Exp Dermatol. 2002;27:135–137.

50. McClain KL, Kozinetz CA. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007;48:44–49.

51. Simko SJ, Tran HD, Jones J, Bilgi M, Beaupin LK, Coulter D, et al. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer. 2014;61:479–487.

52. Gadner H, Minkov M, Grois N, Pötschger U, Thiem E, Aricò M, Astigarraga I,Braier J, Donadieu J, Henter JI, Janka-Schaub G, McClain KL, Weitzman S,

Windebank K, Ladisch S; Histiocyte Society. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013 Jun 20;121(25):5006-14.

53.Gadner H, Heitger A, Grois N, Gatterer-Menz I, Ladisch S. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group. Med Pediatr Oncol. 1994;23(2):72-80.

54. Minkov M, Prosch H, Steiner M, et al. Langerhans cell histiocytosis in neonates. Pediatr Blood Cancer 2005; 45:802.

55. Lau L, Krafchik B, Trebo MM, Weitzman S. Cutaneous Langerhans cell histiocytosis in children under one year. Pediatr Blood Cancer 2006; 46:66.

56. Hoeger PH, Nanduri VR, Harper JI, et al. Long term follow up of topical mustine treatment for cutaneous Langerhans cell histiocytosis. Arch Dis Child 2000; 82:483.

57. Steen AE, Steen KH, Bauer R, Bieber T. Successful treatment of cutaneous Langerhans cell histiocytosis with low-dose methotrexate. Br J Dermatol 2001; 145:137.

58. McClain KL, Kozinetz CA. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer 2007; 48:44.

59. Lindahl LM, Fenger-Grøn M, Iversen L. Topical nitrogen mustard therapy in patients with Langerhans cell histiocytosis. Br J Dermatol 2012; 166:642.

60. Heisig A, Sörensen J, Zimmermann SY, Schöning S, Schwabe D, Kvasnicka HM, Schwentner R, Hutter C, Lehrnbecher T. Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature. Oncotarget. 2018 Apr 24;9(31):22236-22240.

61. Titgemeyer C, Grois N, Minkov M, Flucher-Wolfram B, Gatterer-Menz I, Gadner H. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study. Med Pediatr Oncol. 2001;37:108–114.

62. Lahey ME. Prognostic factors in histiocytosis X. Am J Pediatr Hematol Oncol1981; 3: 57–60.

63. Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr2001; 138: 728–734.

64. Morimoto A, Ikushima S, Kinugawa N, Ishii E, Kohdera U, Sako M, Fujimoto J,Bessho F, Horibe K, Tsunematsu Y, Imashuku S; Japan Langerhans Cell Histiocytosis Study Group. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer. 2006 Aug 1;107(3):613-9.

65.Ceci A, de Terlizzi M, Colella R, Loiacono G, Balducci D, Surico G, Castello M, Testi AM, De Bernardi B, Indolfi P, et al. Langerhans cell histiocytosis in childhood: results from the Italian Cooperative AIEOP-CNR-H.X '83 study. Med Pediatr Oncol. 1993;21(4):259-64.

66. Haupt R, Nanduri V, Calevo MG, Bernstrand C, Braier JL, Broadbent V, Rey G,McClain KL, Janka-Schaub G, Egeler RM. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer. 2004 May;42(5):438-44.

67.Larralde M, Rositto A, Giardelli M, Gatti CF, Santos Muñoz A. Congenital self-healing histiocytosis (Hashimoto-Pritzker). Int J Dermatol. 1999 Sep;38(9):693-6.

68.Fernandez-Flores A, Manjon JA, Manzarbeitia F. Double immunostaining with CD1A and CD68 in the phenotypic characterization of indeterminate cell histiocytosis. Cesk Patol. 2008 Apr;44(2):37-9.

69. Wood GS, Hu CH, Beckstead JH, et al. The indeterminate cell proliferative disorder: report of a case manifesting as an unusual cutaneous histiocytosis.J Dermatol Surg Oncol. 1985;11:1111.

 70. Haimovic A, Chernoff K, Hale CS, et al. Indeterminate cell histiocytosis that presented clinically as benign cephalic histiocytosis. Dermatol OnlineJ. 2015;20:12

71. Brown RA, Kwong BY, McCalmont TH, et al. ETV3-NCOA2 in indeterminate cell histiocytosis: clonal translocation supports sui generis. Blood. 2015;126:2344–2345.

72. Li Y, Bai HX, Su C, Zhang G. Generalized Indeterminate Cell Histiocytosis Presenting as Eroded Papules and Crusts. Am J Dermatopathol. 2017 Jul;39(7):542-544.

73. Rezk SA, Spagnolo DV, Brynes RK, et al. Indeterminate cell tumor: a rare dendritic neoplasm. Am J Surg Pathol. 2008;32:1868–1876.

74. Bettington A, Lai J, Kennedy C. Indeterminate dendritic cell tumour presenting in a patient with follicular lymphoma. Pathology. 2011 June; 43(4): p. 372-4

75. Wang CH, Chen GS. Indeterminate cell histiocytosis: a case report. Kaohsiung J Med Sci. 2004;20:24–30.

76. Ratzinger G, Walter H, Metze D, Zelger B. G, Zelger B. Indeterminate cell histiocytosis: fact or fiction? J CutanPathol 2005;32:552-560.

77. Ventura F, Pereira T, da Luz DM, Marques H, Pardal F, Brito C. Indeterminate Cell Histiocytosis in Association with Acute myeloid Leukemia. Dermatol Res Pract. 2010;2010:569345.

78. Caputo C, Marzano A, Passoni E, Berti E. Unusual variants of non Langerhans cell histiocytosis. J Am Acad Dermatol 2007; 57: 1031-45

79. Bard S, Torchia D, Connelly E, Duarte A, Badiavas E, Schachner L. S100-negative indeterminate cell histiocytosis in an Africa American child responsive to narrow ultraviolet B. Pediatric Dermatology 2011;28:524-527.

80. Ishibashi M, Ouchi T, Tanikawa A, Ishiko A Indeterminate cell histiocytosis successfully treated with ultraviolet B phototherapy. Clin Exp Dermatol. 2008 May;33(3):301-4.

81. Toth B, Katona M, Harsing J, Szepesi A, Karpati S. Indeterminate cell histiocytosis in a pediatric patient: successful treatment with Thalidomide. Pathol Oncol Res 2012;18:535-538.

82. Burns M, Ahmed A, Callahan G, Le L, Cockerell C. Treatment of indeterminate cell histiocytosis with pravastatin. J Am Acad Dermatol. 2011 May; 64(5): e85-6

83. Fournier J, Ingraffea A, Pedvis-Leftick A. Successful treatment of indeterminate cell histiocytosis with low-dose methotrexate. J Dermatol 2011;38:937-939

84. Whittaker S.J. et al. Indeterminate cell histiocytosis responding to total skin electron beam therapy. Br J Dermatol 2008 Apr;158(4): 838-840

85. Logemann N, Thomas B, Yetto T. Indeterminate cell histiocytosis successfully treated with narrowband UVB. Dermatol Online J. 2013 Oct 16;19(10):20031.

86. Dehner LP. Juvenile xanthogranulomas in the first two decades of life: A clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. Am J Surg Pathol 2003; 27: 579–593.

87. Weitzman S and Jaffe R (2005) Uncommon histiocytic disorders: the non-Langerhans cell histiocytoses. Pediatr Blood Cancer 45(3):256–264.

88. Chu AC. The confusing state of the histiocytoses. Br J Dermatol. 2000 Sep;143(3):475-6.

89. Janssen D, Harms D. Juvenile xanthogranuloma in childhood and adolescence: A clinicopathologic study of 129 patients from the Kiel pediatric tumor registry. Am J Surg Pathol 2005; 29: 21–28.

90. Chakraborty R, Hampton OA, Shen X, et al. (2014) Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 124(19):3007–3015.

91.Azorín D, Torrelo A, Lassaletta A, de Prada I, Colmenero I, Contra T, González-Mediero I. Systemic juvenile xanthogranuloma with fatal outcome. Pediatr Dermatol. 2009 Nov-Dec;26(6):709-12.

92. Hara T, Ohga S, Hattori Set al. Prolonged severe pancytopenia preceding the cutaneous lesions of juvenile xanthogranuloma. Pediatr Blood Cancer2006;47:103–106.

93. Kesserwan C, Boue DR, Kahwash SB. Isolated juvenile xanthogranuloma in the bone marrow: report of a case and review of the literature. Pediatr Dev Pathol2007;10:161–164.

94. Samara WA, Khoo CT, Say EA, et al. Juvenile Xanthogranuloma Involving the Eye and Ocular Adnexa: Tumor Control, Visual Outcomes, and Globe Salvage in 30 Patients. Ophthalmology 2015; 122:2130.

95. Vendal Z, Walton D, Chen T. Glaucoma in juvenile xanthogranuloma. Semin Ophthalmol 2006; 21:191.

96. SANDERS TE. Intraocular juvenile xanthogranuloma (nevoxanthogranuloma): a survey of 20 cases. Trans Am Ophthalmol Soc 1960; 58:59.

97. Cambiaghi S, Restano L, Caputo R. Juvenile xanthogranuloma associated with neurofibromatosis 1: 14 patients without evidence of hematologic malignancies. Pediatr Dermatol 2004; 21:97.

98. Ferrari F, Masurel A, Olivier-Faivre L, Vabres P. Juvenile xanthogranuloma and nevus anemicus in the diagnosis of neurofibromatosis type 1. JAMA Dermatol 2014; 150:42.

99. Fenot M, Stalder JF, Barbarot S. Juvenile xanthogranulomas are highly prevalent but transient in young children with neurofibromatosis type 1. J Am Acad Dermatol 2014; 71:389.

100.Raygada M, Arthur DC, Wayne AS, Rennert OM, Toretsky JA, Stratakis CA.Juvenile xanthogranuloma in a child with previously unsuspected neurofibromatosis type 1 and juvenile myelomonocytic leukemia. Pediatr Blood Cancer. 2010 Jan;54(1):173-5.

101. Song M, Kim SH, Jung DS, et al. Structural correlations between dermoscopic and histopathological features of juvenile xanthogranuloma. J Eur Acad Dermatol Venereol 2011; 25:259.

102. Freyer DR, Kennedy R, Bostrom BC et al. Juvenile xanthogranuloma: forms of systemic disease and their clinical implications. J Pediatr 1996; 129:227–37.

103. Haughton AM, Horii KA, Shao L et al. Disseminated juvenile xanthogranulomatosis in a newborn resulting in liver transplantation. J Am Acad Dermatol 2008; 58(2 Suppl.):S12–15.

104.Chang MW, Frieden IJ, Good W. The risk intraocular juvenile xanthogranuloma: survey of current practices and assessment of risk. J Am Acad Dermatol 1996; 34:445.

105. Hernandez-Martin A, Baselga E, Drolet BA, Esterly NB. Juvenile xanthogranuloma. J Am Acad Dermatol 1997; 36:355.

106. Stover DG, Alapati S, Regueira O, et al.(2008) Treatment of juvenile xanthogranuloma. Pediatr Blood Cancer 51(1):130–133

107. Wang B, Jin H, Zhao Y, Ma J. The clinical diagnosis and management options for intracranial juvenile xanthogranuloma in children: based on four cases and another 39 patients in the literature. Acta Neurochir (Wien) 2016; 158:1289.

108.Maintz L, Wenzel J, Irnich M, Reinhard H, Bieber T. Successful treatment of systemic juvenile xanthogranulomatosis with cytarabine and

2-chlorodeoxyadenosine: case report and review of the literature. Br J Dermatol.2017 Feb;176(2):481-487.

109.Ugurlu S, Bartley GB, Gibson LE. Necrobiotic xanthogranuloma: long-term outcome of ocular and systemic involvement. Am J Ophthalmol.2000 May;129(5):651-7.

110.Kossard S, Winkelmann RK. Necrobiotic xanthogranuloma with paraproteinemia. J Am Acad Dermatol. 1980 Sep;3(3):257-70.

111.J.D Bullock, G.B Bartley, R.J Campbell, BYanes, P.J Connelly, W Funkhouser Necrobiotic xanthogranuloma with paraproteinemia. Case report and a pathogenetic theory Ophthalmology, 93 (1986), pp. 1233-1236

112. Char DH, LeBoit PE, Ljung BM, Wara W. Radiation therapy for ocular necrobiotic xanthogranuloma. Arch Ophthalmol. 1987 Feb;105(2):174-5.

113.Rappersberger K, Wrba F, Heinz R, Zonzits E, Hönigsmann H. [Necrobiotic xanthogranuloma in paraproteinemia]. Hautarzt. 1989 Jun;40(6):358-63.

114. Spicknall KE, Mehregan DA. Necrobiotic xanthogranuloma. Int J Dermatol 2009; 48:1.

115. Wood AJ, Wagner MV, Abbott JJ, Gibson LE. Necrobiotic xanthogranuloma: a review of 17 cases with emphasis on clinical and pathologic correlation. Arch Dermatol 2009; 145:279.

116. Mehregan DA, Winkelmann RK. Necrobiotic xanthogranuloma. Arch Dermatol 1992; 128:94.

117. Szalat R, Arnulf B, Karlin L, et al. Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy. Blood 2011; 118:3777. DOI:10.1002/pbc.21830

118. DeLuca IJ, Grossman ME. Vulvar necrobiotic xanthogranuloma. J Am Acad Dermatol 2014; 71:e247.

119. Koch PS, Goerdt S, Géraud C. Erythematous papules, plaques, and nodular lesions on the trunk and within preexisting scars. JAMA Dermatol 2013; 149:1103.

120. Rayner SA, Duncombe AS, Keefe M, et al. Necrobiotic xanthogranuloma occurring in an eyelid scar. Orbit 2008; 27:191.

121. Gün D, Demirçay Z, Demirkesen C. Necrobiotic xanthogranuloma in a burn scar. Int J Dermatol 2004; 43:293.

122. Mohsenin A, Sinard J, Huang JJ. Necrobiotic xanthogranuloma and chronic lymphocytic leukemia of the conjunctiva masquerading as scleritis and uveitis. Clin Ophthalmol 2012; 6:2045.

123. N.A Tucker, M.J Discepola, G Blanco, M.NBurnier JrNecrobiotic xanthogranuloma without dermatologic involvement

Can J Ophthalmol, 32 (1997), pp. 396-399

124. Johnston KA, Grimwood RE, Meffert JJ, Deering KC. Necrobiotic xanthogranuloma with paraproteinemia: an evolving presentation. Cutis 1997; 59: 333–336.

125. Plotnick H, Taniguchi Y, Hashimoto K, et al.Periorbital necrobiotic xanthogranuloma and stage 1 multiple myeloma. J Am Acad Dermatol 1991; 25: 373–377.

126. Khan M, Ahmed I, Carr R. An unusual subcutaneous lump. Clin Exp Dermatol 2012; 37:808.

127. Balagula Y, Straus DJ, Pulitzer MP, Lacouture ME. Necrobiotic xanthogranuloma associated with immunoglobulin m paraproteinemia in a patient with Waldenström macroglobulinemia. J Clin Oncol 2011; 29:e305.

128. Oumeish OY, Oumeish I, Tarawneh M, et al. Necrobiotic xanthogranuloma associated with paraproteinemia and non-Hodgkin's lymphoma developing into chronic lymphocytic leukemia: the first case reported in the literature and review of the literature. Int J Dermatol 2006; 45:306.

129. Vieira V, Del Pozo J, Martínez W, et al. Necrobiotic xanthogranuloma associated with lymphoplasmacytic lymphoma. Palliative treatment with carbon dioxide laser. Eur J Dermatol 2005; 15:182.

130. Ryan E, Warren LJ, Szabo F. Necrobiotic xanthogranuloma: response to chlorambucil. Australas J Dermatol 2012; 53:e23.

131. Criado PR, Vasconcellos C, Pegas JR, et al. Necrobiotic xanthogranuloma with lambda paraproteinemia: case report of successful treatment with melphalan and prednisone. J Dermatolog Treat 2002; 13:87.

132. Meyer S, Szeimies RM, Landthaler M, Hohenleutner S. Cyclophosphamide-dexamethasone pulsed therapy for treatment of recalcitrant necrobiotic xanthogranuloma with paraproteinemia and ocular involvement. Br J Dermatol 2005; 153:443.

133. Khan IJ, Azam NA, Sullivan SC, et al. Necrobiotic xanthogranuloma successfully treated with a combination of dexamethasone and oral cyclophosphamide. Can J Ophthalmol 2009; 44:335.

134. Plotnick H, Taniguchi Y, Hashimoto K, et al. Periorbital necrobiotic xanthogranuloma and stage I multiple myeloma. Ultrastructure and response to pulsed dexamethasone documented by magnetic resonance imaging. J Am Acad Dermatol 1991; 25:373.

135. Hallermann C, Tittelbach J, Norgauer J, Ziemer M. Successful treatment of necrobiotic xanthogranuloma with intravenous immunoglobulin. Arch Dermatol 2010; 146:957.

136. Goede JS, Misselwitz B, Taverna C, et al. Necrobiotic xanthogranuloma successfully treated with autologous stem cell transplantation. Ann Hematol 2007; 86:303.

137. Silapunt S, Chon SY. Generalized necrobiotic xanthogranuloma successfully treated with lenalidomide. J Drugs Dermatol 2010; 9:273.

138. Venencie PY, Le Bras P, Toan ND, et al. Recombinant interferon alfa-2b treatment of necrobiotic xanthogranuloma with paraproteinemia. J Am Acad Dermatol 1995; 32:666.

139. Georgiou S, Monastirli A, Kapranos N, et al. Interferon alpha-2a monotherapy for necrobiotic xanthogranuloma. Acta Derm Venereol 1999; 79:484.

140. Finelli LG, Ratz JL. Plasmapheresis, a treatment modality for necrobiotic xanthogranuloma. J Am Acad Dermatol 1987; 17:351.

141. Wei YH, Cheng JJ, Wu YH, et al. Necrobiotic xanthogranuloma: response to dapsone. Dermatol Ther 2015; 28:7.

142. Al-Niaimi FA, Dawn G, Cox NH. Necrobiotic xanthogranuloma without paraproteinaemia: marked improvement with psoralen ultraviolet A treatment. Clin Exp Dermatol 2010; 35:275.

143. Rodriguez O, Meyers C, Weiss BM, et al. Necrobiotic Xanthogranuloma Treated With Topical Nitrogen Mustard (Mechlorethamine). JAMA Dermatol 2016; 152:589.

144.Elner VM, Mintz R, Demirci H, Hassan AS. Local corticosteroid treatment of eyelid and orbital xanthogranuloma. Trans Am Ophthalmol Soc. 2005;103:69-73;discussion 73-4.

145. Gianotti F, Caputo R, Ermacora E. Singular "infantile histiocytosis with cells with intracytoplasmic vermiform particles". Bull Soc Fr Dermatol Syphiligr. 1971;78:232–233.

146. Jih DM, Salcedo SL, Jaworsky C. Benign cephalic histiocytosis: a case report and review. J Am Acad Dermatol. 2002;47:908–913

147. Koca R, Bektaş S, Altinyazar HC, Sezer T. Benign cephalic histiocytosis: a case report. Ann Dermatol. 2011 Nov;23(4):508-11.

148.Kim BC, Choi WJ, Seung NR, Park EJ, Cho HJ, Kim KH, Kim KJ. A case of benign cephalic histiocytosis. Ann Dermatol. 2011 Sep;23 Suppl 1:S16-9.

149. Weston WL, Travers SH, Mierau GW, Heasley D, Fitzpatrick J. Benign cephalic histiocytosis with diabetes insipidus. Pediatr Dermatol. 2000;17:296–298.

150. Saez-De-Ocariz M, Lopez-Corella E, Duran-McKinster C, Orozco-Covarrubias L, Ruiz-Maldonado R. Benign cephalic histiocytosis preceding the development of insulin-dependent diabetes mellitus. Pediatr Dermatol. 2006;23:101–102

151. Rodriguez-Jurado R, Duran-McKinster C, Ruiz-Maldonado R. Benign cephalic histiocytosis progressing into juvenile xanthogranuloma: a non-Langerhans cell histiocytosis transforming under the influence of a virus? Am J Dermatopathol. 2000;22:70–74.

152. Zelger BG, Zelger B, Steiner H, Mikuz G. Solitary giant xanthogranuloma and benign cephalic histiocytosis--variants of juvenile xanthogranuloma. Br J Dermatol. 1995;133:598–604.

153. Sidwell RU, Francis N, Slater DN, Mayou SC. Is disseminated juvenile xanthogranulomatosis benign cephalic histiocytosis. Pediatr Dermatol. 2005;22:40–43.

154. Goday JJ, Raton JA, Landa N, Eizaguirre X, Diaz-Pérez JL. Benign cephalic histiocytosis--study of a case. Clin Exp Dermatol. 1993;18:280–282.

155. Gianotti R, Alessi E, Caputo R. Benign cephalic histiocytosis: a distinct entity or a part of a wide spectrum of histiocytic proliferative disorders of children? A histopathological study. Am J Dermatopathol. 1993 Aug;15(4):315-9.

156.D'Auria AA, De Clerck B, Kim G. Benign cephalic histiocytosis with S-100 protein positivity. J Cutan Pathol. 2011 Oct;38(10):842-3.

157. Winkelmann RK, Muller SA. Generalised eruptive histiocytoma: a benign papular histiocytic reticulosis. Arch Dermatol. 1963;88:586–96.

158.Aggarwal K, Gupta S, Jain VK, Sen R, Gupta S. Generalized eruptive histiocytoma. Indian Dermatol Online J. 2010 Jul;1(1):27-9.

159.Lan Ma H, Metze D, Luger TA, Steinhoff M. Successful treatment of generalized eruptive histiocytoma with PUVA. J Dtsch Dermatol Ges. 2007 Feb;5(2):131-4.

160. Ashworth J, Archard L, Woodrow D, Cream JJ. Multiple eruptive histiocytoma cutis in an atopic. Clin Exp Dermatol. 1990;15:454–6

161. Seward JL, Malone JC, Callen JP. Generalized eruptive histiocytosis. J Am Acad Dermatol 2004; 50: 116–120.

162.Wee SH, Kim HS, Chang SN, Kim DK, Park WH. Generalized eruptive histiocytoma: a pediatric case. Pediatr Dermatol. 2000 Nov-Dec;17(6):453-5.

163. Vázquez-Blanco M, Peteiro C, Toribio J. [Generalized eruptive histiocytoma].Actas Dermosifiliogr. 2006 Jan-Feb;97(1):35-8.

164. Cardoso F, Serafini NB, Reis BD, Nuñez MD, Nery JA, Lupi O. Generalized eruptive histiocytoma: a rare disease in an elderly patient. An Bras Dermatol. 2013 Jan-Feb;88(1):105-8.

165.Tamiya H, Tsuruta D, Takeda E, Moriwaki K, Kobayash H, Ishii M. Generalized eruptive histiocytoma with rapid progression and resolution following exanthema subitum. Clin Exp Dermatol. 2005 May;30(3):300-1.

166. Jang KA, Lee HJ, Choi JH, Koh JK, Moon KC. Generalized eruptive histiocytoma of childhood. Br J Dermatol 1999; 140: 174–176.

167. Matsushima Y, Ohnishi K, Ishikawa O. Generalized eruptive histiocytoma of childhood associated with rheumatic fever. Eur J Dermatol 1999; 9: 548–50.

168.Kwinter J, DeKoven J. Generalized eruptive histiocytoma treated with isotretinoin. J Cutan Med Surg. 2009 May-Jun;13(3):146-50.

169. Jha VK, Kumar R, Kunwar A, Singh A, Kumar M, Kumar M, Prasad R. Efficacy of Vinblastine and Prednisone in Multicentric Reticulohistiocytosis With Onset in Infancy. Pediatrics. 2016 Jun;137(6).

170.Tajirian AL, Malik MK, Robinson-Bostom L, Lally EV. Multicentric reticulohistiocytosis. Clin Dermatol. 2006 Nov-Dec;24(6):486-92.

171.Selmi C, Greenspan A, Huntley A, Gershwin ME. Multicentric reticulohistiocytosis: a critical review. Curr Rheumatol Rep. 2015 Jun;17(6):511.

172.Bennàssar A, Mas A, Guilabert A, Julià M, Mascaró-Galy JM, Herrero C. Multicentric reticulohistiocytosis with elevated cytokine serum levels. J Dermatol. 2011 Sep;38(9):905-10.

173. Sobjanek M, Sławińska M, Romaszkiewicz A, Sokołowska-Wojdyło M, Jasiel-Walikowska E, Nowicki R. Dermoscopic features of periungual papules in multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2017 Oct;31(10):e442-e443.

174.Lim K, D'Souza J, Vasquez JB, Vuyyuru S. Looks Can Be Deceiving: A Case Report on Multicentric Reticulohistiocytosis Successfully Treated with Rituximab. Cureus. 2017 May 3;9(5):e1220.

175. Luz FB, Gaspar TAP, Kalil-Gaspar N et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol2001;15:524–531.

176. Tait TJ, Bird HA, Ford GP. Multicentric reticulohistiocytosis: presentation with the cutaneous features of dermatomyositis. Br J Rheumatol 33: 100-101, 1994

177. Hsiung SH, Chan EF, Elenitsas R, Kolasinski SL, Schumacher HR, Werth VP. Multicentric reticulohistiocytosis presenting with clinical features of dermatomyositis. J Am Acad Dermatol 48: S11-S14, 2003.

178. Toz B, Büyükbabani N, İnanç M. Multicentric reticulohistiocytosis: Rheumatology perspective. Best Pract Res Clin Rheumatol. 2016 Apr;30(2):250-260.

179. Outland JD, Peiran SJ, Schikler KN et al. Multicentric reticulohistiocytosis in a 14 year old girl. Pediatr Dermatol 2002;19:527–531.

180. McKenna DB, Mooney EE, Young MM et al. Multiple cutaneous reticulohistiocytosis. Br. J. Dermatol. 1998; 139: 544–6.

181. Snow JL, Muller SA. Malignancy-associated multicentric reticulohistiocytosis: a clinical, histological and immunophenotypic study. Br. J. Dermatol. 1995; 133: 71–6.

182. Hemmady KD, Someshwar SS, Jerajani HR. Multiple Cutaneous Reticulohistiocytoma. Indian J Dermatol. 2016 Jan-Feb;61(1):121.

183. Tariq S, Hugenberg ST, Hirano-Ali SA, Tariq H. Multicentric reticulohistiocytosis (MRH): case report with review of literature between 1991 and 2014 with in depth analysis of various treatment regimens and outcomes.Springerplus. 2016 Feb 25;5:180.

184.Pacheco-Tena C, Reyes-Cordero G, Ochoa-Albíztegui R, Ríos-Barrera V, González-Chávez SA. Treatment of multicentric reticulohistiocytosis with tocilizumab. J Clin Rheumatol. 2013 Aug;19(5):272-6.

185. Ansarin H, Berenji Ardestani H, Tabaie SM, Shayanfar N. Xanthoma disseminatum with tumor-like lesion on face. Case Rep Dermatol Med. 2014;2014:621798.

186. J. Altman and R. K. Winkelman, “Xanthoma disseminatum,” Archives of Dermatology, vol. 86, pp. 582–596, 1962.

187. Gong HZ, Zheng HY, Li J. Xanthoma disseminatum. Lancet. 2017 Oct 11. pii:S0140-6736(17)31934-7.

188. J. Y. Kim, H. Daejung, Y. S. Choe et al., “A case of xanthoma disseminatum accentuating over the eyelids,” Annals of Dermatology, vol. 22, no. 3, pp. 353–357, 2010.

189. J. J. Powell, P. Marren, F. Wojnarowska, and C. Davies, “Xanthoma disseminatum with multi-system involvement and fatal outcome,” Journal of the European Academy of Dermatology and Venereology, vol. 12, no. 3, pp. 276–278, 1999

190. Khezri, L. E. Gibson, and A. Tefferi, “Xanthoma disseminatum: effective therapy with 2-chlorodeoxyadenosine in a case series,” Archives of Dermatology, vol. 147, no. 4, pp. 459–464, 2011

191. Krishna CV, Parmar NV, Ganguly S, Kuruvila S. Xanthoma disseminatum with extensive koebnerization associated with familial hypertriglyceridemia. JAAD Case Rep. 2016 Jul 5;2(3):253-6.

192. B. Zelger, R. Cerio, G. Orchard, P. Fritsch, and E. Wilson-Jones, “Histologic and immunohistochemical study comparing xanthoma disseminatum and histiocytosis X,” Archives of Dermatology, vol. 128, no. 9, pp. 1207–1212, 1992.

193. Knobler RM, Neumann RA, Gebhart W, Radaskiewicz T, Ferenci P, Widhalm K. Xanthoma disseminatum with progressive involvement of the central nervous and hepatobiliary systems. J Am Acad Dermatol. 1990 Aug;23(2 Pt 2):341-6.

194. R. Caputo, S. Veraldi, R. Grimalt et al., “The various clinical patterns of Xanthoma disseminatum. Considerations on seven cases and review of the literature,” Dermatology, vol. 190, no. 1, pp. 19–24, 1995

195. S. Savaşan, L. Smith, C. Scheer, R. Dansey, and E. Abella, “Successful bone marrow transplantation for life threatening xanthogranuloma disseminatum in neurofibromatosis type-1,” Pediatric Transplantation, vol. 9, no. 4, pp. 534–536, 2005.

196. Büyükavci M, Selimoglu A, Yildirim U, Ertekin V, Atasoy M. Xanthoma disseminatum with hepatic involvement in a child. Pediatr Dermatol. 2005 Nov-Dec;22(6):550-3.

197. Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy: a pseudolymphomatous benign disorder: analysis of 34 cases. Cancer. 1972;30:1143–1188.

198. Eiras Jda C, Schettini AP, Lima LL, et al. Cutaneous Rosai-Dorfman disease: a case report. An Bras Dermatol. 2010;85:687–690.

199. Ortonne N, Fillet AM, Kosuge H, et al. Cutaneous Destombes-Rosai-Dorfman disease: absence of detection of HHV-6 and HHV-8 in skin. J Cutan Pathol. 2002;29:113–118.

200. Kuo TT, Chen TC, Lee LY, et al. IgG4-positive plasma cells in cutaneous Rosai-Dorfman disease: an additional immunohistochemical feature and possible relationship to IgG4-related sclerosing disease. J Cutan Pathol. 2009;36:1069–1073.

201. Molho-Pessach V, Ramot Y, Camille F, Doviner V, Babay S, Luis SJ, Broshtilova V, Zlotogorski A. H syndrome: the first 79 patients. J Am Acad Dermatol. 2014 Jan;70(1):80-8.

202.Kutlubay Z, Bairamov O, Sevim A, Demirkesen C, Mat MC. Rosai-Dorfman disease: a case report with nodal and cutaneous involvement and review of the literature. Am J Dermatopathol. 2014 Apr;36(4):353-7.

203. Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol. 1990;7:19–73.

204. Pitamber HV, Grayson W. Five cases of cutaneous Rosai-Dorfman disease. Clin Exp Dermatol. 2003;28:17–21.

205. Kusutani N, Tamiya H, Tsuruta D, et al. Apoptosis of neutrophils resulting after emperipolesis in cutaneous Rosai-Dorfman disease: a new ultrastructural finding. J Cutan Pathol. 2011;38:529–531.

206. Brenn T, Calonje E, Granter SR, et al. Cutaneous Rosai-Dorfman disease is a distinct clinical entity. Am J Dermatopathol. 2002;24:385–391.

207. Wang KH, Chen WY, Liu HN, et al. Cutaneous Rosai-Dorfman disease: clinicopathological profiles, spectrum and evolution of 21 lesions in six patients. Br J Dermatol. 2006;154:277–286

208. Foucar E, et al. Sinus histiocytosis with massive lymphadenopathy: an analysis of 14 deaths occurring in a patient registry. Cancer 1984; 54:1834.

209. Chappell JA, Burkemper NM, Frater JL, et al. Cutaneous Rosai-Dorfman disease and morphea: coincidence or association? Am J Dermatopathol. 2009;31:487–489.

210. Kelly WF, Bradey N, Scoones D. Rosai-Dorfman disease presenting as a pituitary tumour. Clin Endocrinol. 1999;50:133–137.

211. Shi XY, Ma DL, Fang K. Cutaneous Rosai-Dorfman disease presenting as a granulomatous rosacea-like rashs. Chin Med J (Engl). 2011;124:793–794.

212. Cangelosi JJ, Prieto VG, Ivan D. Cutaneous Rosai-Dorfman disease with increased number of eosinophils: coincidence or histologic variant? Arch Pathol Lab Med. 2011;135:1597–1600

213. Rajasekharan C, Ratheesh NS, Nandinidevi R, et al. Rosai Dorfman disease: appearances can be deceptive. BMJ Case Rep. 2012.

214. Schee MM, et al. Sinus histiocytosis with massive lymphadenopathy. J Am Acad Dermatol 1997; 37:643.

215. Fening K, Bechtel M, Peters S, et al. Cutaneous Rosai-Dorfman disease persisting after surgical excision: report of a case treated with acitretin. J Clin Aesthet Dermatol. 2010;3:34–36.

216. Tjiu JW, Hsiao CH, Tsai TF. Cutaneous Rosai-Dorfman disease: remission with thalidomide treatment. Br J Dermatol. 2003;148: 1060–1061.

217. Gebhardt C, Averbeck M, Paasch U, et al. A case of cutaneous RosaiDorfman disease refractory to imatinib therapy. Arch Dermatol. 2009; 145:571–574.

218. Sun NZ, Galvin J, Cooper KD. Cutaneous Rosai-Dorfman disease successfully treated with low-dose methotrexate. JAMA Dermatol. 2014; 150:787–788.

219. Haroche J, Arnaud L, and Amoura Z (2012) Erdheim-Chester disease.Curr Opin Rheumatol 24(1):53–59.

220. Arnaud L, Hervier B, Néel A, Hamidou MA, Kahn JE, Wechsler B, Pérez-Pastor G, Blomberg B, Fuzibet JG, Dubourguet F, Marinho A, Magnette C, Noel V, Pavic M,Casper J, Beucher AB, Costedoat-Chalumeau N, Aaron L, Salvatierra J, Graux C,Cacoub P, Delcey V, Dechant C, Bindi P, Herbaut C, Graziani G, Amoura Z, Haroche J. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood. 2011 Mar 10;117(10):2778-82.

221. Haroche J, Cohen-Aubart F, Emile JF, Maksud P, Drier A, Tolédano D, Barete S, Charlotte F, Cluzel P, Donadieu J, Benameur N, Grenier PA, Besnard S, Ory JP,Lifermann F, Idbaih A, Granel B, Graffin B, Hervier B, Arnaud L, Amoura Z.Reproducible and sustained efficacy of targeted therapy with vemurafenib inpatients with BRAF(V600E)-mutated Erdheim-Chester disease. J Clin Oncol. 2015 Feb10;33(5):411-8.

222. Haroche J, Abla O. Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester disease. Hematology Am Soc Hematol Educ Program. 2015;2015:571-8.

223. Taunton OD, Yeshurun D, Jarratt M. Progressive nodular histiocytoma. Arch Dermatol. 1978 Oct;114(10):1505-8.

224. Zelger BW, Staudacher C, Orchard G, et al. Solitary and generalized variants of spindle cell xanthogranuloma (progressive nodular histiocytosis). Histopathology 1995; 27: 11–19.

225. Glavin FL, Chatwall H, Karimi K. Progressive nodular histiocytosis: a case report with literature review, and discussion of differential diagnosis and classification. J Cutan Pathol 2009; 36: 1286–1292.

226. Beswick SJ, Kirk JM, Bradshaw K, et al.Progressive nodular histiocytosis in a child with a hypothalamic tumor. Br J Dermatol 2002; 146: 138–140.

227. Gonzalez Ruíz A, Bernal Ruíz AI, Aragoneses Fraile H, Peral Martinez I, García Muñoz M. Progressive nodular histiocytosis accompanied by systemic disorders. Br J Dermatol. 2000 Sep;143(3):628-31.

228.Nofal A, Assaf M, Tawfik A, Elsayed N, Nofal E, Elnakib N, Elmosalamy K.Progressive nodular histiocytosis: a case report and literature review. Int J Dermatol. 2011 Dec;50(12):1546-51.

229.Newman B, Hu W, Nigro K, Gilliam AC. Aggressive histiocytic disorders that can involve the skin. J Am Acad Dermatol. 2007 Feb;56(2):302-16.

230. Torres L, Sanchez JL, Rivera A, Gonzalez A. Progressive nodular histiocytosis. J Am Acad Dermatol 1993; 29: 278–280.

231. Breier F, Zelger B, Reiter Het al. Papular xanthoma: a clinicopathological study of 10 cases. J Cutan Pathol2002; 29: 200–206.

232. Bork K, Hoede N. Hereditary progressive mucinous histiocytosis in women: report of three members in a family. Arch Dermatol 1988;124:1225-9.

233. Bork K. Hereditary progressive mucinous histiocytosis: immunohistochemical and ultrastructural studies in an additional family. Arch Dermatol 1994;130:1300-4.

234. Wong D, Killingsworth M, Crosland G, Kossard S. Hereditary progressive mucinous histiocytosis. Br J Dermatol 1999;141: 1101-5.

235. Henter J, Elinder G, Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncol 1991;18:29-33.

236. Morrell D, Pepping M, Scott J, Esterly N, Drolet B. Cutaneous manifestations of hemophagocytic lymphohistiocytosis. Arch Dermatol 2002;138:1208-12.

237. Favara B. Hemophagocytic lymphohistiocytosis: a hemophagocytic syndrome. Semin Diagn Pathol 1992;9:63-74.

238. Coutinho I, Moreira S, Ramos L, Robalo Cordeiro M, Cardoso J, Gonçalo M,Tellechea O. Plaque-like papular xanthoma: a new variant of non-Langerhans cell disease. J Eur Acad Dermatol Venereol. 2016 Feb;30(2):332-3.

239. Ducatman B, Wick M, Morgan T, Banks P, Pierre R. Malignant histiocytosis: a clinical, histologic, and immunohistochemical study of 20 cases. Hum Pathol 1984;15:368-77.

240. Rilke F, Carbone A, Musumeci R, Pilotti S, De Lena M, Bonadonna G. Malignant histiocytosis: a clinicopathologic study of 18 consecutive cases. Tumori 1978;64:211-27.

241. Morgan N, Fretzin D, Variakojis D, Caro W. Clinical and pathologic cutaneous manifestations of malignant histiocytosis. Arch Dermatol 1983;119:367-72.

242. Brugieres L, Caillaud JM, Patte C, Rodary C, Bernard A, Kalifa C, Hartmann O, Lemerle J. Malignant histiocytosis: therapeutic results in 27 children treated with a single polychemotherapy regimen. Med Pediatr Oncol. 1989;17(3):193-6.

243.Trevisan F, Xavier CA, Pinto CA, Cattete FG, Stock FS, Martins ML. Case report of cutaneous histiocytic sarcoma: diagnostic and therapeutic dilemmas. An Bras Dermatol. 2013 Sep-Oct;88(5):807-10.

244.Rosenberg SA, Niglio SA, Jo VY, Goydos JS. Interdigitating dendritic cell sarcoma presenting in the skin: diagnosis and the role of surgical resection, chemotherapy and radiotherapy in management. Rare Tumors. 2014 Dec 11;6(4):5573.

245. Soler AP, Miller M, Smith TL. Langerhans cell sarcoma of the skin in

association with superficial atypical Langerhans cell proliferation. Rare Tumors. 2017 Oct 23;9(3):7037.

246.Wu A, Pullarkat S. Follicular Dendritic Cell Sarcoma. Arch Pathol Lab Med. 2016 Feb;140(2):186-90.

**Mastositoz**

1. Tharp MD. Mastocytosis. In: Bolognia JL, Jorizzo JL, Schaffer JV, editor. Dermatology. Vol. 2. ed: Elsevier; 2013. p. 1993-03.

2. Le M, Miedzybrodzki B, Olynych T, Chapdelaine H, Ben-Shoshan M. Natural history and treatment of cutaneous and systemic mastocytosis. Postgrad Med. 2017; 21:1-6.

3. Brockow K. Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin North Am. 2014;34(2):283-95.

4. Frieri M, Quershi M. Pediatric mastocytosis: a review of the literature. Pediatr Allergy Immunol Pulmonol. 2013;26:175–80.

5. Akoglu G, Erkin G, Cakir B, et al. Cutaneous mastocytosis: demographic aspects and clinical features of 55 patients. J Eur Acad Dermatol Venereol 2006;20:969-73.

6. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405.

7. Bonadonna P, Lombardo C. Drug allergy in mastocytosis. Immunol Allergy Clin North Am 2014;34:397.

8. Potier A, Lavigne C, Chappard D et al. Cutaneous manifestations in Hymenoptera and Diptera anaphylaxis: relationship with basal serum tryptase. Clin Exp Allergy. 2009;39(5):717–25.

9. Moura DS, Georgin-Lavialle S, Gaillard R, Hermine O. Neuropsychological features of adult mastocytosis. Immunol Allergy Clin North Am. 2014;34(2):407-22.

10. Azana JM, Torrelo A, Matito A. Update on Mastocytosis (Part 1) Pathophysiology, Clinical Features, and Diagnosis. Actas Dermosifiliogr. 2016;107(1):5-14.

11. Middelkamp Hup MA, Heide R, Tank B, et al. Comparison of mastocytosis with onset in children and adults. J Eur Acad Dermatol Venereol. 2002;16(2):115–120.

12. Tharp MD. Mastocytosis. In: Fitzpatricks dermatology. Katz G, Paller G, Wolff L, editor. Dermatology. Vol. 2. ed: Mc GrawHill; 2012. p. 1809-18.

13. Klaiber N, Kumar S, Irani AM. Mastocytosis in Children. Curr Allergy Asthma Rep. 2017;17(11):80.

14. Vanó-Galván S, Alvarez-Twose I, de las Heras EL et al. Dermoscopic features of skin lesions in patients with mastocytosis. Arch Dermatol. 2011;147:932-40.

15. Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res. 2001;25:519---28

16. Vaes M, Benghiat FS, Hermine O. Targeted Treatment Options in Mastocytosis. Front Med (Lausanne). 2017;20;4:110.

**Vasküler tümörler**

ISSVA Classification of Vascular Anomalies ©2018 International Society for the Study of Vascular Anomalies Available at "issva.org/classification" Accessed.

2. Wassef M, Blei F, Adams D, et al; ISSVA Board and Scientific Committee. Vascular Anomalies Classification: Recommendations From the International Society for the Study of Vascular Anomalies. Pediatrics 2015; 136: e203-14.

3. Sevinir B. Çocukluk çağında hemanjiomlar ve klinik özellikleri-Derleme. J Curr Pediatr 2006; 4: 1-6.

4. Ersoy Evans S. İnfantil Hemanjiyomlar. Türkderm 2011; 45 Özel Sayı 2: 133-7.

5. North PE, Waner M, Mizeracki A, et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol 2001; 137: 559-70.

6. Claesson-Welsh L. Healing hemangiomas. Nat Med 2008; 14: 1147-8.

7. Drolet BA, Frieden IJ. Characteristics of infantile hemangiomas as clues to pathogenesis: does hypoxia connect the dots? Arch Dermatol 2010; 146: 1295-9.

8. Boye E, Yu Y, Paranya G, et al. Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest 2001; 107: 745-52.

9. Ritter MR, Reinisch J, Friedlander SF, Friedlander M. Myeloid cells in infantile hemangioma. Am J Pathol 2006; 168: 621-8.

10. Requena L, Sangueza OP. Cutaneous vascular proliferations. Part II. Hyperplasias and benign neoplasms. J Am Acad Dermatol 1997; 37: 887-919.

11. Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med 1999; 341: 173-81.

12. Frieden IJ, Eichenfield LF, Esterly NB, et al. Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Committee. J Am Acad Dermatol 1997; 37: 631-7.

13. Suh KY, Frieden IJ. Infantile hemangiomas with minimal or arrested growth: a retrospective case series. Arch Dermatol 2010; 146: 971-6.

14. Ma EH, Robertson SJ, Chow CW, Bekhor PS. Infantile Hemangioma with Minimal or Arrested Growth: Further Observations on Clinical and Histopathologic Findings of this Unique but Underrecognized Entity. Pediatr Dermatol 2017; 34: 64-71.

15. Chang LC, Haggstrom AN, Drolet BA, et al; Hemangioma Investigator Group. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 2008; 122: 360-7.

16. Metry DW, Hebert AA. Benign cutaneous vascular tumors of infancy: when to worry, what to do. Arch Dermatol 2000; 136: 905-14.

17. Maguiness SM, Hoffman WY, McCalmont TH, Frieden IJ. Early white discoloration of infantile hemangioma: a sign of impending ulceration. Arch Dermatol 2010; 146: 1235-9.

18. Chiller KG, Passaro D, Frieden IJ. Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch Dermatol 2002; 138: 1567-76.

19. Haggstrom AN, Lammer EJ, Schneider RA, Marcucio R, Frieden IJ. Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development. Pediatrics 2006; 117: 698-703.

20. Sepulveda A, Buchanan EP. Vascular tumors. Semin Plast Surg 2014; 28: 49-57.

21. Christison-Lagay ER, Burrows PE, Alomari A, et al. Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry. J Pediatr Surg 2007; 42: 62-7.

22. Metry DW, Garzon MC, Drolet BA, et al. PHACE syndrome: current knowledge, future directions. Pediatr Dermatol 2009; 26: 381-98.

23. Iacobas I, Burrows PE, Frieden IJ, et al. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies. J Pediatr 2010; 157: 795-801.e1-7.

24. Chamlin SL, Haggstrom AN, Drolet BA, et al Multicenter prospective study of ulcerated hemangiomas. J Pediatr 2007; 151: 684-9,689.e1.

25. Grzesik P, Wu JK. Current perspectives on the optimal management of infantile hemangioma. Pediatric Health Med Ther 2017; 8: 107-116.

26. Orlow SJ, Isakoff MS, Blei F. Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a "beard" distribution. J Pediatr 1997; 131: 643-6.

27. Ceisler EJ, Santos L, Blei F. Periocular hemangiomas: what every physician should know. Pediatr Dermatol 2004; 21: 1-9.

28. Merrow AC, Gupta A, Patel MN, Adams DM. 2014 Revised Classification of Vascular Lesions from the International Society for the Study of Vascular Anomalies: Radiologic-Pathologic Update. Radiographics 2016; 36: 1494-516.

29. Drolet BA, Chamlin SL, Garzon MC, et al. Prospective study of spinal anomalies in children with infantile hemangiomas of the lumbosacral skin. J Pediatr 2010; 157: 789.

30. Bruckner AL, Frieden IJ. Hemangiomas of infancy. J Am Acad Dermatol 2003; 48: 477-93.

31. Brockman RM, Humphrey SR, Moe DC, et al. Mimickers of Infantile Hemangiomas. Pediatr Dermatol 2017; 34: 331-336.

32. Ovadia SA, Landy DC, Cohen ER, Yang EY, Thaller SR. Local administration of β-blockers for infantile hemangiomas: a systematic review and meta-analysis. Ann Plast Surg 2015; 74: 256-62.

33. Püttgen K, Lucky A, Adams D, et al; Hemangioma Investigator Group. Topical Timolol Maleate Treatment of Infantile Hemangiomas. Pediatrics 2016; 138.

34. Garzon MC, Lucky AW, Hawrot A, Frieden IJ. Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. J Am Acad Dermatol 2005; 52: 281-6.

35. Chen MT, Yeong EK, Horng SY. Intralesional corticosteroid therapy in proliferating head and neck hemangiomas: a review of 155 cases. J Pediatr Surg 2000; 35: 420-3.

36. Ho NT, Lansang P, Pope E. Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study. J Am Acad Dermatol 2007; 56: 63-8.

37. Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 2013; 131: 128-40.

38. Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol 2009; 26: 610-4.

39. Vivas-Colmenares GV, Bernabeu-Wittel J, Alonso-Arroyo V, et al. Effectiveness of propranolol in the treatment of infantile hemangioma beyond the proliferation phase. Pediatr Dermatol 2015; 32: 348-52.

40. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg 1999; 104: 1616-23.

41. Kelly ME, Juern AM, Grossman WJ, et al. Immunosuppressive effects in infants treated with corticosteroids for infantile hemangiomas. Arch Dermatol 2010; 146) :767-74.

42. Fawcett SL, Grant I, Hall PN, et al. Vincristine as a treatment for a large haemangioma threatening vital functions. Br J Plast Surg 2004; 57: 168-71.

43. Jiménez-Hernández E, Dueñas-González MT, Quintero-Curiel JL, et al. Treatment with interferon-alpha-2b in children with life-threatening hemangiomas. Dermatol Surg 2008 ; 34: 640-7.

44. Couto RA, Maclellan RA, Zurakowski D, Greene AK. Infantile hemangioma:clinical assessment of the involuting phase and implications for management.Plast Reconstr Surg 2012; 130: 619-24.

45. Kanada KN, Merin MR, Munden A, Friedlander SF. A prospective study of cutaneous findings in newborns in the United States: correlation with race,ethnicity, and gestational status using updated classification and nomenclature. J Pediatr 2012; 161: 240-5.

46. Krol A, MacArthur CJ. Congenital hemangiomas: rapidly involuting and noninvoluting congenital hemangiomas. Arch Facial Plast Surg 2005; 7: 307-11.

47. Roncero M, Martinez de Salinas A, Izquierdo N, Unamuno P. Rapidly involuting congenital haemangioma. Clin Exp Dermatol 2009; 34: 937-8.

48. Amouri M, Mesrati H, Chaaben H, et al. Congenital hemangioma. Cutis 2017; 99: E31-E33.

49. Lee PW, Frieden IJ, Streicher JL, et al. Characteristics of noninvoluting congenital hemangioma: a retrospective review. J Am Acad Dermatol 2014; 70: 899-903.

50. Nasseri E, Piram M, McCuaig CC, et al. Partially involuting congenital hemangiomas: a report of 8 cases and review of the literature. J Am Acad Dermatol 2014; 70: 75-9.

51. Powell J, Blouin MM, David M, Dubois J. Bleeding in congenital hemangiomas:crusting as a clinical predictive sign and usefulness of tranexamic acid. Pediatr Dermatol 2012; 29: 182-5.

52. Andreu-Barasoain M, Naz E, Díaz M, López-Estebaranz JL. Rapidly involuting congenital hemangioma associated with transient anemia and thrombocytopenia. Int J Dermatol 2013; 52: 1025-6.

53. Weitz NA, Lauren CT, Starc TJ, et al. Congenital cutaneous hemangioma causing cardiac failure: a case report and review of the literature. Pediatr Dermatol2013; 30: e180-90.

54. Sadick M, Wohlgemuth WA, Huelse R, et al. Interdisciplinary Management of Head and Neck Vascular Anomalies: ClinicalPresentation, Diagnostic Findings and Minimalinvasive Therapies. Eur J Radiol Open 2017; 4: 63-68.

55. Al Dhaybi R, Powell J, McCuaig C, Kokta V. Differentiation of vascular tumors from vascular malformations by expression of Wilms tumor 1 gene: evaluation of 126 cases. J Am Acad Dermatol 2010; 63: 1052-7.

56. Frieden IJ, Rogers M, Garzon MC. Conditions masquerading as infantile haemangioma: Part 2. Australas J Dermatol 2009; 50: 153-68.

57. Brás S, Mendes-Bastos P, Amaro C. Rapidly involuting congenital hemangioma. An Bras Dermatol 2017; 92: 861-863.

58. Sabharwal A, Aguirre A, Zahid TM, et al. Acquired tufted angioma of upper lip: case report and review of the literature. Head Neck Pathol 2013; 7: 291-4.

59. Colmenero I, Hoeger PH. Vascular tumours in infants. Part II: vascular tumours of intermediate malignancy [corrected] and malignant tumours. Br J Dermatol 2014; 171: 474-84.

60. Lee B, Chiu M, Soriano T, Craft N. Adult-onset tufted angioma: a case report and review of the literature. Cutis 2006; 78: 341-5.

61. Herron MD, Coffin CM, Vanderhooft SL. Tufted angiomas: variability of the clinical morphology. Pediatr Dermatol 2002; 19: 394-401.

62. Croteau SE, Liang MG, Kozakewich HP, et al. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. J Pediatr 2013; 162: 142-7.

63. O'Rafferty C, O'Regan GM, Irvine AD, Smith OP. Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon. Br J Haematol 2015; 171: 38-51.

64. Liu XH, Li JY, Qu XH, et al. Treatment of kaposiform hemangioendothelioma and tufted angioma. Int J Cancer 2016; 139: 1658-66.

65. Drolet BA, Trenor CC 3rd, Brandão LR, et al. Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma. J Pediatr 2013; 163: 285-91.

66. Wang Z, Li K, Dong K, Xiao X, Zheng S. Successful treatment of Kasabach-Merritt phenomenon arising from Kaposiform hemangioendothelioma by sirolimus. J Pediatr Hematol Oncol 2015; 37: 72-3.

67. Wang H, Duan Y, Gao Y, Guo X. Sirolimus for Vincristine-Resistant Kasabach-Merritt Phenomenon: Report of Eight Patients. Pediatr Dermatol 2017; 34: 261-265.

68. Perkins P, Weiss SW. Spindle cell hemangioendothelioma. An analysis of 78 cases with reassessment of its pathogenesis and biologic behavior. Am J Surg Pathol 1996; 20: 1196-204.

69. Wick MR. Vascular tumors of the skin. http://uscapknowledgehub.org/site~/96th/pdf/companion14h04.pdf

70. Hoeger PH, Colmenero I. Vascular tumours in infants. Part I: benign vascular tumours other than infantile haemangioma. Br J Dermatol 2014; 171: 466-73.

71. Guo R, Gavino AC. Angiolymphoid hyperplasia with eosinophilia. Arch Pathol Lab Med 2015; 139: 683-6.

72. Giblin AV, Clover AJ, Athanassopoulos A, Budny PG. Pyogenic granuloma - the quest for optimum treatment: audit of treatment of 408 cases. J Plast Reconstr Aesthet Surg 2007; 60: 1030-5.

73. Dastgheib L, Maghami Z, Aslani FS. Infantile multiple large pyogenic granuloma on burned skin. Case report and review of literature. An Bras Dermatol 2016; 91: 212-4.

74. Gencoglan G, Inanir I, Gündüz K. Pyogenic granuloma in two children successfully treated with imiquimod 5% cream. Pediatr Dermatol 2009; 26: 366-8.

75. Lee J, Sinno H, Tahiri Y, Gilardino MS. Treatment options for cutaneous pyogenic granulomas: a review. J Plast Reconstr Aesthet Surg 2011; 64: 1216-20.

76. Ranga SM, Kuchangi NC, Shankar VS, et al. Retiform hemangioendothelioma: an uncommon pediatric vascular neoplasm. Indian J Dermatol 2014; 59: 633.

77. Rani S, Singh J, Ahuja AK, Bhardwaj M. Retiform hemangioendothelioma: A rare entity at atypical site. Indian J Dermatol Venereol Leprol 2016; 82: 550-2.

78. Jothi EA, Sundaram M, Namasivayam J, Jothi M. A rare presentation of retiform hemangioendothelioma in the external auditory canal. Case Rep Otolaryngol 2014; 2014: 715035.

79. Kuo CL, Chen PC, Li WY, Chu PY. Retiform hemangioendothelioma of the neck. J Pathol Transl Med 2015; 49: 171-3.

80. Tamhankar AS, Vaidya A, Pai P. Retiform hemangioendothelioma over forehead: A rare tumor treated with chemoradiation and a review of literature. J Cancer Res Ther 2015; 11: 657.

81. Shang Leen SL, Fisher C, Thway K. Composite hemangioendothelioma: clinical and histologic features of an enigmatic entity. Adv Anat Pathol 2015; 22: 254-9.

82. Bhat A, Chowdappa V. Composite Hemangioendothelioma: Report of a Rare Case. J Clin Diagn Res 2016; 10: ED01-ED03.

83. Rokni GR, Montazer F, Sharifian M, Goldust M. Composite hemangioendothelioma of the forehead and right eye; a case report. BMC Dermatol 2017; 17: 15.

84. McNab PM, Quigley BC, Glass LF, Jukic DM. Composite hemangioendothelioma and its classification as a low-grade malignancy. Am J Dermatopathol 2013; 35: 517-22.

85. Stojsic Z, Brasanac D, Stojanovic M, Boricic M. Cutaneous composite hemangioendothelioma: case report and review of published reports. Ann Saudi Med 2014; 34: 182-8.

86. Ward KA, Ecker PM, White RR, et al. Papillary intralymphatic angioendothelioma of the thigh: A case report and review of the literature. Dermatol Online J 2010; 16: 4.

87. Schwartz RA, Dabski C, Dabska M. The Dabska tumor: a thirty-year retrospect. Dermatology 2000; 201: 1-5.

88. Eng OS, Borah GL, Gannon CJ. CASE REPORT Successful Treatment of a Rare Massive Dabska Tumor. Eplasty 2013 10; 13:e46.

89. Kugler A, Koelblinger P, Zelger B, et al. Papillary intralymphatic angioendothelioma (PILA), also referred to as Dabska tumour, in an 83-year-old woman. J Eur Acad Dermatol Venereol 2016; 30: e59-e61.

90. Hornick JL, Fletcher CDM. Pseudomyogenic Hemangioendothelioma: A Distinctive, Often Multicentric Tumor With Indolent Behavior. Am J Surg Pathol 2011; 35: 190-201.

91. Raftopoulos E, Royer M, Warren M, et al. Pseudomyogenic Hemangioendothelioma: Case Report and Review of the Literature. Am J Dermatopathol 2018; 0: 1–5.

92. Rullo R, Addabbo F, Rullo F, Festa VM. Primary Polymorphous Hemangioendothelioma of the

Maxillary Soft Tissue: Clinical and Immunopathological Aspects of a Rare Vascular Neoplasm.

In vivo 2014; 28: 249-254.

93. Mariggiò G, Koch S, Schulz TF. Kaposi sarcoma herpesvirus pathogenesis. Philos Trans R Soc Lond B Biol Sci 2017; 372.

94. De Paoli P, Carbone A. Kaposi's Sarcoma Herpesvirus: twenty years after its discovery. Eur Rev Med Pharmacol Sci 2016; 20: 1288-94.

95. Schwartz RA. Kaposi's sarcoma: an update. J Surg Oncol 2004; 87: 146-51.

96. Schneider JW, Dittmer DP. Diagnosis and Treatment of Kaposi Sarcoma. Am J Clin Dermatol 2017; 18: 529-539.

97. Shon W, Billings SD. Cutaneous Malignant Vascular Neoplasms. Clin Lab Med 2017; 37: 633-646.

98. Spiker AM, Ramsey ML. Cancer, Angiosarcoma. 2017 Jun 29. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018- Available from http://www.ncbi.nlm.nih.gov/books/NBK441983

99. Rosenberg A, Agulnik M. Epithelioid Hemangioendothelioma: Update on Diagnosis and Treatment. Curr Treat Options Oncol 2018; 19: 19.

100. Sardaro A, Bardoscia L, Petruzzelli MF, Portaluri M. Epithelioid hemangioendothelioma: an overview and update on a rare vascular tumor. Oncol Rev 2014; 8: 259.

101. Mcculloch M, Russin M, Nachat A. Recurrence of Epithelioid Hemangioendothelioma during Pregnancy: Case Report and Systematic Review. Perm J 2016; 20: 84-9.

***Lenfatik tümörler***

1. Elluru RG, Balakrishnan K, Padua HM. Lymphatic malformations: diagnosis and management. Semin Pediatr Surg 2014; 23: 178-85.

2. Sun RW, Tuchin VV, Zharov VP, Galanzha EI, Richter GT. Current status,pitfalls and future directions in the diagnosis and therapy of lymphatic malformation. J Biophotonics. 2017 Aug 29. doi: 10.1002/jbio.201700124.

3. ISSVA Classification of Vascular Anomalies ©2018 International Society for the Study of Vascular Anomalies Available at "issva.org/classification" Accessed.

4. Vaselga G. Vascular malformations. In: Dermatology. Bolognia JL, Schaffer JV, Cerroni L, editors. Fourth edition. Elsevier Limited, 2018: 1805-27.

5. Maguiness SM, Garzon MC. Vascular Malformations. In: Neonatal and Infant Dermatology. Third edition. Elsevier Saunders. 2015: 352-68.

6. Habif TP. Vascular tumors and malformations. Clinical Dermatology. Sixth edition. 2016: 901-22.

7. Patel GA, Schwartz RA. Cutaneous lymphangioma circumscriptum: frog spawn on the skin. Int J Dermatol 2009; 48: 1290-5.

8. Bae BG, Do JE, Kim YJ, Noh S, Oh SH. Cutaneous lymphangioma as a diagnostic clue for thoracic lymphangiomatosis. Br J Dermatol 2010; 163: 875-7.

9. Fernandes VM, Fargo JH, Saini S, et al. Kaposiform lymphangiomatosis: unifying features of a heterogeneous disorder. Pediatr Blood Cancer 2015; 62: 901-4.

10. Larkin SC, Wentworth AB, Lehman JS, Tollefson MM. A case of extensive acquired progressive lymphangioma. Pediatr Dermatol 2018 Apr 6. doi: 10.1111/pde.13486.

11. Massa AF, Menezes N, Baptista A, et al. Cutaneous Lymphangioma circumscriptum - dermoscopic features. An Bras Dermatol 2015; 90: 262-4.

12. Hassanein AH, Mulliken JB, Fishman SJ, et al. Lymphatic malformation: risk of progression during childhood and adolescence. J Craniofac Surg 2012; 23: 149-52.

**Kas tümörleri**

1. Jain S, Patro S, Darkase B ve ark. Multiple acquired smooth muscle hamartomas with thick-walled blood vessels on scalp J Cutan Pathol. 2018;1–4

2. Kwon KS, Lee CW, Seo KH. Acquired vulvar smooth muscle hamartoma: A case report and review of the literature. J Dermatol 2000;27:56-59.

3. Schmidt CS, Bentz ML. Congenital smooth muscle hamartoma: The importance of differentiation from melanocytic nevi. J Craniofac Surg 2005;16(5):926-9.

4. Miettinen M. Smooth muscle tumors of soft tissue and non-uterine viscera: biology and prognosis. Mod Pathol. 2014 ;27 Suppl 1:S17-29.

5. Holst VA, Junkins-Hopkins JM, Elenitsas R. Cutaneous smooth muscle neoplasms: clinical features, histologic findings, and treatment options. J Am Acad Dermatol. 2002;46(4):477-90.

6. Bilgiç Ö, Tunçez Akyürek F, Altınyazar HC. Pseudo Darier sign: A distinctive finding for congenital smooth muscle hamartoma. J Pediatr. 2016;169:318.

7. Günlemez A, Bayramgürler D, Erçin C ve ark. Congenital smooth muscle hamartoma on the scalp. Int J Dermatol. 2009;48(6):633-5.

8. Zarineh A, Kozovska ME, Brown WG, ve ark. Smooth muscle hamartoma associated with a congenital pattern melanocytic nevus, a case report and review of the literature. J Cutan Pathol. 2008;35 Suppl 1:83-6.

9. Garman ME, Blumberg MA, Ernst R, Raimer SS. Familial leiomyomatosis: a review and discussion of pathogenesis. Dermatology. 2003;207(2):210-3.

10.Malik K, Patel P, Chen J, Khachemoune A. Leiomyoma cutis: a focused review on presentation, management, and association with malignancy. Am J Clin Dermatol. 2015;16(1):35-46.

11. Malhotra P, Walia H, Singh H, Ramesh V. Leiomyoma cutis: A clinicopathological series of 37 cases. Indian J Dermatol. 2010;55(4):337–341.

12. Holst VA, Junkins-Hopkins JM, Elenitsas R. Cutaneous smooth muscle neoplasms: clinical features, histologic findings, and treatment options. J Am Acad Dermatol. 2002;46(4):477-90.

13. Sahoo B, Radotra BD, Kaur I, Kumar B. Zosteriform Pilar Leiomyoma. Journal Dermatol. 2001; 28: 759–761.

 14. Mitra A, Gudgeon PW, Merchant W, Shah M. A case of diffuse pilar leiomyoma or acquired smooth muscle hamartoma? Clin Exp Dermatol. 2009;34,e145–e147.

15. Mohammad A. Basendwh M, Fatani M, Baltow B. Reed's Syndrome: A case of multiple cutaneous leiomyomas treated with liquid nitrogen cryotherapy. Case Rep Dermatol. 2016;8(1):65–70.

16. Patt JC, Haines N. Soft tissue sarcomas in skin: presentations and management. Semin Oncol. 2016;43(3):413-8.

17. Kohlmeyer J, Steimle‐Grauer SA, Hein R. Cutaneous sarcomas. 2017;15(6):630-648.

18. Miettinen M, Fetsch JF. Evaluation of biological potential of smooth muscle tumours. Histopathol 2006;48: 97–105.

19. Miettinen M. Smooth muscle tumors of soft tissue and non-uterine viscera: biology and prognosis. Mod Pathol 2014; 27: S17–S29.

20. Idriss MH, Elston DM. S100A6 expression in cutaneous smooth muscle neoplasms. APMIS. 2015;123(10):832-6.

21. Glazer ES, Prieto-Granada C, Zager JS. Current approaches to cutaneous sarcomas: Dermatofibrosarcoma protuberans and cutaneous leiomyosarcoma. Curr Probl Cancer. 2015;39(4):248-57

22. Aneiros-Fernandez J, Antonio Retamero J, Husein-Elahmed H ve ark. Primary cutaneous and subcutaneous leiomyosarcomas: evolution and prognostic factors. Eur J Dermatol. 2016;26(1):9-12.

23. Hao J, Diao QC, Wang SP. Ve ark. Rhabdomyomatous mesenchymal hamartoma: case report and literature review. Int J Dermatol. 2015;54(10):1183-5.

24. Mazza JM, Linnell E, Votava HJ ve ark. Biopsy-proven spontaneous regression of a rhabdomyomatous mesenchymal hamartoma. Pediatr Dermatol. 2015;32(2):256-62.

25. Kim HS, Kim YJ, Kim JW, Yu DS . Rhabdomyomatous mesenchymal

Hamartoma. J Eur Acad Dermatol Venereol. 2007;21(4):564-5.

26. Ortak T, Orbay H, Ünlü E ve ark. Rhabdomyomatous Mesenchymal Hamartoma. J Craniofac Surg. 2005;16(6):1135-1137.

27. Sherley-Dale AC, Carr RA, Holmes RC.Rhabdomyomatous mesenchymal hamartoma resembling scleroderma ‘en coup de sabre’: a case report and literature review. Br J Dermatol 2010 162, pp208–234

28. Williams NP, Shue AC. Rhabdomyomatous mesenchymal hamartoma: a clinical overview and report of a case with spontaneous regression. West Indian Med J 2009;58:607–609.

**Fibröz ve histiyositik tümörler**

1. Trace AP, Enos CW, Mantel A, Harvey VM. Keloids and hypertrophic scars: A spectrum of clinical challenges Am J Clin Dermatol 2016;17:201–223.

2. Mari W, Alsabri SG, Tabal N. et al. Novel insights on understanding of keloid scar: Article review. J Am Coll Clin Wound Spec 2016;7:1–7.

3. Ogawa R. Keloid and hypertrophic scars are the result of

chronic inflammation in the reticular dermis. Int J Mol Sci 2017;18: 606

4. Berman B, Maderal A, Raphael B. Keloids and hypertrophic scars: pathophysiology, classification, and treatment. Dermatol Surg 2017;43:S3–S18

5. Tu Y, Lineaweaver WC, Zhang F. TGF-β1 -509C/T polymorphism and susceptibility to keloid disease: a systematic review and meta-analysis. Scar Burn Heal 2017;3:1–10.

6. Andrews JP, Marttala J, Macarak E. et al. Keloids: The paradigm of skin fibrosis. Pathomechanisms and treatment Matrix Biol. (2016) 51, 37–46.

7.Luzar B, Calonje E. Cutaneous fibrohistiocytic tumours-an update. Histopathol 2010;56:148-165.

8. Myers DJ, Fillman EP: Dermatofibroma. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-2017 Dec 19.

9. Romano RC, Fritchie KJ. Fibrohistiocytic tumours. Clin Lab Med 2017;37:603-631.

10. Costigan DC, Doyle LA. Advances in the clinicopathological and molecular classification of cutaneous mesenchymal neoplasms. Histopathol 2016;68:776-795.

11. Han TY, M.D., Chang HS, Lee JHK. A clinical and histopathological study of 122 cases of dermatofibroma (benign fibrous histiocytoma). Ann Dermatol. 2011;23(2):185–192.

12. Zarchi K, Kromann CB,Wortsman X, Jemec GBE. Usefulness of ultrasound for the diagnosis of dermatofibroma. Med Ultrason 2016;18(1):132-133.

13. Bogucki B, Neuhaus I, Hurst EA. Dermatofibrosarcoma protuberans: A review of the Literature. Dermatol Surg 2012;38:537–551

14. Llombart B, Serra-Guillén C, Monteagudo C et al. Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management

Seminars in Diagnostic Pathology 2013;30:13-28 .

15. Acosta AE, Ve´lez CS. Dermatofibrosarcoma protuberans. Curr Treat Options Oncol 2017;18:56.

16. Thway K, Noujaim J, Jones RL. et al. Dermatofibrosarcoma protuberans: pathology, genetics, and potential therapeutic strategies. Ann Diagn Pathol 2016;25:64–71.

17. Loghdey MS, Varma S, Rajpara SM ET AL. Mohs micrographic surgery for dermatofibrosarcoma protuberans (DFSP): A single-centre series of 76 patients treated by frozen-section Mohs micrographic surgery with a review of the literature. JPRAS 2014;67:1315-1321.

18. Reha J, Katz SC. Dermatofibrosarcoma protuberans. Surg Clin N Am 2016;96:1031–1046.

19. Noujaim j, Thway K, Fisher C et al. Dermatofibrosarcoma protuberans: from translocation to targeted therapy. Cancer Biol Med 2015;10:375-384

20. Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010;28(10)1772–9.

21. Fu Y, Kang H, Zhao H, et al. Sunitinib for patients with locally advanced or

distantly metastatic dermatofibrosarcoma protuberans but resistant to imatinib.

Int J Clin Exp Med 2015;8(5):8288–94.

22. Kamar FG, Kairouz VF, Sabri AN. Dermatofibrosarcoma protuberans (DFSP) successfully treated with sorafenib: case report. Clin Sarcoma Res 2013;3(1):5.

23. Wollina U, Langner D,Schönlebe J. Dermatofibrosarcoma protuberans: retrospective single center analysis over 16 years. Open Access Maced J Med Sci. 2018;25;6(1):35-37.

24. Billings SD, Folpe AL: Cutaneou. and subcutaneous fibrohistiocytic tumors of intermediate malignancy. An update. Am J Dermatopathol 2004;26:141-155.

25. Jha P, Moosavi C, Fanburg-Smith JC. Giant cell fibroblastoma: an update and addition of 86 new cases from the Armed Forces Institute of Pathology, in honor of Dr. Franz M. Enzinger. Ann Diagn Pathol 11;2007: 81– 88.

26. Hassan MJ, Ahmad SS, Hasan H. Giant cell fibroblastoma: A case report. Oman Med J 2012; 27(3).

27. Fonseca de Lima LA, Lisboa GM, Alves da Silva Filho A: Multiple dermatomyofibromas. An Bras Dermatol. 2018;93(2):268-70.

28. Mentzel T, Kutzner H. Dermatomyoﬁbroma: clinicopathologic and immunohistochemical analysis of 56 cases and reappraisal of a rare and distinct cutaneous neoplasm. Am J Dermatopathol 2009;31:44–49.

29. Tardío JC, Azorín D, Hern´andez-Nunez A: Dermatomyoﬁbromas presenting in pediatric patients: clinicopathologic characteristics and differential diagnosis. J Cutan Pathol 2011; 38: 967–972.

30. Campagnolo OA, Floriano de Morais C, Ughini MO: Dermatomyofibroma. An Bras Dermatol. 2017;92(1):101-3.

31. Sim JH, Shin J, Vandersteen DP et al. Development of dermatomyofibroma in a male infant. Ann Dermatol. 2011;23(Suppl 1):S72–S74.

32. Ma JE, Wieland CN, Tollefson MMet al: Dermatomyoﬁbromas arising in children: Report of two new cases and review of the literature. Pediatr Dermatol. 2017;34(3):347–351.

33. Lee JH, An JS, Lee ES, Kwon SY et al.Comparison of Sporadic sclerotic fibroma and solitary fibrous tumor in the oral cavity. Yonsei Med J. 2007:30;48(3):535–539.

34. Bhambri S, Bhambri A, Del Rosso JQ: Solitary sclerotic fibroma. J Clin Aesthet Dermatol. 2009;2(6):36–38.

35. Mahmood MN, Salama ME, Chaffins M: Solitary sclerotic fibroma of skin: a possible link with pleomorphic fibroma with immunophenotypic expression for

O13 (CD99) and CD34. J Cutan Pathol 2003; 30: 631–636.

36. Hsieh YJ, Lin YC, Wu YH:Subungual pleomorphic fibroma. J Cutan Pathol 2003: 30: 569–571

37. Tashakori M, Pimente J, Howitt BE: Pleomorphic fibroma of the skin with MDM2 immunoreactivity: A potential diagnostic pitfall. J Cutan Pathol. 2018;45:59–62.

38. Garcia-Doval I, Casas L, Toribio J. Pleomorphic fibroma of the skin, a form of sclerotic fibroma: An immnohistochemical study. Clin Exp Dermatol 1998;23:22-24.

39. Management of digital mucous cysts: a systematic review and treatment algorithm. Jabbour S, Kechichian E, Haber R. Int J Dermatol 2017:56;701–708.

40. Kim EJ, Huh JW, Park HJ. Digital mucous cyst: A clinical-surgical study

Ann Dermatol 2017;29(1):69-73.

41. Zuber T: Office management of digital mucous cysts. Am Fam Physician 2001;64:1987-90.

42. Salerni G, Alonso C: Digital Mucous Cyst. N Engl J Med 2012;366;14(5):1335.

43. Chae JB, Ohn J, Mun JH. Dermoscopic features of digital mucous cysts: A study of 23 cases. J Dermatol 2017;44:1309–1312

44. Minami S, Nakagawa N, Ito T: A Simple and effective technique for the cryotherapy of digital mucous cysts. Dermatol Surg 2007;33:1280–1282

45. Larralde M, Ferrari B, Martinez P. Infantile myofibromatosis. An Bras Dermatol. 2017;92(6):854-7.

46. Kikuchi K, Abe R, Shinkuma S. Spontaneous remission of solitary-type infantile myofibromatosis. Case Rep Dermatol 2011;3:181–185

47. Shih S, Khachemoune A. Acquired digital ﬁbrokeratoma: review of its clinical and dermoscopic features and differential diagnosis. Int J Dermatol. 2018;19. doi: 10.1111/ijd.14046.

48. Yu D, Morgan RF. Acquired digital fibrokeratoma A case report. Ann Plast Surg 2015;74: 304-305.

49. Rubegni P, Sara Poggiali S, Lamberti A. Dermoscopy of acquired digital ﬁbrokeratoma. Australas J Dermatol 2012;53, 47–48.

50. Lu YY, Lu CC, Wu CH. Giant digital ﬁbrokeratoma of the ﬁnger. Int J Dermatol 2014;53:e158–e239.

**Nadir görülen nöral tümörler**

***Nöromalar***

1. Reed RJ, Fine RM, Meltzer HD. Palisaded, encapsulated neuromas of the skin. Arch Dermatol. 1972 Dec;106(6):865-70.

 2. Dubovy SR, Clark BJ. Palisaded encapsulated neuroma (solitary circumscribed neuroma of skin) of the eyelid: report of two cases and review of the literature. Br J Ophthalmol. 2001 Aug;85(8):949-51.

3. Magnusson B. Palisaded encapsulated neuroma (solitary circumscribed neuroma)of the oral mucosa. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Sep;82(3):302-4.

4. Mayorga M, Acebo E, Val-Bernal JF. Palisaded encapsulated neuroma of the nasal fossa. Otolaryngol Head Neck Surg. 1998 Jul;119(1):141-3.

5.Navarro M, Vilata J, Requena C, Aliaga A. Palisaded encapsulated neuroma (solitary circumscribed neuroma) of the glans penis. Br J Dermatol. 2000 May;142(5):1061-2.

6. Newman MD, Milgraum S. Palisaded encapsulated neuroma (PEN): an often misdiagnosed neural tumor. Dermatol Online J. 2008 Jul 15;14(7):12.

7. Argenyi ZB, Cooper PH, Santa Cruz D. Plexiform and other unusual variants of palisaded encapsulated neuroma. J Cutan Pathol. 1993 Feb;20(1):34-9.

8. Argenyi ZB. Immunohistochemical characterization of palisaded, encapsulated neuroma. J Cutan Pathol. 1990 Dec;17(6):329-35.

**Multipl mukokutan nöroma**

1. Misago N, Joh K, Soejima H, Narisawa Y. The possibility that multiple mucocutaneous (palisaded encapsulated and nonencapsulated) neuromas may be a distinct entity. JAMA Dermatol. 2013 Apr;149(4):498-500.

2. Guillet G, Gauthier Y, Tamisier JM, Geniaux M, Leroy JP, Texier L, Surleve-Bazeille JE. Linear cutaneous neuromas (dermatoneurie en stries): a limited phakomatosis with striated pigmentation corresponding to cutaneous hyperneury (featuring multiple endocrine

neoplasia syndrome?). J Cutan Pathol. 1987 Feb;14(1):43-8.

3. Baykal C, Buyukbabani N, Boztepe H, Barahmani N, Yazganoglu KD. Multiple cutaneous neuromas and macular amyloidosis associated with medullary thyroid carcinoma. J Am Acad Dermatol. 2007 Feb;56(2 Suppl):S33-7.

4. Schaffer JV, Kamino H, Witkiewicz A, McNiff JM, Orlow SJ. Mucocutaneous neuromas: an underrecognized manifestation of PTEN hamartoma-tumor syndrome. Arch Dermatol. 2006 May;142(5):625-32.

5. Truchot F, Grézard P, Wolf F, Balme B, Perrot H. Multiple idiopathic mucocutaneous neuromas: a new entity? Br J Dermatol. 2001 Nov;145(5):826-9.

6. Liu GY, Song H, Xu XL. Multiple palisaded encapsulated neuromas in siblings: A case report and review of the published work. J Dermatol. 2016 May;43(5):560-3.

7. Misago N, Toda S, Narisawa Y. The relationship between palisaded encapsulated neuroma and the mucocutaneous neuroma seen in multiple endocrine neoplasia 2bsyndrome: a histopathologic and immunohistochemical study. Am J Dermatopathol.2014 Jul;36(7):562-9.

***Primer malign primitif nöroektodermal tümör / ekstraiskeletal Ewing sarkomu***

1. Yoon JH, Kim H, Lee JW, Kang HJ, Park HJ, Park KD, Park BK, Shin HY, Park JD, Park SH, Ahn HS. Ewing sarcoma/peripheral primitive neuroectodermal tumor in the adrenal gland of an adolescent: a case report and review of the literature. JPediatr Hematol Oncol. 2014 Oct; 36(7):e456-9.

2. Zhao M, Zhang B, Liang F, Zhang J. Primary spinal intradural extraskeletal Ewing sarcoma mimicking a giant nerve sheath tumor: case report and review of theliterature. Int J Clin Exp Pathol. 2014 Dec 1;7(12):9081-5.

3. Tefft M, Vawter GF, Mitus A. Paravertebral "round cell" tumors in children.Radiology. 1969 Jun;92(7):1501-9.

4. Delaplace M, Lhommet C, de Pinieux G, Vergier B, de Muret A, Machet L. Primary cutaneous Ewing sarcoma: a systematic review focused on treatment and outcome. Br J Dermatol. 2012 Apr;166(4):721-6.

5. Oliveira Filho Jd, Tebet AC, Oliveira AR, Nasser K. Primary cutaneous Ewing sarcoma--case report. An Bras Dermatol. 2014 May-Jun;89(3):501-3.

6. Funakoshi T, Sato T, Hosokawa R, Saito M, Amagai M, Ishiko A, Ohyama M.Application of electron microscopic analysis and fluorescent in situhybridization technique for the successful diagnosis of extraskeletal Ewing'ssarcoma. J Dermatol. 2015 Sep;42(9):893-6.

7. Grassetti L, Torresetti M, Brancorsini D, Rubini C, Lazzeri D, Di Benedetto G.A peculiar case of large primary cutaneous Ewing's sarcoma of the foot: Case report and review of the literature. Int J Surg Case Rep. 2015;15:89-92.

8. Terrier-Lacombe MJ, Guillou L, Chibon F, Gallagher G, Benhattar J, Terrier P, Ranchère D, Coindre JM. Superficial primitive Ewing's sarcoma: aclinicopathologic and molecular cytogenetic analysis of 14 cases. Mod Pathol.2009 Jan;22(1):87-94.

9. Yamaguchi U, Hasegawa T, Morimoto Y, Tateishi U, Endo M, Nakatani F, Kawai A, Chuman H, Beppu Y, Endo M, Kurotaki H, Furuta K. A practical approach to the clinical diagnosis of Ewing's sarcoma/primitive neuroectodermal tumour and other small round cell tumours sharing EWS rearrangement using new fluorescence in situ hybridisation probes for EWSR1 on formalin fixed, paraffin wax embedded tissue. JClin Pathol. 2005 Oct;58(10):1051-6.

10. Omori M, Ueno M, Ogawa M, Nagano T. Primary cutaneous extraskeletal Ewing's sarcoma/ PNET: possibility of better prognosis than deep ES/PNET. Eur J Dermatol. 2014 Jan-Feb;24(1):126-7.

***Sinir kılıfı miksoması/Nörotekoma***

1. Harkin JC, Reed RJ. Nerve sheath myxoma. Tumors of the peripheral nervous system. In: Atlas of tumor pathology. Second series, fasicle 3. Washington, DC: Armed Forces Institute of Pathology; 1969. p. 60 –64.

 2. Gallager RL, Helwig EB. Neurothekeoma: a benign cutaneous tumor of neural origin. Am J Clin Pathol 1980;74:759 –764.

3. Papadopoulos EJ, Cohen PR, Hebert AA. Neurothekeoma: report of a case in an infant and review of the literature. J Am Acad Dermatol. 2004 Jan;50(1):129-134.

4. Safadi RA, Hellstein JW, Diab MM, Hammad HM. Nerve sheath myxoma (neurothekeoma) of the gingiva, a case report and review of the literature. Head Neck Pathol. 2010 Sep;4(3): 242-5.

5. Argenyi ZB, LeBoit PE, Cruz DS, Swanson PE, Kutzner H. Nerve sheath myxoma (neurothekeoma) of the skin: light microscopic and immunohistochemical reappraisal of the cellular variant. J Cutan Pathol 1993;20:294 –303.

6. Rudolph P, Schubert C. Myxoid cellular neurothekeoma [letter]. Am J Dermatopathol 2002; 24:92–3.

7. Strumia R, Lombardi AR, Cavazzini L. S-100 negative myxoid neurothekeoma [letter]. Am J Dermatopathol 2001;23:82–3.

8. Fetsch JF, Laskin WB, Miettinen M. Nerve sheath myxoma: a clinicopathologic and immunohistochemical analysis of 57 morphologically distinctive, S-100 protein- and GFAP-positive, myxoid peripheral nerve sheath tumors with a predilection for the extremities and a high local recurrence rate. Am J Surg Pathol 2005;29:1615–1624.

9. Rozza-de-Menezes RE, Andrade RM, Israel MS, Gonçalves Cunha KS. Intraoral nerve sheath myxoma: case report and systematic review of the literature. Head Neck. 2013 Dec;35(12):E397-404.

10. Hurwitz S. Cutaneous tumors in childhood. In: Clinical pediatric dermatology: a textbook of skin disorders of childhood and adolescence. 2nd ed. Philadelphia: Saunders; 1993.p.198 –241.

11. Barnhill RL, Mihm MC. Cellular neurothekeoma: a distinctive variant of neurothekeoma mimicking nevomelanocytic tumors. Am J Surg Pathol 1990;14:113–20.

**Merkel hücreli karsinom**

1. Tothill R, Estall V, Rischin D. Merkel cell carcinoma: emerging biology, current approaches, and future directions. Am Soc Clin Oncol Educ Book.2015:e519-26.

2. Toker C. Trabecular carcinoma of the skin. Arch Dermatol 1972; 105:107.

3. Albores-Saavedra J, Batich K, Chable-Montero F, et al. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol 2010; 37:20.

4. Youlden DR, Soyer HP, Youl PH, et al. Incidence and survival for Merkel cell carcinoma in Queensland, Australia, 1993-2010. JAMA Dermatol 2014; 150:864.

5. Robertson JP, Liang ES, Martin RC. Epidemiology of Merkel cell carcinoma in New Zealand: a population-based study. Br J Dermatol 2015; 173:835.

6. Girschik J, Thorn K, Beer TW, et al. Merkel cell carcinoma in Western Australia: a population-based study of incidence and survival. Br J Dermatol 2011; 165:1051.

7. Clarke CA, Robbins HA, Tatalovich Z, et al. Risk of merkel cell carcinoma after solid organ transplantation. J Natl Cancer Inst 2015; 107.

8. Tadmor T, Aviv A, Polliack A. Merkel cell carcinoma, chronic lymphocytic leukemia and other lymphoproliferative disorders: an old bond with possible new viral ties. Ann Oncol 2011; 22:250.

9. Manganoni MA, Farisoglio C, Tucci G, et al. Merkel cell carcinoma and HIV infection: a case report and review of the literature. AIDS Patient Care STDS 2007; 21:447.

10. Kaae J, Hansen AV, Biggar RJ, et al. Merkel cell carcinoma: incidence, mortality, and risk of other cancers. J Natl Cancer Inst 2010; 102:793.

11. Howard RA, Dores GM, Curtis RE, et al. Merkel cell carcinoma and multiple primary cancers. Cancer Epidemiol Biomarkers Prev 2006; 15:1545.

12. Ratner D, Nelson BR, Brown MD, Johnson TM. Merkel cell carcinoma. J Am Acad Dermatol 1993; 29:143.

13. Tilling T, Moll I. Which are the cells of origin in merkel cell carcinoma? J Skin Cancer 2012; 2012:680410.

14. Santos-Juanes J, Fernández-Vega I, Fuentes N, et al. Merkel cell carcinoma and Merkel cell polyomavirus: a systematic review and meta-analysis. Br J Dermatol 2015; 173:42.

15. Church CD, Nghiem P. How does the Merkel polyomavirus lead to a lethal cancer? Many answers, many questions, and a new mouse model. J Invest Dermatol 2015; 135:1221.

16. Rollison DE, Giuliano AR, Messina JL, et al. Case-control study of Merkel cell polyomavirus infection and cutaneous squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2012; 21:74.

17. Du-Thanh A, Dereure O, Guillot B, Foulongne V. Merkel cell polyomavirus: its putative involvement in a particular subset of cutaneous lymphoma with possibly unfavorable outcome. J Clin Virol 2014; 61:161.

18. Heath M, Jaimes N, Lemos B, et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol 2008; 58:375.

19. Popp S, Waltering S, Herbst C, et al. UV-B-type mutations and chromosomal imbalances indicate common pathways for the development of Merkel and skin squamous cell carcinomas. Int J Cancer 2002; 99:352.

20. Ming M, Zhao B, Qiang L, He YY. Effect of immunosuppressants tacrolimus and mycophenolate mofetil on the keratinocyte UVB response. Photochem Photobiol 2015; 91:242.

21. Harms PW, Vats P, Verhaegen ME, et al. The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma. Cancer Res 2015; 75:3720.

22. Harms PW, Patel RM, Verhaegen ME, et al. Distinct gene expression profiles of viral- and nonviral-associated merkel cell carcinoma revealed by transcriptome analysis. J Invest Dermatol 2013; 133:936.

23. Haymerle G, Fochtmann A, Kunstfeld R, et al. Management of Merkel cell carcinoma of unknown primary origin: the Vienna Medical School experience. Eur Arch Otorhinolaryngol 2015; 272:425.

24. Scalvenzi M, Palmisano F, Ilardi G, et al. Clinical, dermoscopic and histological features of a Merkel cell carcinoma of the hand. J Dermatol Case Rep 2013; 7:15.

25. Pulitzer MP, Brannon AR, Berger MF, et al. Cutaneous squamous and neuroendocrine carcinoma: genetically and immunohistochemically different from Merkel cell carcinoma. Mod Pathol 2015; 28:1023.

26. Chan JK, Suster S, Wenig BM, et al. Cytokeratin 20 immunoreactivity distinguishes Merkel cell (primary cutaneous neuroendocrine) carcinomas and salivary gland small cell carcinomas from small cell carcinomas of various sites. Am J Surg Pathol 1997; 21:226.

27. Leech SN, Kolar AJ, Barrett PD, et al. Merkel cell carcinoma can be distinguished from metastatic small cell carcinoma using antibodies to cytokeratin 20 and thyroid transcription factor 1. J Clin Pathol 2001; 54:727.

28. Leroux-Kozal V, Lévêque N, Brodard V, et al. Merkel cell carcinoma: histopathologic and prognostic features according to the immunohistochemical expression of Merkel cell polyomavirus large T antigen correlated with viral load. Hum Pathol 2015; 46:443.

29. Erstad DJ, Jr JC. Mutational analysis of merkel cell carcinoma. Cancers (Basel) 2014; 6:2116.

30. Iwasaki T, Matsushita M, Nonaka D, et al. Comparison of Akt/mTOR/4E-BP1 pathway signal activation and mutations of PIK3CA in Merkel cell polyomavirus-positive and Merkel cell polyomavirus-negative carcinomas. Hum Pathol 2015; 46:210.

31. Merkel Cell Carcinoma. In: AJCC Staging Manual, Springer, New York 2010. p.315.

32. Harms KL, Healy MA, Nghiem P, et al. Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System. Ann Surg Oncol 2016; 23:3564.

33. Treglia G, Kakhki VR, Giovanella L, Sadeghi R. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with Merkel cell carcinoma: a systematic review and meta-analysis. Am J Clin Dermatol 2013; 14:437.

34. Veness M, Howle J. Radiotherapy alone in patients with Merkel cell carcinoma: the Westmead Hospital experience of 41 patients. Australas J Dermatol 2015; 56:19.

35. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician\_gls/f\_guidelines.asp (Accessed on February 27, 2016).

36. Howle JR, Hughes TM, Gebski V, Veness MJ. Merkel cell carcinoma: an Australian perspective and the importance of addressing the regional lymph nodes in clinically node-negative patients. J Am Acad Dermatol 2012; 67:33.

37. Boyer JD, Zitelli JA, Brodland DG, D'Angelo G. Local control of primary Merkel cell carcinoma: review of 45 cases treated with Mohs micrographic surgery with and without adjuvant radiation. J Am Acad Dermatol 2002; 47:885.

38. Sundaresan P, Hruby G, Hamilton A, et al. Definitive radiotherapy or chemoradiotherapy in the treatment of Merkel cell carcinoma. Clin Oncol (R Coll Radiol) 2012; 24:e131.

39. Chen MM, Roman SA, Sosa JA, Judson BL. The role of adjuvant therapy in the management of head and neck merkel cell carcinoma: an analysis of 4815 patients. JAMA Otolaryngol Head Neck Surg 2015; 141:137.

40. Kachare SD, Wong JH, Vohra NA, et al. Sentinel lymph node biopsy is associated with improved survival in Merkel cell carcinoma. Ann Surg Oncol 2014; 21:1624.

41. Gunaratne DA, Howle JR, Veness MJ. Sentinel lymph node biopsy in Merkel cell carcinoma: a 15-year institutional experience and statistical analysis of 721 reported cases. Br J Dermatol 2016; 174:273.

42. Bhatia S, Storer BE, Iyer JG, et al. Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base. J Natl Cancer Inst 2016; 108.

43. Poulsen M, Rischin D, Walpole E, et al. High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study--TROG 96:07. J Clin Oncol 2003; 21:4371.

44. Nghiem P, Bhatia S, Daud A, et al. Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma. Abstract 22LBA, European Society of Medical Oncology 2015.

45. Morand GB, Madana J, Da Silva SD, et al. Merkel cell carcinoma of the head and neck: poorer prognosis than non-head and neck sites. J Laryngol Otol 2016; 130:393.

46. Poulsen M, Walpole E, Harvey J, et al. Weekly carboplatin reduces toxicity during synchronous chemoradiotherapy for Merkel cell carcinoma of skin. Int J Radiat Oncol Biol Phys 2008; 72:1070.

47. Tarantola TI, Vallow LA, Halyard MY, et al. Unknown primary Merkel cell carcinoma: 23 new cases and a review. J Am Acad Dermatol 2013; 68:433.

48. Foote M, Veness M, Zarate D, Poulsen M. Merkel cell carcinoma: the prognostic implications of an occult primary in stage IIIB (nodal) disease. J Am Acad Dermatol 2012; 67:395.

49. Deneve JL, Messina JL, Marzban SS, et al. Merkel cell carcinoma of unknown primary origin. Ann Surg Oncol 2012; 19:2360.

50. Lebbe C, Becker JC, Grob JJ, et al.; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC). Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. Eur J Cancer. 2015 Nov;51(16):2396-403.

51. Grotz TE, Tarantola TI, Otley CC, et al. Natural history of merkel cell carcinoma following locoregional recurrence. Ann Surg Oncol 2012; 19:2556.

52. Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016; 17:1374.

53.http://www.accessdata.fda.gov/drugsatfda\_docs/label/2017/761049s000lbl.pdf (Accessed on March 25, 2017).

54. Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med 2016; 374:2542.

55.www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-pazopanib-for-merkel-cell-carcinoma-ukmcc-01 (Accessed on April 02, 2016).

56. Fakiha M, Letertre P, Vuillez JP, Lebeau J. Remission of Merkel cell tumor after somatostatin analog treatment. J Cancer Res Ther 2010; 6:382.

57. Moshiri AS, Nghiem P. Milestones in the staging, classification, and biology of Merkel cell carcinoma. J Natl Compr Canc Netw 2014; 12:1255.

58. Paulson KG, Iyer JG, Tegeder AR, et al. Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol 2011; 29:1539.

59. Stetsenko GY, Malekirad J, Paulson KG, et al. p63 expression in Merkel cell carcinoma predicts poorer survival yet may have limited clinical utility. Am J Clin Pathol 2013; 140:838.

60. Samimi M, Molet L, Fleury M, et al. Prognostic value of antibodies to Merkel cell polyomavirus T antigens and VP1 protein in patients with Merkel cell carcinoma. Br J Dermatol 2016; 174:813.

61. Allen PJ, Bowne WB, Jaques DP, et al. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol 2005; 23:2300.

***Granüler hücreli tümör***

1. Abrikossoff A. Myomas originating from transversely striated voluntary musculature. Virchow Arch. 1926;260:215–33.

 2. Feyrter F. Uber die granularen neurogenen Gewachse. Beitr Pathol Anat. 1949;110:181–208.

3. Serpa MS, Costa-Neto H, de Oliveira PT, da Silveira ÉJ, de Medeiros AM. Granular cell tumor in two oral anatomic sites. Eur Arch Otorhinolaryngol. 2016;273:3439-41.

4. Filie AC, Lage JM, Azumi N. Immunoreactivity of S-100 protein, alpha-1 antitrypsin, and CD68 in adult and congenital granular cell tumors. Mod Pathol. 1996;9:888–92.

5. Fisher ER, Wechsler H. Granular cell myoblastoma–a misnomer. Electron microscopic and histochemical evidence concerning its Schwann cell derivation and nature (granular cell schwannoma). Cancer. 1962;15:936–54.

6. Sanford LJ, Gordon S, Travers JB. Familial granular cell tumors: a case report and review of the literature. Pediatr Dermatol. 2013;30:e8-e11.

7. Weiss SW, Goldblum JR, Enzinger FM. Enzinger and Weiss’ Soft Tissue Tumors. 5th ed. Philadelphia, PA: Mosby Elsevier; 2008:878–887.

8. Ravich A, Stout AP, Ravich RA. Malignant granular cell myoblastoma involving the urinary bladder. Ann Surg. 1945;121:361–372.

9. Liu TT, Han Y, Zheng S, Li B, Liu YQ, Chen YX, Liu YF, Wang EH. Primary cutaneous malignant granular cell tumor: a case report in China and review of the literature. Diagn Pathol. 2015;10:113.

10. Pérez-González YC, Pagura L, Llamas-Velasco M, Cortes-Lambea L, Kutzner H, Requena L. Primary cutaneous malignant granular cell tumor: an immunohistochemical study and review of the literature. Am J Dermatopathol. 2015;37:334-40.

11. Singh VA, Gunasagaran J, Pailoor J. Granular cell tumour: malignant or benign? Singapore Med J. 2015;56:513-7.

12. Jardines L, Cheung L, LiVolsi V, Hendrickson S, Brooks JJ. Malignant granular cell tumors: report of a case and review of the literature. Surgery 1994;116:49-54.

13. Boyce R, Beadles CF. A further contribution to the study of the pathology of the hypophysis cerebri. J Pathol Bacteriol 1893;1:359–83

14. Covington MF, Chin SS, Osborn AG. Pituicytoma, spindle cell oncocytoma, and granular cell tumor: clarification and meta-analysis of the world literature since 1893. AJNR Am J Neuroradiol. 2011;32:2067-72.

15. LeBoit PE, Barr RJ, Burall S, Metcalf JS, Yen TS, Wick MR. Primitive polypoid granular-cell tumor and other cutaneous granular-cell neoplasms of apparent nonneural origin. Am J Surg Pathol 1991; 15: 48.

16. Chaudhry IH, Calonje E. Dermal non-neural granular cell tumour (so-called primitive polypoid granular cell tumour): a distinctive entity further delineated in a clinicopathological study of 11 cases. Histopathology 2005; 47:179.

17. Fanburg-Smith JC, Meis-Kindblom JM, Fante R, Kindblom LG. Malignant granular cell tumor of soft tissue: diagnostic criteria and clinicopathologic correlation. Am J Surg Pathol. 1998;22:779-94.

18. Nasser H, Danforth RD Jr, Sunbuli M, et al. Malignant granular cell tumor: case report with a novel karyotype and review of the literature. Ann Diagn Pathol. 2010;14:273–278.

19. Akahane K, Kato K, Ogiso S, Sakaguchi K, Hashimoto M, Ishikawa A, Kato T, Fuwa Y, Takahashi A, Kobayashi K. Malignant granular cell tumor of the breast: case report and literature review. Breast Cancer. 2015;22:317-23.

20. Rekhi B, Jambhekar NA. Morphologic spectrum, immunohistochemical analysis, and clinical features of a series of granular cell tumors of soft tissues: a study from a tertiary referral center. Ann Diagn Pathol 2010;14:162-7.

21. Thacker MM, Humble SD, Mounasamy V, Temple HT, Scully SP. Case report. Granular cell tumors of extremities: comparison of benign and malignant variants. Clin Orthop Relat Res 2006; 455: 267-73.

22. Cardis MA, Ni J, Bhawan J. Granular cell differentiation: A review of the published work. J Dermatol. 2017;44:251-258.

23. Rosai J. Ackerman's Surgical Pathology. St. Louis: Mosby-Yearbook; 1996:2096-7.

24. Elkousy H, Harrelson J, Dodd L, Martinez S, Scully S. Granular cell tumors of the extremities. Clin Orthop Relat Res 2000;380:191-8.

25. Arai E, Nishida Y, Tsukushi S, Sugiura H, Ishiguro N. Intramuscular granular cell tumor in the lower extremities. Clin Orthop Relat Res 2010; 468:1384‑9.

26. Torrijos-Aguilar A, Alegre-de Miguel V, Pitarch-Bort G, Mercader-García P, Fortea-Baixauli JM. Cutaneous granular cell tumor: a clinical and pathologic analysis of 34 cases. Actas Dermosifiliogr 2009; 100:126-32.

**Herediter kutanöz melanoma**

1. Leachman SA, Carucci J, Kohlmann W, et al. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol 2009;61:677e1-14.

2. Bishop DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2a mutations for melanoma. J Natl Cancer Inst 2002;94:894-903.

3. Maubec E, Chaudru V, Mohamdi H, et al. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family. J Am Acad Dermatol 2012;67:1257-1264.

4. Gabree M, Patel D, Rodgers L. Clinical applications of melanoma genetics. Curr Treat Op Oncol 2014;15:336-350.

5. Soura E, Eliades P, Shannon K, et al. Hereditary melanoma: update on syndromes and management-emerging melanoma cancer complexes ang genetic counseling. J Am Acad Dermatol 2016;74:411-420.

6. Aoude LG, Pritchard AL, Robles-Espinoza CD, et al. Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma. J Natl Cancer Inst 2015;107: doi:10.1093/jnci/dju408

7. Yokoyama S, Woods SL, Boyle GM, et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011;480(7375):99-103.

8. Sturm RA, Fox C, McClenahan P, et al. Phenotypic characterization of nevus and tumor patterns in MITF E318K mutation carrier melanoma patients. J Invest Dermatol 2014;134:141-149.

***Xeroderma pigmentozum***

1-Cleaver JE. Defective repair replication of DNA in Xeroderma Pigmentosum. Nature 1968; 218: 62

2-Metin A, Akdeniz N. Kseroderma Pigmentosum. Tüzün Y, Gürer MA, Serdaroğlu S, Oğuz O, Aksungur VL, Eds. Dermatoloji’de. 3. Baskı. İstanbul: Nobel Tıp Kitabevleri; 2008; 1721-36.

3-Kraemer KH, Lee M, Scotto J. Xeroderma Pigmentosum .Cutaneous, ocular and neurologic abnormalities in 830 publisshed cases. Arch Dermatol 1987;123: 241-250.

4-Lehmann AR, Mcgibbon D, Stefanini M. Xseroderma Pigmentosum . Orphanet J Rare Dis 2011;6:70-75.

5- Robins JH,Kraemer KH,Lutzner MaFestoff Hg. Xseroderma Pigmentosum: an inherid disease with sun sensitivity ,multiple cutaneous neoplasm and abnormal DNA repair . Ann Intern Med 1974; 80: 221-248

6-Kraemer KH, DiGiovanna JJ. Xeroderma Pigmentosum. 2003 Jun 20 (uptade 29 sept 2016) Pagon RA, Adam MP, Ardinger HH et al. eds. GEneReviews (internet). Seattle,WA: University of Washington, Seattle 1993-2016. Available from http:/

:// ncbi.nlm.gov/books/NBK1397/)

7-Moriwaki S, Kraemer KH. Xeroderma pigmentosum bridging a gap between clinic and laboratory. Photodermatol Photoimmunol Photomed 2001; 17: 47–54.

8-Hirai Y et al. Heterozygous individuals bearing a founder mutation in the XPA DNA repair gene comprise nearly 1% of the Japanese population. Mutat Res 2006; 601: 171–8.

9- Khatri ML et al. Xeroderma pigmentosum in Libya. Int J Dermatol. 1999; 38: 520–4.

10- Zghal M et al. Xeroderma Pigmentosum: manifestations cutaneus, oculaires et neurologiques a partir de 49 patients tunisiens. Tunis Med. 2005; 83:760–3.

11- Moussaid L et al. Tumeurs cutaneus au cours du xeroderma pigmentosum au Maroc. Ann Dermatol Venereol 2004; 131: 29–33.

12-Metin A, Bekerecioğlu M , Uğraş S, Delice İ. Van'da kseroderma pigmentozum. Türkderm 2000; 34: 45-8.

13 - Kutluhan A, Bekerecioğlu M, Güney E, Metin A. Kseroderma Pigmentosum’un Kulak Burun Bağı Yönü. Auris Nasus Larynx 1999; 26: 457-66.

14- Akdeniz N, Bilgili SG, Çalka Ö, Karadağ AS. Doğu Anadolu'da Keroderma Pigmentosum: 15 olgunun gözden geçirilmesi. Turk J Med Sci 2012; 42: 719-23.

15-Gül U, Kiliç A, Gönül M, Cakmak SK, Soylu S . Xeroderma Pigmentosum. a Turkish case series. Int J Dermatol 2007; 46: 1125-8.

16- Lim HW, Hawk JLM. Photodermatoses. In: Bolognia JL, Jorizzo JL, Rapini RP, editors. Dermatology. 2nd ed. St. Louis (MO): Mosby Elsevier; 2008. p.1333-94.

17-Lichon V, Khachemoune A. Xsroderma pigmentosum: beyond skin cancer. J Drugs Dermatol 2007; 6: 281-8.

18- De Weerd-Kastelein EA, Kaijzer W, Bootsma D,A third complemantation group in xseroderma pigmentosum. Mutat Res 1974; 22: 87-91.

19-Kraemer KH, Coon HG, Peting RA ve ark. Genetic heterojenity in xseroderma pigmentosum: complemantation groups and their relationship to DNA repair rates . Proc Nati Acad Scl USA 1975; 72 :59-63.

20-Kraemer KH, De Weerd-Kastelein EA, Robbins JH ve ark. Five completatiom groups in xseroderma pigmentosum. Mutat Res 1975; 33: 327-34.

21-Aresae S, Kozuka T, Tanaka Tve ark. A sixth compementation group in xseroderma pigmentosum . Mutat Res 1979; 59: 143-6.

22- Jung EG. New form of Molecular Defect in Xeroderma Pigmentosum . Nature 1970; 228: 361-2.

23- Burk PG, Lutzner MA, Clarke D Robbins JH. Ultraviolet-stimulated thymidine incorporation in xeroderma pigmentosum lymphocytes. J Lab Clin Med 1971: 77: 759–67.

24-Cleaver JE. Xeroderma Pigmentozum: variants with normal DNA repair and normal sensitivity to UV light. J Invest Dermatol 1972; 58: 124 -8.

25- Norgauer J, Idzko M, Panther E et al. Xeroderma pigmentosum. Eur J Dermatol 2003; 13: 4-9.

26-LinP, English JC. Topical treatment of xeroderma pigmentosum . P&T 2004; 29: 512-4.

27- Sancar A, Lindsey-Boltz LA, Ünsal-Kaçmaz K, Linn S. Molecular mechanisms of Mammalian DNA repair and the DNA damage check points. Annu Rev Biochem 2004 ;73: 39-85.

28 – Kulaksız G, Sancar A. Nükleotid Eksizyon Onarımı ve Kanser. Türk Biyokimya Dergisi 2007; 32: 104–11.

29- Cooper GM. A Molecular Approach, The Cells: ASM Press, Washington DC 2000; 192-9.

30- Sancar A. Mechanism of DNA excision repair. Science 1984; 266: 1954-6.

31-Huang JC, Svobada DL, Reardon JT, Sancar A. Human nucleotide excision nuclease removes thymine dimers from DNA by incising the 22nd phoshodiester bond 5 ́ and the 6th phosphodiester bond 3’ to the photodimer. Proc Natl Acad Sci USA 1992 89: 3664-8.

32- Sancar A, Reardon JT. Nucleotide excision repair in E.Coli and Man. Adv Protein Chem 2004; 69: 43-71.

33- Sancar A, Rupp WD. A novel repair enzyme: Uvr ABC excision nuclease of Esherishia Coli cuts a DNA strand on both sides of the damaged region Cell. 1983; 33: 249-60.

34-Young AR, Chadwick CA,Harrison GI ve ark. The similarity of action spectra for thymine dimers in human epidermis and erythema suggested that DNA is the chromophore for erytema. J İnvest Dermatol 1998; 111: 982-8.

35-Rapin I, Lindenbaum Y, Dickson DW, Kraemer KH, Robbins JA. Cockayne syndrome and xeroderma pigmentosum: DNA repair disorders with overlaps and paradoxes. Neurology 2000; 55: 1442–9.

36-Bowden NA, Beveridge NJ, Aston KA at all. Understanding Xeroderma Pigmentosum Complementation Groups using Gene Expression profiling after UV-Light Exposure. Int J Mol Sci. 2015; 16: 15985-96.

37-Sehgal, Manika, Singh, Tiratha Raj, 2014. Systems biology approach for mutational and site-specific structural investigation of DNA repair genes for xeroderma pigmentosum. Gene 2014 ; 543: 108–7.

38- Rekaya MB, Messaoud O, Talmoudi F et al. High frequency of the V548A fs X572 XPC mutation in Tunisia: implication for molecular diagnosis. J Human Genet 2009; 54: 426–9.

39- Nishigori C , Moriwaki, S Takebe, H et all. Gene alterations and clinical characteristics of xeroderma pigmentosum group A patients in Japan. Arch Dermatol 1994; 130: 191–7.

40- Moriwaki I, Kraemer KH. Xeroderma pigmentosum bridging a gap between clinic and laboratory. Photodematol Photoimmunol Photomed 2001;17: 47–54.

41- Imoto K, Nadem C , Moriwaki S et al., Ancient origin of a Japanese xeroderma pigmentosum founder mutation. J Dermatol Sci 2013; 69: 175–6.

42-Khan SG, Metin A, Gözükara E ve ark . two essential splice lariat branchpoint sequences in oneintron in a xeroderma pigmentosum. DNA repair gene: mutation result in reduce XPC mRNA levels that corralete with cancer risk. Hum Mol Genet 2004; 13: 343-52.

43-Gözükara EM, Khan SG, Metin A, ve ark . A stop codon in xeroderma pigmentosum group C families in turkey and Italy. Molecular genetic for a comaon ancestor. J Invest Dermatol 2001; 117: 194-204.

44-Ung E G. Xeroderma pigmentosum: heterogeneous syndrome and model for UV carcinogenesis. Bull Cancer 1978; 65: 315–321.

45-Runger MT, DiGiovanna JJ, Kenneth H. Hereditary disorders of genome instability and DNA repair. Fitzpatrick’s Dermatology in General Medicine’de, 8th edition, 2012; 1-35.

46- Wang Y, Cortez D, Yazdi P, Neff, N , Elledge, SJ and Qin J, “BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures,” Genes and Development, 2000 ;14: 927–39.

 47- Coulombe J , Orbach D, Soufir N, Hadj-Rabia S. Primary gingival squamous cell carcinoma in a xeroderma pigmentosum type C patient. J Eur Acad Dermatol Venereol 2015; 30: 157-8.

48 Yang, L-C ,Hsiao Y-P ,Lu C-T et al. “Xeroderma pigmentosum complementation group C protein (XPC) expression in basal cell carcinoma,” In Vivo 2015; 29: 35–8.

49- Kraemer KH, Lee MM, Andrews AD, Lambert WC. he role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm.

Arch Dermatol 1994; 130:1018-21.

50- Courdavaul S, Baudouin C, Charveron M et al. Larger yield of cyclobutane dimersthan Beta okso-7,8-dihdroguanine in the DNA of UVA-irradiated human skin cells. Mutat Res 2004; 556: 135-42.

51- DiGiovanna JJ, Patronas N, Katz D, Abangan D, Kraemer KH. Xeroderma pigmentosum: spinal cord astrocytoma with 9-year survival after radiation and isotretinoin therapy. J Cutan Med Surg 1998;2: 153–8.

52- Butt FMA, Moshi, JR , Owibingire S, , and Chindia LM , “Xeroderma pigmentosum: a review and case series,” J Cranio-Maxillofacial Surg 2010; 38: 534–7.

 53- Pintens S, Pierret L, Keymolen K, Gutermuth J, and De Raeve L. Xeroderma pigmentosum and leukaemia in two sisters. J Eur Acad Dermatol Venereol 2016; 30: e42–e43.

54- Whitmore PV. Skin and muocuos membrane disorders. in: Duane's Ophthalmology 1995 CD-ROM Edition Vol:5 Chapter: 27, 57193-57200/190840.

55-Cleaver JE, Kraemer KH. Xeroderma pigmentosum. in: Seriver CR, Beaudel AL, Siy DV, Volle D editors. The Metabolic Basis of lnherited Disease. New York: Mc Graw-Hill 1989; 2949-7.

56- Zengin N, Zengin G, Karakurt A. ve ark: Kseroderma pigmentosum ve göz. Lepra Mecm 1992; 23: 28-37.

57- Goyal JL, Rao VA. Srinivasan R et al. Oculocutaneous manifestations in xeroderma pigmentosa. Br J Ophthalmol 1994; 78:295-7.

58-Şimşek Ş, Çınal A, Bekercioğlu M, Metin A,Y aşar T. Xeroderma Pigmentozumda Göz Bulguları . N Oftalmoloji 1997; 4: 208-11.

59- Moriwaki S-I, Kraemer KH. Xeroderma pigmentosum bridging a gap between clinic and laboratory. Photodermatol Photoimmunol Photomed 2001; 17: 47–54.

60- Kraemer KH, Patronas NJ , Schiffmann R, Brooks BP, Tamura D, DiGiovanna JJ. Xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome: a complex geno- type-phenotype relationship. Neuroscience 2007; 145: 1388–1396.

61-Roso ́n E, I. Doval G , De La Torre C, Feal C and Cruces M. S ́ındrome de De Sanctis-Cacchione,” Actas Dermo- Sifiliogra ́ficas, 2005; 96: 586–588.

62- DiGiovanna JJ, Kraemer KK. Thining a light on xeroderma pigmentosum . J Invest Dermatol 2012; 132: 785-96.

63- Ueda T, Kanda F, Nishiyama M, Nishigori C, Toda T. Quantitative analysis of brain atrophy in patients with xeroderma pigmentosum group A carrying the founder mutation in Japan. J Neurol Sci 2017; 103-106.

64- Rapin Y, Lindenbaum D, Dickson, W, Kraemer KH, and Robbins JH. Cockayne syndrome and xeroderma pigmentosum: DNA repair disorders with overlaps and paradoxes. Neurology 2000; 55: 1442–9.

65- Lindenbaum Y, Dickson D, Rosenbaum P , Kraemer K , Robbins, J and Rapin I , “Xeroderma pigmentosum/Cockayne syndrome complex: first neuropathological study and review of eight other cases,” Eur J Paed Neurol 2001; 5: 225–42.

66- Niedernhofer J, Garinis GA, Raams A et al. A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature 2006; 444: 1038–43.

67- Cleaver JE, Thomas GH. Rapid diagnosis of sensitivity to ultraviolet light in fibroblasts from dermatological disorders with particular reference to xeroderma pigmentosum. J Invest Dermatol 1988;90:467–71.

68- Cleaver JE, Volpe JPG, Charles WC, et al. Prenatal diagnosis of xeroderma pigmentosum and Cockayne syndrome. Prenatal Diagnosis 1994; 14: 921–8.

69- Kraemer KH. Heritable disease with increased sensitivity to cellular injury . Fitzpactrick’s Dermatology in General Medicine‘de. Eds Fitzpatrick TB, Freedberg IM. 6. Baskı. New York, McGraw-Hill,2003: 1508-21.

70- Kraemer KH. Cellular hypersensitivity and DNA repair. Fitzpactrick’s Dermatology in General Medicine ‘de Ed. Fitzpatrick TB, Freedberg IM. 6. Baskı . New York, McGraw-Hill, 2003: 1791-1811.

71-Mimaki T, İtoh N, Abe J et al. Neurological manifestations in xeoderma pigmentosum. Ann Neurol 1986; 20: 70–5.

72- Mimaki T, Tagawa T, Tanaka J, Sato K, Yabuuchi H. EEG and CT abnormalities in xeroderma pigmentosum. Acta Neurol Scand 1989; 80: 136– 41.

73- Gennery AR, Cant AJ, Jeggo PA. Immunodeficiency associated with DNA repair defects. Clin Exp Immunol. 2000; 121: 1-7.

74- Tokar JP,Kraemer KH, Digiovanna JI. Xeroderma Pigmentosum : a nursing perspective . Dermatol Nurs 1990; 2: 319-27.

75- Tamura D, DİGiovanna JJ, Sikandar G, Kreamer K and K. Living with xeroderma pigmentosum: comprehensive photoprotection for highly photosensitive patients. Photodermatol Photoimmunol Photomed 2014; 30: 146-52.

76-Emmert S, Ueda T, Zumsteg U et al. Strickt sun protection results in mimal skin changes in a patients with xeroderma pigmentosum and a novel c. 29009delG mutation in XPD(ERCC2). Exp Dermatol 2009; 18: 64-8.

77- Milota M,J hones DI, Celaver J, Jamal IS. Xeroderma pigmentosum family support group: helping families and promoting clinical initiatives. DNA repair. (ams) 2011; 10: 792-7.

78- Amura D, DiGiovanna JJ, Kraemer KH. Xeroderma Pigmentosum . In Lebwohl M, Heyman WR, Berth –Jones J. Coulson I Eds. Treatment of Skin Disease . London: Elsevier.2010; 789-792.

79- Reseeuw D. the treatment of bazal skin carsinom in two sisters with xeroderma pigmentosum . Clin Exp Dermatol 2003; 28: 30-2.

 80- Yang JQ , Chen XY , Engle MY, Whang Jy. Multiple facial basal carsinomas in xeroderma pigmentosum treated with topical imiquimod 5% cream. Dermatol Ther 2015; 28: 243-7.

81-Agrawal K, Veliath AJ, Mishra S, Panda KN. Xeroderma pigmentosum: Resurfacing versus dermabrasion. Br J Plast Surg 1992; 45: 311

82- Wee SY, Ahn DS . Facial resurfacing in xeroderma pig-mentosum with chemical peeling. Plast Reconstr Surg 1999 103: 1464.

83-Akan M, Özdemir R, Sungur ·N M. G. Ulusoy NMG , Şenöz O . Combined treatment of xeroderma pigmentosum with full-face chemical peeling and dermabrasion. Eur J Plast Surg 2001; 24:243–6.

84- Anolik JH, Di Giovanna JJ, Gaspart AA. Effect of isotretionin therapy on natural killer cell activity in patient with xeroderma pigmentosum . Br J Dermatol 1998; 236-1.

 85- Di Giovanna JJ. Retinoid cemoprevaentation in the high-risk patient. Med Pediat Oncol 2001; 564-567.

86- Dupuy A1, Sareasın A2 NA damage and gene therapy of xeroderma pigmentosum, a human DNA repair-deficient disease. Mutat Res 2015; 776: 2-8.

87- Zahid S, Brownell I. Repairing DNA damage in xeroderma pigmentosum: T4N5 lotion and gene therapy. J Drugs Dermatol 2008; 7: 405–8.

88-Yarosh D, Klein J, O’Connor A, Hawk J, Rafal E, Wolf, P. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study Xeroderma Pigmentosum Study Group. Lancet 2001; 357: 926-9.

89- Cafardi JA, Elmets CA. T4 endonuclease V: review and application to dermatology. Expert Opin Biol Ther 2008; 8: 229-38.

***Nevoid bazal hücreli karsinom sendromu***

1. Cohen MM Jr. Nevoid basal cell carcinoma syndrome: molecular biology and new hypotheses. Int J Oral Maxillofac Surg 1999; 28: 21.

2. Shanley S, Ratcliffe J, Hockey A, et al. Nevoid basal cell carcinoma syndrome: review of 118 affected individuals. Am J Med Genet 1994; 50: 282.

3. Rahbari H, Mehregan AH. Basal cell epithelioma (carcinoma) in children and teenagers. Cancer 1982; 49: 350.

4. Anderson DE, Taylor WB, Falls HF, Davidson RT. The nevoid basal cell carcinoma syndrome. Am J Hum Genet 1967; 19:12.

5. Nagano T, Bito T, Kallassy M, et al. Overexpression of the human homologue of Drosophila patched (PTCH) in skin tumors: specificity for basal cell carcinoma. Br J Dermatol 1999; 140: 287.

6. Zedan W, Robinson PA, Markham AF, High AS. Expression of the Sonic Hedgehog receptor "PATCHED" in basal cell carcinomas and odontogenic keratocysts. J Pathol 2001; 194: 473.

7. Evans DG, Ladusans EJ, Rimmer S, et al. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet 1993; 30: 460.

8. Howell JB, Anderson DE. "The basal-cell nevus" by Howell and Caro, January 1959. Commentary: The nevoid basal cell carcinoma syndrome. Arch Dermatol 1982; 118: 813.

9. Gorlin RJ. Nevoid basal-cell carcinoma syndrome. Medicine (Baltimore) 1987; 66:98.

10. Winkler PA, Guyuron B. Multiple metastases from basal cell naevus syndrome. Br J Plast Surg 1987; 40: 528.

11. Goldstein AM, Ballet SJ, Peck GL, DiGiovanna JJ. Sun exposure and basal cell carcinomas in the nevoid basal cell carcinoma syndrome. J Am Acad Dermatol 1993; 29:34.

12. Fujii K, Suzuki N, Ishijima S, et al. Abnormal DNA synthesis activity induced by X-rays in nevoid basal cell carcinoma syndrome cells. Biochem Biophys Res Commun 1997; 240: 269.

13. Meara JG, Shah S, Li KK, Cunningham MJ. The odontogenic keratocyst: a 20-year clinicopathologic review. Laryngoscope 1998; 108: 280.

14. Myoung H, Hong SP, Hong SD, et al. Odontogenic keratocyst: Review of 256 cases for recurrence and clinicopathologic parameters. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 91: 328.

15. Brannon RB. The odontogenic keratocyst. A clinicopathologic study of 312 cases. Part I. Clinical features. Oral Surg Oral Med Oral Pathol 1976; 42:54.

16. Chenevix-Trench G, Wicking C, Berkman J, et al. Further localization of the gene for nevoid basal cell carcinoma syndrome (NBCCS) in 15 Australasian families: linkage and loss of heterozygosity. Am J Hum Genet 1993; 53: 760.

17. Gutierrez MM, Mora RG. Nevoid basal cell carcinoma syndrome. A review and case report of a patient with unilateral basal cell nevus syndrome. J Am Acad Dermatol 1986; 15: 1023.

18. Howell JB, Mehregan AH. Pursuit of the pits in the nevoid basal cell carcinoma syndrome. Arch Dermatol 1970; 102: 586.

19. Evans DG, Farndon PA, Burnell LD, et al. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br J Cancer 1991; 64: 959.

20. Hettmer S, Teot LA, Kozakewich H, et al. Myogenic tumors in nevoid basal cell carcinoma syndrome. J Pediatr Hematol Oncol 2015; 37: 147.

21. Walsh SN, Hurt MA. Cutaneous fetal rhabdomyoma: a case report and historical review of the literature. Am J Surg Pathol 2008; 32: 485.

22. Wang C. Childhood rhabdomyosarcoma: recent advances and prospective views. J Dent Res 2012; 91: 341.

23. Southwick GJ, Schwartz RA. The basal cell nevus syndrome: disasters occurring in a series of 36 patients. Cancer 1979; 44: 2294.

24. Jones KL, Wolf PL, Jensen P, et al. The Gorlin syndrome: a genetically determined disorder associated with cardiac tumor. Am Heart J 1986; 111: 1013.

25. Cho JM, Danielson GK, Puga FJ, et al. Surgical resection of ventricular cardiac fibromas: early and late results. Ann Thorac Surg 2003; 76: 1929.

26. Gorlin RJ. Nevoid basal cell carcinoma syndrome. Dermatol Clin 1995; 13: 113.

27. Kraemer BB, Silva EG, Sneige N. Fibrosarcoma of ovary. A new component of the nevoid basal-cell carcinoma syndrome. Am J Surg Pathol 1984; 8: 231.

28. Ratcliffe JF, Shanley S, Chenevix-Trench G. The prevalence of cervical and thoracic congenital skeletal abnormalities in basal cell naevus syndrome; A review of cervical and chest radiographs in 80 patients with BCNS. Br J Radiol 1995; 68: 596.

29. Chiritescu E, Maloney ME. Acrochordons as a presenting sign of nevoid basal cell carcinoma syndrome. J Am Acad Dermatol 2001; 44: 789.

30. Wallace DC, Murphy KJ, Kelly L, Ward WH. The basal cell naevus syndrome. Report of a family with anosmia and a case of hypogonadotrophic hypopituitarism. J Med Genet 1973; 10: 30.

31. Sobotaya, Pena M, Santi M, Ali Ahmed A. Undifferentiated sinonasal carcinoma in a patient with nevoid basal cell carcinoma syndrome. Int J Surg Pathol 2007; 15: 303.

32. Palacios E, Serou M, Restrepo S, Rojas R. Odontogenic keratocysts in nevoid basal cell carcinoma (Gorlin's syndrome): CT and MRI evaluation. Ear Nose Throat J 2004; 83:40.

33. Doctoroffe, Oberlender SA, Purcell SM. Full-face carbon dioxide laser resurfacing in the management of a nevoid basal cell carcinoma syndrome. Dermatol Surg 2003; 29: 1236.

34. Kopera D, Cerroni L, Fink-Puches R, Kerl H. Different treatment modalities for the management of a patient with the nevoid basal cell carcinoma syndrome. J Am Acad Dermatol 1996; 34: 937.

35. Micali G, De Pasquale R, Caltabiano R, et al. Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients with basal cell nevus syndrome: a preliminary report. J Dermatolog Treat 2002; 13: 123.

36. Micali G, Lacarrubba F, Nasca MR, De Pasquale R. The use of imiquimod 5% cream for the treatment of basal cell carcinoma was observed in Gorlin's syndrome. Clin Exp Dermatol 2003; 28 Suppl 1: 19.

37. Vereecken P, Monsieur E, Petein M, Heenen M. Topical application of imiquimod for treatment of high-risk facial basal cell carcinoma in Gorlin syndrome. J Dermatolog Treat 2004; 15: 120.

38. Peck GL, DiGiovanna JJ, Sarnoff DS, et al. Treatment and prevention of basal cell carcinoma with oral isotretinoin. J Am Acad Dermatol 1988; 19: 176.

39. Tangrea JA, Edwards BK, Taylor PR, et al. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group. J Natl Cancer Inst 1992; 84: 328.

40. Howell JB. Nevoid basal cell carcinoma syndrome. Profile of genetic and environmental factors in oncogenesis. J Am Acad Dermatol 1984; 11: 98

41.Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012; 366: 2180.

42. Scheer M, Koch AM, Drebberi, Kübler AC. Primary intraosseous carcinoma of the jaws arising from an odontogenic cyst - a case report. J Craniomaxillofac Surg 2004; 32: 166.

43. Goldberg LH, Landau JM, Moody MN, et al. Resolution of odontogenic keratocysts of the jaw in basal cell nevus syndrome with GDC-0449. Arch Dermatol 2011; 147: 839.

44. Wallin JL, Tanna N, Misra S, et al. Sinonasal carcinoma after irradiation for medulloblastoma in nevoid basal cell carcinoma syndrome. Am J Otolaryngol 2007; 28: 360.

45. Kimonis VE, Goldstein AM, Pastakia B, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 1997; 69: 299

46. Frentz G, Munch-Petersen B, Wulf HC, et al. The nevoid basal cell carcinoma syndrome: sensitivity to ultraviolet and x-ray irradiation. J Am Acad Dermatol 1987; 17: 637.

***Cowden sendromu***

1. Starink Th M, Van Der Veen JPW, Arwert F, et al. The Cowden Sendrom: a clinical and genetic study in 21 patients. Clinical Genetics 1986; 29: 222–33.

2. Schrager CA, Shneider D, Gruener AC, Tsou HC, Peacocke M. Clinical and pathological features of breast disease in Cowden’S syndrome. Hum Pathol 1998; 29. 47–53.

3. Takaya N, Takashi I, Maehara A, et al. Transcatheter embolization of arteriovenous malformations in Cowden disease. Jpn Circ J 1999; 63: 326–9.

4. Pilarski R. Cowden syndrome: a critical review of the clinical literature. J Genet Couns 2009; 18: 13-27.

5. Tok Celebi J, Chen FF, Zhang H, Ping XL, Tsou HC, Peacocke M. Identification of PTEN mutations in five families with Bannayan-Zonana syndrome. Exp Dermatol 1999; 8: 134-9.

6. Hobert JA, Eng C. PTEN hamartoma tumor syndrome: an overview. Genet Med 2009; 11: 687-94.

7. Yen BC, Kahn H, Schiller AL, Klein MJ, Phelps RG, Lebwohl MG. Multiple hamartoma syndrome with osteosarcoma. Arch Pathol Lab Med 1993; 117: 1252-4.

8. Hall JE, Abdollahian DJ, Sinard RJ. Thyroid disease associated with cowden syndrome: A meta-analysis. Head Neck 2013; 35: 1189-94.

9. Fackenthal JD, Marsh DJ, Richardson AL, et al. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet 2001; 38: 159-64.

10. Chen YM, Ott DJ, Wu WC, Gelfand DW. Cowden's disease: a case report and literature review. Gastrointest Radiol 1987, 12: 325-9.

11. Schmeler KM, Daniels MS, Brandt AC, Lu KH. Endometrial cancer in an adolescent: a possible manifestation of Cowden syndrome. Obstet Gynecol 2009; 114: 477-9.

12. Lok C, Viseux V, Avril MF, et al. Brain magnetic resonance imaging in patients with Cowden syndrome. Medicine (Baltimore) 2005; 84: 129-36.

13. Pilarski R, Burt R, Kohlman W, Pho L, Shannon KM, Swisher E. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst 2013; 105: 1607-16.

14. Milas M, Mester J, Metzger R, Shin J, Mitchell J, Berber E. Should patients with Cowden syndrome undergo prophylactic thyroidectomy? Surgery 2012; 152: 1201-10.

15. Bosserhoff AK, Grussendorf-Conen EI, Rubben A, et al. Multiple colon carcinomas in a patient with Cowden syndrome. Int J Mol Med 2006; 18: 643-7.

16. Cnudde F, Boulard F, Muller P, Chevallier J, Teron-Abou B. [Cowden disease: treatment with acitretine]. Ann Dermatol Venereol 1996, 123: 739-41.

17. Cnudde F, Boulard F, Muller P, Chevallier J, Teron-Abou B. [Cowden disease: treatment with acitretine]. Ann Dermatol Venereol 1996, 123: 739-41.

***Carney kompleksi***

1. Correa R, Salpea P, Stratakis CA. Carney complex: an update. Eur J Endocrinol 2015; 173: M85.

2. Stratakisca, Carney JA. The triad of paragangliomas, gastric stromal tumors and pulmonary chondromas (Carney triad), and the dyads of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J Intern Med 2009; 266: 43.

3. Stratakisca, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001; 86: 4041.

4. Kirschner LS, Carney JA, Pack SD, et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 2000; 26: 89.

5. Matyakhina L, Pack S, Kirschner LS, et al. Chromosome 2 (2p16) abnormalities in Carney complex tumors. J Med Genet 2003; 40: 268.

6. Mateus C, Palangiée, Franck N, et al. Heterogeneity of skin manifestations in patients with Carney complex. J Am Acad Dermatol 2008; 59: 801.

7. Shen Z, Hoffman JD, Hao F, Pier E. More than just skin deep: faciocutaneous clues to genetic syndromes with malignancies. Oncologist 2012; 17: 930.

8. Cohen C, Turner ML, Stratakis CA. Pigmented lesions of the conjunctiva in Carney's complex. J Am Acad Dermatol 2000; 42: 145.

9. Lonser RR, Mehta GU, Kindzelski BA, et al. Surgical Management of Carney Complex-Associated Pituitary Pathology. Neurosurgery 2016.

10. Idrees MT, Ulbright TM, Oliva E, et al. The World Health Organization 2016 classification of testicular non-germ cell tumors: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology 2017; 70: 513.

11. Gourgari E, Saloustros E, Stratakis CA. Large-cell calcifying Sertoli cell tumors of the testes in pediatrics. Curr Opin Pediatr 2012; 24: 518.

12. Kaluznya, Matuszewski M, Wojtylak S, et al. A case of Sertoli cell tumor in a patient with atypical Peutz-Jeghers syndrome. Int Urol Nephrol 2012; 44: 1045.

13. Stratakis CA. Hereditary syndromes predisposing to endocrine tumors and their skin manifestations. Rev Endocr Metab Disord 2016; 17: 381.

14. Papageorgiou T, Stratakis CA. Ovarian tumors associated with multiple endocrine neoplasias and related syndromes (Carney complex, Peutz-Jeghers syndrome, von Hippel-Lindau disease, Cowden's disease). Int J Gynecol Cancer 2002; 12: 337.

15. Golden T, Siordia JA. Osteochondromyxoma: a review of a rare carney complex criterion. J Bone Oncol 2016; 5: 194.

16. Carney JA, Toorkey BC. Ductal adenoma of the breast with tubular features. A probable component of the myxomas, spotty pigmentation, endocrine overactivity, and schwannomas. Am J Surg Pathol 1991; 15: 722.

17. Shields LB, Glassman SD, Raque GH, Shields CB. Malignant psammomatous melanotic schwannoma of the spine: A component of Carney complex. Surg Neurol Int 2011; 2: 136.

18. Shetty Roy AN, Radin M, Sarabi D, Shaoulian E. Familial recurrent atrial myxoma: Carney's complex. Clin Cardiol 2011; 34: 83.

19. Maleszewski JJ, Larsen BT, Kip NS, et al. PRKAR1A in the development of cardiac myxoma: a study of 110 cases including isolated and syndromic tumors. Am J Surg Pathol 2014; 38: 1079.

20. Irani AD, Estrera AL, Buja LM, Safi HJ. Biatrial myxoma: a case report and review of the literature. J Card Surg 2008; 23: 385.

21. O'Rourke F, Dean N, Mouradian MS, et al. Atrial myxoma as a cause of stroke: case report and discussion. CMAJ 2003; 169: 1049.

22. Carney JA, Stratakis CA. Ductal adenoma of the breast and the Carney complex. Am J Surg Pathol 1996; 20: 1154.

23. Izquierdo MJ, Pastor MA, Carrasco L, et al. Epithelioid blue naevus of the genital mucosa: report of four cases. Br J Dermatol 2001; 145: 496.

24. Almeida MQ, Stratakis CA. Carney complex and other conditions associated with micronodular adrenal hyperplasias. Best Pract Res Clin Endocrinol Metab 2010; 24: 907.

25. Lodish MB, Stratakis CA. The differential diagnosis of familial lentiginosis syndromes. Fam Cancer 2011; 10: 481.

26. Jelsig AM, Qvist N, Brusgaard K, et al. Hamartomatous polyposis syndromes: a review. Orphanet J Rare Dis 2014; 9: 101.

27. Mester JL, Tilot AK, Rybicki LA, et al. Phenotypic knock-in murine model of PTEN mutations and brain weights. Eur J Hum Genet 2011; 19: 763.

28. Busa T, Milh M, Degardin N, et al. Clinical presentation of PTEN mutations in childhood in the absence of family history of Cowden syndrome. Eur J Paediatr Neurol. 2015 Mar;19: 188-192

29. Pichard DC, Boyce AM, Collins MT, Cowen EW. Oral pigmentation in McCune-Albright syndrome. JAMA Dermatol 2014; 150: 760.

30. O'Neill JF, James WD. Inherited patterned lentiginosis in blacks. Arch Dermatol 1989; 125: 1231.

31. Crocker MK, Gourgari E, Lodish M, Stratakis CA. Use of aromatase inhibitors in large cell calcifying Sertoli cell tumors: effects on gynecomastia, growth velocity, and bone age. J Clin Endocrinol Metab 2014; 99: E2673.

32. Koç Yekedüz M, Şıklar Z, Burgu B, et al. The anastrozole treatment has been used to treat a wide range of neoplasms of the uterus, such as the pre-pubertal gynecomastia. J Clin Res Pediatr Endocrinol 2017; 9: 168-171.

33. Grandonee, del Giudice EM, Cirillo G, et al. Prepubertal gynecomastia in two monozygotic twins with Peutz-Jeghers syndrome: two years' treatment with anastrozole and genetic study. Horm Res Paediatr 2011; 75: 374.

34. Stratakis CA. Carney complex: A familial lentiginosis predisposing to a variety of tumors. Rev Endocr Metab Disord 2016; 17: 367.

**Oral mukozal malignansiler ve lökoplaki**

1. Krahl D, Altenburg A, Zouboulis CC. Reactive hyperplasias,precancerous and malignant lesions of the oral mucosa. J Dtsch Dermatol Ges. 2008 Mar;6(3):217-32.

2. Kuffer R, Lombardi T. Premalignant lesions of the oral mucosa. A discussion about the place of oral intraepithelial neoplasia (OIN). Oral Oncol 2002; 38: 125–130.

3. Renaud-Vilmer C, Cavelier-Balloy B. Precancerous lesions of the buccal epithelium. Ann Dermatol Venereol. 2017 Feb;144(2):100-108.

4. Scully C, Bagan J. Oral squamous cell carcinoma: overview of current understanding of aetiopathogenesis and clinical implications. Oral Dis. 2009 Sep;15(6):388-99.

5. Banoczy J, Gintner Z, Dombi C. Tobacco use and oral leucoplakia. J Dental Educ. 2001;65:322-7

6. Sanketh DS, Patil S, Rao RS. Estimating the frequency of Candida in oral squamous cell carcinoma using Calcofluor White fluorescent stain. J Investig Clin Dent. 2016 Aug;7(3):304-7.

7. Gainza-Cirauqui ML, Nieminen MT, Novak Frazer L, Aguirre-Urizar JM, Moragues MD, Rautemaa R. Production of carcinogenic acetaldehyde by Candida albicans from patients with potentially malignant oral mucosal disorders. J Oral Pathol Med. 2013 Mar;42(3):243-9

8. Villa A, Woo SB. Leukoplakia-A Diagnostic and Management Algorithm. J Oral Maxillofac Surg. 2017 Apr;75(4):723-734.

9. Handlers JP. Diagnosis and management of oral soft-tissue lesions: the use of biopsy, toluidine blue staining, and brush biopsy. J Calif Dent Assoc. 2001 Aug;29(8):602-6.

10. Liu Y, Li J, Liu X, Liu X, Khawar W, Zhang X, Wang F, Chen X, Sun Z. Quantitative risk stratification of oral leukoplakia with exfoliative cytology. PLoS One. 2015 May 15;10(5).

11. Mulki S, Shetty P, Pai P. Oral rinse-based cytology and conventional exfoliative cytology: a comparative study. J Cancer Res Ther. 2015 Jan-Mar;11(1):129-35.

12. Zhang Y, Zhang L, Yang D, Zhang G, Wang X. Treatment of oral refractory large area mucosal leukoplakia with CO2 laser combined with photodynamic therapy: Case report. Photodiagnosis Photodyn Ther. 2017 Dec;20:193-195.

13. Sieroń A, Adamek M, Kawczyk-Krupka A, Mazur S, Ilewicz L. Photodynamic therapy (PDT) using topically applied delta-aminolevulinic acid (ALA) for the treatment of oral leukoplakia. J Oral Pathol Med. 2003 Jul;32(6):330-6.

14. Poveda-Roda R, Bagan JV, Jiménez-Soriano Y, Díaz-Fernández JM, Gavaldá-Esteve C. Retinoids and proliferative verrucous leukoplakia (PVL). A preliminary study. Med Oral Patol Oral Cir Bucal. 2010 Jan 1;15(1):3-9.

15. Gorsky M, Epstein JB. The effect of retinoids on premalignant oral lesions: focus on topical therapy. Cancer. 2002 Sep 15;95(6):1258-64.

16. Chi AC, Day TA, Neville BW. Oral cavity and oropharyngeal squamous cell carcinoma--an update. CA Cancer J Clin. 2015 Sep-Oct;65(5):401-21.

17. Sciubba JJ. Oral cancer. The importance of early diagnosis and treatment. Am J Clin

Dermatol 2001; 2: 239–251.

18. Mupparapu M, Shanti RM. Evaluation and Staging of Oral Cancer. Dent Clin North Am. 2018 Jan;62(1):47-58.

19. Spiotto MT, Jefferson G, Wenig B, Markiewicz M, Weichselbaum RR, Koshy M. Differences in Survival With Surgery and Postoperative Radiotherapy Compared With Definitive Chemoradiotherapy for Oral Cavity Cancer: A National Cancer Database Analysis. JAMA Otolaryngol Head Neck Surg. 2017 Jul 1;143(7):691-699

20. Otsuru M, Ota Y, Aoki T, Sasaki M, Suzuki T, Denda Y, Takahashi M, Akiba T, Kaneko A. A Study of Adjuvant Chemoradiotherapy with Tri-weekly Cisplatin for Postoperative High-risk Oral Squamous Cell Carcinoma. Tokai J Exp Clin Med. 2017 Apr 20;42(1):19-24.

21. Scully C, Hegarty A: The oral cavity and lips. Rook’s Textbook of Dermatology. Eds. Burns T, Breathnach S, Cox N, Griffiths C. 8. Baskı. Massachusetts, Blackwell Publishing, 2010; 69.1- 69.129.

22. Gupta S, Gupta S. Role of human papillomavirus in oral squamous cell carcinoma and oral potentially malignant disorders: A review of the literature. Indian J Dent. 2015 Apr-Jun;6(2):91-8

23. Stokes A, Guerra E, Bible J, Halligan E, Orchard G, Odell E, Thavaraj S. Human papillomavirus detection in dysplastic and malignant oral verrucous lesions. J Clin Pathol. 2012 Mar;65(3):283-6

24. Haiducu ML, Hinek A, Astanehe A, Lee TK, Kalia S. Extracutaneous melanoma epidemiology in British Columbia. Melanom Res. 2014; 24: 377-380.

25. Sortino-Rachou AM, Cancela Mde C, Voti L, Curado MP. Primary oral melanoma: population-based incidence. Oral Oncol. 2009; 45: 254-258.

26. Takagi M, Ishikawa G, Mori W. Primary malignant melanoma of the oral cavity in Japan. With special reference to mucosal melanosis. Cancer. 1974; 34: 358-370.

27. Meleti M, Leemans CR, Mooi WJ, Vescovi P, van der Waal I. Oral malignant melanoma: a review of the literature. Oral Oncol. 2007; 43: 116-121.

28. Lourenço SV, Bologna SB, Hsieh R, Sangueza M, Fernandes JD, Nico MM. Establishment and characterization of an oral mucosal melanoma cell line (MEMO) derived from a longstanding primary oral melanoma. Am J Dermatopathol. 2013; 35: 248-251.

29. Hicks MJ, Flaitz CM. Oral mucosal melanoma: epidemiology and pathobiology. Oral Oncol. 2000; 36: 152-169.

30. Lucchese A, Favia G, Maiorano E, Napoli A, Zanna P, Cicero R, Guida G. Oral malignant melanoma: immunopathological analysis of a multiphasic case. Clin Exp Dermatol. 2010; 35:789-791.

31. Bologna SB, Nico MM, Hsieh R, Coutinho-Camillo CM, Buim ME, Fernandes JD, Sangueza M, Soares FA, Lourenco SV. Adhesion molecules in primary oral mucosal melanoma:study of claudins, integrins and immunoglobulins in a series of 35 cases. Am J Dermatopathol. 2013; 35: 541-554.

32. Prasad ML, Patel SG, Shah JP, Hoshaw-Woodard S, Busam KJ. Prognostic significance of regulators of cell cycle and apoptosis, p16(INK4a), p53, and bcl-2 in primary mucosal melanomas of the head and neck. Head Neck Pathol. 2012;6: 184-190.

33. Tanaka N, Mimura M, Ogi K, Amagasa T. Primary malignant melanoma of the oral cavity: assessment of outcome from the clinical records of 35 patients. Int J Oral Maxillofac Surg. 2004; 33: 761-765.

34. Tanaka N, Mimura M, Kimijima Y, Amagasa T. Clinical investigation of amelanotic malignant melanoma in the oral region. J Oral Maxillofac Surg. 2004; 62: 933-937.

35. Tacastacas JD, Bray J, Cohen YK, Arbesman J, Kim J, Koon HB, Honda K, Cooper KD, Gerstenblith MR. Update on primary mucosal melanoma. J Am Acad Dermatol. 2014; 71:366-375.

36. Olszewska M, Banka A, Gorska R, Warszawik O. Dermoscopy of pigmented oral lesions. J Dermatol Case Rep. 2008; 2: 43-48. PMID: 21886712.

37. Puig S, Malvehy J. Dermoscopic findings of pigmented lesionsof the mucosae. In: Principles of Dermoscopy (MalvehyJ, Puig S, eds) Barcelona. 2002; 289-289.

38. Lin J, Koga H, Takata M, Saida T. Dermoscopy of pigmented lesions on mucocutaneous junction and mucous membrane. Br J Dermatol. 2009; 161: 1255-1261.

39. Barker BF, Carpenter WM, Daniels TE, Kahn MA, Leider AS, Lozada-Nur F, Lynch DP, Melrose R, Merrell P, Morton T, Peters E, Regezi JA, Richards SD, Rick GM, Rohrer MD, SlaterL, Stewart JC, Tomich CE, Vickers RA, Wood NK, Young SK. Oral mucosal melanomas: the WESTOP Banff workshop proceedings. Western Society of Teachers of Oral Pathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997; 83: 672-679.

40. Rudnicka L, Olszewska M, Słowinska M. Early diagnosis of malignant melanoma of the skin and of the oral mucous membrane. Wsp Onkol. 2003; 8: 556-563.

41. Warszawik-Hendzel O, Słowińska M, Olszewska M, Rudnicka L. Melanoma of the oral cavity: pathogenesis, dermoscopy, clinical features, staging and management. J Dermatol Case Rep. 2014 Sep 30;8(3):60-6.

42. Auvinen A, Hietanen M, Luukkonen R, Koskela RS. Brain tumors and salivary gland cancers among cellular telephone users. Epidemiology 2002;13:356.

43. Horn-Ross PL, Ljung BM, Morrow M. Environmental factors and the risk of salivary gland cancer. Epidemiology 1997:414-9.

44. Agulnik M, McGann CF, Mittal BB, Godon SC, Epstein JB. Management of salivary gland malignancies: current and developing therapies. Oncol Rev (2008) 2:86–94.

45. Feller L, Khammissa R, Gugushe T, et al. HIV-associated Kaposi sarcoma in African children. SADJ 2010; 65: 20–22.

46. Feller L, Lemmer J. Oral Kaposi sarcoma. In: Pantonowitz L, Stebbing J, Dezube BJ, eds. Kaposi Sarcoma: a Model of Oncogenesis. Kerala: Research Signpost, 2010: 295–303.

47. Feller L, Jadwat Y, Raubenheimer EJ. Kaposi sarcoma and calcium channel blocker-induced gingival enlargement occurring simultaneously: review of the literature and report of a case. Oral Biosci Med 2004; 4:291–297

48. Patrikidou A, Vahtsevanos K, Charalambidou M, et al. Kaposi’s sarcoma in the head and neck area. Head Neck 2009; 31: 260–268.

49. Kalpidis CD, Lysitsa SN, Lombardi T, et al. Gingival involvement in a case series of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma. J Periodontol 2006; 77: 523–533.

50. Petit JC, Ripamonti U, Hille J. Progressive changes of Kaposi’s sarcoma of the gingiva and palate. Case report in an AIDS patient. J Periodontol 1986; 57: 159–163.

51. Ficcara G, Berson AM, Silverman SJ, et al. Kaposi’s sarcoma of the oral cavity: a study of 134 patients with a review of the pathogenesis, epidemiology, clinical aspects and treatment. Oral Surg Oral Med Oral Pathol 1988; 66: 543–550.

52. Lopez de Blanc S, Sambuelli R, Femopase F, et al. Bacillary angiomatosis affecting the oral cavity Report of two cases and review. J Oral Pathol Med 2000; 29: 91.

53. Fatahzadeh M, Schwartz RA. Oral Kaposi's sarcoma: a review and update. Int J Dermatol. 2013 Jun;52(6):666-72.

54. Paghdal KV, Schwartz RA. Sirolimus (rapamycin): from the soil of Easter Island to a bright future. J Am Acad Dermatol 2007; 57: 1046–1050.

55. Lebbe C, Legendre C, Frances C. Kaposi sarcoma in transplantation. Transplant Rev (Orlando) 2008; 22:252–261.

**Vulvar malignansiler**

1. Eifel PJ, Berek JS, Markman MA: Cancer of the cervix, vagina, and vulva. In: DeVita VT Jr, Lawrence TS, Rosenberg SA,eds: Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2011, 1311-44.

2. Finan MA, Barre G. Bartholin's gland carcinoma, malignant melanoma and other rare tumours of the vulva. Best Pract Res Clin Obstet Gynaecol. 2003;17(4):609-33.

3. Bornstein J, Goldstein AT, Stockdale CK, et al.2015 ISSVD, ISSWSH and IPPS Consensus terminology and classification of persistent vulvar pain and vulvodynia. Obstet Gynecol. 2016;127(4):745-51.

4. Pepas L, Kaushik S, Bryant A, et al.: Medical interventions for high grade vulval intraepithelial neoplasia. Cochrane Database Syst Rev (4): CD007924, 2011.

5. van de Nieuwenhof HP, Massuger LF, van der Avoort IA, et al. Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age. Eur J Cancer. 2009;45(5):851–856.

6. Allbritton JI. Vulvar Neoplasms, benign and malignant. Obstet Gynecol Clin North Am. 2017;44(3):339-352.

7. PDQ® Adult Treatment Editorial Board. PDQ Vulvar Cancer Treatment. Bethesda, MD: National Cancer Institute. Updated 31/01/2018 https://www.cancer.gov/types/vulvar/hp/vulvar-treatment-pdq.

8. Micheletti L, Preti M, Radici G, et al. Vulvar lichen sclerosus and neoplastic transformation: A retrospective study of 976 Cases. J Low Genit Tract Dis. 2016 Apr;20(2):180-3.

9. The National Comprehensive Cancer Network 2017. Vulvar Cancer Guideline. https://www.nccn.org/professionals/physician\_gls/pdf/vulvar.pdf

10. Franklin EW, Rutledge FD: Epidemiology of epidermoid carcinoma of the vulva. Obstet Gynecol. 1972;39(2): 165-72

11. American Cancer Society: Cancer Facts and Figures 2018. Atlanta, Ga: American Cancer Society, 2018 https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2018.html

12. Shun SS, Luesley D. Malignant diseases of vulva and vagina. In Shaw R, Luesley D, Monga A eds. Gynecology 4th ed. London: Churchill Livingstone. 2010:613-23 .

13. Sideri M, Jones RW, Wilkinson EJ, et al.: Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. J Reprod Med 2005;50 (11): 807-10.

14. Brinton LA, Nasa PC, MallinK, et al: Case-control study of cancer of the vulva. Obstet Gynecol 1990;75(5 ):859-66.

15. Berkman S, Topuz S. TJOD –Vulva kanserinde prognoz ve yönetim. Uzmanlık Sonrası Eğitim ve Güncel Gelişmeler 2004;1:58-64 http://cms.galenos.com.tr/Uploads/Article\_9203/58-64.pdf

16. Lynch PJ. Vulva neoplasms and cysts. Ch 23. In Black M, Ambros-Rudolph C,Edwards L, Lynch P, eds. Obstetric and Gynecologic Dermatology 3rd ed. E-book. Mosby. 2018:267-299

17. Medeiros F. Nascimento AF, Crum CP. Early vulvar squamous neoplasia: advances in classification, diagnosis, and differential diagnosis. Adv Anat Pathol. 2005;12(1):20–26

18. Türk Jinekolojik Onkoloji Derneği (TJOD) Jinekolojik kanserlerin yönetimi kılavuzu: Vulva kanseri http://www.trsgo.org/trsgoData/userfiles/file/VulvaKanseri.pdf

19. Lin G, Chen CY, Liu FY, et al. Computed tomography, magnetic resonance imaging and FDG positron emission tomography in the management of vulvar malignancies. Eur Radiol 2015; 25(5):1267-78.

20. Salani R, Khanna N, Frimer M, Bristow RE, Chen LM. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations.Gynecol Oncol. 2017;146(1):3-10.

21. Oonk MHM, Planchamp F, Baldwin P, et al. European Society of Gynaecological Oncology guidelines for the management of patients with vulvar cancer. Int J Gynecol Cancer 2017;27(4): 832-837

22. Vulva. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010:379-81.

23. Sobin LH, Gospodarowicz MK, Wittekind CH. TNM classification of malignant tumours. 7th ed. Oxford: Wiley-Blackwell; 2009:197-202.

24. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105(2):103-104.

25. British Gynecological Cancer Society. Guidelines for the diagnosis and management of vulval carcinoma 2014 https://www.rcog.org.uk/globalassets/documents/guidelines/vulvalcancerguideline.pdf

26. Saito T, Tabata T, Ikushima H, et al. Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer. Int J Clin Oncol. 2018: 23(2):201–234

27. Stehman FB, Bundy BN, Thomas G, et al.: Groin dissection versus groin radiation in carcinoma of the vulva: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 24 (2): 389-96, 1992.

28. Slomovitz BM, Coleman RL, Oonk MH, van der Zee A, Levenback C. Update on sentinel lymph node biopsy for early-stage vulvar cancer. Gynecol Oncol. 2015;138(2):472-7.

29. Te Grootenhuis NC, van der Zee AG, van Doorn HC, et al. Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I.Gynecol Oncol. 2016;140(1):8-14

30. Van der Zee AG, Oonk MH, De Hullu JA, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol 26 (6): 884-9, 2008.

31. Homesley HD, Bundy BN, Sedlis A, et al.: Prognostic factors for groin node metastasis in squamous cell carcinoma of the vulva (a Gynecologic Oncology Group study) Gynecol Oncol 1993;49(3): 279-83.

32. Hacker NF, Berek JS, Lagasses LD, et al: Management of regional lymph nodes and their prognostic influences in vulvar cancer. Obstet Gynecol 1983;61(4):408-12.

33. Courtney-Brooks M, Sukumvanich P, Beriwal S, Zorn KK, Richard SD, Krivak TC. Does the number of nodes removed impact survival in vulvar cancer patients with node-negative disease. Gynecol Oncol. 2010; 117(2):308-11.

34. Slevin NJ, Pointon RC: Radical radiotherapy for carcinoma of the vulva. Br J Radiol 1989;62(734): 145-7.

35. Kunos C, Simpkins F, Gibbons H, et al.: Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial. Obstet Gynecol 2009;114(3):537-46,

36. Reade CJ, Eriksson LR, Mackay H. Systemic chemotherapy in squamous cell carcinoma of the vulva: Current status and future directions. Gynecol Oncol 2014; 132(3):782-89.

37. Gill BS, Bernard ME, Lin JF, et al. Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: A National Cancer Data Base (NCDB) analysis. Gynecol Oncol 2015; 137(3):365.

38. Gaffney DK, King B, Viswanathan AN, et al. Consensus Recommendations for Radiation Therapy Contouring and Treatment of Vulvar Carcinoma. Int J Radiat Oncol Biol Phys 2016; 95:1191.

39. van Doorn HC, Ansink A, Verhaar-Langereis M, et al.: Neoadjuvant chemoradiation for advanced primary vulvar cancer. Cochrane Database Syst Rev (3): CD003752, 2006

40. Shylasree TS, Bryant A, Howells RE: Chemoradiation for advanced primary vulval cancer. Cochrane Database Syst Rev (4): CD003752, 2011

41. Heaps JM, Fu YS, Montz FJ, Hacker NF, Berek JS. Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecologic Oncology 1990; 38(3): 309–314.

42. Ragnarsson-Olding BK, Nilsson BR, KanterLewensohn LR, et al. Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: predictors of survival. Cancer 1999;86(7): 1285–1293.

43. Iocopani S, Rubio P, Garcia et al. E Prognostic factors of recurrence and survival in vulvar melanoma: Subgroup analysis of the VULvar CANcer study. Int J Gynecol Cancer. 2016;26(7):1307-12.

44. van der Linden M, Meeuwis KA, Bulten J, et al. Paget disease of the vulva. Crit Rev Oncol Hematol. 2016;101:60-74 doi: 10.1016/j.critrevonc.2016.03.008. Epub 2016 Mar 4.

45. Niikura I, Yoshida H, Ito K, et al. Paget’s disease of the vulva: Clinicopathologic study oft ype1 cases treated at a single institution. Int J Gynecol Cancer 2006; 16(3):1212–1215.

46. Delport A. Extramammary Paget’s disease of the vulva: an annotated review of the current literature. Australasian J Dermatol. 2013;54(1)9–21.

47. Tebes S, Cardosi R, Hoffman, M. Paget’s disease of the vulva. Am J Obstet Gynecol 2002;187(2):281–284

48. Chokoeva AA, Tchernev G, Cardoso JC, et al. Vulvar sarcomas: Short guideline for histopathological recognition and clinical management. Part 1. Int J Immunopathol Pharmacol. 2015;28(2):168-77.

49. Magné N, Pacaut C, Auberdiac P, et al. Sarcoma of vulva, vagina and ovary. Best Pract Res Clin Obstet Gynaecol. 2011;25(6):797-801.

50. Nasu K, Kawano Y, Takai N, Kashima K, Miyakawa I. Adenoid cystic carcinoma of Bartholin’s gland. Case report with review of the literature. Gynecol Obstet Invest. 2015; 59(1): 54–58.

51. Donato V, Casorelli A, Bardhi E, Vena F, Marchetti C, Muzii L, Benedetti P. Bartholin gland cancer. Crit Rev Oncol Hematol 2017; 117(9):1-11.

52. Kozakiewicz B, Dmoch-Gajzlerska E, Roszkowska-Purska K. Carcinomas and sarcomas of Bartholin gland. A report of nine cases and review of the literature. Eur J Gynaecol Oncol. 2014;35(3):243-9.

53. Felix JC, Cote RJ, Kramer EE, Saigo P, Goldman GH. Carcinomas of Bartholin’s gland. Histogenesis and the etiological role of human papillomavirus. Am J Pathol. 1993;142(3):925–933

**Penil malignansiler**

1. Brady KL, Mercurio MG, Brown MD. Malignant tumors of the penis. Dermatol Surg. 2013;39(4):527–547.

2. Pettaway CA, Lance RS, Davis JW. Tumors of the penis. In: Alan J Wein ed. Campbell Walsh Urology. Philadelphia:Saunders Elsevier, 2012:901-933

3. Bleeker MCG, Heideman DAM, Snijders PJF, et al. Penile cancer: epidemiology, pathogenesis, and prevention. World J Urol 2009;27(2):141–50.

4. Seyam RM, Bissada NK, Mokhtar AA, et al. Outcome of penile cancer in circumcised men. J Urol. 2006;175(2):557-61.

5. Morris BJ, Gray RH, Castellsague X, et al. The strong protective effect of circumcision against cancer of the penis. Adv Urol 2011;2011:812368.

6. Christodoulidou M, Sahdev V, Houssein S, Muneer A. Epidemiology of penile cancer. Curr Probl Cancer 2015;39(3):126-36

7. Pow-Sang MR, Ferreira U, Pow-Sang JM, Nardi AC, Destefano V. Epidemiology and natural history of penile cancer. Urology 2010;76(2 Suppl 1):2–6.

8. Douglawi A, Masterson TA. Updates on the epidemiology and risk factors for penile cancer. Transl Androl Urol 2017;6(5):785-790.

9. Heller DS. Lesions and neoplasms of the penis: A Review. J Low Genit Tract Dis 2016;20(1):107-11.

10. Survival rates for penil cancer. Atlanta, Ga: American Cancer Society; 2018. https://www.cancer.org/cancer/penile-cancer/detection-diagnosis-staging/survival-rates.html

11. Arya M, Li R, Pegler K, et al. Long-term trends in incidence, survival and mortality of primary penile cancer in England. Cancer Causes Control 2013;24(12):2169-76.

12. Crispen PL, Mydlo JH.Penile intraepithelial neoplasia and other premalignant lesions of the penis.Urol Clin North Am. 2010;37(3):335-42.

13. Barnholtz-sloan JS, Maldonado JL, Pow-sang J, Giuliano AR, Guiliano AR. Incidence trends in primary malignant penile cancer. Urol Oncol 2007;25(5):361–367.

14. Couto TC, Arruda RM, Couto MC, et al. Epidemiological study of penile cancer in Pernambuco: experience of two reference centers. Int Braz J Urol 2014;40(6):738-44.

15. Misra S, Chaturvedi A, Misra NC. Penile carcinoma: a challenge for the developing world. Lancet Oncol 2004;5(4):240-7.

16. Favorito LA, Nardi AC, Ronalsa M, et al. Epidemiologic study on penile cancer in Brazil. Int Braz J Urol 2008;34(5):587-91; discussion 591-3.

17. Van Howe RS, Hodges FM. The carcinogenicity of smegma: debunking a myth. J Eur Acad Dermatol Venereol 2006;20(9):1046-54.

18. Larke NL, Thomas SL, dos Santos Silva I, et al. Male circumcision and penile cancer: a systematic review and meta-analysis. Cancer Causes Control 2011;22(8):1097-110.

19. Madsen BS, van den Brule AJ, Jensen HL, Wohlfahrt J, Frisch M. Risk factors for squamous cell carcinoma of the penis—population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 2008. 17(10):2683-91.

20. Schoen EJ. The relationship between circumcision and cancer of the penis. CA Cancer J Clin 1991;41(5):306-9.

21. Dillner J, von Krogh G, Horenblas S, Meijer CJ. Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl 2000;205:189–93.

22. Harish K, Ravi R. The role of tobacco in penile carcinoma. Br J Urol 1995;75(3):375–7.

23. Barnes KT, McDowell BD, Button A, et al. Obesity is associated with increased risk of invasive penile cancer. BMC Urol 2016(1);16:42.

24. Stern RS. Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A Engl J Med 1990;322(16):1093-7

25. Philippou P, Shabbir M, Ralph DJ, et all. Genital lichen sclerosus/balanitis xerotica obliterans in men with penile carcinoma: a critical analysis. BJU Int. 2013;111(6):970-6.

26. Charlton OA, Smith SD. Balanitis xerotica obliterans: a review of diagnosis and management. Int J Dermatol. 2018 Oct 12. doi: 10.1111/ijd.14236.

27. Pietrzak P, Hadway P, Corbishley CM, et al. Is the association between balanitis xerotica obliterans and penile carcinoma underestimated? BJU Int 2006;98(1):74-6.

28. Krunic AL, Djerdj K, Starcevic-Bozovic A, et al. Pseudoepitheliomatous, keratotic and micaceous balanitis. Case report and review of the literature. Urol Int. 1996;56(2):125-8.

29. Cubilla AL, Velazquez EF, Amin MB, et al. The World Health Organisation 2016 classification of penile carcinomas: a review and update from the International Society of Urological Pathology expert-driven recommendations.Histopathology 2018;72(6):893-904.

30. Batur AF. Penis Kanserlerine Genel Bakış. Üroonkoloji Bülteni 2014;13(3):146-152

31. Salami SS, Montgomery JS. Surveillance strategies in the management of penile cancer. Transl Androl Urol 2017; 6(5):868-873

32. Hakenberg OW, Compérat EM, Minhas S, Necchi A, Protzel C, Watkin N. EAU Guidelines on penile cancer: 2014 Update. Eur Urol 2015; 67(1):142-50.

33. Van Poppel H, Watkin NA, Osanto S, Moonen, et al. Penile cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013. 24 Suppl 6:vi115-24. https://doi.org/10.1093/annonc/mdt357

34. NCCN Clinical Practice Guidelines in Oncology: Penile Cancer. National Comprehensive Cancer Network. https://www.tri-kobe.org/nccn/guideline/urological/english/penile.pdf. Version 2.2017 — March 10, 2017.

35. Yeung, L.L., Brandes, S.B. Dynamic sentinel lymph node biopsy as the new paradigm for the management of penile cancer. Urol Oncol. 2013;31(5):693-6.

36. Perdona S, Autorino R, De Sio M, et al. Dynamic sentinel node biopsy in clinically node-negative penile cancer versus radical inguinal lymphadenectomy: a comparative study. Urology. 2005; 66(6):1282-6.

37. Sanchez DF, Cañete S, Fernández-Nestosa MJ, et al. HPV- and non-HPV-related subtypes of penile squamous cell carcinoma (SCC): Morphological features and differential diagnosis according to the new WHO classification (2015). Semin Diagn Pathol. 2015;32(3):198-221.

38. Naumann CM, Colberg C, Juptner M, et al. Evaluation of the diagnostic value of preoperative sentinel lymph node (SLN) imaging in penile carcinoma patients without palpable inguinal lymph nodes via single photon emission computed tomography/computed tomography (SPECT/CT) as compared to planar scintigraphy. Urol Oncol. 2018;36(3):92.e17-92 https://doi.org/10.1016/j.urolonc.2017.11.012

39. Tabatabaei S, Harisinghani M, McDougal WS. Regional lymph node staging using lymphotropic nanoparticle enhanced magnetic resonance imaging with ferumoxtran-10 in patients with penile cancer. J Urol. 2005;174(3):923-7;

40. Solsona E, Bahl A, Brandes SB, et al. New developments in the treatment of localized penile cancer. Urology. 2010; 76(2 Suppl 1):S36-42.

41. Ozsahin M, Jichlinski P, Weber DC, et al. Treatment of penile carcinoma: to cut or not to cut?Int J Radiat Oncol Biol Phys. 2006; 1;66(3):674-9.

42. Joshi SS, Handorf E, Strauss D. et al. Treatment trends and outcomes for patients with lymph node-positive cancer of the penis. JAMA Oncol. 2018; 4(5): 643–649

43. Kamel M. Organ sparing surgery. J Urol 2017;198(4):770-779

44. Alnajjar HM, Lam W, Bolgeri M, et al. Treatment of carsinoma in situ of the glans penis with topical chemotherapy agents. Eur Urol 2012;62(5):923-8

45. Manjunath A, Brenton T, Wylie S, Corbishley CM, Watkin NA. Topical therapy for non-invasive penile cancer (Tis)-updated results and toxicity. Transl Androl Urol. 2017; 6(5):803-808

46. Deen K, Burdon-Jones D. Imiquimod in the treatment of penile intraepithelial neoplasia: An update. Australas J Dermatol. 2017;58(2):86-92.

47. Paoly J, Ternesten Bratel A, Löwhagen GB, et al. Penile intragenital neoplasia : results of photodynamic therapy. Acta Derm Venereal 2006;86(5):418-21.

48. Meijer RP, Boon T, van Venrooij GE, Wijburg C. Long- term follow- up after laser therapy for penile carcinoma. Urology 2007;69(4):759–762.

49. Bandieramonte, G. Colecchia M, Mariani L,et al. Peniscopically controlled CO2 laser excision for conservative treatment of in situ and T1 penile carcinoma: report on 224 patients. Eur Urol 2008, 54(4): 875–882.

50. Schlenker, B. et al. Organ- preserving neodymium- yttrium-aluminium- garnet laser therapy for penile carcinoma: a long- term follow- up. BJU Int 2016;106(6):786–790.

51. Tang DH, Yan S, Ottenhof SR, Draeger D,et al. Laser ablation as monotherapy for penile squamous cell carcinoma: A multi-center cohort analysis. Urol Oncol 2018;36(4):147-152.

52. Marchionne E, Perez C, Hui A, Khachemoune A. Penile squamous cell carcinoma: a review of the literature and case report treated with Mohs micrographic surgery. An Bras Dermatol. 2017;92(1):95-9.

53. Shindel AW, Mann MW, Lev RY, et al. Mohs micrographic surgery for penile cancer: management and long-term followup. J Urol. 2007; 178(5):1980-5.

54. Tward J. The case for nonsurgical therapy of nonmetastatic penile cancer. Nat Rev Urol. 2018;15(9):574-584.

55. Rippentrop JM, Joslyn SA, Konety BR. Squamous cell carcinoma of the penis: evaluation of data from the surveillance, epidemiology, and end results program. Cancer 2004;101(6):1357-63

56. Ficarra V. Prognostic factors in squamous cell carcinoma of the penis. Nat Clin Pract Urol 2007;4(3):140-6.

57. Pandey D, Mahajan V, Kannan RR. Prognostic factors in node-positive carcinoma of the penis. J Surg Oncol. 2006;93(2):133-8.

58. Burt LM, Shrieve DC, Tward JD. Stage presentation, care patterns, and treatment outcomes for squamous cell carcinoma of the penis. Int J Radiat Oncol Biol Phys. 2014;88(1):94-100.

59. Lont AP, Kroon BK, Gallee MP, et al. Pelvic lymph node dissection for penile carcinoma: extent of inguinal lymph node involvement as an indicator for pelvic lymph node involvement and survival. J Urol. 2007;177(3):947-52

60. Nelson BA, Cookson MS, Smith JA Jr, et al. Complications of inguinal and pelvic lymphadenectomy for squamous cell carcinoma of the penis: a contemporary series. J Urol. 2004;172(2):494-7.

61. Crook J. Contemparary role of radiotherapy Urol Clin N Am 2016;(4):435–448.

62. Haas GP, Blumenstein BA, Gagliano RG, et al. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol 1999;161(6):1823–1825.

63. Sharma, Djajadiningrat R, Zargar-Shoshtari KP. et al. Adjuvant chemotherapy is associated with improved overall survival in pelvic node- positive penile cancer after lymph node dissection: a multi- institutional study. Urol Oncol 2015;33, 496.e17–23. doi:10.1016/j.urolonc.2015.05.008

64. Pagliaro LC, Williams DL, Daliani D, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 28(24):3851–3857.

65. Bermejo C, Busby JE, Spiess PE, et al. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol. 2007;177(4):1335-8

66. Luo WX, He JP, Li X, Liu JY. Neoadjuvant chemotherapy with cetuximab for locally advanced penile cancer. J Can Res Ther 2015;11(4):1041. doi: 10.4103/0973-1482.151945

67. Necchi A. Lo Vullo S, Perrone F, et al. First- line therapy with dacomitinib, an orally available pan- HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open- label, single- arm, single- centre, phase 2 study. BJU Int. 2018;121(3):348–356.

68. Souza MAC1, Zacchi SR1, Viana KCG2, Souza CB3, Zandonade E1, Amorim MHC1. Survival analysis of penile cancer patients treated at a tertiary oncology hospital. Ciênc. saúde coletiva. 2018;23(8):2479-2486.

69. Nguyen H, Saadat P, Bennett RG. Penile basal cell carcinoma: two cases treated with Mohs micrographic surgery and remarks on pathogenesis. Dermatol Surg 2006;32:135–44.

70. Gibson GE, Ahmed I. Perianal and genital basal cell carcinoma: a clinicopathologic review of 51 cases. J Am Acad Dermatol 2001;45:68–71

71. Jaffe HW, Bregman DJ, Selik RM. Acquired immune deficiency syndrome in the United States: the first 1,000 cases. J Infect Dis 1983;148(2):339.

72. Woldrich JM, Silberstein JL, Saltzstein SL, et al. Penile Kaposi’s sarcoma in the state of California. Cancer J Urol 2012;19(2):6178–82.

73. Dehner LP, Smith BH. Soft tissue tumors of the penis: a clinicopathologic study of 46 cases. Cancer 1970;25(6):1431-47.

74. Stillwell TJ, Zincke H, Gaffey TA, Woods JE. Malignant melanoma of the penis. J Urol 1988;140(1):72–5.

75. Sa´nchez-Ortiz R, Huang SF, Tamboli P, et al. Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience. J Urol 2005;173(6):1958–65.

76. Bagby CM, MacLennan GT. Extramammary Paget’s disease of the penis and scrotum. J Urol 2009;182(6):2908–9.

77. Lam C, Funaro D. Extramammary Paget’s disease: summary of current knowledge. Dermatol Clin 2010;28(4):807–26.

78. Yang WJ, Kim DS, Im YJ, et al. Extramammary Paget’s disease of penis and scrotum. Urology 2005;65(5):972–5.

79. Cubilla AL, Ayala MT, Barreto JE, Bellasai JG, Nöel JC. Surface adenosquamous carcinoma of the penis. A report of three cases. Am J Surg Pathol. 1996;20(2):156-60.

80. Zhang K, Da J, Yao HJ, Zheng DC, et al. Metastatic tumors of the penis: a report of 8 cases and review of the literature. Medicine (Baltimore). 2015;94(1):e132. doi: 10.1097/MD.0000000000000132.

81. Chaux A, Amin M, Cubilla AL, Young RH. Metastatic tumors to the penis: a report of 17 cases and review of the literature. Int J Surg Pathol 2011;19(5):597-606.

82. Powell BL, Craig JB, Muss HB. Secondary malignancies of the penis. J Clin Oncol 1986;29(8):543-4.

**Tırnak malignansileri**

1. Park JH, Lee DY, Kim N. Nail neoplasms. J Dermatol 2017;44(3):279-87.

2. Morey VM, Garg B, Kotwal PP. Glomus tumours of the hand: Review of literature. J Clin Orthop Trauma 2016;7(4):286-91.

3. Mravic M, LaChaud G, Nguyen A, Scott MA, Dry SM, James AW. Clinical and histopathological diagnosis of glomus tumor: an institutional experience of 138 cases. Int J Surg Pathol 2015;23(3):181-88.

4. Samaniego E, Crespo A, Sanz A. Key diagnostic features and treatment of subungual glomus tumor. Actas Dermosifiliogr 2009 ;100(10):875-882.

5. Boon LM, Brouillard P, Irrthum A, et al. A gene for inherited cutaneous venous anomalies ("glomangiomas") localize chromosome 1p21-22. Am J Hum Genet. 1999 ;65(1):125-33.

6. Brouillard P, Ghassibé M, Penington A, et al. Four common glomulin mutations cause two thirds of glomuvenous malformations ("familial glomangiomas"): evidence for a founder effect. J MedGenet. 2005 ;42(2):13.

7. Anakwe RE, McEachan JE. A glomus tumour beneath the painful unpolished nail. CMAJ. 2010 7;182(12):1329.

8. Baran R, Richert B. Common nail tumors. Dermatol Clin 2006 ;24(3):297-311.

9. Drapé JL, Idy-Peretti I, Goettmann S, et al. Subungual glomus tumors: evaluation with MR imaging. Radiology 1995 ;195(2):507-15.

10. Lin YC, Hsiao PF, Wu YH, Sun FJ, Scher RK. Recurrent digital glomus tumor: analysis of 75 cases. Dermatol Surg 2010 ;36(9):1396-400.

11. Richert B, Lecerf P, Caucanas M, André J. Nail tumors. Clin Dermatol 2013;31(5):602-17.

12. Drapé JL, Idy-Peretti I, Goettmann S, Salon A, Abimelec P, Guérin-Surville H, Bittoun J. MR imaging of digital mucoid cysts. Radiology. 1996;200(2):531-6.

13. Epstein E. A simple technique for managing digital mucous cysts. Arch Dermatol. 1979; 115: 1315-1316.

14. Böhler-Sommeregger K, Kutschera-Hienert G. Cryosurgical management of myxoid cysts. J DermatolSurgOncol. 1988; 14:1405-1408.

15. Dawber RP, Sonnex T, Leonard J, et al. Myxoid cysts of finger: treatment by liquid nitrogen spray cryosurgery. ClinExpDermatol 1983; 8:153-157.

16. Audebert C. Treatment of mucoid cysts of fingers and toes by injection of sclerosant. Dermatol Clin. 1989;7: 179-181.

17. Huerter CJ, Wheeland RG, Bailin PL, et al. Treatment of digital myxoid cysts with carbondioxide laser vaporization. J Dermatol Surg Oncol 1987;13:723-27.

18. Kasdan ML, Stallings SP, Leis VM, Wolens D. Outcome of surgically treated mucous cysts of thehand. J Hand Surg Am 1994;19(3):504-7.

19. de Berker D, Lawrence C. Ganglion of the distal interphalangeal joint (myxoidcyst): therapy by identification and repair of the leak of joint fluid. Arch Dermatol 2001;137(5):607-10.

20. Stell HH. Garlic-clove fibroma. JAMA 1965; 29 (191) 1082-1083.

21. Haneke E. Epidermoid carcinoma (Bowen’s disease) of the nail apparatus simulating acquired ungual fibrokeratoma. Skin Cancer. 1991; 6:217-21.

22. Kint A, Baran R. Histopathologic study of Koenen tumours. Are they different from acquired digital fibrokeratoma? J Am Acad Dermatol 1988;18:369-372.

23. Baran R, Mikhail G, Costini B, Tosti A, Goettmann-Bonvallot S. Distal digital keratoacanthoma: two cases with a review of the literature. Dermatol Surg 2001 ;27(6):575-9.

24. Lovett JE, Haines TA, Bentz ML, Shestak KC, Flynn KJ, Kapadia SB. Subungual keratoacanthoma masquerading as a chronic paronychia. Ann Plast Surg 1995 ;34(1):84-7.

25. Young A, Manolson P, Cohen B, Klapper M, Barrett T. Painful subungal dyskeratotic tumors in incontinentia pigmenti. J Am Acad Dermatol 2005;52(4):726-9.

26. André J, Richert B. Subungual keratoacanthoma. Ann Dermatol Venereol 2012 ;139(1):68-72.

27. Honma M, Kato N, Hashimoto M, Takahashi H, Ishida-Yamamoto A, Lizuka H. Subungual keratoacanthoma: analysis of cell proliferation and copy number variation of oncogenes compared with periungual squamous cell carcinoma. Clin Exp Dermatol 2011 ;36(1):57-62.

28. Pellegrini Jr VD, Tompkins A. Manangement of subungal keratoacanthoma. J Hand Surg Am 1986;11:718-24.

29. Schulze KE, Hebert AA. Diagnostic features, differential diagnosis, and treatment of subungual osteochondroma. Pediatr Dermatol 1994;11(1):39-41.

30. Russell JD, Nance K, Nunley JR, Maher IA. Subungual exostosis. Cutis. 2016;98(2):128-9.

31. Davis DA, Cohen PR. Subungual exostosis: case report and review of the literature. Pediatr Dermatol 1996 ;13(3):212-8.

32. García Carmona FJ, Pascual Huerta J, Fernández Morato D. A proposed subungual exostosis clinical classification and treatment plan. J Am Podiatr Med Assoc 2009;99(6):519-24.

33. Haneke E. Important malignant and new nail tumors. J Dtsch Dermatol Ges 2017 ;15(4):367-86.

34. Tosti A, Schneider SL, Ramirez-Quizon MN, Zaiac M, Miteva M. Clinical, dermoscopic, and pathologic features of onychopapilloma: A review of 47 cases. J Am Acad Dermatol 2016;74(3):521-6.

35. Baran R, Kint A. Onychomatrixoma. Filamentous tufted tumour in the matrix of a funnel-shaped nail: a new entity (report of three cases). Br J Dermatol 1992;126(5):510-5.

36. Lee DY. The relation of onychomatricoma to onychodermis in the nail unit. Ann Dermatol 2013;25(3):394-5.

37. Soto R, Wortsman X, Corredoira Y. Onychomatricoma: clinical and sonographic findings. Arch Dermatol 2009 ;145(12):1461-2.

38. Goettmann S, Drape JL, Idy-Peretti I, et al. Magnetic resonance imaging: a new tool in the diagnosis of tumours of the nail apparatus. Br J Dermatol 1994;130(6):701-10.

39. Fetsch JF, Laskin WB, Miettinen M. Superficial acral fibromyxoma: a clinicopathologic and immunohistochemical analysis of 37 cases of a distinctive soft tissue tumor with a predilection for the fingers and toes. Hum Pathol 2001;32(7):704-14.

40. Hollmann TJ, Bovée JV, Fletcher CD. Digital fibromyxoma (superficial acral fibromyxoma): a detailed characterization of 124 cases. Am J Surg Pathol 2012 ;36(6):789-98.

41. Piraccini BM, Iorizzo M. Drug reactions affecting the nail unit: diagnosis and management. Dermatol Clin 2007 ;25(2):215-21.

42. Wollina U. Multiple eruptive periungual pyogenic granulomas during anti-CD20 monoclonal antibody therapy for rheumatoid arthritis. J Dermatol Case Rep 2010 19;4(3):44-6.

43. Richert B. Frictional pyogenic granuloma of the nail bed. Dermatology. 2001;202(1):80-1.

44. Tosti A, Baran R, Peluso AM, Fanti PA, Liguori R. Reflex sympathetic dystrophy with prominent involvement of the nail apparatus. J Am Acad Dermatol 1993;29(5Pt 2):865-8.

45. Mazereeuw-Hautier J, Bonafé JL. Bilateral Beau's lines and pyogenic granulomas following Guillain-Barré syndrome. Dermatology 2004;209(3):237-8.

46. Siragusa M, Schepis C, Cosentino FI, Spada RS, Toscano G, Ferri R. Nail pathology in patients with hemiplegia. Br J Dermatol 2001;144(3):557-60.

47. Piraccini BM, Bellavista S, Misciali C, Tosti A, de Berker D, Richert B. Periungual and subungual pyogenic granuloma. Br J Dermatol 2010 ;163(5):941-53.

48. Perrin C, Cannata GE, Bossard C, Grill JM, Ambrossetti D, Michiels JF. Onychocytic matricoma presenting as pachymelanonychia longitudinal. A new entity (report of five cases). Am J Dermatopathol 2012 ;34(1):54-9.

49. Sass U, Kolivras A, Richert B, et al. Acantholytic tumor of the nail: acantholytic dyskeratotic acanthoma. J Cutan Pathol. 2009;36(12):1308-11.

50. Haneke E. 'Onycholemmal' horn. Dermatologica. 1983;167(3):155-8.

51. Telang GH, Jellinek N. Multiple calcified subungual epidermoid inclusions. J Am Acad Dermatol 2007; 56: 336-9.

52. Haneke E. Common and uncommon nail tumours. 20th Dermatopathology Meeting, Vars, France, 29.1-4.2.2012.

53. Sass U, Kolivras A, Richert B, et al. Acantholytic tumor of the nail: acantholytic dyskeratotic acanthoma. J CutanPathol 2009 ;36(12):1308-11.

54. Lambertini M, Piraccini BM, Fanti PA, Dika E. Mohs micrographic surgery for nail unit tumours: an update and a critical review of the literature. J Eur Acad Dermatol Venereol 2018 Apr 28.

55. Tosti A, Piraccini BM. Biology of nails and nail disorders. In: Goldsmith LA, Stephen Katz SI, Gilchrest B, Paller A, Leffell DJ, Wolff K, editors. 8th ed. Fitzpatrick's Dermatology in General Medicine. USA: McGraw Hill Eighth Edition, 2012, p. 1009-1030.

56. Young LC, Tuxen AJ, Goodman G. Mohs' micrographic surgery as treatment for squamous dysplasia of the nail unit. Australas J Dermatol 2012;53(2):123-127.

57. Costa C, Villani A, Russo D, Cappello M, De Fata Salvatores G, Scalvenzi M. Squamous Cell Carcinomas in Two Cases of Nail Lichen Planus: Is There a RealAssociation? Dermatol Ther (Heidelb) 2018 May 31.

58. Haneke E. Ungual melanoma—controversies in diagnosis and treatment. Dermatol Ther 2012;25(6):510–524.

59. Dika E, Altimari A, Patrizi A, et al. KIT, NRAS, and BRAF mutations in nail apparatus melanoma. Pigment Cell Melanoma Res 2013 ;26(5):758-60.

60. Starace M, Dika E, Fanti PA, et al. Nail apparatus melanoma: dermoscopic and histopathologiccorrelations on a series of 23 patients from a single centre. J Eur Acad Dermatol Venereol 2018 ;32(1):164-173.

61. High WA, Quirey RA, Guillen DR, Munoz G, Taylor RS. Presentation, ~ histopathologic findings and clinical outcomes in 7 cases of melanoma in situ of the nail unit. Arch Dermatol 2004; 140(9): 1102–1106.

62. Ozdemir F, Errico MA, Yaman B, Karaarslan I. Acral lentiginous melanoma in the Turkish population and a new dermoscopic clue for the diagnosis. Dermatol Pract Concept 2018 30;8(2):140-148.

63. Koga H, Saida T, Uhara H. Key point in dermoscopic differentiation between early nail apparatus melanoma and benign longitudinal melanonychia. J Dermatol. 2011 ;38(1):45-52.

64. Benati E, Ribero S, Longo C, et al. Clinical and dermoscopic clues to differentiate pigmented nail bands: an International Dermoscopy Society study. J Eur Acad Dermatol Venereol 2017 ;31(4):732-736.

65. Perrin C. Tumors of the nail unit. A review. Part II: acquired localized longitudinal pachyonychia and masked nail tumors. Am J Dermatopathol 2013 ;35(7):693-709.

66. Perrin C, Langbein L, Ambrossetti D, Erfan N, Schweizer J, Michiels JF. Onychocytic carcinoma: a new entity. Am J Dermatopathol 2013;35(6):679-84.

67. Wang L, Gao T, Wang G. Invasive onychocytic carcinoma. J Cutan Pathol 2015 ;42(5):361-7.

**Kutanöz metastazlar**

1. Talmadge JE, Fidler IJ. AACR Centennial Series: The Biology of Cancer Metastasis: Historical Perspective. Cancer Res. 2010 July 15; 70(14): 5649–5669.

2.Schadt CR, Callen JP. Metastatic Disease. In: Callen JP, Jorizzo JL, Zone JJ, Piette W, Rosenbach MA, Vleugels RA, editors. Dermatological Signs of Systemic Disease E-Book. Elsevier Health Sciences; 2016;p.155-158.

3. Weimann ETS, Botero EB, Mendes C, Santos MAS, Stelini RF, Zelenika CRT. Cutaneous metastasis as the first manifestation of occult malignant breast neoplasia. An Bras Dermatol. 2016;91(5 Supl 1):S105-7.

4. Fernández-Antón Martínez MC, Parra-Blanco V, Avilés Izquierdo JA, Suárez Fernández RM. Cutaneous metastases of internal tumors. Actas Dermosifiliogr. 2013 Dec;104(10):841-53.

5. Chernoff KA, Marghoob AA, Lacouture ME, Deng L, Busam KJ, Myskowski PL. Dermoscopic findings in cutaneous metastases. JAMA Dermatol. 2014 Apr;150(4):429-33.

6. Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC. Malignant Epithelial Tumors. Cutaneous Metastasis. In: Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC, editors. Dermatology. Springer Science & Business Media; 2012; p.1485-1488.

7. Schwartz RA. Cutaneous Metastatic Disease. Skin Cancer: Recognition and Management. John Wiley & Sons, 2008; p.267-281.

8. Sariya D, Ruth K, Adams-McDonnell R, et al. Clinicopathologic correlation of cutaneous metastases: experience from a cancer center. Arch Dermatol. 2007 May;143(5):613-20.

9. Piette WW. Metastatic Disease. In: Callen JP, Jorizzo JL, Bolognia JL, Piette W, Zone JJ, editors. Dermatological Signs of Internal Disease E-Book. Elsevier Health Sciences, 2009; p.117-123.

10. Patterson JW. Cutaneous metastases. Weedon's Skin Pathology E-Book. Elsevier Health Sciences, 2014; p. 1118-1126.

11. Schulman JM, Pauli ML, Neuhaus IM, et al. The distribution of cutaneous metastases correlates with local immunologic milieu. J Am Acad Dermatol. 2016;74(3):470-476.

12. Hu SC, Chen GS, Wu CS, Chai CY, Chen WT, Lan CC. Rates of cutaneous metastases from different internal malignancies: experience from a Taiwanese medical center. J Am Acad Dermatol. 2009 Mar;60(3):379-87.

13. Wong CY, Helm MA, Kalb RE, Helm TN, Zeitouni NC. The presentation, pathology, and current management strategies of cutaneous metastasis. N Am J Med Sci. 2013; Sep;5(9):499-504.

14. Fitzpatrick JE. Cutaneous Metastases. In: Fitzpatrick JE, Morelli JG, editors. Dermatology Secrets Plus. Elsevier Health Sciences, 2015;p. 434-438.

15. Provost TT. Cutaneous Metastasis. In: Provost TT, Flynn JA, editors. Cutaneous Medicine: Cutaneous Manifestations of Systemic Disease. PMPH-USA, 2001;p. 357-366.

16. Margaritescu I. Cutaneous metastasis of breast carcinoma. Rare Malignant Skin Tumors. In: Rongioletti F, Margaritescu I, Smoller BR, editors. Springer-Verlag New York, 2016; p.313-316.

 17. Smoller BR, Trap KM. Cutaneous Metastasis. In: Crowe D, Morgan M, Somach S, Trapp K, editors. Deadly dermatologic diseases: clinicopathologic atlas and text. Cham: Springer International Publishing Switzerland; 2016; p. 47–54.

18. Fernández-Rueda P, Ruiz-López P, Ramírez-Negrín MA, Fuentes-Suárez A, Toussaint-Caire S and Vega-Memije ME. Cutaneous metastasis of renal cell carcinoma: A case report and review of the literature. Gac Med Mex. 2015;151:497-501.

19. Gül U, Kiliç A, Akbaş A, Aslan E, Demiriz M. Alopecia neoplastica due to metastatic colon adenocarcinoma. Acta Derm Venereol. 2007;87(1):93-4.

20. Margaritescu I. Cutaneous metastasis of lung cancer. Rare Malignant Skin Tumors. In: Rongioletti F, Margaritescu I, Smoller BR, editors. Springer-Verlag New York, 2016; p.321-323.

21. Fonseca NL Jr, Lucci LM, Cha SB, Rossetti C, Rehder JR. Metastatic eyelid disease associated with primary breast carcinoma: case report. Arq Bras Oftalmol.2009 May-Jun;72(3):390-3.

22. Santos-Juanes J, López-Escobar M, Villanueva Palicio N,et al. Zosteriform cutaneous metastasis from a breast carcinoma. Med Cutan Iber Lat Am. 2007;35:89-93.

23. Scolyer RA, Murali R, Thompson JF. Cutaneous Metastases In: Klaus J. Busam, editor. Elsevier Health Sciences, 2010;p.637-650.

24. António AM, Alves JV, Goulão J, Bártolo E. Ovarian carcinoma presenting as cutaneous nasal metastasis. An Bras Dermatol. 2016 Sep-Oct;91(5 suppl 1):101-104.

25. Cohen PR. Metastatic tumors to the nail unit: subungual metastases. Dermatol Surg. 2001 Mar;27(3):280-93.

26. Diaz LM, Norman RA. Zosteriform Cutaneous Metastases. Clinical Cases in Skin Cancer Surgery and Treatment. In: Paul SP, Norman RA, editors. Springer, 2015;p.173-179.

27. Habif TP. Premalignant and malignant nonmelanoma skin tumors. Cutaneous Metastasis. Clinical Dermatology. Elsevier Health Sciences, 2015; 852-854.

28. Chopra R, Chhabra S, Samra SG, Thami GP, Punia RP, Mohan H. Cutaneous metastases of internal malignancies: a clinicopathologic study. Indian J Dermatol Venereol Leprol. 2010 Mar-Apr;76(2):125-31.

29. Nesseris I, Tsamakis C, Gregoriou S, Ditsos I, Christofidou E, Rigopoulos D. Cutaneous metastasis of colon adenocarcinoma: case report and review of the literature. An Bras Dermatol. 2013;88(6 Suppl 1):56-8.

30. Rongioletti F. Miscellanea of cutaneous metastases. Rare Malignant Skin Tumors. In: Rongioletti F, Margaritescu I, Smoller BR, editors. Springer-Verlag New York, 2016; p.311-334.

31. Bubna AK. Imiquimod - Its role in the treatment of cutaneous malignancies. Indian J Pharmacol.. 2015;47(4):354-359.

**Paraneoplastik dermatozlar**

1. McLean DI. Toward a definition of cutaneous paraneoplastic syndrome. Clinics in dermatology. 1993;11(1):11-3.

2. Chung VQ, Moschella SL, Zembowicz A, Liu V. Clinical and pathologic findings of paraneoplastic dermatoses. Journal of the American Academy of Dermatology. 2006;54(5):745-62; quiz 63-6.

3. Brenner S, Tamir E, Maharshak N, Shapira J. Cutaneous manifestations of internal malignancies. Clinics in dermatology. 2001;19(3):290-7.

4. Boyce S, Harper J. Paraneoplastic dermatoses. Dermatologic clinics. 2002;20(3):523-32.

5. Silva JA, Mesquita Kde C, Igreja AC, Lucas IC, Freitas AF, Oliveira SM, et al. Paraneoplastic cutaneous manifestations: concepts and updates. Anais brasileiros de dermatologia. 2013;88(1):9-22.

6. Kurzrock R, Cohen PR. Mucocutaneous paraneoplastic manifestations of hematologic malignancies. The American journal of medicine. 1995;99(2):207-16.

7. Cohen PR, Kurzrock R. Mucocutaneous paraneoplastic syndromes. Seminars in oncology. 1997;24(3):334-59.

8. Phiske MM. An approach to acanthosis nigricans. Indian dermatology online journal. 2014;5(3):239-49.

9. Pipkin CA, Lio PA. Cutaneous manifestations of internal malignancies: an overview. Dermatologic clinics. 2008;26(1):1-15, vii.

10. Mekhail TM, Markman M. Acanthosis nigricans with endometrial carcinoma: case report and review of the literature. Gynecologic oncology. 2002;84(2):332-4.

11. Krawczyk M, Mykala-Ciesla J, Kolodziej-Jaskula A. Acanthosis nigricans as a paraneoplastic syndrome. Case reports and review of literature. Polskie Archiwum Medycyny Wewnetrznej. 2009;119(3):180-3.

12. Thiers BH, Sahn RE, Callen JP. Cutaneous manifestations of internal malignancy. CA: a cancer journal for clinicians. 2009;59(2):73-98.

13. Higgins EM, du Vivier AW. Cutaneous manifestations of malignant disease. British journal of hospital medicine. 1992;48(9):552-4, 8-61.

14. Karakas Y, Esin E, Lacin S, Ceyhan K, Heper AO, Yalcin S. A case of acanthosis nigricans as a paraneoplastic syndrome with squamous cell lung cancer. OncoTargets and therapy. 2016;9:4815-20.

15. Stuart CA, Driscoll MS, Lundquist KF, Gilkison CR, Shaheb S, Smith MM. Acanthosis nigricans. Journal of basic and clinical physiology and pharmacology. 1998;9(2-4):407-18.

16. Pentenero M, Carrozzo M, Pagano M, Gandolfo S. Oral acanthosis nigricans, tripe palms and sign of leser-trelat in a patient with gastric adenocarcinoma. International journal of dermatology. 2004;43(7):530-2.

17. Scheinfeld N. A review of the cutaneous paraneoplastic associations and metastatic presentations of ovarian carcinoma. Clinical and experimental dermatology. 2008;33(1):10-5.

18. Deen J, Moloney T, Burdon-Jones D. Severe, Malignant Acanthosis Nigricans Associated with Adenocarcinoma of the Endometrium in a Young Obese Female. Case reports in dermatology. 2017;9(1):30-7.

19. Ramos ESM, Carvalho JC, Carneiro SC. Cutaneous paraneoplasia. Clinics in dermatology. 2011;29(5):541-7.

20. Ferraz de Campos FP, Narvaez MR, Reis PV, Gomes AC, Paraskevopoulos DK, Santana F, et al. Acanthosis Nigricans associated with clear-cell renal cell carcinoma. Autopsy & case reports. 2016;6(1):33-40.

21. Kleyn CE, Lai-Cheong JE, Bell HK. Cutaneous manifestations of internal malignancy: diagnosis and management. American journal of clinical dermatology. 2006;7(2):71-84.

22. Safai B, Grant JM, Kurtz R, Lightdale CJ, Good RA. Cutaneous manifestation of internal malignancies (I). Acanthosis nigricans. International journal of dermatology. 1978;17(4):312-5.

23. Yu Q, Li XL, Ji G, Wang Y, Gong Y, Xu H, et al. Malignant acanthosis nigricans: an early diagnostic clue for gastric adenocarcinoma. World journal of surgical oncology. 2017;15(1):208.

24. Schwartz RA, Williams ML. Acquired ichthyosis: a marker for internal disease. American family physician. 1984;29(2):181-4.

25. Griffin LJ, Massa MC. Acquired ichthyosis and pityriasis rotunda. Clinics in dermatology. 1993;11(1):27-32.

26. Dilek I, Demirer T, Ustun C, Arat M, Koc H, Beksac M, et al. Acquired ichthyosis associated with chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation in a patient with chronic myelogenous leukemia. Bone marrow transplantation. 1998;21(11):1159-61.

27. Aram H. Acquired ichthyosis and related conditions. International journal of dermatology. 1984;23(7):458-61.

28. Ameen M, Chopra S, Darvay A, Acland K, Chu AC. Erythema gyratum repens and acquired ichthyosis associated with transitional cell carcinoma of the kidney. Clinical and experimental dermatology. 2001;26(6):510-2.

29. Patsatsi A, Kyriakou A, Karavasilis V, Tsatsou F, Lazaridis G, Kalabalikis D, et al. Acquired ichthyosis triggered by an osseous hemangiopericytoma: a case report and review of the literature. Case reports in dermatology. 2014;6(1):10-5.

30. Martin-Cascon M, Sanchez-Guirao AJ, Herranz-Marin MT. Paraneoplastic acquired ichthyosis in lung cancer. Archivos de bronconeumologia. 2015;51(11):609.

31. Patel N, Spencer LA, English JC, 3rd, Zirwas MJ. Acquired ichthyosis. Journal of the American Academy of Dermatology. 2006;55(4):647-56.

32. Moore RL, Devere TS. Epidermal manifestations of internal malignancy. Dermatologic clinics. 2008;26(1):17-29, vii.

33. Friedmann AC, Ameen M, Swale VJ. Familial pityriasis rotunda in black-skinned patients; a first report. The British journal of dermatology. 2007;156(6):1365-7.

34. Hasson I, Shah P. Pityriasis rotunda. Indian journal of dermatology, venereology and leprology. 2003;69(1):50-1.

35. Borghi A, Ricci M, Ruina G, Corazza M, Virgili A. When the exception proves the rule: pityriasis rotunda of difficult classification. International journal of dermatology. 2016;55(2):218-9.

36. Atas H, Gonul M, Koyuncu D, Alper M. Pityriasis rotunda: a case from Turkey. International journal of dermatology. 2016;55(6):e362-4.

37. Batra P, Cheung W, Meehan SA, Pomeranz M. Pityriasis rotunda. Dermatology online journal. 2009;15(8):14.

38. Bakry OA, Samaka RM. Photoletter to the editor: Pityriasis Rotunda. Journal of dermatological case reports. 2012;6(3):90-2.

39. Suzuki Y, Aoshima M, Fujiyama T, Ito T, Tokura Y. Pityriasis rotunda associated with acute myeloid leukemia. The Journal of dermatology. 2018;45(1):105-6.

40. Patel S, Zirwas M, English JC, 3rd. Acquired palmoplantar keratoderma. American journal of clinical dermatology. 2007;8(1):1-11.

41. Asemota E, Markova A, Ho J, Lichtman MK. Disseminated punctate keratoderma: a rare case report and review of the literature. Dermatology online journal. 2017;23(3).

42. Cognetta AB, Jr., Wolfe CM, Herbst AT. Palmoplantar keratoses and Bowen's disease in a Vietnam veteran: Could Agent Blue be implicated? The Australasian journal of dermatology. 2016;57(2):e66-8.

43. Kallini JR, Sadeghani K, Khachemoune A. Paraneoplastic palmoplantar keratoderma secondary to metastatic uterine adenocarcinoma. Cutis. 2017;99(3):E32-E5.

44. Murata Y, Kumano K, Tani M, Saito N, Kagotani K. Acquired diffuse keratoderma of the palms and soles with bronchial carcinoma: report of a case and review of the literature. Archives of dermatology. 1988;124(4):497-8.

45. Ehst BD, Minzer-Conzetti K, Swerdlin A, Devere TS. Cutaneous manifestations of internal malignancy. Current problems in surgery. 2010;47(5):384-445.

46. Requena L, Aguilar A, Renedo G, Martin L, Pique E, Farina MC, et al. Tripe palms: a cutaneous marker of internal malignancy. The Journal of dermatology. 1995;22(7):492-5.

47. Cohen PR, Grossman ME, Almeida L, Kurzrock R. Tripe palms and malignancy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1989;7(5):669-78.

48. Braverman IM. Skin manifestations of internal malignancy. Clinics in geriatric medicine. 2002;18(1):1-19, v.

49. Costa MC, Martinez NS, Belicha MG, Leal F. Acanthosis nigricans and "tripe palm" as paraneoplastic manifestations of metastatic tumor. Anais brasileiros de dermatologia. 2012;87(3):498-500.

50. Danesh MJ, Saylor DK, Leard LE, North JP, Fox LP. Acquired acanthosis nigricans with tripe palms in a patient with interstitial lung disease. JAAD case reports. 2016;2(1):59-62.

51. Chakraborty PP, Datta S, Mandal SK, Kumar M. Tripe palm: a cutaneous manifestation of gastric carcinoma. BMJ case reports. 2014;2014.

52. da Costa Franca AF, Siqueira NS, Carvalheira JB, Saad MJ, Souza EM. Acanthosis nigricans, tripe palms and the sign of Leser-Trelat in a patient with a benign hepatic neoplasia. Journal of the European Academy of Dermatology and Venereology : JEADV. 2007;21(6):846-8.

53. Bolognia JL. Bazex syndrome: acrokeratosis paraneoplastica. Seminars in dermatology. 1995;14(2):84-9.

54. Bazex A, Griffiths A. Acrokeratosis paraneoplastica--a new cutaneous marker of malignancy. The British journal of dermatology. 1980;103(3):301-6.

55. Bolognia JL, Brewer YP, Cooper DL. Bazex syndrome (acrokeratosis paraneoplastica). An analytic review. Medicine. 1991;70(4):269-80.

56. Shah KR, Boland CR, Patel M, Thrash B, Menter A. Cutaneous manifestations of gastrointestinal disease: part I. Journal of the American Academy of Dermatology. 2013;68(2):189 e1-21; quiz 210.

57. Humphrey SR, Hussain AS, Chandran R, Wilson B, George B. Acute Onset of Acrokeratosis Paraneoplastica (Bazex Syndrome). JAMA dermatology. 2015;151(6):677-8.

58. Akhyani M, Mansoori P, Taheri A, Asadi Kani Z. Acrokeratosis paraneoplastica (Bazex syndrome) associated with breast cancer. Clinical and experimental dermatology. 2004;29(4):429-30.

59. Ljubenovic MS, Ljubenovic DB, Binic, II, Jankovic AS, Jovanovic DL. Acrokeratosis paraneoplastica (Bazex syndrome). Indian journal of dermatology, venereology and leprology. 2009;75(3):329.

60. Yeh JS, Munn SE, Plunkett TA, Harper PG, Hopster DJ, du Vivier AW. Coexistence of acanthosis nigricans and the sign of Leser-Trelat in a patient with gastric adenocarcinoma: a case report and literature review. Journal of the American Academy of Dermatology. 2000;42(2 Pt 2):357-62.

61. Heaphy MR, Jr., Millns JL, Schroeter AL. The sign of Leser-Trelat in a case of adenocarcinoma of the lung. Journal of the American Academy of Dermatology. 2000;43(2 Pt 2):386-90.

62. Aussy A, Boyer O, Cordel N. Dermatomyositis and Immune-Mediated Necrotizing Myopathies: A Window on Autoimmunity and Cancer. Frontiers in immunology. 2017;8:992.

63. Owen CE. Cutaneous manifestations of lung cancer. Seminars in oncology. 2016;43(3):366-9.

64. Callen JP. Dermatomyositis. Lancet. 2000;355(9197):53-7.

65. Callen JP. When and how should the patient with dermatomyositis or amyopathic dermatomyositis be assessed for possible cancer? Archives of dermatology. 2002;138(7):969-71.

66. Wolff M, Mancuso C, Lal K, Dicostanzo D, Gropper C. Paraneoplastic Dermatomyositis with Cutaneous and Myopathic Disease Responsive to Adrenocorticotropic Hormone Therapy. The Journal of clinical and aesthetic dermatology. 2017;10(1):57-62.

67. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357(9250):96-100.

68. Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. The Journal of rheumatology. 2000;27(6):1542-5.

69. Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin PF, et al. Breast cancer in systemic lupus. Lupus. 2017;26(3):311-5.

70. Azrielant S, Tiosano S, Watad A, Mahroum N, Whitby A, Comaneshter D, et al. Correlation between systemic lupus erythematosus and malignancies: a cross-sectional population-based study. Immunologic research. 2017;65(2):464-9.

71. Choi MY, Flood K, Bernatsky S, Ramsey-Goldman R, Clarke AE. A review on SLE and malignancy. Best practice & research Clinical rheumatology. 2017;31(3):373-96.

72. Wada TT, Sato K, Mimura T. A case of systemic lupus erythematosus with multiple nodules in the bilateral lungs and vertebrae. European journal of rheumatology. 2016;3(1):38-40.

73. Rovisco J, Serra S, Abreu P, Coutinho M, Santiago T, Ines L, et al. Paraneoplastic sclerodermiform syndrome--case report. Acta reumatologica portuguesa. 2014;39(1):87-90.

74. Monfort JB, Lazareth I, Priollet P. Paraneoplastic systemic sclerosis: About 3 cases and review of literature. Journal des maladies vasculaires. 2016;41(6):365-70.

75. Jedlickova H, Durcanska V, Vasku V. Paraneoplastic Scleroderma: Are There Any Clues? Acta dermatovenerologica Croatica : ADC. 2016;24(1):78-80.

76. Marek M, Rudny R. Scleroderma of geriatric age and scleroderma-like paraneoplastic syndrome - description of two cases. Reumatologia. 2016;54(2):91-4.

77. Shah AA, Casciola-Rosen L. Mechanistic and clinical insights at the scleroderma-cancer interface. Journal of scleroderma and related disorders. 2017;2(3):153-9.

78. Yamamoto M, Suzuki C, Naishiro Y, Tsukuda H, Murakami R, Yamamoto H, et al. [A case of pseudoscleroderma as paraneoplastic syndrome due to carcinoma of cervical uteri]. Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology. 2003;26(5):293-8.

79. Zhang JQ, Wan YN, Peng WJ, Yan JW, Li BZ, Mei B, et al. The risk of cancer development in systemic sclerosis: a meta-analysis. Cancer epidemiology. 2013;37(5):523-7.

80. Ciolkiewicz M, Domyslawska I, Ciolkiewicz A, Klimiuk PA, Kuryliszyn-Moskal A. Coexistence of systemic sclerosis, scleroderma-like syndromes and neoplastic diseases. Polskie Archiwum Medycyny Wewnetrznej. 2008;118(3):119-26.

81. Sanchez-Guerrero J, Gutierrez-Urena S, Vidaller A, Reyes E, Iglesias A, Alarcon-Segovia D. Vasculitis as a paraneoplastic syndrome. Report of 11 cases and review of the literature. The Journal of rheumatology. 1990;17(11):1458-62.

82. Kurzrock R, Cohen PR. Vasculitis and cancer. Clinics in dermatology. 1993;11(1):175-87.

83. Buggiani G, Krysenka A, Grazzini M, Vasku V, Hercogova J, Lotti T. Paraneoplastic vasculitis and paraneoplastic vascular syndromes. Dermatologic therapy. 2010;23(6):597-605.

84. Yigit M, Sogut O, Yigit E, Turkdogan KA, Kaplan O, Dur A, et al. The relationship between anemia and recurrence of ischemic stroke in patients with Trousseau's syndrome: A retrospective cross-sectional study. Turkish journal of emergency medicine. 2016;16(2):65-8.

85. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. The New England journal of medicine. 2000;343(25):1846-50.

86. Mizoguchi S, Sawai T, Hirota A, Yamamoto S, Nakajima H, Makino K, et al. Trousseau's Syndrome Causing Refractory Deep Venous Thrombosis. Internal medicine. 2017.

87. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood. 2007;110(6):1723-9.

88. Ito S, Yoshitomi H, Pak M, Kawahara H, Oshima T, Ito S, et al. Trousseau syndrome with nonbacterial thrombotic endocarditis in a patient with uterine cancer. Internal medicine. 2013;52(12):1353-8.

89. Kato T, Yasuda K, Iida H, Watanabe A, Fujiuchi Y, Miwa S, et al. Trousseau's syndrome caused by bladder cancer producing granulocyte colony-stimulating factor and parathyroid hormone-related protein: A case report. Oncology letters. 2016;12(5):4214-8.

90. Kwong HL, Tay YK, Park JJ. Trousseau syndrome presenting with penile gangrene. JAAD case reports. 2017;3(2):100-2.

91. Min KW, Gyorkey F, Sato C. Mucin-producing adenocarcinomas and nonbacterial thrombotic endocarditis: pathogenetic role of tumor mucin. Cancer. 1980;45(9):2374-82.

92. Ladizinski B, Federman DG. Trousseau syndrome. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2013;185(12):1063.

93. Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. The New England journal of medicine. 1990;323(25):1729-35.

94. Wieczorek M, Czernik A. Paraneoplastic pemphigus: a short review. Clinical, cosmetic and investigational dermatology. 2016;9:291-5.

95. Paolino G, Didona D, Magliulo G, Iannella G, Didona B, Mercuri SR, et al. Paraneoplastic Pemphigus: Insight into the Autoimmune Pathogenesis, Clinical Features and Therapy. International journal of molecular sciences. 2017;18(12).

96. Mimouni D, Anhalt GJ, Lazarova Z, Aho S, Kazerounian S, Kouba DJ, et al. Paraneoplastic pemphigus in children and adolescents. The British journal of dermatology. 2002;147(4):725-32.

97. Nguyen VT, Ndoye A, Bassler KD, Shultz LD, Shields MC, Ruben BS, et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Archives of dermatology. 2001;137(2):193-206.

98. Kelly S, Schifter M, Fulcher DA, Lin MW. Paraneoplastic pemphigus: two cases of intra-abdominal malignancy presenting solely as treatment refractory oral ulceration. The Journal of dermatology. 2015;42(3):300-4.

99. Yong AA, Tey HL. Paraneoplastic pemphigus. The Australasian journal of dermatology. 2013;54(4):241-50.

100. Wade MS, Black MM. Paraneoplastic pemphigus: a brief update. The Australasian journal of dermatology. 2005;46(1):1-8; quiz 9-10.

101. Czernik A, Camilleri M, Pittelkow MR, Grando SA. Paraneoplastic autoimmune multiorgan syndrome: 20 years after. International journal of dermatology. 2011;50(8):905-14.

102. Yokokura H, Demitsu T, Kakurai M, Umemoto N, Azuma R, Yamada T, et al. Paraneoplastic pemphigus mimicking erosive mucosal lichen planus associated with primary hepatocellular carcinoma. The Journal of dermatology. 2006;33(12):842-5.

103. Broussard KC, Leung TG, Moradi A, Thorne JE, Fine JD. Autoimmune bullous diseases with skin and eye involvement: Cicatricial pemphigoid, pemphigus vulgaris, and pemphigus paraneoplastica. Clinics in dermatology. 2016;34(2):205-13.

104. Lambert J, Bracke S, van Roy F, Pas HH, Bonne S, De Schepper S. Serum plakophilin-3 autoreactivity in paraneoplastic pemphigus. The British journal of dermatology. 2010;163(3):630-2.

105. Poot AM, Diercks GF, Kramer D, Schepens I, Klunder G, Hashimoto T, et al. Laboratory diagnosis of paraneoplastic pemphigus. The British journal of dermatology. 2013;169(5):1016-24.

106. Lee JS, Pei-Lin Ng P, Tao M, Lim WT. Paraneoplastic pemphigus resembling linear IgA bullous dermatosis. International journal of dermatology. 2006;45(9):1093-5.

107. Jiang Q, Zhang BH. Paraneoplastic pemphigus associated with chronic lymphocytic leukemia: A case report. Medicine. 2017;96(8):e6184.

108. Fullerton SH, Woodley DT, Smoller BR, Anhalt GJ. Paraneoplastic pemphigus with autoantibody deposition in bronchial epithelium after autologous bone marrow transplantation. Jama. 1992;267(11):1500-2.

109. Tsuchisaka A, Numata S, Teye K, Natsuaki Y, Kawakami T, Takeda Y, et al. Epiplakin Is a Paraneoplastic Pemphigus Autoantigen and Related to Bronchiolitis Obliterans in Japanese Patients. The Journal of investigative dermatology. 2016;136(2):399-408.

110. Vassileva S, Drenovska K, Manuelyan K. Autoimmune blistering dermatoses as systemic diseases. Clinics in dermatology. 2014;32(3):364-75.

111. Kaplan I, Hodak E, Ackerman L, Mimouni D, Anhalt GJ, Calderon S. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral oncology. 2004;40(6):553-62.

112. Basir N, Telisinghe PU, Chong VH. Gastric Cancer and Paraneoplastic Pemphigus. The Indian journal of surgery. 2015;77(6):545-6.

113. Ohzono A, Sogame R, Li X, Teye K, Tsuchisaka A, Numata S, et al. Clinical and immunological findings in 104 cases of paraneoplastic pemphigus. The British journal of dermatology. 2015;173(6):1447-52.

114. Sinha AA. Paraneoplastic Pemphigus: Autoimmune-Cancer Nexus in the Skin. Anti-cancer agents in medicinal chemistry. 2015;15(10):1215-23.

115. Anhalt GJ. Paraneoplastic pemphigus. The journal of investigative dermatology Symposium proceedings. 2004;9(1):29-33.

116. Anan T, Shimizu F, Hatano Y, Okamoto O, Katagiri K, Fujiwara S. Paraneoplastic pemphigus associated with corneal perforation and cutaneous alternariosis: a case report and review of cases treated with rituximab. The Journal of dermatology. 2011;38(11):1084-9.

117. Das A, Das S, Das SK, Basuthakur S. A case of paraneoplastic bullous pemphigoid in association with squamous cell carcinoma of lung. Journal of postgraduate medicine. 2015;61(3):197-9.

118. Chadwick PW, Spitz FR, Kwa DM, Johnson WC, Heymann WR. Bullous pemphigoid associated with a lymphoepithelial cyst of the pancreas. Cutis. 2016;98(4):264-8.

119. Thoma-Uszynski S, Uter W, Schwietzke S, Hofmann SC, Hunziker T, Bernard P, et al. BP230- and BP180-specific auto-antibodies in bullous pemphigoid. The Journal of investigative dermatology. 2004;122(6):1413-22.

120. Mirgh SP, Jobanputra YB, Sharma P, Mishra VA, Shah VD, Sharma A. Bullous Pemphigoid as a Harbinger of Metastatic Cholangiocarcinoma - A Rarity. The Journal of the Association of Physicians of India. 2017;65(5):98-100.

121. Balestri R, Magnano M, La Placa M, Patrizi A, Angileri L, Tengattini V, et al. Malignancies in bullous pemphigoid: A controversial association. The Journal of dermatology. 2016;43(2):125-33.

122. Bishnoi A, Narang T, Handa S, Vishwajeet V, Saikia UN, Kapoor R, et al. Paraneoplastic bullous pemphigoid associated with penile squamous cell carcinoma. Journal of the European Academy of Dermatology and Venereology : JEADV. 2017.

123. Nassiri M, Robertson MJ, Hertzberg L, Czader MB. Primary effusion anaplastic large cell lymphoma in a patient with long-standing dermatitis herpetiformis and celiac disease. Annals of hematology. 2013;92(2):279-81.

124. Hartke J, Trevino J, Akram S. Dermatitis Herpetiformis: Rare Cutaneous Manifestation of Colon Adenocarcinoma. Journal of gastrointestinal cancer. 2012;43 Suppl 1:S161-3.

125. Alonso-Llamazares J, Gibson LE, Rogers RS, 3rd. Clinical, pathologic, and immunopathologic features of dermatitis herpetiformis: review of the Mayo Clinic experience. International journal of dermatology. 2007;46(9):910-9.

126. Shigeta M, Saiki M, Tsuruta D, Ohata C, Ishii N, Ono F, et al. Two Japanese cases of dermatitis herpetiformis associated each with lung cancer and autoimmune pancreatitis but showing no intestinal symptom or circulating immunoglobulin A antibodies to any known antigens. The Journal of dermatology. 2012;39(12):1002-5.

127. Djahansouzi S, Nestle-Kraemling C, Dall P, Bender HG, Hanstein B. Herpes gestationis may present itself as a paraneoplastic syndrome of choriocarcinoma-a case report. Gynecologic oncology. 2003;89(2):334-7.

128. Tindall JG, Rea TH, Shulman I, Quismorio FP, Jr. Herpes gestationis in association with a hydatidiform mole. Immunopathologic studies. Archives of dermatology. 1981;117(8):510-2.

129. Inani K, Meziane M, Bouyahyaoui Y, Mernissi FZ, Sekal M, Harmouch T, et al. [Choriocarcinoma: a hidden face of pemphigoid gestationis]. Gynecologie, obstetrique & fertilite. 2014;42(5):357-9.

130. Takatsuka Y, Komine M, Ohtsuki M. Pemphigoid gestationis with a complete hydatidiform mole. The Journal of dermatology. 2012;39(5):474-6.

131. Wilson BD, Birnkrant AF, Beutner EH, Maize JC. Epidermolysis bullosa acquisita: a clinical disorder of varied etiologies. Two cases and a review of immunologic and other reported findings. Journal of the American Academy of Dermatology. 1980;3(3):280-91.

132. Radfar L, Fatahzadeh M, Shahamat Y, Sirois D. Paraneoplastic epidermolysis bullosa acquisita associated with multiple myeloma. Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry. 2006;26(4):159-63.

133. Lombardo GA, Pilla MA, Benucci R, Monopoli A, Baliva G, Gobello T, et al. Paraneoplastic Epidermolysis Bullosa Acquisita Associated with Thyroid Carcinoma. Acta dermato-venereologica. 2016;96(3):414-5.

134. Chamberlain AJ, Cooper SM, Allen J, Dean D, Baxter KF, Goodfield MJ, et al. Paraneoplastic immunobullous disease with an epidermolysis bullosa acquisita phenotype: two cases demonstrating remission with treatment of gynaecological malignancy. The Australasian journal of dermatology. 2004;45(2):136-9.

135. Watsky KL, Orlow SJ, Bolognia JL. Figurate and bullous eruption in association with breast carcinoma. Archives of dermatology. 1990;126(5):649-52.

136. Almeyda J. Epidermolysis bullosa associated with neoplasm of the bronchus. The British journal of dermatology. 1972;87(1):70-1.

137. Engineer L, Dow EC, Braverman IM, Ahmed AR. Epidermolysis bullosa acquisita and multiple myeloma. Journal of the American Academy of Dermatology. 2002;47(6):943-6.

138. Thawani R, Moghe A, Idhate T, Kalra M, Mahajan A, Anderson KE. Porphyria cutanea tarda in a child with acute lymphoblastic leukemia. QJM : monthly journal of the Association of Physicians. 2016;109(3):191-2.

139. Sokmen M, Demirsoy H, Ersoy O, Gokdemir G, Akbayir N, Karaca C, et al. Paraneoplastic porphyria cutanea tarda associated with cholangiocarcinoma: case report. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology. 2007;18(3):200-5.

140. Agarwal R, Peters TJ, Coombes RC, Vigushin DM. Tamoxifen-related porphyria cutanea tarda. Medical oncology. 2002;19(2):121-3.

141. Remenyik E, Ujj G, Kiss A, Koszo F, Horkay I. Porphyria cutanea tarda and chronic lymphoid leukemia. Photodermatology, photoimmunology & photomedicine. 1996;12(4):180-2.

142. Bertoli LF, Barton JC. Remission of porphyria cutanea tarda after anastrozole treatment of breast cancer. Clinical breast cancer. 2007;7(9):716-8.

143. Yang CS, Robinson-Bostom L, Landow S. Linear IgA bullous dermatosis associated with metastatic renal cell carcinoma. JAAD case reports. 2015;1(2):91-2.

144. Tiger JB, Rush JT, Barton DT, Danilov AV, Chapman MS. Urticarial linear IgA bullous dermatosis (LABD) as a presenting sign of chronic lymphocytic leukemia (CLL). JAAD case reports. 2015;1(6):412-4.

145. Adamic M, Potocnik M, Pavlovic MD. Linear IgA bullous dermatosis in a patient with advanced pancreatic carcinoma. Clinical and experimental dermatology. 2008;33(4):503-5.

146. Lai-Cheong JE, Groves RW, Banerjee P. Linear IgA bullous dermatosis associated with adenocarcinoma of the ascending colon. Journal of the European Academy of Dermatology and Venereology : JEADV. 2007;21(7):978-9.

147. Bakos N, Krasznai G, Begany AA. Erythema Gyratum Repens an Immunological Paraneoplastic Dermatosis. Pathology oncology research : POR. 1997;3(1):59-61.

148. Tchernev G, Chokoeva AA, Vidolova NG, Ivanova B, Mangarov H, Nikolovska D, et al. Erythema gyratum repens: a pathogenetic mystery and therapeutic challenge. Wiener medizinische Wochenschrift. 2017;167(5-6):117-9.

149. Liau MM, Long V, Yang SS. Erythema gyratum repens: a paraneoplastic eruption. BMJ case reports. 2016;2016.

150. Serrao V, Martins A, Ponte P, Baptista J, Apetato M, Feio AB. Erythema gyratum repens as the initial manifestation of lung cancer. European journal of dermatology : EJD. 2008;18(2):197-8.

151. De La Torre-Lugo EM, Sanchez JL. Erythema gyratum repens. Journal of the American Academy of Dermatology. 2011;64(5):e89-90.

152. Eubanks LE, McBurney E, Reed R. Erythema gyratum repens. The American journal of the medical sciences. 2001;321(5):302-5.

153. Campbell L, Freedman JR, O'Donoghue M, Chevalier M, Dy LC, Tharp MD. Erythema gyratum repens without associated malignancy. Journal of the American Academy of Dermatology. 2011;65(1):e22-3.

154. Ekinci AP, Aslan MSE. Paraneoplastik özellik gösteren reaktif dermatozlar/Paraneoplastic importance of reactive dermatoses. Turkderm. 2013;47(2):69.

155. Chodkiewicz HM, Cohen PR. Paraneoplastic erythema annulare centrifugum eruption: PEACE. American journal of clinical dermatology. 2012;13(4):239-46.

156. Ziemer M, Eisendle K, Zelger B. [Erythema annulare centrifugum. A clinical reaction pattern]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 2010;61(11):967-72.

157. Mu EW, Sanchez M, Mir A, Meehan SA, Pomeranz MK. Paraneoplastic erythema annulare centrifugum eruption (PEACE). Dermatology online journal. 2015;21(12).

158. Ravic-Nikolic A, Milicic V, Jovovic-Dagovic B, Ristic G. Gyrate erythema associated with metastatic tumor of gastrointestinal tract. Dermatology online journal. 2006;12(6):11.

159. Panasiti V, Devirgiliis V, Curzio M, Rossi M, Roberti V, Bottoni U, et al. Erythema annulare centrifugum as the presenting sign of breast carcinoma. Journal of the European Academy of Dermatology and Venereology : JEADV. 2009;23(3):318-20.

160. Leventhal JS, Braverman IM. Skin manifestations of endocrine and neuroendocrine tumors. Seminars in oncology. 2016;43(3):335-40.

161. Tierney EP, Badger J. Etiology and pathogenesis of necrolytic migratory erythema: review of the literature. MedGenMed : Medscape general medicine. 2004;6(3):4.

162. Tremblay C, Marcil I. Necrolytic Migratory Erythema: A Forgotten Paraneoplastic Condition. Journal of cutaneous medicine and surgery. 2017;21(6):559-61.

163. Gao Y, Wang C, Gao Y, Chen H, Peng B, Chen W, et al. Glucagonoma syndrome with serous oligocystic adenoma: A rare case report. Medicine. 2017;96(43):e8448.

164. Blackford S, Wright S, Roberts DL. Necrolytic migratory erythema without glucagonoma: the role of dietary essential fatty acids. The British journal of dermatology. 1991;125(5):460-2.

165. Nakashima H, Komine M, Sasaki K, Mitsui H, Fujimoto M, Ihn H, et al. Necrolytic migratory erythema without glucagonoma in a patient with short bowel syndrome. The Journal of dermatology. 2006;33(8):557-62.

166. Alexander EK, Robinson M, Staniec M, Dluhy RG. Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome. Clinical endocrinology. 2002;57(6):827-31.

167. Bewley AP, Ross JS, Bunker CB, Staughton RC. Successful treatment of a patient with octreotide-resistant necrolytic migratory erythema. The British journal of dermatology. 1996;134(6):1101-4.

168. Wollina U. Pyoderma gangrenosum--a review. Orphanet journal of rare diseases. 2007;2:19.

169. Ruocco E, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G. Pyoderma gangrenosum: an updated review. Journal of the European Academy of Dermatology and Venereology : JEADV. 2009;23(9):1008-17.

170. Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. Journal of the American Academy of Dermatology. 1996;34(3):395-409; quiz 10-2.

171. Wollina U. Clinical management of pyoderma gangrenosum. American journal of clinical dermatology. 2002;3(3):149-58.

172. O'Loughlin S, Perry HO. A diffuse pustular eruption associated with ulcerative colitis. Archives of dermatology. 1978;114(7):1061-4.

173. Mlika RB, Riahi I, Fenniche S, Mokni M, Dhaoui MR, Dess N, et al. Pyoderma gangrenosum: a report of 21 cases. International journal of dermatology. 2002;41(2):65-8.

174. Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB, Jr., White WL, Callen JP. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine. 2000;79(1):37-46.

175. Sweet RD. An Acute Febrile Neutrophilic Dermatosis. The British journal of dermatology. 1964;76:349-56.

176. Paydas S. Sweet's syndrome: a revisit for hematologists and oncologists. Critical reviews in oncology/hematology. 2013;86(1):85-95.

177. Cohen PR, Kurzrock R. Sweet's syndrome revisited: a review of disease concepts. International journal of dermatology. 2003;42(10):761-78.

178. Kim MJ, Choe YH. EPONYM. Sweet syndrome. European journal of pediatrics. 2010;169(12):1439-44.

179. Corazza M, Lauriola MM, Borghi A, Marzola A, Virgili A. Sweet's syndrome: a retrospective clinical, histopathological and immunohistochemical analysis of 11 cases. Acta dermato-venereologica. 2008;88(6):601-6.

180. Costa-Silva M, Pedrosa A, Azevedo F, Mota A. Neutrophilic dermatosis of the dorsal hands: a restrictive designation for an acral entity. Acta dermatovenerologica Alpina, Pannonica, et Adriatica. 2016;25(4):85-6.

181. Buck T, Gonzalez LM, Lambert WC, Schwartz RA. Sweet's syndrome with hematologic disorders: a review and reappraisal. International journal of dermatology. 2008;47(8):775-82.

182. Cohen PR, Kurzrock R. Sweet's syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. Clinics in dermatology. 2000;18(3):265-82.

183. Shapiro L, Baraf CS, Richheimer LL. Sweet's syndrome (acute febrile neutrophilic dermatosis). Report of a case. Archives of dermatology. 1971;103(1):81-4.

184. Sfrijan D, Visan SM, Diaconu B, Zurac S, Scurtu C. A Case of Sweet's Syndrome Secondary to Myelodysplastic Syndrome - Diagnostic and Treatment Challenges. Maedica. 2016;11(2):154-7.

185. Diamantino Fda E, Raimundo PM, Fidalgo AI. Sweet's Syndrome and relapsing polychondritis signal myelodysplastic syndrome. Anais brasileiros de dermatologia. 2011;86(4 Suppl 1):S173-7.

186. Han L, Huang Q, Liao KH, Chen LJ, Kong WY, Fu WW, et al. Multicentric reticulohistiocytosis associated with liver carcinoma: report of a case. Case reports in dermatology. 2012;4(2):163-9.

187. Özcan D, Güleç AT. Two diseases with paraneoplastic characteristics: Dermatomyositis and multicentric reticulohistiocytosis. TURKDERM-ARCHIVES OF THE TURKISH DERMATOLOGY AND VENEROLOGY. 2013;47:90-5.

188. Schadt CR. The cutaneous manifestations of gastrointestinal malignancy. Seminars in oncology. 2016;43(3):341-6.

189. Selmi C, Greenspan A, Huntley A, Gershwin ME. Multicentric reticulohistiocytosis: a critical review. Current rheumatology reports. 2015;17(6):511.

190. Pacheco-Tena C, Reyes-Cordero G, Ochoa-Albiztegui R, Rios-Barrera V, Gonzalez-Chavez SA. Treatment of multicentric reticulohistiocytosis with tocilizumab. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2013;19(5):272-6.

191. Yeter KC, Arkfeld DG. Treatment of multicentric reticulohistiocytosis with adalimumab, minocycline, methotrexate. International journal of rheumatic diseases. 2013;16(1):105-6.

192. El-Haddad B, Hammoud D, Shaver T, Shahouri S. Malignancy-associated multicentric reticulohistiocytosis. Rheumatology international. 2011;31(9):1235-8.

193. Luz FB, Gaspar TAP, Kalil-Gaspar N, Ramos-e-Silva M. Multicentric reticulohistiocytosis. Journal of the European Academy of Dermatology and Venereology : JEADV. 2001;15(6):524-31.

194. Lesher JL, Jr., Allen BS. Multicentric reticulohistiocytosis. Journal of the American Academy of Dermatology. 1984;11(4 Pt 2):713-23.

195. Hu L, Mei JH, Xia J, Hao QS, Cheng LP, Wu YH. Erythema, papules, and arthralgia associated with liver cancer: report of a rare case of multicentric reticulohistiocytosis. International journal of clinical and experimental pathology. 2015;8(3):3304-7.

196. Kossard S, Winkelmann RK. Necrobiotic xanthogranuloma with paraproteinemia. Journal of the American Academy of Dermatology. 1980;3(3):257-70.

197. Bhari N, Chiramel MJ, Vedi KK, Nath D, Sandip S, Kumar R, et al. Necrobiotic xanthogranuloma with multiple myeloma. Clinical and experimental dermatology. 2015;40(7):811-4.

198. Spicknall KE, Mehregan DA. Necrobiotic xanthogranuloma. International journal of dermatology. 2009;48(1):1-10.

199. Oumeish OY, Oumeish I, Tarawneh M, Salman T, Sharaiha A. Necrobiotic xanthogranuloma associated with paraproteinemia and non-Hodgkin's lymphoma developing into chronic lymphocytic leukemia: the first case reported in the literature and review of the literature. International journal of dermatology. 2006;45(3):306-10.

200. Wood AJ, Wagner MV, Abbott JJ, Gibson LE. Necrobiotic xanthogranuloma: a review of 17 cases with emphasis on clinical and pathologic correlation. Archives of dermatology. 2009;145(3):279-84.

201. Aydıngöz İE, Akkaya AD. Paraneoplastik özellik gösteren metabolik hastalıklar.

202. Balagula Y, Straus DJ, Pulitzer MP, Lacouture ME. Necrobiotic xanthogranuloma associated with immunoglobulin m paraproteinemia in a patient with Waldenstrom macroglobulinemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(11):e305-7.

203. Hallermann C, Tittelbach J, Norgauer J, Ziemer M. Successful treatment of necrobiotic xanthogranuloma with intravenous immunoglobulin. Archives of dermatology. 2010;146(9):957-60.

204. Alegria-Landa V, Cerroni L, Kutzner H, Requena L. Paraprotein deposits in the skin. Journal of the American Academy of Dermatology. 2017;77(6):1145-58.

205. Schreml S, Szeimies RM, Vogt T, Landthaler M, Schroeder J, Babilas P. Cutaneous amyloidoses and systemic amyloidoses with cutaneous involvement. European journal of dermatology : EJD. 2010;20(2):152-60.

206. Oliveira EV, Pozetti AC, Pozetti EM, Antonio JR, Michalany NS. Primary systemic amyloidosis associated with multiple myeloma. Anais brasileiros de dermatologia. 2012;87(1):119-22.

207. Agarwal A, Chang DS, Selim MA, Penrose CT, Chudgar SM, Cardones AR. Pinch Purpura: A Cutaneous Manifestation of Systemic Amyloidosis. The American journal of medicine. 2015;128(9):e3-4.

208. Fernandez-Flores A, Castanon-Gonzalez JA, Guerrero-Ramos B, Castro-Gaytan A, Saeb-Lima M. Systemic amyloidosis presenting with glans penis involvement. Journal of cutaneous pathology. 2014;41(10):791-6.

209. Gontijo JRV, Pinto JM, Paula MC. Case for diagnosis. Systemic light chain amyloidosis with cutaneous involvement. Anais brasileiros de dermatologia. 2017;92(5):731-2.

210. Kourelis TV, Gertz M, Zent C, Lacy M, Kyle R, Kapoor P, et al. Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. American journal of hematology. 2013;88(5):375-8.

211. Lavorato FG, Alves Mde F, Maceira JM, Unterstell N, Serpa LA, Azulay-Abulafia L. Primary systemic amyloidosis, acquired cutis laxa and cutaneous mucinosis in a patient with multiple myeloma. Anais brasileiros de dermatologia. 2013;88(6 Suppl 1):32-5.

212. Bhutani M, Shahid Z, Schnebelen A, Alapat D, Usmani SZ, editors. Cutaneous manifestations of multiple myeloma and other plasma cell proliferative disorders. Seminars in oncology; 2016: Elsevier.

213. Oh SJ, Oh SH, Jun JY, Park JH, Lee JH, Lee DY, et al. Paraneoplastic atypical scleromyxedema with advanced gastric cancer. JAAD case reports. 2017;3(5):376-8.

214. Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. Journal of the American Academy of Dermatology. 2001;44(2):273-81.

215. Kitamura W, Matsuoka Y, Miyagawa S, Sakamoto K. Immunochemical analysis of the monoclonal paraprotein in scleromyxedema. The Journal of investigative dermatology. 1978;70(6):305-8.

216. Chan JC, Trendell-Smith NJ, Yeung CK. Scleromyxedema: a cutaneous paraneoplastic syndrome associated with thymic carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(3):e27-9.

217. Sroa N, Campbell S, Bechtel M. Intravenous immunoglobulin therapy for scleromyxedema: a case report and review of literature. Journal of drugs in dermatology : JDD. 2010;9(3):263-5.

218. Fett NM, Toporcer MB, Dalmau J, Shinohara MM, Vogl DT. Scleromyxedema and dermato-neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib. American journal of hematology. 2011;86(10):893-6.

219. Lacy MQ, Hogan WJ, Gertz MA, Dispenzieri A, Rajkumar SV, Hayman S, et al. Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. Archives of dermatology. 2005;141(10):1277-82.

220. Acikgoz G, Ozmen I, Huseynov S, Gamsizkan M, Caliskan E, Arca E, et al. A case of atypical scleromyxedema without gammopathy treated with cyclosporine. Indian journal of dermatology, venereology and leprology. 2014;80(3):278.

221. Dalcin D, Manser C, Mahler R. Malignant Down: Hypertrichosis Lanuginosa Acquisita Associated With Endometrial Adenocarcinoma. Journal of cutaneous medicine and surgery. 2015;19(5):507-10.

222. Worsnop F, Campalani E. Paraneoplastic hypertrichosis lanuginosa acquisita: a delayed presentation in quiescent chronic lymphocytic leukaemia. Clinical and experimental dermatology. 2014;39(5):669-70.

223. Wendelin DS, Pope DN, Mallory SB. Hypertrichosis. Journal of the American Academy of Dermatology. 2003;48(2):161-79; quiz 80-1.

224. Wyatt JP, Anderson HF, Greer KE, Cordoro KM. Acquired hypertrichosis lanuginosa as a presenting sign of metastatic prostate cancer with rapid resolution after treatment. Journal of the American Academy of Dermatology. 2007;56(2 Suppl):S45-7.

225. Frank JA, Rojek N, Foreman RS. A case of hypertrichosis lanuginosa acquisita as a sign of malignancy. European journal of dermatology : EJD. 2017;27(1):66-7.

226. Perez-Losada E, Pujol RM, Domingo P, Matias-Guiu X, Lenti J, Lopez-Pousa A, et al. Hypertrichosis lanuginosa acquisita preceding extraskeletal Ewing's sarcoma. Clinical and experimental dermatology. 2001;26(2):182-3.

227. Nguyen KD, Osehobo E, Alleyne CH, Jr. Hypertrichosis lanuginosa acquisita associated with intracranial melanoma: case illustration. Journal of neurosurgery. 2017:1-2.

228. Levine D, Miller S, Al-Dawsari N, Barak O, Gottlieb AB. Paraneoplastic dermatoses associated with gynecologic and breast malignancies. Obstetrical & gynecological survey. 2010;65(7):455-61.

**Sitoloji**

1. Spriggs AI. History of cytodiagnosis. J Clin Pathol 1977; 30 (12): 1091-1102.

2. Hunter JAA, Holubar K. The man behind the eponym. Arnault Tzanck, his work and times. Am J Dermatopathol 1985; 7 (2): 121-123.

3. Ruocco E, Brunetti G, Del Vecchio M, Ruocco V. The practical use of cytology for diagnosis in dermatology. J Eur Acad Dermatol Venereol 2011; 25 (2): 125-129.

4. Durdu M, Baba M, Seçkin D. The value of Tzanck smear test in diagnosis of erosive, vesicular, bullous, and pustular skin lesions. J Am Acad Dermatol 2008; 59 (6): 958-964.

5. Durdu M, Ilkit M. First step in the differential diagnosis of folliculitis: cytology. Crit Rev Microbiol 2013; 39 (1): 9-25.

6. Durdu M, Ruocco V. Clinical and cytologic features of antibiotic-resistant acute paronychia. J Am Acad Dermatol 2014; 70 (1): 120-126.

7. Durdu M, Baba M, Seçkin D. More experiences with the Tzanck smear test: cytologic findings in cutaneous granulomatous disorders. J Am Acad Dermatol 2009; 61 (3): 441-450.

8. Eryılmaz A, Durdu M, Baba M, Yıldırım FE. Diagnostic reliability of the Tzanck smear in dermatologic diseases. Int J Dermatol 2014; 53 (2): 178-186.

9. Durdu M, Seçkin D, Baba M. The Tzanck smear test: rediscovery of a practical diagnostic tool. Skinmed 2011; 9 (2): 23-32.

10. Durdu M, Baba M, Seçkin D. Dermatoscopy versus Tzanck smear test: a comparison of the value of two tests in the diagnosis of pigmented skin lesions. J Am Acad Dermatol 2011; 65 (5): 972-982.

11. Durdu M. Tzanck yaymada basamaklı tanı yaklaşımı. Ankara: Türkiye Klinikleri Matbaası; 2017.

12. Daskalopoulou D, Galanopoulou A, Statiropoulou P, Papapetrou S, Pandazis I, Markidou S. Cytologically interesting cases of primary skin tumors and tumor-like conditions identified by fine-needle aspiration biopsy. Diagn Cytopathol 1998; 19 (1): 17-28.

13. Vega-Memije E, Loris NM, Maxtein LM, Dominguez L. Cytodiagnosis of cutaneous basal and squamous cell carcinoma. Int J Dermatol 2000; 39: 116-120.

14. Baba M, Durdu M, Seçkin D. A useful alternative approach for the treatment of well-demarcated Basal cell carcinoma: surgical excision and margin control with Tzanck smear test. Dermatol Surg 2010; 36 (5): 659-664.

15. Knoepp SM, Hookim K, Placido J, Fields KL, Roh MH. The application of immunocytochemistry to cytologic direct smears of metastatic merkel cell carcinoma. Diagn Cytopathol 2013; 41 (8): 729-733.

16. Rojo BG, Solano JG, Sanchez CS, Romero SM, Ortega VV, Guillermo MP. On the limited value of fine-needle aspiration for the diagnosis of benign melanocytic proliferations of the skin. Diagn Cytopathol 1998; 19 (6): 441-445.

17. Fassina A, Olivotto A, Cappellesso R, Vendraminelli R, Fassan M. Fine-needle cytology of cutaneous juvenile xanthogranuloma and langerhans cell histiocytosis. Cancer Cytopathol 2011; 119 (2): 134-140.

18. Harman M, Akdeniz S, Balci G, Uzunlar AK. A brownish-red plaque in an adult. Indian J Dermatol Venereol Leprol 2009; 75 (1): 101.

**Dermoskopi**

1. Braun RP, Rabinovitz HS, Krischer J, ve ark. Dermoscopy of pigmented seborrheic keratosis: A morphological study. Arch Dermatol 2002;138:1556-60.
2. Zaballos P, Ara M, Puig S, Malvehy J. Dermoscopy of sebaceous hyperplasia. Arch Dermatol 2005;141:808.
3. Zelger B, Zelger BG, Burgdorf WH. Dermatofibroma: A critical evaluation. Int J Surg Pathol 2004;12:333-44.
4. Zaballos P, Puig S, Llambrich A, Malvehy J. Dermoscopy of dermatofibromas: A prospective morphological study of 412 cases. Arch Dermatol 2008;144:75-83
5. Zaballos P, Daufi C, Puig D, ve ark. Dermoscopy of solitary angiokeratoma. Arch Dermatol 2007;143:318-25.
6. Zaballos P, Llambrich A, Cuellar F, Puig S, Malvehy J. Dermoscopic findings in pyogenic granuloma. Br J Dermatol 2006;154:1108-11.
7. Cheng ST, Ke CL, Lee CH, Wu CS, Chen GS, Hu SC. Rainbow pattern in Kaposi's sarcoma under polarized dermoscopy: A dermoscopic pathological study. Br J Dermatol 2009;160:801-9.
8. Argenziano G, Longo C, Cameron A, ve ark. Blue-black rule:a simple dermoscopic clue to recognize pigmented nodular melanoma. Br J Dermatol 2011;165:1251-55.
9. Russu T, Piccolo V, Lallas A, ve ark. Dermoscopy of malignant skin tumors: what’s new? Dermatology 2017;233:64-73.
10. Lallas A, Tzellos T, Kyrgidis A, ve ark. Accuracy of dermoscopic criteria for discriminating superficial from other subtypes of basal cell carcinoma. J Am Acad Dermatol 2014;70:303-11.
11. Zalaudek I, Kreusch J, Giacomel J, Ferraro G, Catricala C, Argenziona G. How to diagnose nonpigmented skin tumors. A review of vascular structures seen with dermoscopy:part II. Nonmelonocytic skin tumors. J Am Acad Dermatol 2010;63:377-86.
12. Stolz W, Schiffner R, Burgdorf WH. Dermoscopy for facial pigmented lesions. Clin Dermatol 2002;20:276-78.
13. Dalle S, Parmentier L, Moscarella E, Phan A, Argenziano G, Thomas L. Dermoscopy of merkel cell carcinoma. 2012;224:140-44.
14. Donghi D, Kerl K, Dummer R, Schoenewolf N, Cozzio A. Cutaneous angiosarkoma own experience over 13 years. Clinical features, disease course, and immunohistochemical profiles. J Eur Acad Dermatol Venereol 2010;24:1230-34.
15. Oiso N, Matsuda H, Kawada A. Various color gradations as a dermoscopic feature of cutaneous angiosarcoma of the scalp. Australas J Dermatol 2013;54:36-8.
16. Bernard J, Poulalhan N, Argenziano G, Debarbieux S, Dalle S, Thomas L.Dermoscopy of dermatofibromasarcoma protuberans:a study of 15 cases. Br J Dermatol 2013;169:85-90.

***Ultrasonografi***

1. Kleinarman R, Whang TB, Bard RL, Marmur ES. Ultrasound in dermatology: principles and applications. J Am Acad Dermatol 2012; 67: 478-87.

2. MacFarlane D, Shah K, Wysong A, Wortsman X, Humphreys TR.The role of imaging in the management of patients with nonmelanoma skin cancer: Diagnostic modalities and applications. J Am Acad Dermatol 2017; 76: 579-588.

3. Dudea SM, Lenghel M, Botar-Jid C, Vasilescu D, Duma M. Ultrasonography of superficial lymph nodes: benign vs. malignant. Med Ultrason 2012; 14: 294-306.

4. de Bondt RB, Nelemans PJ, Hofman PA ve ark. Detection of lymph node metastases in head and neck cancer: a meta-analysis comparing US, USgFNAC, CT and MR imaging. Eur J Radiol 2007; 64: 266-72.

5. Uren RF, Howman-Giles R, Thompson JF ve ark. High-resolution ultrasound to diagnose melanoma metastases in patients with clinically palpable lymph nodes. Australas Radiol 1999; 43: 148-52.

6. Marone U, Catalano O, Caracò C ve ark. Can high-resolution ultrasound avoid the sentinel lymph-node biopsy procedure in the staging process of patients with stage I-II cutaneous melanoma? Ultraschall Med 2012; 33: 179-85.

7. Uhara H, Hayashi K, Koga H, Saida T. Multiple hypersonographic spots in basal cell carcinoma. Dermatol Surg 2007; 33: 1215-9.

8. Harland CC, Kale SG, Jackson P, Mortimer PS, Bamber JC. Differentiation of common benign pigmented skin lesions from melanoma by high-resolution ultrasound. Br J Dermatol 2000; 143: 281-9.

9. Jambusaria-Pahlajani A, Schmults CD, Miller CJ ve ark. Test characteristics of high-resolution ultrasound in the preoperative assessment of margins of basal cell and squamous cell carcinoma in patients undergoing Mohs micrographic surgery. Dermatol Surg 2009; 35: 9-15.

10. Gupta AK, Turnbull DH, Foster FS, Harasiewicz KA, Shum DT, Prussick R, Watteel GN, Hurst LN, Sauder DN.High frequency 40-MHz ultrasound. A possible noninvasive method for the assessment of the boundary of basal cell carcinomas. Dermatol Surg. 1996 Feb;22(2):131-6.

11. Lassau N, Spatz A, Avril MF ve ark. Value of high-frequency US for preoperative assessment of skin tumors. Radiographics 1997; 17: 1559-65.

12. Desai TD, Desai AD, Horowitz DC, Kartono F, Wahl T. The use of high-frequency ultrasound in the evaluation of superficial and nodular basal cell carcinomas. Dermatol Surg 2007; 33: 1220-7.

13. Bobadilla F, Wortsman X, Muñoz C, Segovia L, Espinoza M, Jemec GB. Pre-surgical high resolution ultrasound of facial basal cell carcinoma: correlation with histology. Cancer Imaging 2008; 8: 163-72.

14. Schmid-Wendtner MH, Burgdorf W. Ultrasound scanning in dermatology. Arch Dermatol 2005; 141: 217-24.

15. Quintana-Codina M, Creus-Vila L, Iglesias-Plaza A ve ark. Sonographic appearance of subungual squamous cell carcinoma in the hand. J Clin Ultrasound 2017; 26.

16. Goyal U, Pan J, Cui H, Stea B .Does ultrasound measurement improve the accuracy of electronic brachytherapy in the treatment of superficial non-melanomatous skin cancer? J Contemp Brachytherapy 2017; 9: 14-19.

17. Alfageme Roldán F. Ultrasound skin imaging. Actas Dermosifiliogr 2014: 105: 891-9.

18. Fu T, Aasi SZ, Hollmig ST. Management of high-risk squamous cell carcinoma of the skin. Current Treatment Options in Oncology 2016; 17: 34.

19. Marmur ES, Berkowitz EZ, Fuchs BS, Singer GK, Yoo JY. Use of high-frequency, high-resolution ultrasound before Mohs surgery. Dermatol Surg 2010; 36: 841-7.

20. Serrone L, Solivetti FM, Thorel MF, Eibenschutz L, Donati P, Catricalà C. High frequency ultrasound in the preoperative staging of primary melanoma: a statistical analysis. Melanoma Res 2002; 12: 287-90.

21. Fernández Canedo I, de Troya Martín M, Fúnez Liébana R ve ark. Preoperative

15-MHz ultrasound assesment of tumor thickness in malignant melanoma. Actas Dermasifiliogr 2013; 104: 227-31.

22. Hayashi K, Koga H, Uhara H, Saida T. High-frequency 30-MHz sonography in preoperative assessment of tumor thickness of primary melanoma: usefulness in determination of surgical margin and indication for sentinel lymph node biopsy. Int J Clin Oncol 2009; 14: 426-30.

23. Machet L, Belot V, Naouri M ve ark. Preoperative measurement of thickness of cutaneous melanoma using high-resolution 20 MHz ultrasound imaging: A monocenter prospective study and systematic review of the literature. Ultrasound Med Biol 2009; 35: 1411-20.

24. Music MM, Hertl K, Kadivec M, Pavlović MD, Hocevar M. Pre-operative ultrasound with a 12-15 MHz linear probe reliably differentiates between melanomathicker and thinner than 1 mm. J Eur Acad Dermatol Venereol 2010; 24: 1105-8.

25. Hoffmann K. Jung J. el Gammal S. Altmeyer P. Malignant Melanoma in 20-MHz B Scan Sonography. Dermatology 1992; 185: 49-55.

26. Lassau N, Lamuraglia M, Koscielny S ve ark. Prognostic value of angiogenesis evaluated with high-frequency and colour Doppler sonography for preoperative assessment of primary cutaneous melanomas: correlation with recurrence after a 5 year follow-up period. Cancer Imaging 2006; 6: 24-9.

27. Srivastava A, Woodcock JP, Mansel RE ve ark. Doppler ultrasound flowmetry predicts 15 year outcome in patients with skin melanoma. Indian J Surg 2012; 74: 278-83.

28. Barcaui Ede O, Carvalho AC, Lopes FP, Pineiro-Maceira J, Barcaui CB.High frequency ultrasound with color Doppler in dermatology. An Bras Dermatol 2016; 91: 262-73.

29. Alfageme Roldan F. Elastography in Dermatology. Actas Dermosifiliogr 2016 ; 107: 652-60.

**Konfokal mikroskopi**

1. Mayer J. Systematic review of the diagnostic accuracy of dermatoscopy in detecting malignant melanoma. Med J Aust. 1997;167(4):206-10.

2. Argenziano G, Soyer HP, Chimenti S, Talamini R, Corona R, Sera F, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. Journal of the American Academy of Dermatology 2003; 48(5):679–93.

3. Mogensen M, Jemec GB. Diagnosis of nonmelanoma skin cancer/keratinocyte carcinoma: a review of diagnostic accuracy of nonmelanoma skin cancer diagnostic tests and technologies. Dermatol Surg. 2007; 33(10):1158-74.

4. Horn M, Gerger A, Koller S, Weger W, Langsenlehner U, Krippl P, Kerl H, Samonigg H, Smolle J. The use of confocal laser-scanning microscopy in microsurgery for invasive squamous cell carcinoma. Br J Dermatol. 2007; 156(1):81-4.

5. Alarcon I, Carrera C, Palou J et al. Impact of in vivo reflectance confocal microscopy on the number needed to treat melanoma in doubtful lesions. Br J Dermatol. 2014; 170: 802–8.

6. Minsky M. Memoir on inventing the confocal scanning microscope. Scanning 10: 1988: 128-138.

7. Rajadhyaksha M, Grossman M, Esterowitz D, Webb RH, Anderson RR. In vivo confocal scanning laser microscopy of human skin: melanin provides strong contrast. J Invest Dermatol . 1995;104(6):946e52.

8. González S, Swindells K, Rajadhyaksha M, Torres A. Changing paradigms in dermatology: confocal microscopy in clinical and sur- gical dermatology. Clin Dermatol. 2003;21(5): 359-69.

9. Busam KJ, Charles C, Lee G, Halpern AC. Morphologic features of melanocytes, pigmented keratinocytes, and melanophages by in vivo confocal scanning laser microscopy. Mod Pathol. 2001; 14(9):862e8.

10. Rajadhyaksha M, Marghoob A, Rossi A, Halpern AC, Nehal KS. Reflectance confocal microscopy of skin in vivo: from bench to bedside. Lasers in Surgery and Medicine. 2017; 49:7-19.

11. Rajadhyaksha M, González S, Zavislan JM, Anderson RR, Webb RH. In vivo confocal scanning laser microscopy of human skin II: advances in instrumentation and comparison with histology. J Invest Dermatol. 1999 ;113(3):293-303.

12. Huzaira M, Rius F, Rajadhyaksha M, Anderson RR, González S. Topographic variations in normal skin, as viewed by in vivo reflectance confocal microscopy. J Invest Dermatol. 2001 ;116(6):846-52.

13. Calzavara-Pinton P, Longo C, Venturini M, Sala R, Pellacani G. Reflectance confocal microscopy for in vivo skin imaging. Photochem Photobiol. 2008; 84(6):1421-30.

14. Hofmann-Wellenhof R, Wurm EM, Ahlgrimm-Siess V, et al: Reflectance confocal microscopy--state-of-art and research overview. Semin Cutan Med Surg. 2009; 28:172-79.

15. Gonzales S, Gill M, Halpern AC. Normal Skin. Reflectance Confocal Microscopy of cutaneous tumors : an atlas with clinical, dermoscopic, and histological correlations;2008.

16. Clark WH Jr, Elder DE, Van Horn M . The biologic forms of malignant melanoma. Hum Pathol. 1986; 17(5): 443-50.

17. Hofmann-Wellenhof, R., Pellacani, G., Malvehy, J., Soyer, H.P. Reflectance Confocal Microscopy for Skin Diseases;2012.

18. Pellacani G, Cesinaro AM, Seidenari S. Reflectance-mode confocal microscopy for the in vivo characterization of pagetoid melanocytosis in melanomas and nevi. J Invest Dermatol. 2005 ;125(3):532-7.

19. Longo C, Pellacani G. Melanomas. Dermatol Clin. 2016; 34(4): 411-419.

20. Segura S, Pellacani G, Puig S, Longo C, Bassoli S, Guitera P,et al. In vivo microscopic features of nodular melanomas:dermoscopy, confocal microscopy, and histopathologic correlates. Arch Dermatol.2008 ;144(10): 1311-20.

21. Gamo R, Pampín A, Floristán U. Reflectance Confocal Microscopy in Lentigo Maligna. Actas Dermosifiliogr. 2016; 107(10): 830-835.

22. Losi A, Longo C, Cesinaro AM, Benati E, Witkowski A, Guitera P, Pellacani G.Hyporeflective pagetoid cells: a new clue for amelanotic melanoma diagnosis byreflectance confocal microscopy. Br J Dermatol. 2014; 171(1): 48-54.

23. Maier T, Sattler EC, Braun-Falco M, Korting HC, Ruzicka T, Berking C.Reflectance confocal microscopy in the diagnosis of partially and completely amelanotic melanoma: report on seven cases. J Eur Acad Dermatol Venereol. 2013; 27(1):42-52.

24. Pellacani G, De Pace B, Reggiani C, Cesinaro AM, Argenziano G, Zalaudek I,Soyer HP, Longo C. Distinct melanoma types based on reflectance confocal microscopy. Exp Dermatol. 2014; 23(6):414-8.

25. Curchin C, Wurm E, Jagirdar K, Sturm R, Soyer P. Dermoscopy, reflectance confocal microscopy and histopathology of an amelanotic melanoma from an individual heterozygous for MC1R and tyrosinase variant alleles. Australas J Dermatol. 2012; 53(4): 291-4.

26. Chen CS, Elias M, Busam K, Rajadhyaksha M, Marghoob AA. Multimodal in vivo optical imaging, including confocal microscopy, facilitates presurgical margin mapping for clinically complex lentigo maligna melanoma. Br J Dermatol. 2005;153(5):1031-6.

27. Guitera P, Haydu LE, Menzies SW, et al. Surveillance for treatment failure of lentigo maligna with dermoscopy and in vivo confocal microscopy: new descriptors.Br J Dermatol. 2014; 170(6):1305–12.

28. Alarcon I, Carrera C, Alos L, et al. In vivo reflectance confocal microscopy to monitor the response of lentigo maligna to imiquimod. J Am Acad Dermatol 2014;71(1):49–55.

29. Nori S, Rius-Díaz F, Cuevas J et al. Sensitivity and specificity of reflectance-mode confocal microscopy for in vivo diagnosis of basal cell carcinoma: A multicenter study. J Am Acad Dermatol. 2004; 51(6): 923–930.

30. Segura S, Puig S, Carrera C, Palou J, Malvehy J. Dendritic cells in pigmented basal cell carcinoma: a relevant finding by reflectance-mode confocal microscopy. Arch Dermatol. 2007; 143(7): 883-6.

31. Longo C, Lallas A, Kyrgidis A, Rabinovitz H, Moscarella E, Ciardo S,et al. Classifying distinct basal cell carcinoma subtype by means of dermatoscopy and reflectance confocal microscopy. J Am Acad Dermatol. 2014; 71(4):716-724.

32. Chuah SY, Tee SI, Tan WP, Lee SSJ, Ng SK, Chua SH, Thng TGS. Reflectance confocal microscopy is a useful non-invasive tool in the in vivo diagnosis of pigmented basal cell carcinoma in Asians. Australas J Dermatol. 2017; 58(2):130-134.

33. Peppelman M, Wolberink EA, Blokx WA, van de Kerkhof PC, van Erp PE, Gerritsen MJ. In vivo diagnosis of basal cell carcinoma subtype by reflectance confocal microscopy. Dermatology. 2013; 227(3):255-62.

34. Incel P, Gurel MS, Erdemir AV. Vascular patterns of non- pigmented tumoral skin lesions: Confocal perspectives. Skin Res Technol. 2015; 21(3): 333–339.

35. Ahlgrimm-Siess V, Cao T, Oliviero M, Hofmann-Wellenhof R, Rabinovitz HS, Scope A. The vasculature of nonmela- nocytic skin tumors in reflectance confocal microscopy: Vascular features of basal cell carcinoma. Arch Dermatol. 2010; 146(3): 353–354.

36. Goldgeier M, Fox CA, Zavislan JM, Harris D, Gonzalez S. Noninvasive imaging, treatment, and microscopic confirmation of clearance of basal cell carcinoma. Dermatol Surg. 2003; 29(3): 205-10.

37. Longo C, Casari A, Pepe P, et al. Confocal microscopy insights into the treatment and cellular immune response of Basal cell carcinoma to photodynamic therapy. Dermatology 2012; 225(3): 264–70.

38. Ahlgrimm-Siess V, Horn M, Koller S, et al. Monitoring efficacy of cryotherapy for superficial basal cell carcinomaswith in vivo reflectance confocal microscopy:a preliminary study. J Dermatol Sci. 2009; 53(1): 60–4.

39. Yuksel EI, Gurel MS, Erdemir AT, Aksu AE, Bagci IS, Leblebici C. The reflectance confocal microscopy in diagnosis of recurrent basal cell carcinoma. J Dermatolog Treat. 2016; 27(2): 182-90.

40. Venturini M, Gualdi G, Zanca A, Lorenzi L, Pellacani G, Calzavara-Pinton PG. A new approach for presurgical margin assessment by reflectance confocal microscopy of basal cell carcinoma. Br J Dermatol. 2016; 174(2): 380-5.

41. Aghassi D, Anderson RR, González S. Confocal laser microscopic imaging of actinic keratoses in vivo: a preliminary report. J Am Acad Dermatol. 2000 ; 43(1): 42-8.

42. Ishioka P, Maia M, Rodrigues SB, FacchiniLellis R, Hirata SH. In vivo Confocal Laser Microscopy for monitoring of actinic keratosis treatment: a comparison with histopathologic assessment after treatment with topical 5% 5-fluorouracil. J Eur Acad Dermatol Venereol. 2017; 24. [Epub ahead of print]

43. Seyed Jafari SM, Timchik T, Hunger RE. In vivo confocal microscopy efficacy assessment of daylight photodynamic therapy in actinic keratosis patients. Br J Dermatol. 2016; 175(2): 375-81.

44. Malvehy J, Roldán-Marín R, Iglesias-García P, Díaz A, Puig S. Monitoring treatment of field cancerisation with 3% diclofenac sodium 2.5% hyaluronic acid by reflectance confocal microscopy: a histologic correlation. Acta Derm Venereol.2015; 95(1): 45-50.

45. Ulrich M, Kanitakis J, González S, Lange-Asschenfeldt S, Stockfleth E,Roewert-Huber J. Evaluation of Bowen disease by in vivo reflectance confocal microscopy. Br J Dermatol. 2012 ; 166(2): 451-3.

46. Manfredini M, Longo C, Ferrari B, Piana S, Benati E, Casari A, Pellacani G,Moscarella E. Dermoscopic and reflectance confocal microscopy features ofcutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol. 2017; 31(11): 1828-1833.

47. Rishpon A, Kim N, Scope A, Porges L, Oliviero MC, Braun RP, Marghoob AA, Fox CA, Rabinovitz HS. Reflectance confocal microscopy criteria for squamous cell carcinomas and actinic keratoses. Arch Dermatol. 2009; 145(7): 766-72.

48. Bağcı IS, Gürel MS, Aksu AEK, Erdemir AT, Yüksel Eİ, Başaran YK. Reflectance confocal microscopic evaluation of nonmelanocytic lip lesions. Lasers Med Sci. 2017; 32(7):1497-1506.

**Optik koherens tomografi**

1. Gambichler T, Moussa G, Sand M, Sand D, Altmeyer P, Hoffmann K. Applications of optical coherence tomography in dermatology. J Dermatol Sci. 2005;40(2):85-94.

2. Levine A, Wang K, Markowitz O. Optical Coherence Tomography in the Diagnosis of Skin Cancer. Dermatol Clin. 2017;35(4):465-488.

3. Boone MA, Norrenberg S, Jemec GB, Del Marmol V. Imaging of basal cell carcinoma by high-definition optical coherence tomography: histomorphological correlation. A pilot study. Br J Dermatol. 2012;167(4):856-64.

4. Boone MA, Marneffe A, Suppa M, et al. High-definition optical coherence tomography algorithm for the discrimination of actinic keratosis from normal skin and from squamous cell carcinoma. J Eur Acad Dermatol Venereol 2015;29(8):1606-15.

5. Boone MA, Norrenberg S, Jemec GB, Del Marmol V. Imaging actinic keratosis by high-definition optical coherence tomography. Histomorphologic correlation: a pilot study. Exp Dermatol. 2013;22(2):93-7.

6. Malvehy J, Alarcon I, Montoya J, Rodríguez- Azeredo R, Puig S. Treatment monitoring of 0,5% 5-fluorouracil and 10% salicylic acid in clinical and subclinical actinic keratoses with the combination of optical coherence tomography and reflectance confocal microscopy. J Eur Acad Dermatol Venereol 2016;30(2):258-65.

7. Pandey S, Mercer SE, Dallas K, Emanuel PO, Goldenberg G. Evaluation of the prognostic significance of follicular extension in actinic keratoses. J Clin Aesthet Dermatol. 2012;5: 25–28.

8. Marneffe A, Suppa M, Miyamoto M, Del Marmol V, Boone M. Validation of a diagnostic algorithm for the discrimination of actinic keratosis from normal skin and squamous cell carcinoma by means of high-definition optical coherence tomography. Exp Dermatol. 2016;25(9):684-7.

9. Gambichler T, Plura I, Kampilafkos P, et al. Histopathological correlates of basal cell carcinoma in the slice and en face imaging modes of high-definition optical coherence tomography. Br J Dermatol. 2014;170(6):1358-61.

10. Maier T, Braun-Falco M, Hinz T, Schmid-Wendtner MH, Ruzicka T, Berking C. Morphology of basal cell carcinoma in high definition optical coherence tomography: en-face and slice imaging mode, and comparison with histology. J Eur Acad Dermatol Venereol. 2013;27(1): e97-104.

11. Boone M, Suppa M, Miyamoto M, Marneffe A, Jemec G, Del Marmol V. In vivo assessment of optical properties of basal cell carcinoma and differentiation of BCC subtypes by high- definition optical coherence tomography. Biomed Opt Express 2016;7(6):2269-84.

12. Olmedo JM, Warschaw KE, Schmitt JM, Swanson DL. Correlation of thickness of basal cell carcinoma by optical coherence tomography in vivo and routine histologic findings: a pilot study. Dermatol Surg. 2007 Apr;33(4):421-5.

13. Boone MA, Suppa M, Pellacani G, et al. High-definition optical coherence tomography algorithm for discrimination of basal cell carcinoma from clinical BCC imitators and differentiation between common subtypes. J Eur Acad Dermatol Venereol 2015; 29(9):1771-80.

14. Ulrich M, Maier T, Kurzen H, et al. The sensitivity and specificity of optical coherence tomography for the assisted diagnosis of non-pigmented basal cell carcinoma: an observational study. Br J Dermatol 2015;173(2):428-35.

15. Alawi SA, Kuck M, Wahrlich C, et al. Optical coherence tomography for presurgical margin assessment of non-melanoma skin cancer–a practical approach. Exp Dermatol 2013;22:547–51.

16. Wang KX, Meekings A, Fluhr JW et al. Optical coherence tomography-based optimization of Mohs micrographic surgery of basal cellcarcinoma: a pilot study. Dermatol Surg 2013;39:627–33.

17. L Themstrup, GBE Jemec. Optical Coherence Tomography for Skin Cancer and Actinic Keratosis In: Hamblin MR, Avcı P, Gupta GK editors. Imaging in Dermatology. London: Elsevier, 2016; p. 59–67.

18. Sattler E, Kästle R, Welzel J. Optical coherence tomography in dermatology. J Biomed Opt. 2013;18(6):061224.

19. Boone MA, Norrenberg S, Jemec GB, Del Marmol V. High- definition optical coherence tomography imaging of melanocytic lesions: a pilot study. Arch Dermatol Res 2014;306(1):11-26.

20. Picard A, Tsilika K, Long-Mira E, et al. Use of high-definition optical coherent tomography (HD-OCT) for imaging of melanoma. Br J Dermatol 2013;169(4):950-2.

21. Gambichler T, Schmid-Wendtner MH, Plura I, et al. A multicentre pilot study investigating high-definition optical coherence tomography in the differentiation of cutaneous melanoma and melanocytic naevi. J Eur Acad Dermatol Venereol 2015;29(3): 537-41.

**Multifoton lazer mikroskopi**

1. Denk W, Strickler JH, Webb WW. Two-photon laser scanning fluorescence microscopy. Science 1990;248:73-6.

2. Lin SJ, Jee SH, Dong CY. Multiphoton microscopy: a new paradigm in dermatological imaging. Eur J Dermatol 2007;17:361-6.

3. Seidenari S, Arginelli F, Bassoli S, Cautela J, French PM, Guanti M, et al. Multiphoton laser microscopy and fluorescence lifetime imaging for the evaluation of the skin. Dermatol Res Pract 2012;2012:810749.

4. Kabashima K, Izuhara K. Development of in vivo imaging. Allergol Int 2016;65:223-4.

5. Masters BR, So PT, Gratton E. Multiphoton excitation fluorescence microscopy and spectroscopy of in vivo human skin. Biophys J 1997;72:2405-12.

6. Konig K. Clinical multiphoton tomography. J Biophotonics 2008;1:13-23.

7. Zipfel WR, Williams RM, Webb WW. Nonlinear magic: multiphoton microscopy in the biosciences. Nat Biotechnol 2003;21:1369-77.

8. So PT, Dong CY, Masters BR, Berland KM. Two-photon excitation fluorescence microscopy. Annu Rev Biomed Eng 2000;2:399-429.

9. Hoover EE, Squier JA. Advances in multiphoton microscopy technology. Nat Photonics 2013;7:93-101.

10. Yue S, Slipchenko MN, Cheng JX. Multimodal Nonlinear Optical Microscopy. Laser Photon Rev 2011;5.

11. Chung CY, Potma EO. Biomolecular imaging with coherent nonlinear vibrational microscopy. Annu Rev Phys Chem 2013;64:77-99.

12. Konig K, Riemann I. High-resolution multiphoton tomography of human skin with subcellular spatial resolution and picosecond time resolution. J Biomed Opt 2003;8:432-9.

13. Zhao J, Chen J, Yang Y, Zhuo S, Jiang X, Tian W, et al. Jadassohn-Pellizzari anetoderma: study of multiphoton microscopy based on two-photon excited fluorescence and second harmonic generation. Eur J Dermatol 2009;19:570-5.

14. Tsai TH, Jee SH, Dong CY, Lin SJ. Multiphoton microscopy in dermatological imaging. J Dermatol Sci 2009;56:1-8.

15. Zipfel WR, Williams RM, Christie R, Nikitin AY, Hyman BT, Webb WW. Live tissue intrinsic emission microscopy using multiphoton-excited native fluorescence and second harmonic generation. Proc Natl Acad Sci U S A 2003;100:7075-80.

16. Dimitrow E, Riemann I, Ehlers A, Koehler MJ, Norgauer J, Elsner P, et al. Spectral fluorescence lifetime detection and selective melanin imaging by multiphoton laser tomography for melanoma diagnosis. Exp Dermatol 2009;18:509-15.

17. Becker W, Bergmann A, Hink MA, Konig K, Benndorf K, Biskup C. Fluorescence lifetime imaging by time-correlated single-photon counting. Microsc Res Tech 2004;63:58-66.

18. Elson D, Requejo-Isidro J, Munro I, Reavell F, Siegel J, Suhling K, et al. Time-domain fluorescence lifetime imaging applied to biological tissue. Photochem Photobiol Sci 2004;3:795-801.

19. Benati E, Bellini V, Borsari S, Dunsby C, Ferrari C, French P, et al. Quantitative evaluation of healthy epidermis by means of multiphoton microscopy and fluorescence lifetime imaging microscopy. Skin Res Technol 2011;17:295-303.

20. Rice WL, Kaplan DL, Georgakoudi I. Two-photon microscopy for non-invasive, quantitative monitoring of stem cell differentiation. PLoS One 2010;5:e10075.

21. Peleg G, Lewis A, Linial M, Loew LM. Nonlinear optical measurement of membrane potential around single molecules at selected cellular sites. Proc Natl Acad Sci U S A 1999;96:6700-4.

22. Koehler MJ, Kellner K, Kaatz M, Hipler UC. Epidermal changes during UVB phototherapy assessed by multiphoton laser tomography. Skin Res Technol 2016;22:437-442.

23. El Madani HA, Tancrede-Bohin E, Bensussan A, Colonna A, Dupuy A, Bagot M, et al. In vivo multiphoton imaging of human skin: assessment of topical corticosteroid-induced epidermis atrophy and depigmentation. J Biomed Opt 2012;17:026009.

24. Baroli B. Penetration of nanoparticles and nanomaterials in the skin: fiction or reality? J Pharm Sci 2010;99:21-50.

25. Kirejev V, Guldbrand S, Borglin J, Simonsson C, Ericson M. Multiphoton microscopy. a powerful tool in skin research and topical drug delivery science. Journal of drug delivery science and technology 2012;22:250-259.

26. Navarro FA, So PT, Nirmalan R, Kropf N, Sakaguchi F, Park CS, et al. Two-photon confocal microscopy: a nondestructive method for studying wound healing. Plast Reconstr Surg 2004;114:121-8.

27. Simonsson C, Andersson SI, Stenfeldt AL, Bergstrom J, Bauer B, Jonsson CA, et al. Caged fluorescent haptens reveal the generation of cryptic epitopes in allergic contact dermatitis. J Invest Dermatol 2011;131:1486-93.

28. Lu K, Chen J, Zhuo S, Zheng L, Jiang X, Zhu X, et al. Multiphoton laser scanning microscopy of localized scleroderma. Skin Res Technol 2009;15:489-95.

29. Wu X, Zhuo S, Chen J, Liu N. Real-time in vivo imaging collagen in lymphedematous skin using multiphoton microscopy. Scanning 2011;33:463-7.

30. Huck V, Gorzelanny C, Thomas K, Getova V, Niemeyer V, Zens K, et al. From morphology to biochemical state - intravital multiphoton fluorescence lifetime imaging of inflamed human skin. Sci Rep 2016;6:22789.

31. Roberts MS, Dancik Y, Prow TW, Thorling CA, Lin LL, Grice JE, et al. Non-invasive imaging of skin physiology and percutaneous penetration using fluorescence spectral and lifetime imaging with multiphoton and confocal microscopy. Eur J Pharm Biopharm 2011;77:469-88.

32. Klemp M, Meinke MC, Weinigel M, Rowert-Huber HJ, Konig K, Ulrich M, et al. Comparison of morphologic criteria for actinic keratosis and squamous cell carcinoma using in vivo multiphoton tomography. Exp Dermatol 2016;25:218-22.

33. Cicchi R, Massi D, Sestini S, Carli P, De Giorgi V, Lotti T, et al. Multidimensional non-linear laser imaging of Basal Cell Carcinoma. Opt Express 2007;15:10135-48.

34. Galletly NP, McGinty J, Dunsby C, Teixeira F, Requejo-Isidro J, Munro I, et al. Fluorescence lifetime imaging distinguishes basal cell carcinoma from surrounding uninvolved skin. Br J Dermatol 2008;159:152-61.

35. Balu M, Zachary CB, Harris RM, Krasieva TB, Konig K, Tromberg BJ, et al. In Vivo Multiphoton Microscopy of Basal Cell Carcinoma. JAMA Dermatol 2015;151:1068-74.

36. Xiong S, Yang J, Zhuang J. Nonlinear spectral imaging of human normal skin, basal cell carcinoma and squamous cell carcinoma based on two-photon excited fluorescence and second-harmonic generation. Laser Physics 2011;21:1844-1849.

37. Dimitrow E, Ziemer M, Koehler MJ, Norgauer J, Konig K, Elsner P, et al. Sensitivity and specificity of multiphoton laser tomography for in vivo and ex vivo diagnosis of malignant melanoma. J Invest Dermatol 2009;129:1752-8.

38. Seidenari S, Arginelli F, Dunsby C, French PM, Konig K, Magnoni C, et al. Multiphoton laser tomography and fluorescence lifetime imaging of melanoma: morphologic features and quantitative data for sensitive and specific non-invasive diagnostics. PLoS One 2013;8:e70682.

39. Balu M, Kelly KM, Zachary CB, Harris RM, Krasieva TB, Konig K, et al. Distinguishing between benign and malignant melanocytic nevi by in vivo multiphoton microscopy. Cancer Res 2014;74:2688-97.

40. Hirata E, Girotti MR, Viros A, Hooper S, Spencer-Dene B, Matsuda M, et al. Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1/FAK signaling. Cancer Cell 2015;27:574-88.

41. Koehler MJ, Preller A, Kindler N, Elsner P, Konig K, Buckle R, et al. Intrinsic, solar and sunbed-induced skin aging measured in vivo by multiphoton laser tomography and biophysical methods. Skin Res Technol 2009;15:357-63.

42. Breunig HG, Buckle R, Kellner-Hofer M, Weinigel M, Lademann J, Sterry W, et al. Combined in vivo multiphoton and CARS imaging of healthy and disease-affected human skin. Microsc Res Tech 2012;75:492-8.

43. Theer P, Denk W. On the fundamental imaging-depth limit in two-photon microscopy. J Opt Soc Am A Opt Image Sci Vis 2006;23:3139-49.

44. Yazdanfar S, Chen YY, So PT, Laiho LH. Multifunctional imaging of endogenous contrast by simultaneous nonlinear and optical coherence microscopy of thick tissues. Microsc Res Tech 2007;70:628-33.

45. Konig K, Speicher M, Kohler MJ, Scharenberg R, Kaatz M. Clinical application of multiphoton tomography in combination with high-frequency ultrasound for evaluation of skin diseases. J Biophotonics 2010;3:759-73.

46. Sun TY, Haberman AM, Greco V. Preclinical Advances with Multiphoton Microscopy in Live Imaging of Skin Cancers. J Invest Dermatol 2017;137:282-287.

47. Chen X, Nadiarynkh O, Plotnikov S, Campagnola PJ. Second harmonic generation microscopy for quantitative analysis of collagen fibrillar structure. Nat Protoc 2012;7:654-69.

48. Weigelin B, Bakker GJ, Friedl P. Intravital third harmonic generation microscopy of collective melanoma cell invasion: Principles of interface guidance and microvesicle dynamics. Intravital 2012;1:32-43.

49. Lee YJ. Determination of 3D molecular orientation by concurrent polarization analysis of multiple Raman modes in broadband CARS spectroscopy. Opt Express 2015;23:29279-95.

50. Provenzano PP, Eliceiri KW, Keely PJ. Multiphoton microscopy and fluorescence lifetime imaging microscopy (FLIM) to monitor metastasis and the tumor microenvironment. Clin Exp Metastasis 2009;26:357-70.

**Topikal tedavi**

1- Venancio JH, Andrade LM, Esteves NLS, et al. Topotecan-loaded lipid nanoparticles as a viable tool for the topical treatment of skin cancers. J Pharm Pharmacol. 2017; 69(10): 1318-1326.

2- Jose A, Labala S, Ninave KM, Gade SK, Venuganti VVK. Effective Skin Cancer Treatment by Topical Co-delivery of Curcumin and STAT3 siRNA Using Cationic Liposomes. AAPS Pharm Sci Tech 2018; 19(1): 166-175.

3- Ceilley RI. Mechanisms of action of topical 5-fluorouracil: Review and implications for the treatment of dermatological disorders. Journal of Dermatological Treatment 2012; 23: 83–89.

4- Askew DA, Mickan SM, Soyer HP, Wilkinson D. Effectiveness of 5-fluorouracil treatment for actinic keratosis--a systematic review of randomized controlled trials. Int J Dermatol 2009; 48: 453-463.

5- Stockfleth E, Kerl H, Zwingers T, Willers C. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesiondirected option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol 2011; 165: 1101-1108.

6- Kishi P, Price CJ. Life-Threatening Reaction with Topical 5-Fluorouracil. Drug Saf Case Rep 2018; 12;5(1):4.

7- Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res. 1999; 5: 2006–2011.

8- Safwat MA, Soliman GM, Sayed D, Attia MA. Fluorouracil-Loaded Gold Nanoparticles for The Treatment of Skin Cancer: Development, In Vitro Characterization and In Vivo Evaluation in A Mouse Skin Cancer Xenograft Model. Mol Pharm. 2018 Apr 27. doi: 10.1021/acs.molpharmaceut.8b00047. [Epub ahead of print]

9- Rajinikanth SP, Chellian J. Development and evaluation of nanostructured lipid carrier-based hydrogel for topical delivery of 5-fluorouracil. In J Nanomedicine 2106; 11: 5067-77

10- Simon JC, Dominicus R, Karl L, Rodríguez R, Willers C, Dirschka T. A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis. J Eur Acad Dermatol Venereol 2015; 29: 881-889

11- Gupta AK, Paquet M. Network meta-analysis of the outcome ‘participant complete clearance’ in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review. Br J Dermatol 2013; 169: 250-259

12- Tanghetti E, Werschler P. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. J Drugs Dermatol 2007; 6: 144-147

13- Gupta AK, Davey V, Mcphail H. Evaluation of the effectiveness of imiquimod and 5 fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies. J Cutan Med Surg 2005; 9: 209-214.

14- Neugebauer R, Levandoski KA, Zhu Z, et al. A real-world, community-based cohort study comparing the effectiveness of topical fluorouracil versus topical imiquimod for the treatment of actinic keratosis. JAAD 2018; 78: 710-716.

15- Naik MP, Mehta A, Abrol S, Kumar S, Gupta VS. Topical 5% 5-fluorouracil in the treatment of multifocal basal cell carcinoma of the face: A novel chemotherapeutic approach. Orbit 2016; 35(6): 352-354.

16- Florin V, Desmedt E, Vercambre-Darras S, Mortier L. Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. Invest New Drugs 2012; 30: 1641-1645.

17- Yoon J, Phibbs CS, Chow A, Weinstock MA; Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial Group. Impact of topical fluorouracil cream on costs of treating keratinocyte carcinoma (nonmelanoma skin cancer) and actinic keratosis. J Am Acad Dermatol. 2018 Mar 2. pii: S0190-9622(18)30344-X. doi: 10.1016/j.jaad.2018.02.058. [Epub ahead of print])

18- Haserick J, Richardson JH, Grant DJ. Remission of lesions in mycosis fungoides following topical application of nitrogen mustard: a case report. Cleve Clin Jf Med. 1959:144–147.

19- Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013; 149(1): 25-32.

20- Liner K, Brown C, McGrirt LY. Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data. Drug Design, Development and Therapy 2018:12 241–254.

21- Nguyen CV, Bohjahen KA. Skin-Directed Therapies in Cutaneous T-Cell Lymphoma. Dermatol Clin 2015; 33:683–696.

22- Talpur R, Venkatarajan S, Duvic M. Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma. Expert Rev Clin Pharmacol. 2014;7(5):591-7.

23- Kim YH. Management with topical nitrogen mustard in mycosis fungoides. Dermatologic Therapy 2003; 288-298.

24- Zackheim HS. Treatment of mycosis fungoides with topical nitrosourea compounds. Arch Dermatol 1972:106: 177–182.

25- Zackheim HS. Topical carmustine (BCNU) in the treatment of mycosis fungoides. Dermatologic Therapy 2003; 16: 299–302

26- Zackheim HS, Epstein EH, Jr, Crain WR. Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. J Am Acad Dermatol 1990: 22: 802–810.

27- MacArtur KM, Jariwala N, Kim EJ, Rook AH. Topical carmustine as monotherapy or as multimodality therapy for folliculotropic mycosis fungoides. Acta Derm Venereol 2017; 97(3): 373-374.

28- Al-Badr AA, Alodhaib MM. Dacarbazine. Profiles Drug Subst Excip Relat Methodol. 2016; 41:323-377.

29- Hafeez A, Kazmi I. Dacarbazine nanoparticle topical delivery system for the treatment of melanoma. Sci Rep 2017; 7(1): 16517

30- Peris K, Stockfleth E, Gupta G, et al. Efficacy of imiquimod 3.75% from Lmax according to the number of actinic keratosis lesions. J Eur Acad Dermatol Venereol 2015; 29: 2470-2473.

31- Hanna E, Abadi R, Abbas O. Imiquimod in dermatology: an overwiev. Int J Dermatol 2016; 55:831-844.

32- Urosevic M, Dummer R, Conrad C, et al. Disease independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 2005; 97: 1143–1153.

33- Akkilic-Materna M, Massone C,Komericki P. Imiquimod and lymphatic field clearance: A new hypothesis based on a remote immune action on skin cancer. Acta Derm Venereol 2011; 91: 432-435.

34- Bath-Hextall FJ, Perkins W, Bong J, et al. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2007; (1): CD003412.

35- Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized,vehicle- controlled studies. J Am Acad Dermatol 2004; 50: 722–733.

36- Papakostas D, Stockfleth E. Topical treatment of basal cell carcinoma with the immune response modifier imiquimod. Future Oncol 2015;11(22):2985-2990.

37- Sawado M, Kato J, Yamashita T, et al. Imiquimod %5 cream as a therapeutic option for extramammary Paget’s disease. J Dermatol 2018; 45(2): 216-219.

38- Dogan A, Hilal Z, Krentel H, et al. Paget’s disease of the vulva treated with imiquimod: Case report and systematic review of the literature. Gynecol Obstet Invest 2017; 82: 1-7.

39- Dodds A, Chia A, Shumack S. Actinic keratosis: rationale and management. Dermatol Ther (Heidelb) 2014; 4: 11-31.

40- Imashuku S, Kobayashi M, Nishii Y, Nishimura K. Topical imiquimod for the treatment of relapsed cutaneous Langerhans cell histiocytosis after chemotherapy in an elderly patient. Case Reports Dermatol Med 2018; 2018:1680871.

41- Heber G, Helbig D, Pönitzsch I, Wetzig T, Harth W, Simon JC. Complete remission of cutaneous and subcutaneous melanoma metastases of the scalp with imiquimod therapy. JDDG 2009;7:534-536.

42- Oskay T, Kömürcü Ş. Deri tümörleri ve imikimod tedavisi. Int J Hemat Oncol 2006; 16(3): 155-164.

43- Hofbauer G, Anliker M, Boehncke WH, et al. Swiss clinical practice guidelines on field cancerization of the skin. Swiss Med Wkly 2014; 144: w14026

44- Zackheim HS. Treatment of patch-stage mycosis fungoides with topical corticosteroids. Dermatologic Therapy 2003; 16: 283-287.

45- Schadt CR. Topical and oral bexarotene. Dermatol Therapy 2013; 26: 400-403.

46- Querfeld C, Nagelli LV, Rosen ST, Kuzel TM, Guitard J. Bexaroten in the treatment of cutaneous T-cell lymphoma. Expert Opin Pharmacother 2006; 7(7): 907-915

47- Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens VJ. Phase 1 and 2 trial o f bexarotene gel for skin directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol. 2002;138(3):325-332.

48- Heald P, Mehlmauer M, Martin AG, Crowley CA, Yocum RC, Reich SD; Worldwide Bexarotene Study Group. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial.J Am Acad Dermatol. 2003; 49(5):801-815.

49- Apisarnthanarax N, Talpur R, Ward S, Ni X, Kim HW, Duvic M. Tazarotene %0.1 jel for refractory mycosis fungoides lesions: An open-label pilot study. J Am Acad Dermatol 2004; 50: 600-607.

50- Bassiri-Tehrani S, Cohen DE. Treatment of cutaneous T-cell lymphoma with alitretinoin gel. Int J Dermatol 2002; 41: 104-106.

51- Martin GM, Stockfleth E. Diclofenac sodium 3% gel for the management of actinic keratosis: 10+ years of cumulative evidence of efficacy and safety. J Drugs Dermatol 2012; 11: 600-608.

52- Burns EM, Tobler KL, Riggenbach JA, et al. Preventative topical diclofenac treatment differentially decreases tumor burden in male and female Skh-1 mice in a model of UVB-induced cutaneous squamous cell carcinoma. Carcinogenesis 2013; 34(2): 370-377.

53- Ulrich M, Pellacani G, Fernandiz C, Lear JT. Evidence for field cancerisation treatment of actinic keratoses with topical diclofenac in hyaluronic acid. Eur J Dermatol 2014;24(2): 158-67.

54- Keating GM. Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis. Drugs 2012; 72: 2397-2405

55- Bettencourt MS. Effect of Field Treatment of Actinic Keratosis With Ingenol Mebutate Gel on the Identification of Lesions for Biopsy. J Drugs Dermatol 2015; 14: 813-818.

56- Lee DW, Ahn HH, Kye YC, Seo SH. Clinical experience of ingenol mebutate gel fort the treatment of Bowen’s disease. J Dermatol 2018: 45(4): 425-430.

57- Iannazzone SS, Ingordo V. Nodular basal cell carcinoma of the face successfully treated with ingenol mebutate 0.0015 % gel. Dermatol PractConcept2018; 8(2): 12.

**Kriyoterapi**

1. Torre D. Cryosurgical instrumentation and depth dose monitoring. Clin Dermatol 1990; 8: 48–60.

2. Jackson A, Colver G, Dawber R. Cutaneous cryosurgery. 3rd ed. New York: Taylor & Francis; 2006. p. 13-28.

3. Torre, D. Instrumentation and monitoring devices in cryosurgery. in: SA Zacarian (Ed.) Cryosurgery for Skin Cancer and Cutaneous Disorders. CV Mosby, St Louis; 1985: 31–40.

4. Lubritz, RR, Smolewski, SA. Cryosurgery cure rate of actinic keratoses. J Am Acad Dermatol. 1982; 7: 631–632.

5. Lewin-Epstein J. Cryosurgery of benign and precancerous disorders of the oral cavity. In: Zacarian SA (Ed.) Cryosurgery for Skin Cancer and Cutaneous Disorders. CV Mosby, St Louis; 1985: 237–258.

6. Jackson A, Colver G, Dawber R. Cutaneous cryosurgery. 3rd ed. New York: Taylor & Francis; 2006. p. 99-104.

7. Holt PJA. Cryotherapy for skin cancer: results over a 5 year period using liquid nitrogen spray cryosurgery. Br J Dermatol 1988; 119: 231–240.

8. Kuflik EG. Cryosurgery updated. J Am Acad Dermatol. 1994; 31: 925–944.

9. Mallon E, Dawber RPR. Cryosurgery in the treatment of basal cell carcinoma. Dermatol Surg. 22: 85–88, 1996.

10. Dereli T, Ünal İ, Özyurt S, Öztürk A, Erboz S. Deri karsinom ve prekarsinomlarında kriyoterapi uygulaması. TÜRKDERM 1996; 30(2): 77-81.

11. Kuflick EG, Gage AA. The five-year cure rates achieved by cryosurgery for skin cancer. J Am Acad Dermatol 1991: 24; 1002-1004.

**İyonizan radyasyon tedavisi**

1. Ceylan C, Oztürk G, Alper S. Non-melanoma skin cancers between the years of 1990 and 1999 in Izmir, Turkey: demographic and clinicopathological characteristics. J Dermatol. 2003 Feb;30(2):123-31.

2. Soyer H, Rigel D, Wurm E. Actinic keratosis, basal cell carcinoma, and squamous cell carcinoma. In: Bolognia J, Jorizzo J, and Schaffer J, eds. Dermatology, vol. 2. Philadelphia: WB Sauders; 2012: 1773–1793.

3. Lyon TG. The Roentgen rays as curefor disease. Lancet 1896:326

4. Hoppe RT, Wood GS, Abel EA. Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment. Curr Probl Cancer. 1990 Nov-Dec;14(6):293-371.

5. Overgaard J. Radiation treatment of malignant melanoma. Int J Radiat Oncol Biol Phys. 1980 Jan;6(1):41-4.

6. Berson AM, Quivey JM, Harris JW, Wara WM. Radiation therapy for AIDS-related Kaposi's Sarcoma. Int J Radiat Oncol Biol Phys. 1990 Sep;19(3):569-75.

7. Brown PE, Pinkston JA, Blackmon JA, McMahon JM. Merkle cell carcinoma report of a case and possible role for adjuvant radiotherapy. J Surg Oncol. 1987 Feb;34(2):136-41.

8. Halpern JN. Radiation therapy in skin cancer. A historical perspective and current applications. Dermatol Surg. 1997 Nov;23(11):1089-93.

9. Veness M, Richards S. Radiotherapy. In: Bolognia J, Jorizzo J,and Schaffer J, eds. Dermatology, vol. 2. Philadelphia: WB Sauders; 2012: 2291–2301.

10. Okkan S. Dermatolojide radyoterapi. In: Tüzün Y, Kotoğyan A, Aydemir EH, Baransü O, ed. Dermatoloji. İstanbul: Nobel Tıp Kitabevleri 1994. 826-833.

11. Goldschmidt H; Breneman JC, Breneman DL. Ionizing radiation therapy in dermatology. J Am Acad Dermatol 1994 Feb; 30 (2),157-82.

12. Withers RH. Biologic basis mof radiation therapy.In: Principles and practice of radiation oncology. 2nd ed. Philadelphia:JB Lippincott 1992:64-96.

13. Ellis F. Dose, time and fractionation: a clinical hypothesis. Clin Radiol. 1969 Jan;20(1):1-7.

14. Orton CG, Ellis F. A simplification in the use of the NSD concept in practical radiotherapy. Br J Radiol. 1973 Jul;46(547):529-37.

15. Weber BM, Simkins GS. A table fort he rapid determination of RED and TDF values. Br J Radiol 1975;48:929-30.

16. Storck H. Radiotherapy of cutaneous cancers and some other malignancies. J Dermatol Surg Oncol. 1978 Aug;4(8):573-84.

17. Johns HE, Cunningham JR. The physics of radiology. 4th ed. Springfield, CC Thomas,1983. Wyckoff HO. Statement by the ICRU. Med Phys 1976;3-52.

18. Solan MJ, Brady LW, Binnick SA, et al. Skin cancer. In: Perez CA, Brady LW, editors. Principles and practice of radiation oncology. 2nd ed. Philadelphia: J B Lippincott; 1992:479-95.

19. Amdur RJ, Kalbaugh KJ,Ewald LM, ParsonJT,Medenhall WM, Bova FJ, Million RR. Radiation therapy for skin cancer near the eyelid: Kilovoltage Xrays versus electrons. Int J Radiat Oncol Biol Phys 1992;23:769-79.

20. Johnson TS, Garciga CE, Feldman ME, et al. Lowmegavoltage electron beam therapy of head and facial skin cancer using a versatile polystyrene collimator system. Radiology 1975;114:695-9.

21. David C. Electronic brachytherapy and superficial radiation therapy: will you be adding it to your practice. Cutis.2013;92:16-18.

22. Goldschmidt H, Sherwin WK. Reactions to ionizing radiation. J Am Acad Dermatol. 1980 Dec;3(6):551-79.

23. Goldschmidt H. Radiodermatitis and other sequelae of ionizing radiation. In:Demis J, ed. Dermatology, Vol. IV.Philadelphia:Harper&Row 1985.

24. Goldschmidt H, Panizzon RG . Modern dermatologic radiation therapy. New York: Springer, 1991. 37–48.

25. Goldschmidt H, Gorson RO, Lassen M. Dermatologic radiotherapy and thyroid cancer. Dose measurements and risk quantification. Arch Dermatol. 1983 May;119(5):383-90.

26. Goldschmidt H, Gorson RO, Lassen M. Dermatologic radiotherapy and breast cancer. Dose measurements and risk quantification. Arch Dermatol Res. 1982;272(3-4):293-300.

27. Gladstein AH, Kopf AW, Bart RS. Radiotherapy of cutaneous malignancies. In: Goldschmidt H, ed. Physical modalities in dermatologic therapy. New York:Springer-Verlag,1978:95-121.

28. Lovett RD, Perez CA, Shapiro SJ, Garcia DM. External irradiation of epithelial skin cancer. Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):235-42.

29. Cognetta A, Howard B, Heaton H, et.al. Superficial X-ray in the treatment of basal and squamous cell carcinoma: a viable option in select patients. J Am Acad Dermatol.2012;67:1237–1241.

30. Schulte KW, Lippold A, Auras C, et. al. Soft X-ray therapy for cutaneous basal cell and squamous cell carcinomas. J Am Acad Dermatol. 2005;53:993–1001.

31. Zagrodnik B, Kempf W, Seifert E, et. al. Superficial radiotherapy for patients with basal cell carcinoma. Cancer. 2003;98(12):2708–2714.

32. Barysch M, Eggman N, Beyeler M, et. al. Long term recurrence rate of large and difficult to treat cutaneous squamous cell carcinomas after superficial radiotherapy. Dermatology. 2012;224:59–65.

33. Kharofa J, Currey A, and Wilson JF. Patient-reported outcomes in patients with nonmelanomatous skin cancers of the face treated with orthovoltage radiation therapy: a crosssectional study. Int J Radiation Oncol Biol Phys. 2013;87(4):636–637.

34. Petit JY, Avril MF, Margulis A, et. al. Evaluation of cosmetic results of a randomized trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plast Reconstr Surg. 2000;105:2544–2551.

35. Caccialanza M, Piccinno R, Mainardi L. Radiotherapy of extensive basal and squamous cell carcinomas of skin. Skin cancer 1991;6:69-73.

36. Hunter RD, Pereira DT, Pointon RC. Megavoltage electron beam therapy in the treatment of basal and squamous cell carcinomata of the pinna. Clin Radiol. 1982 May 3;33(3):341-5.

**Fotodinamik tedavi**

1. Daniell MD, Hill JS. A history of photodynamic therapy. Aust N Z J Surg. 1991 May;61(5):340-8

2. Szeimies RM, Calzavara-Pinton P, Karrer S, Ortel B, Landthaler M. Topical photodynamic therapy in dermatology. J Photochem Photobiol B. 1996 Nov;36(2):213-9.

3. Kennedy JC, Pottier RH, Pross DC: Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B Biol 1990;6:143-8.

4. Ormrod D, Jarvis B: Topical aminolevulinic acid HCl photodynamic therapy. Am J Clin Dermatol 2000;1:133-9

5. Henderson BW, Dougherty TJ: How does photodynamic therapy work? Photochem Photobiol 1992;55:145-57.

6. Firczuk M1, Nowis D, Gołąb J. PDT-induced inflammatory and host responses. Photochem Photobiol Sci. 2011 May;10(5):653-63.

7. Karrer S, Bosserhoff AK, Weiderer P, Landthaler M, Szeimies RM. Keratinocyte-derived cytokines after photodynamic therapy and their paracrine induction of matrix metalloproteinases in fibroblasts. Br J Dermatol. 2004 Oct;151(4):776-83

8. Chilakamarthi U, Giribabu L. Photodynamic Therapy: Past, Present and Future. Chem Rec. 2017 Aug;17(8):775-802.

9. Moor AC. Signaling pathways in cell death and survival after photodynamic therapy. J Photochem Photobiol B. 2000 Aug;57(1):1-13.

10. Lange C, Bednarski PJ. Photosensitizers for Photodynamic Therapy: Photochemistry in the Service of Oncology. Curr Pharm Des. 2016;22(46):6956-6974.

11. O'Connor AE1, Gallagher WM, Byrne AT. Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy. Photochem Photobiol. 2009 Sep-Oct;85(5):1053-74.

12. Steinbauer JM1, Schreml S, Babilas P, Zeman F, Karrer S, Landthaler M, Szeimies RM. Topical photodynamic therapy with porphyrin precursors--assessment of treatment-associated pain in a retrospective study. Photochem Photobiol Sci. 2009 Aug;8(8):1111-6.

13. Kennedy JC, Marcus SL, Pottier RH. Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): mechanisms and clinical results. J Clin Laser Med Surg. 1996 Oct;14(5):289-304.

14. Siddiqui MA, Perry CM, Scott LJ. Topical methyl aminolevulinate. Am J Clin Dermatol. 2004;5(2):127-37.

15. Togsverd-Bo K, Lerche CM, Poulsen T, Wulf HC, Haedersdal M. Photodynamic therapy with topical methyl- and hexylaminolevulinate for prophylaxis and treatment of UV-induced SCC in hairless mice. Exp Dermatol. 2010 Aug;19(8):166-72.

16. Bedwell J, McRobert AJ, Phillips D; Bown SC: Fluorescence distribution and photodynamic effect of ALA induced Pp9 in the DMH rat colonic tumour model. Br J Cancer 1992;65:818-24.

17. Rebeiz N, Rebeiz CC, Arkins Z, Kelley KW:Photodestruction of tumour cells by induction of endogenous accumulation of protoporphyrin enhancement by 1,10 phenanthroline. J Photochem Photobiol B 1992;55:431-5.

18. Morton CA, Brown SB, Collins S et al. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol 2002; 146: 552 67.

19. Erkiert-Polguj A, Halbina A, Polak-Pacholczyk I, Rotsztejn H. Light-emitting diodes in photodynamic therapy in non-melanoma skin cancers--own observations and literature review. J Cosmet Laser Ther. 2016;18(2):105-10.

20. Calin MA, Diaconeasa A, Savastru D, Tautan M. Photosensitizers and light sources for photodynamic therapy of the Bowen's disease. Arch Dermatol Res. 2011 Apr;303(3):145-51.

21. Haedersdal M, Togsverd-Bo K, Wulf HC. Evidence-based review of lasers, light sources and photodynamic therapy in the treatment of acne vulgaris. J Eur Acad Dermatol Venereol. 2008 Mar;22(3):267-78.

22. Mordon S, Cochrane C, Tylcz JB, Betrouni N, Mortier L, Koncar V. Light emitting fabric technologies for photodynamic therapy. Photodiagnosis Photodyn Ther. 2015 Mar;12(1):1-8.

23. Morton C, McKenna KE, Rhodes LE. Guidelines for topical photodynamic therapy: update. Br J Dermatol 2008; 159: 1245–1266.

24. Fijan S, Honigsman H, Ortel B. Photodynamic therapy of epithelial skin tumours using delta-aminolevulinic acid and desferrioxamine. Br J Dermatol 1995;133: 282-8.

25. Orenstein A, Kostenich G, Roitman L, Tsur H, Katanick D. Photodynamic therapy of malignant lesions of the skin mediated by topical application of 5-aminolevulinic acid in combination with DMSO and EDTA. Lasers in the Life Sciences 1996;7:1-9.

26. Christensen E, Warloe T, Kroon S, Funk J, Helsing P, Soler AM, Stang HJ, Vatne O, Mørk C. Guidelines for practical use of MAL-PDT in non-melanoma skin cancer. J Eur Acad Dermatol Venereol. 2010 May;24(5):505-12.

27. Tarstedt M, Rosdahl I, Berne B, Svanberg K, Wennberg AM. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol 2005; 85: 424–428.

28. Fink-Puches R, Soyer HP, Hofer A et al: Long-term follow-up and histological changes of superficial nonmelanoma skin cancer treated with topical d-aminolevulinic acid photodynamic therapy. Arch Dermatol 1998;134:821-6.

29. Grapengiesser S, Ericson M, Gudmundsson F, Larkö O, Rosén A, Wennberg AM. Pain caused by photodynamic therapy of skin cancer. Clin Exp Dermatol. 2002 Sep;27(6):493-7

30. Braathen LR, Szeimies RM, Basset-Seguin N et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol 2007; 56: 125–143.

31. Kurwa HA, Yong-Gee SA, Seed PT, Markey AC, Barlow RJ: A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol 1999;41:414-8.

32. Ceylan C, Ozdemir F, Erboz S, Kazandı AC, Ozol A. Bazal hücreli karsinomda topikal fotodinamik tedavi. Türkderm Dergisi 1999; 33:153-157.

33. Ceylan C, Ozdemir F, Kazandi AC. The Recurrence and Cosmetic Results After Topical Photodynamic Therapy. Turkderm 2009 Dec;43(4):160-166.

34. Erboz S, Ceylan C, Ozdemir F, Kazandı AC, Ozol A. Solar keratozda fotodinamik tedavi. Türkderm dergisi 1999; 33: 75-78.

35. Smith S, Piacquadio D, Morhenn V et al. Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol 2003; 2:629–35.

36. Morton CA, Horn M, Leman J et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch Dermatol 2006; 142:729–35.

37. Lehmann P. Methyl aminolaevulinate-photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer. Br J Dermatol 2007; 156:793–801.

38. Thissen MR, Schroeter CA, Neumann HA. Photodynamic therapy with delta-aminolaevulinic acid for nodular basal cell carcinomas using a prior debulking technique. Br J Dermatol 2000; 142:338–9.

39. Harth Y, Hirshowitz B, Kaplan B. Modified topical photodynamic therapy of superficial skin tumors, utilizing aminolevulinic acid, penetration enhancers, red light, and hyperthermia. Dermatol Surg. 1998 Jul;24(7):723-6.

40. Soler AM, Angell-Petersen E, Warloe T, Tausjø J, Steen HB, Moan J, Giercksky KE. Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid: a comparison of two light sources. Photochem Photobiol. 2000 Jun;71(6):724-9.

41. Peng Q, Warloe T, Berg K et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 1997; 79:2282–308.

42. Wang I, Bendsoe N, Klinteberg CA et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 2001; 144:832–40.

43. Shieh S, Dee AS, Cheney RT et al. Photodynamic therapy for the treatment of extramammary Paget’s disease. Br J Dermatol 2002; 146:1000–5.

44. Fehr MK, Hornung R, Schwarz VA et al. Photodynamic therapy of vulvar intraepithelial neoplasia III using topically applied 5-aminolevulinic acid. Gynecol Oncol 2001; 80:62–6.

45. Leman JA, Dick DC, Morton CA. Topical 5-ALA photodynamic therapy for the treatment of cutaneous T-cell lymphoma. Clin Exp Dermatol 2002; 27:516–18.

46. Garcia-Zuazaga J, Cooper K, Baron ED. Photodynamic therapy in dermatology: current concepts in the treatment of skin cancer. Expert Rev Anticancer Ther 2005; 5:791–800.

47. Wulf HC, Philipsen P. Allergic contact dermatitis to 5-aminolaevulinic acid methylester but not to 5-aminolaevulinic acid after photodynamic therapy. Br J Dermatol 2004; 150:143–5.

48. Harries MJ, Street G, Gilmour E et al. Allergic contact dermatitis to methyl aminolevulinate (Metvix) cream used in photodynamic therapy. Photodermatol Photoimmunol Photomed 2007; 23:35–6.

49. Chung WY, Lee JM, Lee WY et al. Protective effects of hemin and tetrakis (4-benzoic acid) porphyrin on bacterial mutagenesis and mouse skin carcinogenesis induced by 7,12-dimethylbenz[a] anthracene. Mutat Res 2000; 472:139–45.

50. Fuchs J, Weber S, Kaufmann R. Genotoxic potential of porphyrin type photosensitizers with particular emphasis on 5-aminolevulinic acid: implications for clinical photodynamic therapy. Free Radic Biol Med 2000; 28:537–48.

51. Maydan E, Nootheti PK, Goldman MP. Development of a keratoacanthoma after topical photodynamic therapy with 5-aminolevulinic acid. J Drugs Dermatol 2006; 5:804–6.

**Lazer tedavisi**

1) Marcus RF, Nunez-Gussman J, Martinelli P. Treatment of actinic keratoses and nonmelnoma skin cancer. In Goldberg DJ ed, Lasers and lights Volume 1, Elsevier, 2005, 75-88

2) Mirza FN, Khatri KA. The use of lasers in the treatment of skin cancer: a review. J Cosmetic Laser Therapy 2017; 19: 451-458

3) Chan HHL, Xiang L, Leung JCK, Tsang KWT, Lai KN. In vitro study examining the effect of sub-lethal QS 755 nm lasers on the expression of p16INK4a on melanoma cell lines. Lasers Surg Med 2003; 32: 88-93

4) Calpolim P, Brazzini B, Urso C. Superpulsed CO2 laser treatment of basal cell carcinoma with intraoperatory histopathologic and cytologic examination. Dermatol Surg 2002; 28: 909-912

5) Zane C, Facchinetti E, Arisi M, Ortel B, Calzavara-Pinton P. Pulsed CO2 laser ablation of superficial basal cell of limbs and trunk: a comparative randomized clinical trial with cryotherapy and surgical ablation. Dermatol Surg 2017; 43: 920-927

6) Hsu SH, Gan SD, Nguyen BT, Liang CA. Ablative fractional laser-assisted topical fluorouracil for the treatment of superficial basal cell carcinoma and squamous cell carcinoma in situ: a follow-up study. Dermatol Surg 2016; 42: 1050-1053.

7) Kawakubo M, Demehri S, Manstein D. Fractional laser exposure induces neutrophil infiltration (N1 phenotype) into the tumor and stimulates systemic anti-tumor immune response. PLoS One 2017; 12: e018452

8) Prens SP, de Vries K, Neumann HA, Prens EP. Non-ablative fractional resurfacing in combination with topical tretinoin cream as a field treatment modality for multiple actinic keratosis: a pilot study and a review of other field treatment modalities. J Dermatolog Treat 2013; 24: 227-231.

9) Weiss ET, Brauer JA, Anolik R, Reddy KK, Karen JK, Hale EK et al. 1927-nm fractional resurfacing of facial actinic keratoses: a promising new therapeutic option. J Am Acad Dermatol 2013, 68: 98-102

10) Ortiz AE, Anderson RR, Avram MM. 1064 nm long-pulsed Nd:YAG laser treatment of basal cell carcinoma. Lasers Surg Med 2015; 47: 106-110 1,064 nm Nd:YAG lasers for the treatment of basal cell carcinoma. Lasers Surg Med 2014; 46:1-7

11) Jalian HR, Avram MM, Stankiewicz KJ, Shofner JD, Tannous Z. Combined 585 nm pulsed-dye and 1,064 nm Nd:YAG lasers for the treatment of basal cell carcinoma. Lasers Surg Med 2014; 46: 1-7

12) Konnikov N, Avram M, Jarell A, Tannous Z. Pulsed dye laser as a novel non-surgical treatment for basal cell carcinomas: response and follow-up 12-21 months after treatment. Lasers Surg Med 2011; 43: 72-78

**Elektrokemoterapi**

1. Heller R, Gilbert R, Jaroszeski MJ. Clinical applications of electrochemotherapy. Advanced Drug Delivery Reviews 1999; 35: 119-29.

2. Wolff JA, Budker V. The mechanism of naked DNA uptake and expression. Advances in Genetics 2005; 54: 3-20.

3. Titomirov AV, Sukharev S, Kistanova E. In vivo electroporation and stable transformation of skin cellsof newborn mice by plasmid DNA. Biochimica et Biophysica Acta, 1991; 1008: 131-134.

4. Sajja HK, East MP, Mao H et al. Development of multifunctionel nanoparticles for targeted drug delivery and noninvasive imaging of therapatic effect. Curr Drug Discov Technol 2009; 6(1): 43–51.

5. Escoffre JM, Rols MR. Electrochemotherapy: Progress and Prospects, Current Pharmaceutical Design 2012, 18, 3406-3415.

6. Miklavcic D. Network for Development of Electroporation-Based Technologies and Treatments: COST TD1104. J Membrane Biol, DOI 10.1007/s00232-012-9493-8

7. Escoffre JM , Teissie J, Rols MP. Gene Transfer: How Can the Biological Barriers Be Overcome?. J Membrane Biol 2010; 236:61–74

8. Testori A, Tosti G, Martinoli C et al.Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a nov eltherapeutic approach. Dermatologic Therapy 2010 ;23: 651–661.

9. Yarmush ML, Golberg A, Sersa G et al. Electroporation-Based Technologies for Medicine: Principles, Applications, and Challenges. Annu. Rev. Biomed. Eng. 2014;16:295–320.

10. Mir LM, Banoun H, Paoletti C. Introduction of definite amounts of nonpermeant molecules into living cells after electropermeabilization: direct access to the cytosol. Exp Cell Res 1988;175: 15–25.

11. Okino M, Mohri H. Effects of a high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. Jpn J Cancer Res 1987; 78: 1319–1321.

12. Freeman TS, Wang MA, Weaver JW, Theory of Electroporation of Planar Bilayer Membranes: Predictions of the Aqueous Area, Change in Capacitance, and Pore-Pore Separation. Biophysical Journal 1994;67: 42-56.

13. Mir LM, Orlowski S. The Basis of Electrochemotherapy, Methods in Molecular Medicine 2000;37:99-117.

14. Weaver JC. Electroporation Theory, Plant Cell Electroporation and Electrofusion Protocols 1995; 55:3-28

15. Kotnik T, Kramar P, Pucihar G et al. Cell Membrane Electroporation-Part 1: The Phenomenon. IEEE Electrical Insulation Magazine 2012;28(5):14-23.

16. Gökbel H: Ganong’un Tıbbi Fizyolojisi,1. Baskı.İstanbul.Nobel Tıp Kitabevleri,2015; 36-37.

17. Goni FM, The basic structure and dynamics of cell membranes: an update of the Singer-Nicolson model. Biochim Biophys Acta. 2014;1838(6):1467-76.

18. Lawaczeck R. Defects Structures in Membranes: Routes for the Permession of Small Molecules. Ber.Bunsenges. Phys. Chem 1988; 92: 961-963.

19. Mir LM, Orlowski S. Mechanisms of electrochemotherapy, Advanced Drug Delivery Reviews 1999;35: 107–118.

20. Davalas RV, Mır LM, Rubinsky B. Tissue Ablation with Irreversible Electroporation, Annals of Biomedical Engineering 2005;33: 223–231.

21. Miller L, Leor J, Rubinsky B. Cancer cells ablation with irreversible electroporation. Technol Cancer Res Treat.2005; 4(6):699-705.

22. Wiggermann P, Bruenn K, Baeumler W. Irreversible electroporation (IRE): a minimally invasive therapeutic option in prostate cancer [in German]. Radiologe. 2017;57(8):637-640

23. Golberg A, Yarmush M. Nonthermal, Irreversible Electroporation: Fundamentals, Applications, and Challenges. IEEE Transactions on Biomedical Engineering 2013;60 (3):707-714.

24. Kanthou C, Kranjc S, Sersa G et al., The endothelial cytoskeleton as a target of electroporation-based therapies, Mol Cancer Ther 2006; 5(12):3145-3152.

25. Yabushita H, Yoshikawa K, Hirata M et al., Effects of Electrochemotherapy on CaSki Cells Derived from a Cervical Squamous Cell Carcinoma, Gynecologic Oncology 1997 ;65:297–303.

26. Skarlatos I, Kyrgıas G, Mosa E et al. Electrochemotherapy in Cancer Patients: First Clinical Trial in Greece, in vivo 2011;25: 265-274.

27. Pasquali P, Spugnini E.P, Baldi A. Successful Treatment of a Keratoacanthoma with Electrochemotherapy: A Case Report, Dermatol Ther (Heidelb) 2018; 8: 143-146.

28. Probst U,Fuhrmann I,Beyer L et al.Electrochemotherapy as a New Modality in Intervantional Oncology: A Review. Tecnology in Cancer Research and Treatment 2018;17:1-12.

29. Mali B, Jarm T, Snoj M et al. Antitumor effectiveness of electrochemotherapy: A systematic review and meta-analysis, European Journal of Surgical Oncology (EJSO) 2013;39: 4-16

30. Berkenbrock JA, Machado RG, Suzuki D.O.H. Electrochemotherapy Effectiveness Loss due to Electric Field Indentation between Needle Electrodes: A Numerical Study. Hindawi Journal of Healthcare Engineering 2018;1-8. https://doi.org/10.1155/2018/6024635.

31. Shankayi Z, Firoozabadi SM. Antitumor Efficiency of Electrochemotherapy by High and Low Frequencies and Repetitive Therapy in the Treatment of Invasive Ductal Carcinoma in Balb/c Mice. Cell Journal 2012; 14(2): 110-115.

32. Mir LM, Bases and rationale of the electrochemotherapy, E J C Supplements 2006;4:38-44.

33. Kuwano K, Kunitake R,Maeyama T et al. Attenuation of bleomycin-induced pneumopathy in mice by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol. 2001;280: 316-325.

34. Bertino G, Sersa G, Terlizzi F et al. European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results of the treatment of skin cancer. European Journal of Cancer 2016;63: 41-52.

35. Sersa G, Cemazara M, Miklavcic D et al. Electrochemotherapy: variable anti-tumor effect on different tumor models, Bioelectrochemistry and Bioenergetics 1994;35:23-27.

36. Domenge C, Orlowski S, Luboinski B et al. Antitumor Electrochernotherapy New Advances in the Clinical Protocol, CANCER 1996;77(5):956-963.

37. Kubota Y, Mir LM , Nakada T et al.,Successful treatment of metastatic skin lesions from bladder cancer by electrochemotherapy. J Urology 1998;160:1426.

38. Gehl J, Skovsgaard T, Mir LM. Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. Anticancer Drugs 1998; 9: 319-325.

39. Glass LF, Pepine ML, Fenske NA et al. Bleomycin-mediated electrochemotherapy of metastatic melanoma. Arch Dermatol 1996; 132: 1353-1357.

40. Sersa G, Stabuc B, Cemazar M. Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients. Clin Cancer Res 2000; 6: 863-867.

41. Brizio M, Fava P, Astrua C. Complete regression of melanoma skin metastases after electrochemotherapy plus ipilimumab treatment: an unusual clinical presentation. Eur J Dermatol 2015; 25: 271-272.

42. Heller LC, Heller R. Gene Therapy Preclinical and Clinical Trials for Melanoma. Current Gene Therapy 2010;10:312-317.

43. Staresinic B, Jesenko1 T, Kamensek U. Effect of calcium electroporation on tumour vasculature. Scientific Reports 2018; 8: 9412.

44. Falk H, Matthiessen LW, Wooler G. Calcium electroporation for treatment of cutaneous metastases; a randomized doubleblinded phase II study, comparing the effect of calcium electroporation with electrochemotherapy. Acta Oncologica 2018;57(3):311-319.

45. Mira L.M, Gehld J, Sersae G. et al, Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes, EJC Supplements 4 2006; 14-25.

46. Zupanic A, Ribaric S, Miklavcic D. Increasing the repetition frequency of electric pulse delivery reduces unpleasant sensations that occur in electrochemotherapy. Neoplasma. 2007; 54(3): 246-250.

47. Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline Update 2016. Eur J Cancer. 2016;63: 201-217.

48. Stratigos A, Garbe C, Lebbe C, et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensusbased interdisciplinary guideline. Eur J Cancer. 2015;51:1989–2007.

49. Available from: www.nice.org.uk. National Institute for Health and Care Excellence (NICE). Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma; 2013.

**Cerrahi tedavi genel prensipleri**

1. https://www.nccn.org/professionals/physician\_gls/default.aspx. (Basal Cell Skin Cancer, 08.02.2018’de erişilmiştir)

2. Silverman MK, Kopf AW, Grin CM, et al. Recurrence rates of treated basal cell carcinomas. Part 2: Curettage-electrodesiccation. J Dermatol Surg Oncol 1991; 17: 720-726.

3. Barlow JO, Zalla MJ, Kyle A, et al. Treatment of basal cell carcinoma with curettage alone. J Am Acad Dermatol 2006; 54: 1039-1045.

4. Silverman MK, Kopf AW, Bart RS, et al. Recurrence rates of treated basal cell carcinomas. Part 3: Surgical excision. J Dermatol Surg Oncol 1992; 18: 471-476.

5. Rowe DE, Carroll RJ, Day CL Jr. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol 1989; 15: 424-431.

6. Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. Arch Dermatol 1987; 123: 340-344.

7. Gulleth Y, Goldberg N, Silverman RP, Gastman BR. What is the best surgical margin for a Basal cell carcinoma: a meta-analysis of the literature. Plast Reconstr Surg 2010; 126: 1222-1231.

8. https://www.nccn.org/professionals/physician\_gls/default.aspx. (Squamous Cell Skin Cancer 08.02.2018’de erişilmiştir)

9. Brantsch KD, Meisner C, Schönfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 2008; 9: 713-720.

10. Lansbury L, Bath-Hextall F, Perkins W, et al. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ 2013; 347: f6153.

11. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. İmplications for treatment modality selection. J Am Acad Dermatol. 1992 Jun;26(6): 976-990.

12. Brodland DG1, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol. 1992; 27(2 Pt 1): 241-248.

13. Leibovitch I, Huilgol SC, Selva D, et al. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years. J Am Acad Dermatol 2005; 53(2): 253-260.

14. Khatri VP, Galante JM, Bold RJ, et al. Dermatofibrosarcoma protuberans: reappraisal of wide local excision and impact of inadequate initial treatment. Ann Surg Oncol 2003; 10: 1118-1122.

15. Chang CK, Jacobs IA, Salti GI. Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol 2004; 30: 341-345.

16. https://www.nccn.org/professionals/physician\_gls/default.aspx. (Merkel Cell Carcinoma 08.02.2018’de erişilmiştir)

17. Tai PT, Yu E, Tonita J, Gilchrist J. Merkel cell carcinoma of the skin. J Cutan Med Surg 2000; 4: 186-195.

**Mohs cerrahisi**

1. Snow SN, Mikail GR, editörler. Mohs micrographic surgery. 2. baskı, Wisconsin, The University of Wisconsin Press, 2004.

**Sistemik ilaçlar**

1. Fellner C. Vismodegib (erivedge) for advanced Basal cell carcinoma. P T. 2012; 37: 670-82.

2. Basset-Séguin N, Hauschild A, Kunstfeld R, ve ark. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. Eur J Cancer 2017; 86: 334-348.

3. Sekulic A, Migden MR, Oro AE, ve ark. Efficacy and safety of Vismodegib in advanced basal- cell carcinoma. N Engl J Med. 2012; 366: 2171-9.

4. Glitza Oliva IC, Alqusairi R. Immunotherapy for Melanoma. Adv Exp Med Biol. 2018;995:43-63.

5. Diamantopoulos P, Gogas H. Melanoma immunotherapy dominates the field.

Ann Transl Med. 2016;4(14):269.

6. Trinh VA, Zobniw C, Hwu WJ. The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma. Expert Opin Drug Saf 2017;16(8):933-940.

7. Blume-Peytavi U, Bagot M, Tennstedt D, Saint Aroman M ve ark. Dermatology today and tomorrow: from symptom control to targeted therapy. J Eur Acad Dermatol Venereol. 2019;33 Suppl 1:3-36.

8. Eroglu Z, Ozgun A. Updates and challenges on treatment with BRAF/MEK-inhibitors in melanoma. Expert Opin Orphan Drugs. 2018;6(9):545-551

9. Liu M, Yang X, Liu J, Zhao B, Cai W, Li Y, Hu D. Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials. Oncotarget. 2017; 8(19):32258-32269

10. Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and Anti-CTLA4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Front Oncol. 2018; 28;8:86.

11. Gomes F, Serra-Bellver P, Lorigan P. The role of nivolumab in melanoma.

Future Oncol. 2018;14(13):1241-1252.

12. Deeks ED. Pembrolizumab: A Review in Advanced Melanoma. Drugs. 2016;76(3):375-86

13. Karakök Güngör H, Akay BN. İlerlemiş Melanomada Kullanılan Güncel Tedavi Yöntemleri. Turk J Dermatol 2016;10:137-144.

14. Bhandaru M., Rotte A. Monoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies. In: Steinitz M. (eds) Human Monoclonal Antibodies. Methods in Molecular Biology, vol 1904. 2019, Humana Press, New York, NY

15. Haanen JBAG, Carbonnel F, Robert C et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28(Suppl. 4), iv119–iv142 (2017).

16. Weber JS, Postow M, Lao CD, Schadendorf D. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist 2016; 21; 1230–1240.

**Korunma**

1. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166(5):1069-1080.

2. Ferlay J, Soerjomataram I, Ervik M ve ark. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer, 2013.

3. Arnold M, Holterhues C, Hollestein LM ve ark. Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015. J Eur Acad Dermatol Venereol 2013;28(9):1170–8.

4. Flohil SC, Seubring I, van Rossum MM ve ark. Trends in Basal cell carcinoma incidence rates: a 37-year Dutch observational study. J Invest Dermatol 2013;133:913–8.

5. Birch-Johansen F, Jensen A, Mortensen L ve ark. Trends in the incidence of nonmelanoma skin cancer in Denmark 1978–2007: rapid incidence increase among young Danish women. Int J Cancer 2010;127:2190–8.

6. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000;42:4-7.

7. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html

8. El Ghissassi F, Baan R, Straif K, Grosse Y, Secretan B, Bouvard V, et al. A review of human carcinogens. Lancet Oncol 2009;10:751-2.

9. Matsumura Y, Ananthaswamy HN. Molecular mechanisms of photocarcinogenesis. Front Biosci 2002;7:d765–83.

10. Purdue MP, From L, Armstrong BK ve ark. Etiologic and other factors predicting nevus-associated cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 2005; 14:2015–22.

11. Gallagher RP, Hill GB, Bajdik CD ve ark. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer I. Basal cell carcinoma. Arch Dermatol 1995;131:157–63.

12. Gallagher RP, Hill GB, Bajdik CD ve ark. Sunlight exposure, pigmentation factors, and risk of nonmelanocytic skin cancer II. Squamous cell carcinoma. Arch Dermatol 1995;131:164–9.

13. Armstrong BK, Kricker A. How much melanoma is caused by sun exposure? Melanoma Res 1993; 3:395-401.

14. http://www.who.int/mediacentre/news/notes/2006/np16/en/

15. Green AC, Williams GM, Logan V ve ark. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011;29: 257-63.

16. Santosh K. Katiyar, Harish C ve ark. Dietary proanthocyanidins prevent ultraviolet radiation-induced non-melanoma skin cancer through enhanced repair of damaged DNA-dependent activation of immune sensitivity. Seminars in Cancer Biology, 2017(46):138-145.

17. Afaq F,Katiyar SK. Polyphenols:skin photoprotection and inhibition of photocarcinogenesis. Mini Rev Med Chem 2011;11(14):1200-15.

18. Chen AC, Martin AJ, Choy BN ve ark. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med 2015;373(17):1618-26.

19. Kwasniak LA, Garcia-Zuazaga J. Basal cell carcinoma: Evidence-based medicine and review of treatment modalities. Int J Dermatol 2011;50:645–58.

20. Whiteman DC, Stickley M, Watt P ve ark. Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 2006; 24: 172–7.

21. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 2000;136:1524–30.

22. Wehner MR, Linos E, Parvataneni R ve ark. Timing of subsequent new tumors in patients who present with basal cell carcinoma or cutaneous squamous cell carcinoma. JAMA Dermatol 2015;151(4):382-388.

23. Adami J, Gabel H, Lindelof B ve ark. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003; 89:1221-1227.

24. Lindelof B, Sigurgeirsson B, Gabel H ve ark. Incidence of skin cancer in 5356 patients following organ transplantation. Skin cancers may develop soon after transplantation, and their incidence is associated with the patient's level of immunosuppression, among other factors. Br J Dermatol 2000; 143: 513-519.

25. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348(17):1681-1691.

26. Silverberg MJ, Leyden W, Warton EM ve ark. HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst 2013;105(5):350-360.

27. Lindelöf B, Sigurgeirsson B, Tegner E. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999;141(1):108-12.

28. Stern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst 1998(90):1278-1284.

29. Stern R.S. Follow up Study PUVA. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001(44):755-761.

30. Boniol M, Autier P, Boyle P, Gandini S. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ 2012;345:e4757.

31. Mansh M, Katz KA, Linos E ve ark. Association of skin cancer and indoor tanning in sexual minority men and women. JAMA Dermatol 2015;151(12):1308-1316.

32. Moore SC, Lee IM, Weiderpass E ve ar., et al. Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA Intern Med 2016;176(6):816-825.

33. Reichrath J, Lindqvist PG, De Gruijl FR. A Critical Appraisal of the Recent Reports on Sunbeds from the European Commission’s Scientific Committee on Health, Environmental and Emerging Risks and from the World Health Organization. Anticancer Research 2018;38: 1111-1120.

34. Takebe H, Nishigori C, Tatsumi K. Melanoma and Other Skin Cancers in Xeroderma Pigmentosum Patients and Mutation in Their Cells. J Investigative Dermatol 1989;92(5):236-238.

35. Williams K, Mansh M, Chin-Hong P ve ark. Voriconazole-Associated Cutaneous Malignancy: A Literature Review on Photocarcinogenesis in Organ Transplant Recipients. Clinical Infectious Diseases 2014; 58( 7): 997–1002.

36. Sheu J, Hawryluk EB, Guo D ve ark. Voriconazole phototoxicity in children: a retrospective review. J Am Acad Dermatol 2015;72(2):314-20.

37. Mohan SV, Chang J, Li S ve ark. Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma. JAMA Dermatol 2016;152(5):527-532.

38. Gallagher RP, Hill GB, Bajdik CD ve ark. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer I. Basal cell carcinoma. Arch Dermatol 1995;131:157--63.

39. De Giorgi V, Gori A, Greco A ve ark. Sun-protection behaviour, pubertal development and menarche: factors influencing the melanocytic nevi development. The results of a observational study on 1512 children. J Invest Dermatol 2018.

40. Khlat M, Parkin A, Green A. Mortality from Melanoma in Migrants to Australia: Variation by Age at Arrival and Duration of Stay. Am J Epidemiol 1992; 135: 1103–13.

41. Sanlorenzo M, Wehner MR, Linos E ve ark. The risk of melanoma in airline pilots and cabin crew: a meta-analysis. JAMA Dermatol 2015;151(1):51-8.

42. Thompson Coon J, Boddy K, Stein K ve ark. Does participating in physical activity in outdoor natural environments have a greater effect on physical and mental wellbeing than physical activity indoors? A systematic review. Environ Sci Technol 2011;45(5): 1761-1772.

43. Abraham A, Sommerhalder K, Abel T. Landscape and well-being: a scoping study on the health-promoting impact of outdoor environments. Int J Public Health 2010;55(1):59-69.

44. Feelisch M, Kolb-Bachofen V, Liu D ve ark. Is sunlight good for our heart? Eur Heart J 2010;31(9):1041-1045.

45. Oplander C, Volkmar CM, Paunel-Gorgulu A ve ark. Whole body UVA irradiation lowers systemic blood pressure by release of nitric oxide from intracutaneous photolabile nitric oxide derivates. Circ Res 2009;105(10):1031-1040.

46. Autier P, Boniol M, Pizot C, Mullie P, Vitamin D status and ill health: a systematic review. Lancet Diab Endocrinol 2014;2: 76–89.

47. Bjelakovic G, Gluud LL, Nikolova D ve ark. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev 2014;1:CD007470.

48. Yin L, Grandi N, Raum E ve ark. Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk. Aliment Pharmacol Ther 2009; 30:113–25.

49. Mondul MA, Weinstein SJ, Layne TM ve ark. Vitamin D and Cancer Risk and Mortality: State of the Science, Gaps, and Challenges. Epidemiol Rev 2017; 39(1): 28–48.

50. https://www.cdc.gov/cancer/skin/what\_cdc\_is\_doing/guidelines.htm

51. The Surgeon General's Call to Action to Prevent Skin Cancer. Editors US Department of Health and Human Services. Washington (DC): Office of the Surgeon General (US); 2014. Reports of the Surgeon General(http://www.surgeongeneral.gov)

52. Geller AC, Oliveria SA, Bishop M ve ark. Study of health outcomes in school children: key challenges and lessons learned from the Framingham Schools Natural History of Nevi Study. J Sch Health 2007; 77: 312–318.

53. Wang SQ, Dusza SW. Assessment of sunscreen knowledge: a pilot survey. Br J Dermatol 2009; 161 (3): 28–32.30.

54. http://www.epa.gov/sunwise

55. Kyle JW, Hammitt JK, Lim HW ve ark. Economic evaluation of the U.S. Environmental Protection Agency’s SunWise program: sun protection education for young children. Pediatrics. 2008;121(5):e1074-e1084.

56. Ally MS, Swetter SM, Hirotsu KE ve ark. Promoting sunscreen use and sun-protective practices in NCAA athletes: Impact of SUNSPORT educational intervention for student-athletes, athletic trainers, and coaches. J Am Acad Dermatol 2018;78(2):289-292.

57. Reding DJ, Fischer V, Gunderson P, Lappe K. Skin cancer prevention: a peer education model. Wisc Med J 1995; 94:75--9.

58. Hornung RL, Lennon PA, Garrett JM, DeVellis RF, Weinberg PD, Strecher VJ. Interactive computer technology for skin cancer prevention targeting children. Amer J Prev Med 2000; 18:69-76.

59. Correia O, Correia B, Duarte AF. A Skin Cancer Prevention Campaign: Spreading the Word on Sugar Packets. JAMA Dermatol 2017;153(2):129-130.

60. Buller DB, Berwick M, Lantz K ve ark. Smartphone mobile application delivering personalized, real-time sun protection advice: a randomized clinical trial. JAMA Dermatol 2015;151(5):497-504.

61. Glanz K, Saraiya M, Briss P. Impact of intervention strategies to reduce UVR exposure. David HillJ. Mark ElwoodDallas R (eds.), Prevention of Skin Cancer, 259-293. 2004 Kluwer Academic Publishers.

62. Nilsen LT, Hannevik M, Veierød MB. Ultraviolet exposure from indoor tanning devices: a systematic review. Br J Dermatol 2016;174(4):730-40.

63. https://www.aap.org/en-us/about-the-aap/aap-press-room/news-features-and-safety-tips/Pages/Sun-Safety-and-Protection.aspx

64. Petersen B, Wulf HC. Application of sunscreen-theory and reality. Photodermatol Photoimmunol Photomed 2014; 30:96-101.

65. Schalka S, dos Reis VM, Cuce LC. The influence of the amount of sunscreen applied and its sun protection factor (SPF): evaluation of two sunscreens including the same ingredients at different concentrations. Photodermatol Photoimmunol Photomed 2009; 25:175–180.

66. Russak JE, Chen T, Appa Y ve ark. A comparison of sunburn protection of high-sun protection factor (SPF) sunscreens: SPF 85 sunscreen is significantly more protective than SPF50. J Am Acad Dermatol 2010;62(2):348-349.

67. Williams JD, Maitra P, Atillasoy E ve ark. SPF 1001 sunscreen is more protective against sunburn than SPF 501 in actual use: Results of a randomized, double-blind, split-face, natural sunlight exposure clinical trial. J Am Acad Dermatol https://doi.org/10.1016/j.jaad.2017.12.062 article on press)

68. https://www.skincancer.org/prevention/sun-protection/clothing

69. Tuong W, Kuo S, Sivamani RK. Photoprotective effect of botanicals and vitamins: A systematic review of clinical trials. J Dermatolog Treat 2015;26(6):558-70.

70. Penta D, Somashekar BS, Meeran SM. Epigenetics of skin cancer: Interventions by selected bioactive phytochemicals. Photodermatol Photoimmunol Photomed 2018 ;34(1):42-49.

71. Bavinck JN, Tieben LM, Van der Woude FJ ve ark. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995;13(8):1933-8.

72. McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 1999;140(4):656-60.

73. Kraemer KH, DiGiovanna JJ, Moshell AN ve ark. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988;318(25):1633-7.

74. Kadakia KC, Barton DL, Loprinzi CL ve ark. Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer 2012;118(8):2128-37.

75. Levine N, Moon TE, Cartmel B ve ark. Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev. 1997;6(11):957-61.

76. Moon TE, Levine N, Cartmel B ve ark. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev. 1997;6(11):949-56.

77. https://www.nccn.org/professionals/physician\_gls/pdf/squamous.pdf

78. Sharma P, Montes de Oca MK, Alkeswani AR. Tea Polyphenols for the Prevention of UVB-induced Skin Cancer. Photodermatol Photoimmunol Photomed. 2018;34(1):50-5.

79. Kang NJ, Lee KW, Shin BJ ve ark. Caffeic acid, a phenolic phytochemical in coffee, directly inhibits Fyn kinase activity and UVB-induced COX-2 expression. Carcinogenesis. 2009;30(2):321–330.

80. Lee KJ, Jeong HG. Protective effects of kahweol and cafestol against hydrogen peroxide-induced oxidative stress and DNA damage. Toxicol Lett. 2007;173(2):80–87.

81. Hollenbeck AR, Shebl FM, Mayne ST. Coffee Drinking and Cutaneous Melanoma Risk in the NIH-AARP Diet and Health Study. J Natl Cancer Inst. 2015; 107(2): dju421

82. Wang J, Li X, Zhang D. Coffee consumption and the risk of cutaneous melanoma: a meta-analysis. Eur J Nutr. 2016 Jun;55(4):1317-29,

83. Yew YW2, Lai YC, Schwartz RA. Coffee Consumption and Melanoma: A Systematic Review and Meta-Analysis of Observational Studies. Am J Clin Dermatol 2016;17(2):113-23.

84. Caini S, Cattaruzza S, Bendinelli B ve ark. Coffee, tea and caffeine intake and the risk of non-melanoma skin cancer: a review of the literature and meta-analysis. Eur J Nutr 2017;56(1):1-12.

**Deri kanserlerinde yaşam kalitesi**

1. Lee EH, Klassen AF, Nehal KS, Cano SJ, Waters J, Pusic AL. A systematic review of patient-reported outcome instruments of nonmelanoma skin cancer in the dermatologic population. J Am Acad Dermatol 2013; 69(2):e59-67.

2. Aceituno-Madera P Bı-EA, Arias-Santiago S, Serrano-Ortega S. Evoluci´on de la incidencia del c´ancer de piel en el per´ıodo 1978–2002. Actas Dermo-Sifiliogr´aficas. 2010; 101(1):8.

3. Molho-Pessach V, Lotem M. Ultraviolet radiation and cutaneous carcinogenesis. Curr Probl Dermatol 2007; 35:14-27.

4. Davis RE SJ. Basal and squamous cell cancer of the facial skin. Curr Opin Otolaryngol Head Neck Surg 1997; 5:7.

5. Frankel DH, Hanusa BH, Zitelli JA. New primary nonmelanoma skin cancer in patients with a history of squamous cell carcinoma of the skin. Implications and recommendations for follow-up. J Am Acad Dermatol 1992; 26(5 Pt 1): 720-6.

6. Schreiber MM, Moon TE, Fox SH, Davidson J. The risk of developing subsequent nonmelanoma skin cancers. J Am Acad Dermatol 1990; 23(6 Pt 1):1114-8.

7. Rhee JS, Matthews BA, Neuburg M, Burzynski M, Nattinger AB. Creation of a quality of life instrument for nonmelanoma skin cancer patients. Laryngoscope. 2005; 115(7): 1178-85.

8. Hawkins DM, Jacobsen G, Johnson CC, Lim HW, Eide MJ. Self-reported quality of life after skin cancer in young adults. J Dermatolog Treat 2015; 26(4):357-60.

9. Furr LA, Wiggins O, Cunningham M, et al. A discussion of the psychosocial implications of disfigurement and the future of face transplantation. Plast Reconstr Surg 2007; 120(2):559-65.

10. Fayers P MD. Quality of Life. The Assessment, Analysis and Interpretation of Patient-Reported Outcomes. 2 ed. Chichester: Wiley & Sons; 2007.

11. Both H, Essink-Bot ML, Busschbach J, Nijsten T. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol 2007; 127 (12): 2726-39.

12. Ragnarson Tennvall G, Norlin JM, Malmberg I, Erlendsson A, Haedersdal M. Health Related Quality of Life in Patients With Actinic Keratosis - Results From Patients Treated in Dermatology Specialist Care In Denmark. Value Health. 2014;17(7):A611.

13. Alarcon I, Vinding GR, Christensen KB, et al. Spanish version of the Actinic Keratosis Quality of Life questionnaire. J Eur Acad Dermatol Venereol 2017;31(6):986-91.

14. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19(3):210-6.

15. Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 2001;5(2):105-10.

16. Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996;107(5):707-13.

17. Nijsten TE, Sampogna F, Chren MM, Abeni DD. Testing and reducing skindex-29 using Rasch analysis: Skindex-17. J Invest Dermatol 2006;126(6):1244-50.

18. Rhee JS, Matthews BA, Neuburg M, Logan BR, Burzynski M, Nattinger AB. Validation of a quality-of-life instrument for patients with nonmelanoma skin cancer. Arch Facial Plast Surg 2006;8(5):314-8.

19. Rhee JS, Matthews BA, Neuburg M, Logan BR, Burzynski M, Nattinger AB. The skin cancer index: clinical responsiveness and predictors of quality of life. Laryngoscope 2007;117(3):399-405.

20. Caddick J, Green L, Stephenson J, Spyrou G. The psycho-social impact of facial skin cancers. J Plast Reconstr Aesthet Surg 2012;65(9):e257-9.

21. Burdon-Jones D, Gibbons K. The Skin Cancer Quality of Life Impact Tool (SCQOLIT): a validated health-related quality of life questionnaire for non-metastatic skin cancers. J Eur Acad Dermatol Venereol 2013;27(9):1109-13.

22. Fallowfield L. Quality of life: a new perspective for cancer patients. Nat Rev Cancer 2002;2(11):873-9.

23. Cormier JN, Ross MI, Gershenwald JE, et al. Prospective assessment of the reliability, validity, and sensitivity to change of the Functional Assessment of Cancer Therapy-Melanoma questionnaire. Cancer 2008;112(10):2249-57.

24. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85(5):365-76.

25. Cormier JN, Cromwell KD, Ross MI. Health-related quality of life in patients with melanoma: overview of instruments and outcomes. Dermatol Clin 2012;30(2):245-54.

26. Sigurdardottir V, Bolund C, Sullivan M. Quality of life evaluation by the EORTC questionnaire technique in patients with generalized malignant melanoma on chemotherapy. Acta Oncol 1996;35(2):149-58.

27. Winstanley JB, Young TE, Boyle FM, et al. Cross-cultural development of a quality-of-life measure for patients with melanoma: phase 3 testing of an EORTC Melanoma Module. Melanoma Res 2015;25(1):47-58.

28. Esmann S, Vinding GR, Christensen KB, Jemec GB. Assessing the influence of actinic keratosis on patients' quality of life: the AKQoL questionnaire. Br J Dermatol 2013;168(2):277-83.

29. Mathias SD, Chren MM, Colwell HH, et al. Assessing health-related quality of life for advanced basal cell carcinoma and basal cell carcinoma nevus syndrome: development of the first disease-specific patient-reported outcome questionnaires. JAMA Dermatol 2014;150(2):169-76.

30. Veness MJ. The important role of radiotherapy in patients with non-melanoma skin cancer and other cutaneous entities. J Med Imaging Radiat Oncol 2008;52(3):278-86.

31. Nguyen TH, Ho DQ. Nonmelanoma skin cancer. Curr Treat Options Oncol 2002;3(3):193-203.

32. Rhee JS, Matthews BA, Neuburg M, Smith TL, Burzynski M, Nattinger AB. Skin cancer and quality of life: assessment with the Dermatology Life Quality Index. Dermatol Surg 2004;30(4 Pt 1):525-9.

33. Matthews BA, Rhee JS, Neuburg M, Burzynski ML, Nattinger AB. Development of the facial skin care index: a health-related outcomes index for skin cancer patients. Dermatol Surg 2006;32(7):924-34.

34. Miller SJ, Alam M, Andersen J, et al. Basal cell and squamous cell skin cancers. J Natl Compr Canc Netw 2010;8(8):836-64.

35. Mathias SD, Chren MM, Crosby RD, et al. Reliability and validity of the Advanced Basal Cell Carcinoma Index (aBCCdex). Br J Dermatol 2015;173(3):713-9.

36. Steenrod AW, Smyth EN, Bush EN, et al. A Qualitative Comparison of Symptoms and Impact of Varying Stages of Basal Cell Carcinoma. Dermatol Ther 2015;5(3):183-99.

37. Glanz K, Geller AC, Shigaki D, Maddock JE, Isnec MR. A randomized trial of skin cancer prevention in aquatics settings: the Pool Cool program. Health Psychol 2002;21(6):579-87.

38. Jackson KM, Aiken LS. A psychosocial model of sun protection and sunbathing in young women: the impact of health beliefs, attitudes, norms, and self-efficacy for sun protection. Health Psychol 2000;19(5):469-78.

39. Novak CB, Young DS, Lipa JE, Neligan PC. Evaluation of sun protection behaviour in patients following excision of a skin lesion. Can J Plast Surg 2007;15(1):38-40.

40. Rhee JS, Matthews BA, Neuburg M, Smith TL, Burzynski M, Nattinger AB. Quality of life and sun-protective behavior in patients with skin cancer. Arch Otolaryngol Head Neck Surg 2004;130(2):141-6.

41. Vinding GR, Esmann S, Olesen AB, Hansen LB, Christensen KB, Jemec GB. Interpretation of the skin cancer quality of life score: a validated quality of life questionnaire for non-melanoma skin cancer. Dermatology 2014;229(2):123-9.

42. Blackford S, Roberts D, Salek MS, Finlay A. Basal cell carcinomas cause little handicap. Qual Life Res 1996;5(2):191-4.

43. Rhee JS, Loberiza FR, Matthews BA, Neuburg M, Smith TL, Burzynski M. Quality of life assessment in nonmelanoma cervicofacial skin cancer. Laryngoscope 2003;113(2):215-20.

44. Chren MM, Sahay AP, Bertenthal DS, Sen S, Landefeld CS. Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol 2007;127(6):1351-7.

45. Hulyalkar R, Rakkhit T, Garcia-Zuazaga J. The role of radiation therapy in the management of skin cancers. Dermatol Clin 2011;29(2):287-96.

46. Burdon-Jones D, Thomas P, Baker R. Quality of life issues in nonmetastatic skin cancer. Br J Dermatol 2010;162(1):147-51.

47. Skiveren J, Mikkelsen MR, Daugbjerg H, Wulf HC. Skin reactions and quality of life after x-ray therapy of Basal cell carcinoma. J Skin Cancer 2012;825095.

48. Bates AS, Davis CR, Takwale A, Knepil GJ. Patient-reported outcome measures in nonmelanoma skin cancer of the face: a systematic review. Br J Dermatol 2013;168(6):1187-94.

49. de Troya-Martin M, Rivas-Ruiz F, Blazquez-Sanchez N, et al. Responsiveness of the Spanish Version of the "Skin Cancer Index". J Skin Cancer 2016;8180348.

50. Themstrup L, Jemec GE, Lock-Andersen J. Patients highly value routine follow-up of skin cancer and cutaneous melanoma. Dan Med J 2013;60(10):A4713.

51. Weinstock MA, Lee KC, Chren MM, Marcolivio K, Group VT. Quality of life in the actinic neoplasia syndrome: The VA Topical Tretinoin Chemoprevention (VATTC) Trial. J Am Acad Dermatol 2009;61(2):207-15.

52. Chen T, Bertenthal D, Sahay A, Sen S, Chren MM. Predictors of skin-related quality of life after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. Arch Dermatol 2007;143(11):1386-92.

53. Miller IM, Vinding G, Zarchi K, Esmann S, Murrell DF, Jemec GB. Differences in Disease-specific Quality of Life in Patients with Actinic Keratosis in Australia and Denmark. Acta Dermatovenerol Croat 2016;24(1):25-8.

54. Lear W, Akeroyd JE, Mittmann N, Murray C. Measurement of utility in nonmelanoma skin cancer. J Cutan Med Surg 2008;12(3):102-6.

55. Esmann S, Jemec GB. Management of actinic keratosis patients: a qualitative study. J Dermatolog Treat 2007;18(1):53-8.

56. Waldmann A, Nolte S, Pritzkuleit R, Breitbart EW, Katalinic A. Different aspects of self-reported quality of life in 450 german melanoma survivors. Cancers (Basel) 2011;3(2):2316-32.

57. Kasparian NA. Psychological stress and melanoma: are we meeting our patients' psychological needs? Clin Dermatol 2013;31(1):41-6.

58. Kasparian NA, McLoone JK, Butow PN. Psychological responses and coping strategies among patients with malignant melanoma: a systematic review of the literature. Arch Dermatol 2009;145(12):1415-27.

59. Katharine Hodgkinson PB, Turner J, Amanda O'Reilly KH, et al. Psychosocial Care of Cancer Patients: A Health Professional's Guide to What to Say and Do. Melbourne, Victoria: Ausmed Publications; 2008.

60. Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. Psychooncology 2001;10(1):19-28.

61. de Vries E, Houterman S, Janssen-Heijnen ML, et al. Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of the Netherlands. Ann Oncol 2007;18(6):1110-6.

62. Foot G S-FR. Measuring unmet needs of people living with cancer. Cancer Forum 1995;19:5.

63. Fallowfield LJ, Hall A, Maguire P, Baum M, A'Hern RP. Psychological effects of being offered choice of surgery for breast cancer. BMJ 1994;309(6952):448.

64. Trask PC, Paterson AG, Hayasaka S, Dunn RL, Riba M, Johnson T. Psychosocial characteristics of individuals with non-stage IV melanoma. J Clin Oncol 2001;19(11):2844-50.

65. Loquai C, Schmidtmann I, Beutel M, et al. Quality of life in melanoma patients during adjuvant treatment with pegylated interferon-alpha2b: patients' and doctors' views. Eur J Dermatol 2011;21(6):976-84.

66. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23.

67. Revicki DA, van den Eertwegh AJ, Lorigan P, et al. Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health Qual Life Outcomes 2012;10:66.

68. Bergenmar M, Mansson-Brahme E, Hansson J, Brandberg Y. Surgical resection margins do not influence health related quality of life or emotional distress in patients with cutaneous melanoma: results of a prospective randomised trial. Scand J Plast Reconstr Surg Hand Surg 2010;44(3):146-55.

69. Newton-Bishop JA, Nolan C, Turner F, et al. A quality-of-life study in high-risk (thickness > = or 2 mm) cutaneous melanoma patients in a randomized trial of 1-cm versus 3-cm surgical excision margins. J Investig Dermatol Symp Proc 2004;9(2):152-9.

70. Beasley GM, Caudle A, Petersen RP, et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg 2009;208(5):706-15.

71. Jiang BS, Speicher PJ, Thomas S, Mosca PJ, Abernethy AP, Tyler DS. Quality of life after isolated limb infusion for in-transit melanoma of the extremity. Ann Surg Oncol 2015;22(5):1694-700.

72. Gallais Serezal I, Beaussant Y, Rochigneux P, et al. End-of-life care for hospitalized patients with metastatic melanoma in France: a nationwide, register-based study. Br J Dermatol 2016;175(3):583-92.

73. Hamama-Raz Y, Solomon Z, Schachter J, Azizi E. Objective and subjective stressors and the psychological adjustment of melanoma survivors. Psychooncology 2007;16(4):287-94.

74. Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. Cancer Council Australia and Australian Cancer Network, Sydney and New Zealand Guidelines Group, Wellington, 2008; 101-111.

75. Prigerson HG, Bao Y, Shah MA, et al. Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. JAMA Oncol 2015;1(6):778-84.

76. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363(8):733-42.

**Deri tümörlerinde nanoteknoloji**

1- Tasleem A, Nuzhatun N, Syed SA, Sheikh S, Raheel M, Muzafar RS. Therapeutic and diagnostic applications of nanotechnology in dermatology and cosmetics. J Nanomedine Biotherapeutic Discov 2015: 5; 1.

2- DeLouise LA. Applications of Nanotechnology in Dermatology. Journal of Investigative Dermatology 2012:132;964–975.

3- Lee P, Nasir A, Wong KKY. Emerging nanomedicine for skin cancer. In: Nasir A, Friedman A, Wang S, editors. Nanotechnology in Dermatology, Springer, London, 2013:119-125.

4- Tasleem A, Mohammad A. Nanotechnology-Dermatological Perspective. Int J Nanomed Nanosurg 2016:2(2): doi http://dx.doi.org/10.16966/24703206.112.

5- Nasir A. Nanotechnology and dermatology: Part I-potential of nanotechnology Clinics in Dermatology 2010:28;458–466.

6- Schairer D, Chouake J, Nasir A, Friedman A. Nanotechnology applications in dermatology. In: Brenner S, editor. The clinical nanomedicine handbook, Taylor & Francis Group, USA, 2014:85-194.

7- Antonio JR, Antonio CR, Cardeal ILS, Ballavenuto JMA, Oliveira JR. Nanotechnology in dermatology. An Bras Dermatol. 2014;89(1):126-36.

8- Papakostas D, Rancan F, Sterry W, Blume-Peytavi U, Vogt A. Nanoparticles in dermatology. Arch Dermatol Res. 2011;303:533-50.

9- Kothamasu P, Kanumur H, Ravur N, Maddu C, Parasuramrajam R, Thangavel S. Nanocapsules: the weapons for novel drug delivery systems. Bioimpacts. 2012;2(2):71-81.

10- Landriscina A, Rosen J, Friedman AJ. Nanotechnology, inflammation and the skin barrier: Innovative approaches for skin health and cosmesis. Cosmetics 2015. 2;177-186.

11- Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001; 47: 165–96.

12- Müller RH, Mehnert W, Lucks JS, Schwarz C, Zur Mühlen A, Meyhers H, Freıtas C, Rühl D. Solid lipid nanoparticles (SLN) : an alternative colloidal carrier system for controlled drug delivery. European journal of pharmaceutics and biopharmaceutics 1995; 41: 62-69.

13- Freitas Jr RA. Nanomedicine, Vol I: basic capabilities. Landes Bioscience: Georgetown, TX; 1999

14- Lohani A, Verma A, Joshi H, Yadav N, Karki N. Nanotechnology-based cosmeceuticals. ISRN Dermatol. 2014; 22: 843687. doi: 10.1155/2014/843687. eCollection 2014.

15- Azeem A, Anwer MK, Talegaonkar S. Niosomes in sustained and targeted drug delivery: some recent advances. J Drug Target 2009; 17: 671–89.

16- Gangadharappa HV, Gupta NV, Prasad M SC, Shivakumar HG. Current trends in microsponge drug delivery system. Curr Drug Deliv. 2013;10(4):453-65.

17- Liu H, Tu Z, Feng F, Shi H, Chen K, Xu X. Virosome, a hybrid vehicle for effi cient and safe drug delivery and its emerging application in cancer treatment. Acta Pharm. 2015:65(2); 105–116.

18- Schäfer-Korting M, Mehnert W, Korting HC. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev. 2007;59:427-43

19- Walther C, Meyer K, Rennert R, Neundorf I. Quantum dot-carrier peptide conjugates suitable for imaging and delivery applications. Bioconjug Chem. 2008;19:2346-56. 24.

20- Zhou M, Nakatani E, Gronenberg LS, Tokimoto T, Wirth MJ, Hruby VJ, et al. Peptidelabeled quantum dots for imaging GPCRs in whole cells and as single molecules. Bioconjug Chem. 2007;18:323-32.

21- Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 2005 Mar;19(3):311-30

22- Huang X, Peng X, Wang Y, Wang Y, Shin DM, El-Sayed MA, Nie S. A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands. ACS Nano. 2010 Oct 26;4(10):5887-96.

23- Huang HC, Barua S, Sharma G, Dey SK, Rege K Inorganic nanoparticles for cancer imaging and therapy. J Control Release. 2011 Nov 7;155(3):344-57.

24- Ilbasmiş-Tamer S, Yilmaz S, Banoğlu E, Değim IT. Carbon nanotubes to deliver drug molecules. J Biomed Nanotechnol. 2010 Feb;6(1):20-7.

25- Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci. 2001;14:101-14.

26- Zhang LW, Monteiro-Riviere NA. Mechanisms of quantum dot nanoparticle cellular uptake.Toxicol Sci. 2009;110(1):138-55.

27- Cevc G and Vierl U. Nanotechnology and the transdermal route: a state of the art review and critical appraisal. J Control Release 2010; 141: 277–99.

28- Farokhzad OC. Nanotechnology for drug delivery: the perfect partnership. Expert Opin Drug Deliv 2008; 5: 927–9.

29- Tran MA, Watts RJ, Robertson GP. Use of liposomes as drug delivery vehicles for treatment of melanoma. Pigment Cell Melanoma Res. 2009;22:388-99.

30- Xin Y, Huang Q, Tang JQ, Hou XY, Zhang P, Zhang LZ, Jiang G. Nanoscale drug delivery for targeted chemotherapy. Cancer Lett. 2016, 28;379(1):24-31.

31- Hia J, Nasir A. Photonanodermatology: the interface of photobiology, dermatology and nanotechnology. Photodermatol Photoimmunol Photomed. 2011;27(1):2-9

32- Kim JK, Nasir A, Nelson KC. Nanotchnology and the diagnosis of cutaneous malignencies. In: Nasir A, Friedman A, Wang S, editors. Nanotechnology in Dermatology, Springer, London, 2013:127-132.

33- Eden JG, Park S-J, Ostrom NP, Chen K-F. Recent advances in microcavity plasma devices and arrays: a versatile photonic platform J Phys D Appl Phys. 2005;38:1644-8.

34- Zuo L, Wei W, Morris M, Wei J, Gorbounov M, Wei C. New technology and clinical applications of nanomedicine. Med Clin North Am. 2007;91(5):845-62.

35- Jain KK. Nanotechnology in clinical laboratory diagnostics. Clin Chim Acta. 2005;358:37-54

36- Shiohara A, Hoshino A, Hanaki K, Suzuki K, Yamamoto K. On the cyto-toxicity caused by quantum dots. Microbiol Immunol. 2004;48(9):669-75.

37- Lovric J, Bazzi HS, Cuie Y, Fortin GR, Winnik FM, Maysinger D. Differences in subcellular distribution and toxicity of green and red emitting CdTe quantum dots. J Mol Med 2005;83:377-85.

38- Saraceno R, Chiricozzi A, Gabellini M, Chimenti S. Emerging applications of nanomedicine in dermatology. Skin Res Technol. 2013 Feb;19(1):e13-9

39- Ahmed, N et al. Theranostic applications of nanoparticles in câncer. Drug Discov Today. 2012;17:928-34. 109

40- Solanki A, Kim JD, Lee KB. Nanotechnology for regenerative medicine: nanomaterials for stem cells imaging. Nanomedicine (Lond). 2008;3:567-78.

41- Boixeda P, Feltes F, Santiago JL, Paoli J. Future prospects in dermatologic applications of lasers, nanotechnology, and other new technologies. Actas Dermosifiliogr. 2015;106(3):168-79.

42- Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. Nanomedicine. 2007;3:20-31.

43- Wang MD, Shin DM, Simons JW, Nie S. Nanotechnology for targeted cancer therapy. Expert Rev Anticancer Ther. 2007;7(6):833-7.

44- Elder D. Tumor progression, early diagnosis and prognosis of melanoma. Acta Oncol. 1999;38:535-47.

45- Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res. 2007;17:117-27

46- Salazar-Onfray F, Lo ´pez M, Lundqvist MA et al. Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker. Br J Cancer 2002; 87:414–22

47- Hild W, Pollinger K, Caporale A et al. G protein-coupled receptors function as logic gates for nanoparticle binding and cell uptake. Proc Natl Acad Sci USA 2010;107:10667–72

48-Chen Y, Bathula SR, Yang Q et al. Targeted nanoparticles deliver siRNA to melanoma. J Invest Dermatol 2010; 130:2790–8.

49- Parhi P, Mohanty C, Sahoo SK. Nanotechnology-based combinational drug delivery:133. an emerging approach for cancer therapy. Drug Discov Today. 2012;17:1044-52.

50- Ahmed, N et al. Theranostic applications of nanoparticles in câncer. Drug Discov109. Today. 2012;17:928-34.

51- Farrera C, Andon FT, Feliu N. Carbon Nanotubes as Optical Sensors in Biomedicine. ACS Nano 2017 11 (11), 10637-10643.

52- Naserzadeh P, Ansari Esfeh F, Kaviani M, Ashtari K, Kheirbakhsh R, Salimi A, Pourahmad J. Single-walled carbon nanotube, multi-walled carbon nanotube and Fe2O3 nanoparticles induced mitochondria mediated apoptosis in melanoma cells. Cutan Ocul Toxicol. 2017;18:1-10.

53- Arias JL. Novel strategies to improve the anticancer action of 5-fluorouracil by using drug delivery systems. Molecules. 2008;13(10):2340-69.

54- Shibu ES, Hamada M, Muras N, Biju V. Nanomaterials formulations for photothermal and photodynamic therapy of cancer. Journal of Photochemistry and Photobiology C: Photochemistry Reviews 2013. 15, 53-72.

55- Dickerson EB, Dreaden EC, Huang X, El-Sayed IH, Chu H, Pushpanketh S, et al.88. Gold nanorod assisted near-infrared plasmonic photothermal therapy (PPTT) of squamous cell carcinoma in mice. Cancer Lett. 2008;269:57-66.

56- El-Sayed IH, Huang X, El-Sayed MA. Selective laser photo-thermal therapy of epit-89. helial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett. 2006;239:129-35.

57- Lu W, Xiong C, Zhang G, Huang Q, Zhang R, Zhang JZ, et al. Targeted photother-90. mal ablation of murine melanomas with melanocyte-stimulating hormone analogconjugated hollow gold nanospheres. Clin Cancer Res. 2009;15:876-86.

58- Chatterjee DK, Fong LS, Zhang Y. Nanoparticles in photodynamic therapy: an emerging paradigm. Adv Drug Deliv Rev. 2008;60:1627-37.

59- Hamblin MR, Chiang LY, Lakshmanan S, Huang YY, Garcia-Diaz M, Karimi M, de Souza Rastelli AN, Chandran R. Nanotechnology for photodynamic therapy: a perspective from the Laboratory of Dr. Michael R. Hamblin in the Wellman Center for Photomedicine at Massachusetts General Hospital and Harvard Medical School. Nanotechnol Rev. 2015; 4(4): 359–372

60- Rancan F, Helmreich M, Mölich A, Ermilov EA, Jux N, Röder B, et al. Synthesis and93. in vitro testing of a pyropheophorbide-a-fullerene hexakis adduct immunoconjugate for photodynamic therapy. Bioconjug Chem. 2007;18:1078-86.

61- Khdair A, Chen D, Patil Y, Ma L, Dou QP, Shekhar MP, et al. Nanoparticle-mediated94. combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. J Control Release. 2010;141:137-44.

62- Gamaleia NF, Shton IO. Gold mining for PDT: great expectations from tiny nanoparticles. Photodiagnosis Photodyn. Ther. 2015; 12:221–231]

63- Vankayala R, Lin CC, Kalluru P, Chiang CS, Hwang KC. Gold nanoshells-mediated bimodal photodynamic and photothermal cancer treatment using ultra-low doses of near infra-red light. Biomaterials. 2014; 35:5527–5538.

64- Li Y, Wen T, Zhao R, Liu X, Ji T, Wang H, Shi X, Shi J, Wei J, Zhao Y, Wu X, Nie G. Localized electric field of plasmonic nano-platform enhanced photodynamic tumor therapy. ACS Nano. 2014; 8:11529–11542.

65- Nasir A. Nanotechnology and dermatology: Part II—risks of nanotechnology. Clinics in Dermatology 2010:28;581–588.

66- Araujo L, Lobenberg R, Kreuter J. Influence of the surfactant concentration on the body distribution of nanoparticles. J Drug Target 1999;6:373-85.

67- Oberdörster G, Gelein RM, Ferin J, Weiss B. Association of particulate air pollution and acute mortality: involvement of ultrafine particles? Inhal Toxicol 1995;7:111-24.

68. Oberdörster G, Sharp Z, Atudorei V, et al. Extrapulmonary translocation of ultrafine carbon particles following whole-body inhalation exposure of rats. J Toxicol Environ Health A 2002;65:1531-43.

69. Oberdörster G. Significance of particle parameters in the evaluation of exposure-dose-response relationships of inhaled particles. Inhal Toxicol 1996;8:73-89.

70- Mura S, Couvreur P. Nanotheranostics for personalized medicine, Adv Drug Deliv Rev. 2012;64:1394-416.

71- Brown DM, Wilson MR, MacNee W, Stone V, Donaldson K. Size dependent proinflammatory effects of ultrafine polystyrene particles: a role for surface area and oxidative stress in the enhanced activity of ultrafines. Toxicol Appl Pharmacol 2001;175:191-9.

72- Hetland RB, Cassee FR, Refsnes M, et al. Release of inflammatory cytokines, cell toxicity and apoptosis in epithelial lung cells after exposure to ambient air particles of different size fractions. Toxicol In Vitro 2004;18:203-12.

73- Niska K, Zielinska E, Radomski MW, Inkielewicz-Stepniak I. Metal nanoparticles in dermatology and cosmetology: Interactions with human skin cells. Chem Biol Interact. 2017. pii: S0009-2797(16)30629-9.

74- Beck-Speier I, Dayal N, Karg E, et al. Oxidative stress and lipid mediators induced in alveolar macrophages by ultrafine particles. Free Radic Biol Med 2005;38:1080-92.

75- Sayes CM, Gobin AM, Ausman KD, Mendez J, West JL, Colvin VL. Nano-C(60) cytotoxicity is due to lipid peroxidation. Biomaterials 2005;26:7587-95.

76- Schins RPF, Donaldson K. Nuclear factor kappa-B activation by particles and fibres. Inhal Toxicol 2000;12:317-26.

77- Oberdörster G, Oberdörster E, Oberdörster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005;113:823-39.

78- Oberdörster G. Toxicology of ultrafine particles: in vivo studies. Phil Trans Roy Soc London Series 2000;358:2719-40.

79- Oberdörster G, Maynard A, Donaldson K, et al. Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part Fibre Toxicol 2005;2:8.

**Deneysel kanser modelleri**

1. Nehal KS and Bichakjian CK. Update on Keratinocyte Carcinomas. N Engl J Med 2018; 379:363-374.

2. Robinson JK. Sun exposure, sun protection, and vitamin D. JAMA. 2005; 294(12):1541-3.

3.Shaikh WR, Dusza SW, Weinstock MA, Oliveria SA, Geller AC, Halpern AC. Melanoma Thickness and Survival Trends in the United States, 1989 to 2009. J Natl Cancer Inst. 2015;108(1). pii: djv294.

4. Benam KH, Dauth S, Hassell B, Herland A, Jain A, Jang KJ, Karalis K, Kim HJ, MacQueen L, Mahmoodian R, Musah S, Torisawa YS, van der Meer AD, Villenave R, Yadid M, Parker KK, and Ingber DE. Engineered In Vitro Disease Models Annu. Rev. Pathol. Mech. Dis. 2015;10:195-262.

5. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, López CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein BH, Miller-Graziano C, Calvano SE, Mason PH, Cobb JP, Rahme LG, Lowry SF, Maier RV, Moldawer LL, Herndon DN, Davis RW, Xiao W, Tompkins RG; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program.Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3507-12.

6. Yu JY, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917–20.

7. Barutello 1, Rolih V, Arigoni M, Tarone L, Conti L, Quaglino E, Buracco P, Cavallo F, Riccardo F. Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy. Int J Mol Sci. 2018 Mar 10;19(3). pii: E799.

8. Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat. Rev. Immunol. 2015, 15, 669–682.

9. Esch EW, Bahinski A, Huh D. Organs-on-chips at the frontiers of drug discovery. Nat. Rev. Drug Discov. 14, 248–260.

10. Ben-David U, Ha G, Tseng YY, Greenwald N, Oh C, Shih J, McFarland JM, Wong B, Boehm JS, Beroukhim R, Golub TR. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat. Genet. 2017, 49, 1567–1575.

11. Riccardo F, Aurisicchio L, Impellizeri JA, Cavallo F. The importance of comparative oncology in translational medicine. Cancer Immunol. Immunother. 2014, 64, 137–148.

12. Perna D, Karreth FA, Rust AG, Perez-Mancera PA, Rashid M, Iorio F, Alifrangis C, Arends MJ, Bosenberg MW, Bollag G, Tuveson DA, Adams DJ. BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. Proc. Natl. Acad. Sci. USA 2015, 112, E536–E545.

13. Kober J, Gugerell A, Schmid M, Zeyda M, Buchberger E, Nickl S, Hacker S, Ankersmit HJ, Keck M. Wound Healing Effect of Conditioned Media Obtained From Adipose Tissue on Human Skin Cells: A Comparative in Vitro Study. Ann Plast Surg. 2016 Aug; 77(2):156-63.

14. DeCicco-Skinner KL, Henry GH, Cataisson C, Tabib T, Gwilliam JC, Watson NJ, Bullwinkle EM, Falkenburg L, O'Neill RC, Morin A, Wiest JS. Endothelial cell tube formation assay for the in vitro study of angiogenesis. J Vis Exp 2014;(91):e51312.

15. Termini L and Boccardo E. Epithelial Organotypic Cultures: A Viable Model to Address Mechanisms of Carcinogenesis by Epitheliotropic Viruses Curr Top Med Chem. 2018;18(4):246-255.

16.MariaPonec. Skin constructs for replacement of skin tissues for in vitro testing. Advanced Drug Delivery Reviews. Volume 54, Supplement, 1 November 2002, Pages S19-S30.

17. Bergers LIJC, Reijnders CMA, van den Broek LJ, Spiekstra SW, de Gruijl TD, Weijers EM, Gibbs S. Immune-competent human skin disease models. Drug Discov Today. 2016 Sep;21(9):1479-1488.

18. van den Broek LJ, Bergers LIJC, Reijnders CMA, Gibbs S. Progress and Future Prospectives in Skin-on-Chip Development with Emphasis on the use of Different Cell Types and Technical Challenges. Stem Cell Rev. 2017 Jun;13(3):418-429.

19. Pupovac A, Senturk B, Griffoni C, Maniura-Weber K, Rottmar M, McArthur SL. Toward Immunocompetent 3D Skin Models. Adv. Healthcare Mater. 2018, 7, 1701405-1701426.

20. Netzlaff F, Lehr CM, Wertz PW, Schaefer UF. The human epidermis models EpiSkin, SkinEthic and EpiDerm: an evaluation of morphology and their suitability for testing phototoxicity, irritancy, corrosivity, and substance transport. Eur. J. Pharm. Biopharm. 2005, 60, 167.

21. Leist M, Lidbury BA, Yang C, Hayden PJ, Kelm JM, Ringeissen S, Detroyer A, Meunier JR, Rathman JF, Jackson GR Jr, Stolper G, Hasiwa N. Novel technologies and an overall strategy to allow hazard assessment and risk prediction of chemicals, cosmetics, and drugs with animal-free methods. ALTEX. 2012;29(4):373-88.

22. Ackermann K, Borgia SL, Korting HC, Mewes KR, Schäfer-Korting M. The Phenion full-thickness skin model for percutaneous absorption testing. Skin Pharmacol. Physiol. 2010, 23, 105.

23. Davies LC, Boberg E, Le Blanc K. Commentary: Role of Mesenchymal Stromal Cell-Mediated Crosstalk with Macrophages in Graft-versus-Host Disease and Tissue Repair. Biol Blood Marrow Transplant. 2017 Jun;23(6):861-862

24. Chau DY, Johnson C, MacNeil S, Haycock JW, Ghaemmaghami AM. The development of a 3D immunocompetent model of human skin. Biofabrication. 2013 Sep;5(3):035011.

25. Monsuur HN, Boink MA, Weijers EM, Roffel S, Breetveld M, Gefen A, van den Broek LJ, Gibbs S. Methods to study differences in cell mobility during skin wound healing in vitro. J Biomech. 2016 May 24;49(8):1381-1387.

26. Kühbacher A, Henkel H, Stevens P, Grumaz C, Finkelmeier D, Burger-Kentischer A, Sohn K, Rupp S. Central Role for Dermal Fibroblasts in Skin Model Protection against Candida albicans. J Infect Dis. 2017 Jun 1;215(11):1742-1752

27. Linde N, Gutschalk CM, Hoffmann C, Yilmaz D, Mueller MM. Integrating macrophages into organotypic co-cultures: a 3D in vitro model to study tumor-associated macrophages. PLoS One. 2012;7(7):e40058.

28. Edmondson R, Broglie JJ, Adcock AF, Yang L. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol. 2014 May;12(4):207-18.

29. Ouwehand K1, Spiekstra SW, Waaijman T, Scheper RJ, de Gruijl TD, Gibbs S. Technical advance: Langerhans cells derived from a human cell line in a full-thickness skin equivalent undergo allergen-induced maturation and migration. J Leukoc Biol. 2011 Nov;90(5):1027-33.

 30. Ouwehand K, Spiekstra SW, Waaijman T, Breetveld M, Scheper RJ, de Gruijl TD, Gibbs S. CCL5 and CCL20 mediate immigration of Langerhans cells into the epidermis of full thickness human skin equivalents. Eur J Cell Biol. 2012 Oct;91(10):765-73.

31. Kosten IJ, Spiekstra SW, de Gruijl TD, Gibbs S. MUTZ-3 derived Langerhans cells in human skin equivalents show differential migration and phenotypic plasticity after allergen or irritant exposure. Toxicol Appl Pharmacol. 2015 Aug 15;287(1):35-42

32 Lindner D, Zietsch C, Becher PM, Schulze K, Schultheiss HP, Tschöpe C, Westermann D. Differential expression of matrix metalloproteases in human fibroblasts with different origins. Biochem Res Int. 2012;2012:875742.

 33. Almine JF, Wise SG, Hiob M, Singh NK, Tiwari KK, Vali S, Abbasi T, Weiss AS. Elastin sequences trigger transient proinflammatory responses by human dermal fibroblasts. FASEB J. 2013 Sep;27(9):3455-65.

34. Chan EC, Kuo SM, Kong AM, Morrison WA, Dusting GJ, Mitchell GM, Lim SY, Liu GS. Three Dimensional Collagen Scaffold Promotes Intrinsic Vascularisation for Tissue Engineering Applications. PLoS One. 2016 Feb 22;11(2):e0149799.

35. Groeber F, Engelhardt L, Lange J, Kurdyn S, Schmid FF, Rücker C, Mielke S, Walles H1, Hansmann J1. A first vascularized skin equivalent as an alternative to animal experimentation. ALTEX. 2016;33(4):415-422.

36. Yu Y, Alkhawaji A, Ding Y, Mei J. Decellularized scaffolds in regenerative medicine. Oncotarget. 2016 Sep 6;7(36):58671-58683.

37. Maas-Szabowski N, Stärker A, Fusenig NE. Epidermal tissue regeneration and stromal interaction in HaCaT cells is initiated by TGF-alpha. J Cell Sci. 2003 Jul 15;116(Pt 14):2937-48.

38. Reijnders CM, van Lier A, Roffel S, Kramer D, Scheper RJ, Gibbs S. Development of a Full-Thickness Human Skin Equivalent In Vitro Model Derived from TERT-Immortalized Keratinocytes and Fibroblasts. Tissue Eng Part A. 2015 Sep;21(17-18):2448-59

39. Ramadan Q, Ting FC. In vitro micro-physiological immune-competent model of the human skin. Lab Chip. 2016 May 21;16(10):1899-908.

40. Wufuer M, Lee G, Hur W, Jeon B, Kim BJ, Choi TH, Lee S. Skin-on-a-chip model simulating inflammation, edema and drug-based treatment Sci Rep. 2016 Nov 21;6:37471.

41. Rosińczuk J, Taradaj J, Dymarek R, Sopel M. Mechanoregulation of Wound Healing and Skin Homeostasis. Biomed Res Int. 2016;2016:3943481.

42. Gledhill K, Guo Z, Umegaki-Arao N, Higgins CA, Itoh 1, Christiano AM. Melanin Transfer in Human 3D Skin Equivalents Generated Exclusively from Induced Pluripotent Stem Cells. PLoS One. 2015; 10(8 ) : e0136713.

43. Wagner I, Materne EM, Brincker S, Süssbier U, Frädrich C, Busek M, Sonntag F, Sakharov DA, Trushkin EV, Tonevitsky AG, Lauster R, Marx U. A dynamic multi-organ-chip for long-term cultivation and substance testing proven by 3D human liver and skin tissue co-culture. Lab Chip. 2013;13(18):3538-47.

44. Ataç 1, Wagner I, Horland R, Lauster R, Marx U, Tonevitsky AG, Azar RP, Lindner G. Skin and hair on-a-chip: in vitro skin models versus ex vivo tissue maintenance with dynamic perfusion. Lab Chip. 2013; 13(18):3555-61.

45. Abaci HE, Gledhill K, Guo Z, Christiano AM, Shuler ML. Pumpless microfluidic platform for drug testing on human skin equivalents. Lab Chip. 2015;15(3):882-8.

46. Turley, S.J.; Cremasco, V.; Astarita, J.L. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat. Rev. Immunol. 2015, 15, 669–682

47. Beaumont, K.; Mohana-Kumaran, N.; Haass, N. Modeling Melanoma In Vitro and In Vivo. Healthcare (Basel). 2013 Dec 23;2(1):27-46.

48. Ud-Din S, Bayat A. Non-animal models of wound healing in cutaneous repair: In silico, in vitro, ex vivo, and in vivo models of wounds and scars in human skin. Wound Repair Regen. 2017 Apr;25(2):164-176

49 Coricovac D, Dehelean C, Moaca EA, Pinzaru I, Bratu T, Navolan D, Boruga O. Cutaneous Melanoma A Long Road from Experimental Models to Clinical Outcome: A Review. Int J Mol Sci. 2018 May 24;19(6). pii: E1566.

50. van der Weyden L, Patton EE, Wood GA, Foote AK, Brenn T, Arends MJ, Adams DJ. Cross-species models of human melanoma. J. Pathol. 2016, 238, 152–165.

 51. Ha L, Noonan FP, De Fabo EC, Merlino G. Animal models of melanoma. J. Investig. Dermatol. Symp. Proc. 2005, 10, 86–88.

52. Schook LB, Collares TV, Hu W, Liang Y, Rodrigues FM, Rund LA, Schachtschneider KM, Seixas FK, Singh K, Wells KD, Walters EM, Prather RS, Counter CM. A genetic porcine model of cancer. PLoS ONE 2015, 10, e0128864.

53. Idilli AI, Precazzini F, Mione MC, Anelli V. Zebrafish in Translational Cancer Research: Insight into Leukemia, Melanoma, Glioma and Endocrine Tumor Biology. Genes (Basel). 2017 Sep 20;8(9). pii: E236.

54. Bomirski A, Słominski A, Bigda J. The natural history of a family of transplantable melanomas in hamsters. Cancer Metastasis Rev. 1988, 7, 95–118.

55. Thang ND, Yajima I, Nakagawa K, Tsuzuki T.; Kumasaka MY, Ohgami N, Ly TB, Iwamoto T, Watanabe D, Kato M. A novel hairless mouse model for malignant melanoma. J. Dermatol. Sci. 2012, 65,207–212.

56. Kawaguchi K, Igarashi K, Li S, Han Q, Tan Y, Kiyuna T, Miyake K, Murakami T1, Chmielowski B, Nelson SD, Russell TA, Dry SM, Li Y, Unno M, Eilber FC, Hoffman RM. Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model. Oncotarget. 2017;8(49):85516-85525.

57. Tanaka R, Goshima F, Esaki S, Sato Y, Murata T, Nishiyama Y, Watanabe D, Kimura H. The efficacy of combination therapy with oncolytic herpes simplex virus HF10 and dacarbazine in a mouse melanoma model. Am. J. Cancer Res. 2017, 7, 1693–1703.

58 Soica C, Danciu C, Savoiu-Balint G, Borcan F, Ambrus R, Zupko I, Bojin F, Coricovac D, Ciurlea S, Avram S, Dehelean CA, Olariu T, Matusz P. Betulinic Acid in Complex with a Gamma-Cyclodextrin Derivative Decreases Proliferation and in Vivo Tumor Development of Non-Metastatic and Metastatic B164A5 Cells. Int. J. Mol. Sci. 2014, 15, 8235–8255.

59. Huang R, Andersen LMK, Rofstad EK. Metastatic pathway and the microvascular and physicochemical microenvironments of human melanoma xenografts. J. Transl. Med. 2017;15: 203.

60. Crawford M, Leclerc V,Dagnino L. A reporter mouse model for in vivo tracing and in vitro molecular studies of melanocytic lineage cells and their diseases. Biol. Open 2017; 6: 1219–1228.

61. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977; 197: 893–895.

62. Becker JC, Houben R, Schrama D, Voigt H, Ugurel S, Reisfeld RA. Mouse models for melanoma: A personal perspective. Exp Dermatol. 2010 Feb;19(2):157-64.

63. Liu Q, Das M, Liu Y, Huang L. Targeted drug delivery to melanoma. Adv Drug Deliv Rev. 2018 Mar 1;127:208-22.

64. Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived – but they can be improved. Cancer Biol Ther 2003; 2: S134–S139.

65. Kuzu OF, Nguyen FD, Noory MA, Sharma A. Current State of Animal (Mouse) Modeling in Melanoma Research. Cancer Growth Metastasis 2015;8: 81–94.

66. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977; 197: 893–895.

67. Karageorgis A, Claron M, Jugé R, Aspord C, Thoreau F, Leloup C, Kucharczak J, Plumas J, Henry M, Hurbin A, Verdié P, Martinez J, Subra G, Dumy P, Boturyn D, Aouacheria A, Coll JL. Systemic Delivery of Tumor-Targeted Bax-Derived Membrane-Active Peptides for the Treatment of Melanoma Tumors in a Humanized SCID Mouse Model. Mol Ther. 2017 Feb 1;25(2):534-546.

68. Pfarr K, Danciu C, Arlt O, Neske C, Dehelean C, Pfeilschifter JM, Radeke HH. Simultaneous and Dose Dependent Melanoma Cytotoxic and Immune Stimulatory Activity of Betulin. PLoS ONE 2015, 10, e0118802.

69. Danciu C, Oprean C, Coricovac DE, Andreea C, Cimpean A, Radeke H, Soica C, Dehelean C. Behaviour of four different B16 murine melanoma cell sublines: C57BL/6J skin. Int J Exp Pathol. 2015 Apr;96(2):73-80.

70. Khaled WT, Liu P. Cancer mouse models: past, present and future Semin Cell Dev Biol. 2014 Mar;27:54-60.

71. Einarsdottir BO, Bagge RO, Bhadury J, et al. Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions. Oncotarget 2014; 5: 9609–9618.

72.Tanaka S, Saito Y, Kunisawa J, et al. Development of mature and functional human myeloid subsets in hematopoietic stem cell-engrafted NOD/SCID/IL2rγKO mice. J Immunol 2012; 188: 6145–6155.

73. Hoffman, R.M. Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma. Int. J. Mol. Sci. 2017, 18, 1875

74. Sharpless NE, Bardeesy N, Lee KH, et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 2001; 413: 86–91.

75. Campagne C, Reyes-Gomez E, Battistella M, et al. Histopathological atlas and proposed classification for melanocytic lesions in Tyr::NRas(Q61K); Cdkn2a(−/−) transgenic mice. Pigment CellMelanoma Res 2013; 26: 735–742.

76. Gaffal E, Landsberg J, Bald T, et al. Neonatal UVB exposure accelerates melanoma growth and enhances distant metastases in Hgf- Cdk4(R24C) C57BL/6 mice. Int J Cancer 2011; 129: 285–294.

77. Pérez-Guijarro, E.; Day, C.P.; Merlino, G.; Zaidi, M.R. Genetically engineered mouse models of melanoma. Cancer 2017, 123, 2089–2103.

78. Colebatch, A.J.; Scolyer, R.A. Trajectories of premalignancy during the journey from melanocyte to melanoma. Pathology 2018, 50, 16–23.

79. Ha, L.; Noonan, F.P.; De Fabo, E.C.; Merlino, G. Animal models of melanoma. J. Investig. Dermatol. Symp. Proc. 2005, 10, 86–88.

80. Dehelean, C.A.; Soica, C.; Pinzaru, I.; Coricovac, D.; Danciu, C.; Pavel, I.; Borcan, F.; Spandidos, D.A.; Tsatsakis, A.M.; Baderca, F. Sex differences and pathology status correlated to the toxicity of some common carcinogens in experimental skin carcinoma. Food Chem. Toxicol. 2016, 95, 149–158.

81.Simpson RM, Bastian BC, Michael HT, et al. Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma. Pigment Cell Melanoma Res 2014; 27: 37–47.

82. Zhao ZZ, Duffy DL, Thomas SA, et al. Polymorphisms in the syntaxin 17 gene are not associated with human cutaneous malignant melanoma. Melanoma Res 2009; 19: 80–86.

83. White R, Rose K, Zon L. Zebrafish cancer: the state of the art and the path forward. Nature Rev Cancer 2013; 13: 624–636.

84. Vidwans SJ, Flaherty KT, Fisher DE, et al. A melanoma molecular disease model. PloS One 2011; 6: e18257.

85. Zon L. Translational research: the path for bringing discovery to patients. Cell Stem Cell 2014; 14: 146–148.